{"bfd2266a8c254e87ca79237501ee5f452843b8f5": [["Whilst the body of literature on the novel coronavirus disease 2019 (COVID-19)-related cardiac complications rapidly expands alongside the exponential surge of confirmed cases, 1 print and social media pose both significant challenges and opportunities in propagating an infodemic during the COVID-19 pandemic.", [["cardiac", "ANATOMY", 87, 94], ["coronavirus disease", "DISEASE", 43, 62], ["COVID-19", "CHEMICAL", 69, 77], ["cardiac complications", "DISEASE", 87, 108], ["coronavirus", "ORGANISM", 43, 54], ["cardiac", "ORGAN", 87, 94], ["the novel coronavirus disease", "PROBLEM", 33, 62], ["COVID", "TEST", 69, 74], ["cardiac complications", "PROBLEM", 87, 108], ["social media", "TREATMENT", 189, 201], ["the COVID", "TEST", 288, 297], ["pandemic", "PROBLEM", 301, 309], ["body", "ANATOMY_MODIFIER", 11, 15], ["cardiac", "ANATOMY", 87, 94], ["complications", "OBSERVATION", 95, 108]]]], "1c94d7a308acd1d96bd486746e13c6d7d274762f": [["IntroductionFlagella and cilia propel swimming eukaryotic cells and drive fluids on epithelial tissues of higher organisms [1] .", [["Flagella", "ANATOMY", 12, 20], ["cilia", "ANATOMY", 25, 30], ["cells", "ANATOMY", 58, 63], ["fluids", "ANATOMY", 74, 80], ["epithelial tissues", "ANATOMY", 84, 102], ["Flagella", "GENE_OR_GENE_PRODUCT", 12, 20], ["cilia", "CELLULAR_COMPONENT", 25, 30], ["cells", "CELL", 58, 63], ["epithelial tissues", "TISSUE", 84, 102], ["swimming eukaryotic cells", "CELL_TYPE", 38, 63], ["IntroductionFlagella", "TREATMENT", 0, 20], ["cilia propel swimming eukaryotic cells", "TREATMENT", 25, 63], ["higher organisms", "PROBLEM", 106, 122]]], ["The inner structure of the eukaryotic flagellum is an arrangement of microtubules (MTs) and accessory proteins called the axoneme (Ax).", [["inner structure", "ANATOMY", 4, 19], ["flagellum", "ANATOMY", 38, 47], ["microtubules", "ANATOMY", 69, 81], ["MTs", "ANATOMY", 83, 86], ["axoneme", "ANATOMY", 122, 129], ["flagellum", "CELLULAR_COMPONENT", 38, 47], ["microtubules", "CELLULAR_COMPONENT", 69, 81], ["MTs", "CELLULAR_COMPONENT", 83, 86], ["axoneme", "CELLULAR_COMPONENT", 122, 129], ["Ax", "GENE_OR_GENE_PRODUCT", 131, 133], ["microtubules", "PROTEIN", 69, 81], ["MTs", "PROTEIN", 83, 86], ["accessory proteins", "PROTEIN", 92, 110], ["axoneme", "PROTEIN", 122, 129], ["Ax", "PROTEIN", 131, 133], ["inner", "OBSERVATION_MODIFIER", 4, 9], ["eukaryotic flagellum", "OBSERVATION", 27, 47]]], ["A highly conserved structure in evolution, the Ax typically consists of nine cylindrically arranged MT doublets cross-bridged by motor proteins of the dynein family.", [["MT", "GENE_OR_GENE_PRODUCT", 100, 102], ["dynein", "GENE_OR_GENE_PRODUCT", 151, 157], ["Ax", "DNA", 47, 49], ["motor proteins", "PROTEIN", 129, 143], ["dynein family", "PROTEIN", 151, 164], ["A highly conserved structure", "PROBLEM", 0, 28], ["highly conserved", "OBSERVATION_MODIFIER", 2, 18], ["structure", "OBSERVATION", 19, 28]]], ["An internal central pair of MTs is connected by radial spokes to the nine peripheral doublets, determining the typical \"9+2\" axonemal structure.", [["MTs", "ANATOMY", 28, 31], ["radial spokes", "ANATOMY", 48, 61], ["axonemal", "ANATOMY", 125, 133], ["MTs", "CELLULAR_COMPONENT", 28, 31], ["axonemal", "CELLULAR_COMPONENT", 125, 133], ["MTs", "PROTEIN", 28, 31], ["9+2\" axonemal structure", "PROTEIN", 120, 143], ["internal", "ANATOMY_MODIFIER", 3, 11], ["central", "ANATOMY_MODIFIER", 12, 19], ["MTs", "OBSERVATION_MODIFIER", 28, 31], ["radial", "ANATOMY_MODIFIER", 48, 54], ["peripheral doublets", "OBSERVATION", 74, 93], ["axonemal structure", "OBSERVATION", 125, 143]]], ["Motor proteins hydrolyze ATP to generate forces that induce doublet sliding.", [["ATP", "CHEMICAL", 25, 28], ["ATP", "CHEMICAL", 25, 28], ["ATP", "SIMPLE_CHEMICAL", 25, 28], ["Motor proteins", "PROTEIN", 0, 14], ["Motor proteins hydrolyze ATP", "PROBLEM", 0, 28], ["doublet sliding", "TREATMENT", 60, 75]]], ["Due to mechanical constraints exerted by linking proteins (nexins) and the basal body, dynein-induced sliding of MTs translates into bending movements of the whole structure.", [["basal body", "ANATOMY", 75, 85], ["MTs", "ANATOMY", 113, 116], ["nexins", "GENE_OR_GENE_PRODUCT", 59, 65], ["basal body", "CELLULAR_COMPONENT", 75, 85], ["dynein", "GENE_OR_GENE_PRODUCT", 87, 93], ["MTs", "CELLULAR_COMPONENT", 113, 116], ["nexins", "PROTEIN", 59, 65], ["dynein", "PROTEIN", 87, 93], ["MTs", "PROTEIN", 113, 116], ["mechanical constraints", "PROBLEM", 7, 29], ["dynein-induced sliding of MTs", "TREATMENT", 87, 116], ["mechanical constraints", "OBSERVATION", 7, 29], ["basal", "ANATOMY_MODIFIER", 75, 80], ["body", "ANATOMY", 81, 85]]], ["Motor proteins are thought to self regulate their activity via mechanical feedback, generating the periodic beats of flagella, see e.g. [6] and [19] .IntroductionDespite a general consensus on the existence of a self-regulatory mechanism, the inner working of the Ax is still not fully understood and it is still a subject of active research [33] .", [["flagella", "ANATOMY", 117, 125], ["flagella", "CELLULAR_COMPONENT", 117, 125], ["Ax", "GENE_OR_GENE_PRODUCT", 264, 266], ["Motor proteins", "PROTEIN", 0, 14], ["Motor proteins", "PROBLEM", 0, 14], ["mechanical feedback", "TREATMENT", 63, 82], ["the periodic beats of flagella", "PROBLEM", 95, 125]]], ["While bending-through-sliding is the accepted fundamental mechanism of flagellar motility, how specific flagellar shapes are determined is not yet clear.", [["flagellar", "ANATOMY", 71, 80], ["flagellar", "ANATOMY", 104, 113], ["flagellar motility", "PROBLEM", 71, 89], ["flagellar motility", "OBSERVATION", 71, 89]]], ["For the most studied swimming microorganisms, such as animal sperm cells and the biflagellate alga Chlamydomonas reinhardtii, the flagellar beat is, to a good approximation, planar.", [["sperm cells", "ANATOMY", 61, 72], ["biflagellate alga Chlamydomonas reinhardtii", "ANATOMY", 81, 124], ["sperm cells", "CELL", 61, 72], ["biflagellate alga Chlamydomonas reinhardtii", "ORGANISM", 81, 124], ["animal sperm cells", "CELL_TYPE", 54, 72], ["Chlamydomonas reinhardtii", "SPECIES", 99, 124], ["Chlamydomonas reinhardtii", "SPECIES", 99, 124], ["swimming microorganisms", "PROBLEM", 21, 44], ["animal sperm cells", "PROBLEM", 54, 72], ["the biflagellate alga Chlamydomonas reinhardtii", "PROBLEM", 77, 124], ["alga Chlamydomonas reinhardtii", "OBSERVATION", 94, 124], ["flagellar beat", "OBSERVATION", 130, 144], ["good", "OBSERVATION_MODIFIER", 154, 158]]], ["For these organisms, beat planarity is thought to be induced by the inter-doublet links between one pair of MTs, typically those numbered 5 and 6 [18] .", [["MTs", "ANATOMY", 108, 111], ["MTs", "CELLULAR_COMPONENT", 108, 111], ["MTs", "PROTEIN", 108, 111], ["these organisms", "PROBLEM", 4, 19], ["beat planarity", "PROBLEM", 21, 35], ["thought to be", "UNCERTAINTY", 39, 52]]], ["These links inhibit the relative sliding of the 5-6 MTs pair, thus selecting a beating plane that passes through the center of the Ax and the midpoint between the inhibited MTs.", [["MTs", "ANATOMY", 173, 176], ["Ax", "GENE_OR_GENE_PRODUCT", 131, 133], ["MTs", "CELLULAR_COMPONENT", 173, 176], ["5-6 MTs pair", "DNA", 48, 60], ["Ax", "PROTEIN", 131, 133], ["relative", "OBSERVATION_MODIFIER", 24, 32], ["sliding", "OBSERVATION_MODIFIER", 33, 40], ["Ax", "ANATOMY", 131, 133], ["inhibited MTs", "OBSERVATION", 163, 176]]], ["Figure 1 . a) A specimen of freely swimming Euglena gracilis, and b) a sketch of the cross section of its flagellum seen from the distal end.", [["specimen", "ANATOMY", 16, 24], ["flagellum", "ANATOMY", 106, 115], ["Euglena gracilis", "ORGANISM", 44, 60], ["flagellum", "CELLULAR_COMPONENT", 106, 115], ["Euglena gracilis", "SPECIES", 44, 60], ["Euglena gracilis", "SPECIES", 44, 60], ["A specimen of freely swimming Euglena gracilis", "TEST", 14, 60], ["flagellum", "ANATOMY_MODIFIER", 106, 115], ["distal", "ANATOMY_MODIFIER", 130, 136]]], ["The flagellar inner structure is composed by the paraflagellar rod (PFR, textured), and the axoneme (Ax).", [["inner structure", "ANATOMY", 14, 29], ["paraflagellar rod", "ANATOMY", 49, 66], ["axoneme", "ANATOMY", 92, 99], ["axoneme", "CELLULAR_COMPONENT", 92, 99], ["paraflagellar rod", "PROTEIN", 49, 66], ["PFR", "PROTEIN", 68, 71], ["Ax", "PROTEIN", 101, 103], ["the paraflagellar rod", "TREATMENT", 45, 66], ["flagellar", "ANATOMY_MODIFIER", 4, 13], ["inner", "ANATOMY_MODIFIER", 14, 19], ["paraflagellar rod", "OBSERVATION", 49, 66]]], ["The PFR is connected via bonding links to the axonemal doublets 1, 2, and 9 (our numbering convention).", [["axonemal", "ANATOMY", 46, 54], ["PFR", "PROTEIN", 4, 7], ["axonemal doublets 1, 2, and 9", "PROTEIN", 46, 75], ["The PFR", "TREATMENT", 0, 7]]], ["The inner structure of the flagellum is enclosed by the flagellar membrane (dotted line).", [["inner structure", "ANATOMY", 4, 19], ["flagellum", "ANATOMY", 27, 36], ["flagellar membrane", "ANATOMY", 56, 74], ["flagellum", "CELLULAR_COMPONENT", 27, 36], ["flagellar membrane", "CELLULAR_COMPONENT", 56, 74], ["inner", "OBSERVATION_MODIFIER", 4, 9], ["flagellum", "ANATOMY_MODIFIER", 27, 36], ["enclosed", "OBSERVATION", 40, 48], ["flagellar membrane", "OBSERVATION", 56, 74]]], ["By inhibiting MTs' sliding the PFR selects the spontaneous bending plane of the Ax (dashed line).", [["MTs", "ANATOMY", 14, 17], ["MTs", "CELLULAR_COMPONENT", 14, 17], ["MTs", "PROTEIN", 14, 17], ["PFR", "DNA", 31, 34], ["Ax (dashed line", "CELL_LINE", 80, 95], ["sliding the PFR", "TREATMENT", 19, 34], ["the Ax (dashed line", "TREATMENT", 76, 95], ["Ax", "ANATOMY", 80, 82]]], ["The solid line that joins the Ax center r a and the PFR center r p cross at an angle \u03c6 p the spontaneous bending plane.IntroductionA remarkable deviation from the flagellar structure of the aforementioned organisms is found in euglenids and kinetoplastids.", [["euglenids", "ANATOMY", 227, 236], ["kinetoplastids", "ANATOMY", 241, 255], ["euglenids", "CANCER", 227, 236], ["kinetoplastids", "CANCER", 241, 255], ["The solid line", "TREATMENT", 0, 14], ["the spontaneous bending plane", "TREATMENT", 89, 118], ["IntroductionA remarkable deviation", "PROBLEM", 119, 153], ["the aforementioned organisms", "PROBLEM", 186, 214], ["kinetoplastids", "PROBLEM", 241, 255], ["solid line", "OBSERVATION", 4, 14], ["spontaneous bending", "OBSERVATION", 93, 112], ["deviation", "OBSERVATION", 144, 153], ["flagellar", "OBSERVATION_MODIFIER", 163, 172], ["organisms", "OBSERVATION", 205, 214]]], ["These flagellated protists have a whole extra element attached alongside the Ax [7] , a slender structure made of a lattice-like arrangement of proteins called \"paraxial\" or \"paraflagellar\" rod (PFR), see Figure 1 .", [["PFR", "PROTEIN", 195, 198], ["a whole extra element", "TREATMENT", 32, 53], ["paraxial\"", "PROBLEM", 161, 170], ["\"paraflagellar\" rod", "PROBLEM", 174, 193]]], ["The latter name is more common, but the former is possibly more accurate [24] .", [["more common", "OBSERVATION_MODIFIER", 19, 30]]], ["PFRs are attached via bonding links to up to four axonemal MTs, depending on the species [32] .", [["MTs", "ANATOMY", 59, 62], ["PFRs", "SIMPLE_CHEMICAL", 0, 4], ["PFRs", "PROTEIN", 0, 4], ["axonemal MTs", "PROTEIN", 50, 62], ["PFRs", "TREATMENT", 0, 4]]], ["PFRs are thought to be passive but, at least in the case of Euglena, some degree of activity is not completely ruled out [21] .IntroductionIn this paper, we put forward and test the hypothesis that the distinctive beating style of Euglena Gracilis, sometimes dubbed \"spinning lasso\" [5] , arises due to PFR-Ax mechanical interaction.IntroductionIn order to put our hypothesis into context, we observe that the flagellar beat of PFR-bearing kinetoplastid organisms, such as Leishmania and Crithidia, is planar [9] .", [["PFRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Euglena", "CELLULAR_COMPONENT", 60, 67], ["PFR", "GENE_OR_GENE_PRODUCT", 428, 431], ["PFR", "PROTEIN", 428, 431], ["Euglena", "PROBLEM", 60, 67], ["Euglena Gracilis", "PROBLEM", 231, 247], ["PFR", "TEST", 303, 306], ["the flagellar beat", "TEST", 406, 424], ["PFR", "TEST", 428, 431], ["bearing kinetoplastid organisms", "PROBLEM", 432, 463], ["Leishmania", "PROBLEM", 473, 483], ["Crithidia", "PROBLEM", 488, 497], ["thought to be", "UNCERTAINTY", 9, 22], ["passive", "OBSERVATION", 23, 30], ["Euglena", "ANATOMY", 60, 67], ["activity", "OBSERVATION", 84, 92], ["Euglena Gracilis", "ANATOMY", 231, 247], ["bearing kinetoplastid organisms", "OBSERVATION", 432, 463]]], ["An apparent exception to beat planarity in kinetoplastids is found in the pathogenic parasite Trypanosoma brucei, which shows a characteristic non-planar \"drill-like\" motion [17] .", [["kinetoplastids", "CANCER", 43, 57], ["Trypanosoma brucei", "ORGANISM", 94, 112], ["Trypanosoma brucei", "SPECIES", 94, 112], ["Trypanosoma brucei", "SPECIES", 94, 112], ["beat planarity in kinetoplastids", "PROBLEM", 25, 57], ["the pathogenic parasite Trypanosoma brucei", "PROBLEM", 70, 112], ["a characteristic non-planar \"drill", "PROBLEM", 126, 160], ["beat planarity", "OBSERVATION", 25, 39], ["pathogenic", "OBSERVATION_MODIFIER", 74, 84], ["parasite", "OBSERVATION_MODIFIER", 85, 93], ["Trypanosoma brucei", "OBSERVATION", 94, 112], ["characteristic", "OBSERVATION_MODIFIER", 128, 142], ["non-planar", "OBSERVATION_MODIFIER", 143, 153], ["\"drill", "OBSERVATION", 154, 160]]], ["However, Trypanosoma's flagellum is not free, like that of Leishmania and Crithidia, but it is attached to the organism for most of its length, wrapped helically around the cell body.", [["flagellum", "ANATOMY", 23, 32], ["cell body", "ANATOMY", 173, 182], ["Trypanosoma's flagellum", "ORGANISM", 9, 32], ["Crithidia", "CELLULAR_COMPONENT", 74, 83], ["cell body", "CELLULAR_COMPONENT", 173, 182], ["Trypanosoma's flagellum", "PROBLEM", 9, 32], ["Leishmania", "PROBLEM", 59, 69], ["Crithidia", "PROBLEM", 74, 83], ["Trypanosoma", "OBSERVATION_MODIFIER", 9, 20], ["not", "UNCERTAINTY", 36, 39], ["free", "OBSERVATION_MODIFIER", 40, 44], ["Leishmania", "OBSERVATION", 59, 69], ["cell body", "OBSERVATION", 173, 182]]], ["According to [2] the flagellum-body mechanical interaction could alone explain Trypanosomes' distinctive motion.", [["body", "ANATOMY", 31, 35], ["the flagellum-body mechanical interaction", "TREATMENT", 17, 58], ["distinctive motion", "OBSERVATION", 93, 111]]], ["Confirming this conclusion, [34] showed that Trypanosoma mutants with body-detached flagellum generate fairly planar beating.", [["body", "ANATOMY", 70, 74], ["flagellum", "ANATOMY", 84, 93], ["Trypanosoma mutants", "ORGANISM", 45, 64], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["Trypanosoma mutants", "PROBLEM", 45, 64], ["detached flagellum", "PROBLEM", 75, 93], ["Trypanosoma mutants", "OBSERVATION", 45, 64], ["planar beating", "OBSERVATION", 110, 124]]], ["It is conjectured that the PFR-Ax bonds operate as the 5-6 interdoublet links in Chlamydomonas and sperm cells, inhibiting MTs sliding and selecting a plane of 2/24 beat [36] .IntroductionEuglena's spinning lasso beat does not conform to this scenario.", [["sperm cells", "ANATOMY", 99, 110], ["MTs", "ANATOMY", 123, 126], ["Chlamydomonas", "CELL", 81, 94], ["sperm cells", "CELL", 99, 110], ["MTs", "CELLULAR_COMPONENT", 123, 126], ["Euglena", "CELLULAR_COMPONENT", 188, 195], ["PFR", "PROTEIN", 27, 30], ["5-6 interdoublet links", "DNA", 55, 77], ["Chlamydomonas and sperm cells", "CELL_TYPE", 81, 110], ["the PFR", "TEST", 23, 30], ["Chlamydomonas and sperm cells", "TREATMENT", 81, 110], ["MTs sliding", "TREATMENT", 123, 134], ["sperm cells", "OBSERVATION", 99, 110]]], ["Indeed, the beating style of Euglena is characterized by high asymmetry and non-planarity.", [["Euglena", "CELLULAR_COMPONENT", 29, 36], ["high asymmetry and non-planarity", "PROBLEM", 57, 89], ["Euglena", "ANATOMY", 29, 36], ["high asymmetry", "OBSERVATION", 57, 71]]], ["The full 3d flagellar kinematics of freely swimming cells has recently been revealed [25] thanks to a mixed approach based on hydrodynamic theory and image analysis.", [["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["freely swimming cells", "CELL_TYPE", 36, 57], ["a mixed approach", "TREATMENT", 100, 116], ["image analysis", "TEST", 150, 164]]], ["As we report in the first part of this paper, the geometry of the spinning lasso is characterized by travelling waves of torsion with alternating sign along the flagellum length.IntroductionWe argue that the key to the emergence of non-planarity lies in a prominent asymmetry in the structure of PFR-Ax attachment in euglenid flagella.", [["flagellum", "ANATOMY", 161, 170], ["euglenid flagella", "ANATOMY", 317, 334], ["torsion", "DISEASE", 121, 128], ["PFR-Ax", "GENE_OR_GENE_PRODUCT", 296, 302], ["euglenid flagella", "CELLULAR_COMPONENT", 317, 334], ["PFR", "PROTEIN", 296, 299], ["Ax", "PROTEIN", 300, 302], ["the spinning lasso", "TREATMENT", 62, 80], ["torsion", "PROBLEM", 121, 128], ["a prominent asymmetry", "PROBLEM", 254, 275], ["PFR", "TEST", 296, 299], ["torsion", "OBSERVATION", 121, 128], ["flagellum", "ANATOMY_MODIFIER", 161, 170], ["length", "OBSERVATION_MODIFIER", 171, 177], ["prominent", "OBSERVATION_MODIFIER", 256, 265], ["asymmetry", "OBSERVATION", 266, 275], ["Ax", "ANATOMY", 300, 302], ["euglenid flagella", "ANATOMY", 317, 334]]], ["Figure 1 shows a sketch of the cross section of the euglenid flagellum redrawn from [20] , see also [4] .", [["euglenid flagellum", "ANATOMY", 52, 70]]], ["The PFR is attached to three MTs, which we number 1, 2, and 9.", [["MTs", "ANATOMY", 29, 32], ["MTs", "CELLULAR_COMPONENT", 29, 32], ["PFR", "PROTEIN", 4, 7], ["The PFR", "TEST", 0, 7]]], ["We consider two lines.", [["two lines", "TREATMENT", 12, 21], ["two lines", "OBSERVATION", 12, 21]]], ["One line (dashed) passes through the center of the Ax and MT 1, in the middle of the bonding complex.", [["MT 1", "GENE_OR_GENE_PRODUCT", 58, 62], ["Ax and MT 1", "PROTEIN", 51, 62], ["bonding complex", "PROTEIN", 85, 100], ["line", "OBSERVATION", 4, 8], ["Ax", "ANATOMY", 51, 53], ["middle", "ANATOMY_MODIFIER", 71, 77], ["bonding complex", "OBSERVATION", 85, 100]]], ["The other line (solid) connects the center of the Ax and the center of the PFR.", [["Ax", "GENE_OR_GENE_PRODUCT", 50, 52], ["Ax", "PROTEIN", 50, 52], ["PFR", "PROTEIN", 75, 78], ["the PFR", "TREATMENT", 71, 78], ["line", "OBSERVATION_MODIFIER", 10, 14], ["solid", "OBSERVATION_MODIFIER", 16, 21], ["Ax", "ANATOMY", 50, 52]]], ["The two lines cross each other.", [["two", "OBSERVATION_MODIFIER", 4, 7], ["lines", "OBSERVATION", 8, 13]]], ["This is the structural feature on which we build our model.IntroductionIn the model we assume that the bonding links to the PFR select the local spontaneous beating plane of the Ax, from the same principle of MTs' sliding inhibition discussed above.", [["MTs", "ANATOMY", 209, 212], ["Ax", "GENE_OR_GENE_PRODUCT", 178, 180], ["PFR", "PROTEIN", 124, 127], ["Ax", "PROTEIN", 178, 180], ["the Ax", "TREATMENT", 174, 180], ["MTs' sliding inhibition", "TREATMENT", 209, 232]]], ["The local spontaneous beating plane so generated passes through the dashed line in Figure 1 .", [["The local spontaneous beating plane", "TREATMENT", 0, 35], ["the dashed line", "TREATMENT", 64, 79]]], ["We follow closely [14] and [27] in our modeling of the Ax, while we use a simple elastic spring model for the PFR.", [["a simple elastic spring model", "TREATMENT", 72, 101], ["the PFR", "TREATMENT", 106, 113]]], ["We show that, under generic actuation, the two flagellar components cannot be simultaneously in their respective states of minimal energy, and this crucially depends on the offset between the spontaneous beating plane of the Ax (dashed line in Figure 1 ) and the line joining the PFR-Ax centers (solid line in Figure 1 ).", [["PFR", "PROTEIN", 280, 283], ["the two flagellar components", "TREATMENT", 39, 67], ["the Ax (dashed line", "TREATMENT", 221, 240], ["the line joining the PFR-Ax centers (solid line", "TREATMENT", 259, 306], ["minimal", "OBSERVATION_MODIFIER", 123, 130], ["energy", "OBSERVATION", 131, 137], ["solid line", "OBSERVATION", 296, 306]]], ["Instead, the typical outcome is an elastically frustrated configuration of the system, in which the two competing components drive each other out of plane.", [["elastically", "OBSERVATION_MODIFIER", 35, 46], ["frustrated", "OBSERVATION", 47, 57]]], ["Under dyneins activation patterns that, in absence of extra-axonemal structures, would produce an asymmetric beat similar to those of Chlamydomonas [23] , or Volvox [26] , the model specifically predicts the torsional signature of the spinning lasso, which we discuss in the following Section.IntroductionInterestingly, the lack of symmetry of the spinning lasso beat produces swimming trajectories with rotations coupled with translations [25] .", [["extra-axonemal structures", "ANATOMY", 54, 79], ["an asymmetric beat", "PROBLEM", 95, 113], ["dyneins activation", "OBSERVATION", 6, 24], ["asymmetric", "OBSERVATION_MODIFIER", 98, 108], ["torsional signature", "OBSERVATION", 208, 227]]], ["In turn, cell body rotations have a role in phototaxis (see Discussion and Outlook Section and [12] ).", [["cell body", "ANATOMY", 9, 18], ["cell", "CELL", 9, 13], ["cell body rotations", "TREATMENT", 9, 28], ["cell body", "OBSERVATION", 9, 18]]], ["In the light of these observations, our analysis shows that the beat of the euglenid flagellum can be seen as an example of a biological function arising from the competition between antagonistic structural components.", [["euglenid flagellum", "ANATOMY", 76, 94], ["our analysis", "TEST", 36, 48], ["the beat of the euglenid flagellum", "PROBLEM", 60, 94], ["euglenid flagellum", "ANATOMY", 76, 94]]], ["It is not dissimilar from the body-flagellum interaction in Trypanosoma, which generates 3d motility.", [["body", "ANATOMY", 30, 34], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["Trypanosoma", "PROBLEM", 60, 71], ["not", "UNCERTAINTY", 6, 9], ["dissimilar", "OBSERVATION_MODIFIER", 10, 20], ["body", "ANATOMY", 30, 34], ["flagellum", "OBSERVATION_MODIFIER", 35, 44], ["interaction", "OBSERVATION", 45, 56], ["Trypanosoma", "OBSERVATION_MODIFIER", 60, 71]]], ["For instance in plants, a mechanism of seed dispersal arises from the mechanical competition between the two valves of the seed pods, see, e.g., [3] for Bauhinia variegata and [15] for Cardamine hirsuta.", [["seed", "ANATOMY", 39, 43], ["seed pods", "ANATOMY", 123, 132], ["seed", "ORGANISM_SUBDIVISION", 39, 43], ["pods", "ORGANISM_SUBDIVISION", 128, 132], ["Bauhinia variegata", "ORGANISM", 153, 171], ["[15]", "SIMPLE_CHEMICAL", 176, 180], ["Cardamine hirsuta", "ORGANISM", 185, 202], ["Bauhinia variegata", "SPECIES", 153, 171], ["Bauhinia variegata", "SPECIES", 153, 171], ["Cardamine hirsuta", "SPECIES", 185, 202], ["Bauhinia variegata", "PROBLEM", 153, 171], ["Cardamine hirsuta", "PROBLEM", 185, 202], ["valves", "OBSERVATION", 109, 115], ["seed pods", "OBSERVATION", 123, 132]]], ["Contraction by antagonistic muscles is key for animal movement and, in particular, for the functioning of hydrostatic skeletons (used from wormlike invertebrates to arms and tentacles of cephalopods, to the trunk of elephants, see [16] ).", [["muscles", "ANATOMY", 28, 35], ["tentacles", "ANATOMY", 174, 183], ["trunk", "ANATOMY", 207, 212], ["muscles", "ORGAN", 28, 35], ["tentacles", "ORGANISM_SUBDIVISION", 174, 183], ["trunk", "ORGANISM_SUBDIVISION", 207, 212], ["hydrostatic skeletons", "PROBLEM", 106, 127], ["hydrostatic skeletons", "OBSERVATION", 106, 127], ["trunk", "ANATOMY", 207, 212]]], ["A similar principle of antagonistic contraction along perpendicularly oriented families of fibers is at work at the sub-cellualr level, for example in the antagonistic motor protein dynamics in contractile ring structures important in cell division and development (see, e.g., [8] ).", [["fibers", "ANATOMY", 91, 97], ["contractile ring structures", "ANATOMY", 194, 221], ["cell", "ANATOMY", 235, 239], ["fibers", "CELLULAR_COMPONENT", 91, 97], ["cell", "CELL", 235, 239], ["antagonistic contraction", "PROBLEM", 23, 47], ["contractile ring structures", "TREATMENT", 194, 221], ["antagonistic contraction", "OBSERVATION", 23, 47], ["contractile ring", "OBSERVATION", 194, 210], ["cell division", "OBSERVATION", 235, 248]]], ["At the same sub-cellular scale, competing elastic forces arising from lipid-protein interactions are often crucial in determining the stability of complex shapes of the cellular membrane [31] , and in the case of the overall structure of the coronavirus envelope [29] .ObservationsWe first analyze the experimental data from the 3d reconstruction of the beating euglenid flagellum obtained in [25] for freely swimming organisms.", [["cellular", "ANATOMY", 16, 24], ["cellular membrane", "ANATOMY", 169, 186], ["cellular", "CELL", 16, 24], ["cellular membrane", "CELLULAR_COMPONENT", 169, 186], ["coronavirus", "ORGANISM", 242, 253], ["competing elastic forces", "PROBLEM", 32, 56], ["lipid-protein interactions", "TREATMENT", 70, 96], ["the coronavirus envelope", "PROBLEM", 238, 262], ["the 3d reconstruction", "TREATMENT", 325, 346], ["the beating euglenid flagellum", "TEST", 350, 380], ["freely swimming organisms", "PROBLEM", 402, 427], ["elastic forces", "OBSERVATION", 42, 56], ["stability", "OBSERVATION_MODIFIER", 134, 143], ["complex", "OBSERVATION_MODIFIER", 147, 154], ["shapes", "OBSERVATION_MODIFIER", 155, 161], ["cellular membrane", "OBSERVATION", 169, 186]]], ["Swimming Euglenas follow generalized helical trajectories coupled with rotation around the major axis of the cell body.", [["cell body", "ANATOMY", 109, 118], ["cell body", "CELLULAR_COMPONENT", 109, 118], ["generalized helical trajectories", "PROBLEM", 25, 57], ["major axis", "ANATOMY_MODIFIER", 91, 101], ["cell", "ANATOMY", 109, 113], ["body", "ANATOMY_MODIFIER", 114, 118]]], ["It is precisely this rotation that allows for a 3d reconstruction of flagellar shapes from 2d videomicroscopy images.", [["flagellar", "ANATOMY", 69, 78], ["a 3d reconstruction of flagellar shapes", "TREATMENT", 46, 85], ["2d videomicroscopy images", "TEST", 91, 116]]], ["Euglenas take many beats to close one complete turn around their major body axis.", [["body", "ANATOMY", 71, 75], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["Euglenas", "TREATMENT", 0, 8], ["major body", "ANATOMY_MODIFIER", 65, 75], ["axis", "ANATOMY", 76, 80]]], ["So, while rotating, Euglenas show their flagellar beat to the observer from many different sides.", [["flagellar beat", "OBSERVATION", 40, 54]]], ["Stereomatching techniques can then be employed to reconstruct the flagellar beat in full (assuming periodicity and regularity of the beat).", [["Stereomatching techniques", "TREATMENT", 0, 25]]], ["Figure 2 shows N = 10 different curves in space describing the euglenid flagellum in different instants within a beat taken from [25] .", [["euglenid flagellum", "ANATOMY", 63, 81], ["Figure", "TEST", 0, 6], ["different curves in space", "PROBLEM", 22, 47], ["the euglenid flagellum", "PROBLEM", 59, 81]]], ["The reconstruction fits well experimental data from multiple specimens.", [["specimens", "ANATOMY", 61, 70], ["The reconstruction", "TREATMENT", 0, 18], ["multiple specimens", "TEST", 52, 70]]], ["The figure also illustrates the calculated torsion of the flagellar curve at each instant (not previously published).", [["calculated torsion", "OBSERVATION", 32, 50], ["flagellar", "OBSERVATION_MODIFIER", 58, 67], ["curve", "OBSERVATION_MODIFIER", 68, 73]]], ["Torsion, the rate of change of the binormal vector, is the geometric quantity that measures the deviation of a curve from a planar path (see the Results Section below for the formal definition).", [["binormal vector", "DNA", 35, 50], ["Torsion", "PROBLEM", 0, 7], ["the binormal vector", "TREATMENT", 31, 50], ["geometric", "OBSERVATION_MODIFIER", 59, 68], ["quantity", "OBSERVATION_MODIFIER", 69, 77]]], ["The spinning lasso shows here a distinct torsional signature characterized by torsion peaks of alternate sign, traveling from the proximal to the distal end of the flagellum.ObservationsTo further investigate Euglena's flagellar beat we observed stationary cells trapped at the tip of a capillary.", [["flagellum", "ANATOMY", 164, 173], ["cells", "ANATOMY", 257, 262], ["capillary", "ANATOMY", 287, 296], ["flagellum", "CELLULAR_COMPONENT", 164, 173], ["Euglena", "CELLULAR_COMPONENT", 209, 216], ["cells", "CELL", 257, 262], ["capillary", "TISSUE", 287, 296], ["stationary cells", "CELL_TYPE", 246, 262], ["The spinning lasso", "TEST", 0, 18], ["a distinct torsional signature", "PROBLEM", 30, 60], ["torsion peaks of alternate sign", "PROBLEM", 78, 109], ["Euglena's flagellar beat", "TEST", 209, 233], ["stationary cells", "PROBLEM", 246, 262], ["torsional signature", "OBSERVATION", 41, 60], ["torsion peaks", "OBSERVATION", 78, 91], ["proximal", "ANATOMY_MODIFIER", 130, 138], ["distal", "ANATOMY_MODIFIER", 146, 152], ["flagellum", "ANATOMY_MODIFIER", 164, 173], ["stationary cells", "OBSERVATION", 246, 262], ["tip", "OBSERVATION_MODIFIER", 278, 281], ["capillary", "ANATOMY_MODIFIER", 287, 296]]], ["In this setting the flagellum is not perturbed by the hydrodynamic forces associated with Euglena's rototranslating swimming motion.", [["flagellum", "ANATOMY", 20, 29], ["flagellum", "CELLULAR_COMPONENT", 20, 29], ["Euglena", "CELLULAR_COMPONENT", 90, 97], ["flagellum", "ANATOMY_MODIFIER", 20, 29], ["not", "UNCERTAINTY", 33, 36], ["perturbed", "OBSERVATION", 37, 46], ["hydrodynamic forces", "OBSERVATION", 54, 73]]], ["We recorded trapped Euglenas during periodic beating.", [["Euglenas", "SIMPLE_CHEMICAL", 20, 28]]], ["Then, we rotated the capillary and recorded the same beating cell from different viewpoints.", [["capillary", "ANATOMY", 21, 30], ["cell", "ANATOMY", 61, 65], ["capillary", "TISSUE", 21, 30], ["cell", "CELL", 61, 65], ["beating cell", "CELL_TYPE", 53, 65], ["beating cell", "OBSERVATION", 53, 65], ["different viewpoints", "OBSERVATION", 71, 91]]], ["Videomicroscopy images from one specimen are shown in .", [["specimen", "ANATOMY", 32, 40], ["Videomicroscopy images", "TEST", 0, 22]]], ["While with fixed specimens we cannot reconstruct reliably the 3d flagellar shapes, Figure 3 shows that there is a high stereographical consistency with the flagellar shapes obtained from swimming organisms.", [["specimens", "ANATOMY", 17, 26], ["fixed specimens", "TEST", 11, 26], ["a high stereographical consistency", "PROBLEM", 112, 146], ["the flagellar shapes", "PROBLEM", 152, 172], ["flagellar shapes", "OBSERVATION", 156, 172]]], ["Flagellar non-planarity is thus not intrinsically associated with swimming, which reinforce the idea that the mechanism that generates non-planar flagellar shapes might be structural in origin.", [["flagellar", "ANATOMY", 146, 155], ["Flagellar non-planarity", "PROBLEM", 0, 23]]], ["Moreover, these observations justify the choice we made in our study to focus on a model of flagellar mechanics for stationary organisms, allowing for substantial simplifications.", [["flagellar", "ANATOMY", 92, 101], ["our study", "TEST", 59, 68], ["stationary organisms", "PROBLEM", 116, 136], ["substantial simplifications", "PROBLEM", 151, 178]]], ["As a final remark we observe how, from a simple geometric construction, we can show that the torsional pattern in Figure 2 is consistent with Euglena's flagellar shapes as seen from common 2d microscopy, for either swimming or trapped organisms.", [["Euglena", "CELLULAR_COMPONENT", 142, 149], ["the torsional pattern", "TEST", 89, 110], ["Euglena's flagellar shapes", "PROBLEM", 142, 168], ["common 2d microscopy", "TEST", 182, 202], ["trapped organisms", "PROBLEM", 227, 244], ["torsional pattern", "OBSERVATION", 93, 110], ["consistent with", "UNCERTAINTY", 126, 141], ["flagellar shapes", "OBSERVATION", 152, 168]]], ["Typically, the 2d outline (i.e. the projection on the optic plane) of a beating euglenid flagellum is that of a looping curve, see e.g. [30] for independent observations.", [["a beating euglenid flagellum", "TREATMENT", 70, 98], ["a looping curve", "TEST", 110, 125]]], ["Consider now an idealized 3d model of the spinning lasso geometry: a curve with two singular points of concentrated torsion with opposite sign, such as the one shown in Figure 3 .", [["concentrated torsion", "PROBLEM", 103, 123], ["concentrated torsion", "OBSERVATION", 103, 123]]], ["If we move along the curve, from proximal end to distal end, we first remain on a fixed plane (blue).", [["the curve", "TEST", 17, 26], ["a fixed plane (blue", "TREATMENT", 80, 99], ["proximal", "ANATOMY_MODIFIER", 33, 41], ["distal", "OBSERVATION_MODIFIER", 49, 55], ["end", "OBSERVATION_MODIFIER", 56, 59]]], ["These abrupt changes correspond to concentrated torsional peaks of opposite sign.", [["These abrupt changes", "PROBLEM", 0, 20], ["concentrated torsional peaks of opposite sign", "PROBLEM", 35, 80], ["abrupt", "OBSERVATION", 6, 12], ["concentrated", "OBSERVATION_MODIFIER", 35, 47], ["torsional peaks", "OBSERVATION", 48, 63], ["opposite sign", "OBSERVATION", 67, 80]]], ["When seen in a two dimensional projection, this torsion dipole generates a looping curve that closely matches euglenid flagella's outlines during a spinning lasso beat.Mechanical modelWe model Ax and PFR as cylindrical structures with deformable centerlines, see Figure 4 .", [["this torsion dipole", "PROBLEM", 43, 62], ["a looping curve", "PROBLEM", 73, 88], ["a spinning lasso beat", "TREATMENT", 146, 167], ["Mechanical modelWe model Ax", "TREATMENT", 168, 195], ["deformable centerlines", "TREATMENT", 235, 257], ["deformable centerlines", "OBSERVATION", 235, 257]]], ["The euglenid flagellum is the composite structure consisting of Ax and PFR attached together.", [["euglenid flagellum", "ANATOMY", 4, 22], ["Ax", "GENE_OR_GENE_PRODUCT", 64, 66], ["Ax", "PROTEIN", 64, 66], ["PFR", "PROTEIN", 71, 74], ["Ax and PFR", "TREATMENT", 64, 74], ["euglenid", "ANATOMY", 4, 12], ["flagellum", "ANATOMY_MODIFIER", 13, 22], ["composite structure", "OBSERVATION", 30, 49]]], ["We suppose that the Ax is the only active component of the flagellum, whereas the PFR is purely passive.", [["flagellum", "ANATOMY", 59, 68], ["Ax", "GENE_OR_GENE_PRODUCT", 20, 22], ["flagellum", "CELLULAR_COMPONENT", 59, 68], ["Ax", "PROTEIN", 20, 22], ["PFR", "PROTEIN", 82, 85], ["active", "OBSERVATION_MODIFIER", 35, 41], ["component", "OBSERVATION_MODIFIER", 42, 51], ["flagellum", "ANATOMY_MODIFIER", 59, 68], ["passive", "OBSERVATION", 96, 103]]], ["Our mechanical model builds on the definition of the total internal energy of the flagellumMechanical modelwhich is given by the sum of three terms: the passive (elastic) internal energy W a pas of the Ax, the active internal energy W a act of the Ax (generated by dynein action), and the (passive, elastic) internal energy W p of the PFR.", [["dynein", "GENE_OR_GENE_PRODUCT", 265, 271], ["Ax", "PROTEIN", 202, 204], ["Ax", "PROTEIN", 248, 250], ["dynein", "PROTEIN", 265, 271], ["PFR", "PROTEIN", 335, 338], ["the flagellumMechanical modelwhich", "TREATMENT", 78, 112], ["the PFR", "TREATMENT", 331, 338], ["mechanical model", "OBSERVATION_MODIFIER", 4, 20]]], ["The passive internal energy of the Ax is given byMechanical modelwhich is formally identical to the classical expression for the energy of elastic (inextensible) rods.", [["elastic (inextensible) rods", "PROBLEM", 139, 166], ["passive", "OBSERVATION_MODIFIER", 4, 11], ["internal", "OBSERVATION_MODIFIER", 12, 20]]], ["We denoted with U 1 and U 2 the bending strains, U 3 is the twist, while B a and C a are the bending and twist moduli, respectively.", [["U 2", "GENE_OR_GENE_PRODUCT", 24, 27], ["U 3", "GENE_OR_GENE_PRODUCT", 49, 52], ["the bending strains", "PROBLEM", 28, 47]]], ["L is the total length of the Ax centerline r a .", [["total", "OBSERVATION_MODIFIER", 9, 14], ["length", "OBSERVATION_MODIFIER", 15, 21], ["centerline", "ANATOMY_MODIFIER", 32, 42]]], ["Bending strains and twist depend on the arc length s of the centerline, and they are defined as follows.", [["Bending strains", "PROBLEM", 0, 15]]], ["We associate to the curve r a an orthonormal frame d i (s), with i = 1, 2, 3, which determines the orientation of the orthogonal sections of the Ax (enclosed by light blue circles in Figure 4 ).", [["sections", "ANATOMY", 129, 137], ["Ax", "ANATOMY", 145, 147]]], ["The unit vectors d 1 (s) and d 2 (s) define the plane of the orthogonal section at s.", [["The unit vectors d", "TREATMENT", 0, 18], ["the orthogonal section", "TREATMENT", 57, 79]]], ["The unit vector d 3 (s) = \u2202 s r a (s) lies perpendicular to the section.", [["The unit vector d", "TREATMENT", 0, 17]]], ["Bending strains and twist are then given byMechanical modelThus, U 1 and U 2 measure the bending of the Ax on the local planes d 1 -d 3 and d 2 -d 3 , respectively, while the twist U 3 is given by the rotation rate of the orthonormal frame around the centerline's tangent d 3 .Mechanical modelWe remark here that we do not consider the Ax as a \"filled\" beam but as a hollow tubular structure; its elasticity comes from the individual MTs lying on its outer surface.", [["tubular", "ANATOMY", 374, 381], ["MTs", "ANATOMY", 434, 437], ["outer surface", "ANATOMY", 451, 464], ["U 1", "GENE_OR_GENE_PRODUCT", 65, 68], ["U 2", "GENE_OR_GENE_PRODUCT", 73, 76], ["U 3", "GENE_OR_GENE_PRODUCT", 181, 184], ["tubular", "TISSUE", 374, 381], ["MTs", "CELLULAR_COMPONENT", 434, 437], ["outer surface", "CELLULAR_COMPONENT", 451, 464], ["U 1 and U 2", "DNA", 65, 76], ["1 -d 3 and d 2 -d 3", "DNA", 129, 148], ["twist U 3", "DNA", 175, 184], ["orthonormal frame", "DNA", 222, 239], ["centerline's tangent d 3", "DNA", 251, 275], ["Bending strains", "PROBLEM", 0, 15], ["byMechanical model", "TREATMENT", 41, 59], ["the twist U 3", "TEST", 171, 184], ["the rotation rate", "TEST", 197, 214], ["Mechanical model", "TREATMENT", 277, 293], ["a \"filled\" beam", "TREATMENT", 342, 357], ["a hollow tubular structure", "PROBLEM", 365, 391], ["Ax", "ANATOMY", 104, 106], ["hollow tubular", "OBSERVATION_MODIFIER", 367, 381], ["structure", "OBSERVATION", 382, 391], ["elasticity", "OBSERVATION_MODIFIER", 397, 407], ["MTs", "OBSERVATION_MODIFIER", 434, 437], ["outer", "OBSERVATION_MODIFIER", 451, 456], ["surface", "OBSERVATION_MODIFIER", 457, 464]]], ["The derivation of (2) from a detailed model of the Ax is given in Appendix A.Mechanical modelThe active internal energy of the Ax is defined as minus the total mechanical work of the dyneinsMechanical modelwhere \u03b3 1 and \u03b3 2 are the two variables that quantifies the shear (i.e. collective sliding) of MTs, while H 1 and H 2 are the corresponding shear forces exerted by molecular motors.", [["MTs", "ANATOMY", 301, 304], ["H", "CHEMICAL", 312, 313], ["H 2", "CHEMICAL", 320, 323], ["\u03b3 2", "GENE_OR_GENE_PRODUCT", 220, 223], ["MTs", "CELLULAR_COMPONENT", 301, 304], ["H 1", "GENE_OR_GENE_PRODUCT", 312, 315], ["H 2", "GENE_OR_GENE_PRODUCT", 320, 323], ["MTs", "PROTEIN", 301, 304], ["H 1", "PROTEIN", 312, 315], ["H 2", "PROTEIN", 320, 323], ["the Ax", "TREATMENT", 47, 53], ["Appendix", "ANATOMY", 66, 74], ["active", "OBSERVATION_MODIFIER", 97, 103], ["internal", "OBSERVATION_MODIFIER", 104, 112], ["shear forces", "OBSERVATION", 346, 358], ["molecular motors", "OBSERVATION", 370, 386]]], ["Following [28] we also allow for singular shear forces, H 1 and H 2 , concentrated at the distal end of the Ax.", [["H 2", "GENE_OR_GENE_PRODUCT", 64, 67], ["singular shear forces", "TREATMENT", 33, 54], ["distal", "ANATOMY_MODIFIER", 90, 96]]], ["The shear variables are related to the MTs' kinematics by the following formulas.", [["MTs", "ANATOMY", 39, 42], ["The shear variables", "PROBLEM", 0, 19], ["shear", "OBSERVATION_MODIFIER", 4, 9]]], ["The MTs' centerlines r j , for j = 1, 2 . . .", [["MTs", "ANATOMY", 4, 7]]], ["9 , are given by r j (s) = C(s, \u03c6 j ), where \u03c6 j = 2\u03c0(j \u2212 1)/9, andMechanical modelis the parametrization of the cylindrical surface of the Ax (\u03c1 a is the Ax radius) in terms of the centerline arc length s and the angle \u03c6.", [["Ax radius", "PROTEIN", 155, 164], ["C(s", "TEST", 27, 30], ["Mechanical modelis", "TEST", 67, 85], ["cylindrical", "ANATOMY_MODIFIER", 113, 124], ["surface", "ANATOMY_MODIFIER", 125, 132], ["Ax", "ANATOMY", 140, 142], ["centerline", "ANATOMY_MODIFIER", 182, 192], ["arc length", "OBSERVATION", 193, 203], ["angle", "ANATOMY_MODIFIER", 214, 219]]], ["In Appendix A we show how the shear variables are related to the individual sliding of MTs with respect to their neighbours 6/24 (35) , and we compute the relations between the dynein forces acting on each pair of adjacent MTs and the shear forces H 1 and H 2 (36) .", [["MTs", "ANATOMY", 87, 90], ["MTs", "ANATOMY", 223, 226], ["MTs", "CELLULAR_COMPONENT", 87, 90], ["dynein", "GENE_OR_GENE_PRODUCT", 177, 183], ["MTs", "CELLULAR_COMPONENT", 223, 226], ["MTs", "PROTEIN", 87, 90], ["dynein", "PROTEIN", 177, 183], ["the shear forces H", "TEST", 231, 249], ["Appendix", "ANATOMY", 3, 11], ["dynein forces", "OBSERVATION", 177, 190]]], ["A special axonemal deformation with \u03b3 2 = 0 is shown in Figure 4 .", [["axonemal", "ANATOMY", 10, 18], ["axonemal", "CELLULAR_COMPONENT", 10, 18], ["A special axonemal deformation", "TEST", 0, 30], ["axonemal deformation", "OBSERVATION", 10, 30]]], ["The Ax is in this case bent into a circular arc, and the centerline r a lies on the plane generated by the unit vectors d 1 and d 3 .", [["Ax", "GENE_OR_GENE_PRODUCT", 4, 6], ["Ax", "DNA", 4, 6], ["unit vectors d 1 and d 3", "DNA", 107, 131], ["circular arc", "OBSERVATION", 35, 47], ["centerline", "ANATOMY_MODIFIER", 57, 67]]], ["The material section is a planar ellipse centered in r a (s) which connects points of neighbouring MTs' corresponding to the same arc length.", [["MTs", "ANATOMY", 99, 102], ["MTs", "CELLULAR_COMPONENT", 99, 102], ["The material section", "TREATMENT", 0, 20], ["a planar ellipse", "PROBLEM", 24, 40], ["planar ellipse", "OBSERVATION", 26, 40], ["r", "ANATOMY_MODIFIER", 53, 54], ["neighbouring MTs", "OBSERVATION", 86, 102], ["arc", "OBSERVATION_MODIFIER", 130, 133], ["length", "OBSERVATION_MODIFIER", 134, 140]]], ["Formula (5) says that \u03b3 1 (s) is the tangent of the angle at which the material sections at s intersect the orthogonal sections at s.", [["sections", "ANATOMY", 80, 88], ["sections", "ANATOMY", 119, 127]]], ["Shear variables and bending strains are coupledMechanical modelThe above formulas, which result from the constrained kinematics of the axonemal structure (as explained further in Appendix A), underlie the essential mechanism of axonemal motility: collective sliding of MTs generates bending of the whole Ax.", [["axonemal", "ANATOMY", 135, 143], ["axonemal", "ANATOMY", 228, 236], ["MTs", "ANATOMY", 269, 272], ["axonemal", "CELLULAR_COMPONENT", 135, 143], ["axonemal", "CELLULAR_COMPONENT", 228, 236], ["MTs", "CELLULAR_COMPONENT", 269, 272], ["axonemal structure", "PROTEIN", 135, 153], ["MTs", "PROTEIN", 269, 272], ["Shear variables", "PROBLEM", 0, 15], ["bending strains", "PROBLEM", 20, 35], ["Mechanical model", "TREATMENT", 47, 63], ["The above formulas", "TREATMENT", 63, 81], ["axonemal motility", "PROBLEM", 228, 245], ["collective sliding of MTs", "TREATMENT", 247, 272], ["axonemal structure", "OBSERVATION", 135, 153], ["Appendix", "ANATOMY", 179, 187], ["axonemal motility", "OBSERVATION", 228, 245]]], ["We point out here that there is no coupling between the shear variables \u03b3 1 , \u03b3 2 and the twist U 3 , a fact that will have consequences in the remainder.", [["\u03b3 1", "GENE_OR_GENE_PRODUCT", 72, 75], ["\u03b3 2", "GENE_OR_GENE_PRODUCT", 78, 81], ["U 3", "GENE_OR_GENE_PRODUCT", 96, 99], ["no", "UNCERTAINTY", 32, 34]]], ["The special axonemal deformation in Figure 4 shows the case in which U 1 (s) = 0 and U 2 (s) = K, so the Ax is bent into a circular arc of radius 1/K. While \u03b3 2 (s) = 0, the shear variable \u03b3 1 (s) = Ks increases linearly with s.", [["axonemal", "ANATOMY", 12, 20], ["axonemal", "CELLULAR_COMPONENT", 12, 20], ["Ax", "PROTEIN", 105, 107], ["The special axonemal deformation", "TEST", 0, 32], ["U", "TEST", 85, 86], ["K", "TEST", 95, 96], ["the shear variable \u03b3", "TEST", 170, 190], ["axonemal deformation", "OBSERVATION", 12, 32]]], ["Material and orthogonal sections coincide at the base (the basal body impose no shear at s = 0) and the angle between them grows as we move along the centerline towards the distal end of the Ax.", [["sections", "ANATOMY", 24, 32], ["basal body", "ANATOMY", 59, 69], ["orthogonal sections", "TEST", 13, 32], ["orthogonal sections", "OBSERVATION", 13, 32], ["base", "ANATOMY_MODIFIER", 49, 53], ["basal", "ANATOMY_MODIFIER", 59, 64], ["body", "ANATOMY_MODIFIER", 65, 69], ["no", "UNCERTAINTY", 77, 79], ["shear", "OBSERVATION_MODIFIER", 80, 85], ["angle", "OBSERVATION_MODIFIER", 104, 109], ["centerline", "ANATOMY_MODIFIER", 150, 160], ["distal", "ANATOMY_MODIFIER", 173, 179]]], ["In order for the Ax to bend, MTs from one side of the Ax must be driven driven towards the distal end while the others must be driven toward the proximal end.Mechanical modelWe remark here that (4) defines the most general active internal energy generated by molecular motors, and we do not assume at this stage any specific (spatial) organization of dynein forces.", [["MTs", "ANATOMY", 29, 32], ["MTs", "CELLULAR_COMPONENT", 29, 32], ["Ax", "GENE_OR_GENE_PRODUCT", 54, 56], ["dynein", "GENE_OR_GENE_PRODUCT", 351, 357], ["MTs", "PROTEIN", 29, 32], ["dynein", "PROTEIN", 351, 357], ["the Ax", "TREATMENT", 13, 19], ["distal", "OBSERVATION_MODIFIER", 91, 97], ["proximal", "ANATOMY_MODIFIER", 145, 153], ["dynein forces", "OBSERVATION", 351, 364]]], ["We will introduce specific shear forces later in the Results Section.Mechanical modelThe PFR is modeled as an elastic cylinder with circular cross sections of radius \u03c1 p and rest length L. We assume that the PFR can stretch and shear.", [["sections", "ANATOMY", 147, 155], ["PFR", "PROTEIN", 89, 92], ["PFR", "PROTEIN", 208, 211], ["Mechanical model", "TREATMENT", 69, 85], ["The PFR", "TEST", 85, 92], ["an elastic cylinder", "TREATMENT", 107, 126], ["circular cross sections of radius \u03c1 p and rest length L.", "TREATMENT", 132, 188]]], ["The total internal energy of the PFR is given byMechanical modelwhere V 1 and V 2 are the shear strains, V 3 is the stretch, D p and E p are the shear and stretching moduli, respectively.", [["V 2", "GENE_OR_GENE_PRODUCT", 78, 81], ["V 3", "GENE_OR_GENE_PRODUCT", 105, 108], ["PFR", "PROTEIN", 33, 36], ["the PFR", "TREATMENT", 29, 36], ["the shear strains", "TEST", 86, 103], ["stretching moduli", "OBSERVATION", 155, 172]]], ["We are neglecting here the PFR's bending and twisting resistance.", [["twisting resistance", "PROBLEM", 45, 64]]], ["Classical estimations on homogeneous elastic rods, see e.g. [13] , show that bending and twist moduli scale with the forth power of the cross section radius, whereas shear and stretching moduli scale with the second power and hence they are dominant for small radii.", [["Classical estimations on homogeneous elastic rods", "PROBLEM", 0, 49], ["twist moduli scale", "TEST", 89, 107], ["stretching moduli scale", "TEST", 176, 199], ["small radii", "PROBLEM", 254, 265], ["homogeneous", "OBSERVATION_MODIFIER", 25, 36], ["elastic rods", "OBSERVATION", 37, 49], ["stretching moduli", "OBSERVATION", 176, 193], ["dominant", "OBSERVATION", 241, 249], ["small radii", "OBSERVATION", 254, 265]]], ["We assume that dynein forces are strong enough to induce shear in the PFR, thus PFR's bending and twist contributions to the energy of the flagellum become negligible.", [["flagellum", "ANATOMY", 139, 148], ["dynein", "GENE_OR_GENE_PRODUCT", 15, 21], ["flagellum", "CELLULAR_COMPONENT", 139, 148], ["dynein", "PROTEIN", 15, 21], ["PFR", "PROTEIN", 80, 83], ["dynein forces", "PROBLEM", 15, 28], ["the PFR", "TEST", 66, 73], ["PFR's bending", "PROBLEM", 80, 93], ["dynein forces", "OBSERVATION", 15, 28], ["negligible", "OBSERVATION", 156, 166]]], ["We are also neglecting Poisson effects by treating the PFR cross sections as rigid.Mechanical modelThe PFR shear strains and stretch are defined as follows.", [["sections", "ANATOMY", 65, 73], ["the PFR cross sections", "TREATMENT", 51, 73], ["rigid", "PROBLEM", 77, 82], ["Mechanical model", "TREATMENT", 83, 99], ["The PFR shear strains", "TREATMENT", 99, 120], ["shear strains", "OBSERVATION", 107, 120]]], ["The cross sections centers of the PFR lie on the curve r d , and their orientations are given by the orthonormal frame g i (s), with i = 1, 2, 3.", [["sections", "ANATOMY", 10, 18], ["PFR", "PROTEIN", 34, 37]]], ["The unit vectors g 1 (s) and g 2 (s) determine the cross section plane centered at r p (s), while the unit vector g 3 (s) is orthogonal to it.", [["The unit vectors g", "TREATMENT", 0, 18], ["the cross section plane", "TREATMENT", 47, 70], ["the unit vector g", "TREATMENT", 98, 115]]], ["Shear strains and stretch are given by the formulas Figure 4 . a) Geometry of the Ax.", [["Shear strains", "PROBLEM", 0, 13]]], ["MTs lie on a tubular surface C(s, \u03c6) parametrized by generalized polar coordinates s and \u03c6, where s is the arc length of the axonemal centerline r a .", [["MTs", "ANATOMY", 0, 3], ["tubular surface", "ANATOMY", 13, 28], ["axonemal", "ANATOMY", 125, 133], ["MTs", "CELLULAR_COMPONENT", 0, 3], ["\u03c6", "PROTEIN", 89, 90]]], ["The unit vectors d 1 (s) and d 2 (s) lie on the orthogonal cross sections of the Ax (light blue circles).", [["sections", "ANATOMY", 65, 73], ["The unit vectors d", "TREATMENT", 0, 18], ["Ax", "ANATOMY", 81, 83]]], ["The material sections of the Ax are given by the curves \u03c6 \u2192 C(s, \u03c6) (red), which connect points of neighbouring axonemal MTs corresponding to the same arc length s.", [["sections", "ANATOMY", 13, 21], ["axonemal MTs", "ANATOMY", 112, 124], ["Ax", "GENE_OR_GENE_PRODUCT", 29, 31], ["axonemal MTs", "GENE_OR_GENE_PRODUCT", 112, 124], ["axonemal MTs", "PROTEIN", 112, 124], ["the Ax", "TREATMENT", 25, 31], ["the curves", "TEST", 45, 55], ["neighbouring", "OBSERVATION", 99, 111], ["axonemal MTs", "OBSERVATION", 112, 124]]], ["Bend deformations of the axoneme are generated by the shear (collective sliding) of MTs.", [["axoneme", "ANATOMY", 25, 32], ["MTs", "ANATOMY", 84, 87], ["axoneme", "CELLULAR_COMPONENT", 25, 32], ["MTs", "CELLULAR_COMPONENT", 84, 87], ["Bend deformations of the axoneme", "PROBLEM", 0, 32]]], ["The shear is quantified by the angle between the orthogonal sections and the material sections of the Ax. b) Geometry of the euglenid flagellum, detail of the Ax-PFR attachment.", [["sections", "ANATOMY", 60, 68], ["sections", "ANATOMY", 86, 94], ["euglenid flagellum", "ANATOMY", 125, 143], ["shear", "OBSERVATION_MODIFIER", 4, 9], ["euglenid", "ANATOMY", 125, 133], ["flagellum", "ANATOMY_MODIFIER", 134, 143], ["Ax", "ANATOMY", 159, 161], ["PFR attachment", "OBSERVATION", 162, 176]]], ["The unit vectors g 1 (s) and g 2 (s) generate the plane of the PFR's cross sections.", [["sections", "ANATOMY", 75, 83], ["The unit vectors g", "TREATMENT", 0, 18]]], ["The vector g 1 (s) is parallel to the outer unit normal to the axonemal surface N(s, \u03c6 p ), while g 2 (s) is parallel to the tangent vector to the material section \u2202 \u03c6 C(s, \u03c6 p ).Mechanical modelThe shear strains thus depend on the orientation of the cross sections with respect to the centerline (tangent), while the stretch measures the elongation of the centerline.Mechanical modelThe PFR-Ax attachment couples the kinematics of the two substructures, see Figure 4 .", [["axonemal surface", "ANATOMY", 63, 79], ["sections", "ANATOMY", 257, 265], ["PFR", "PROTEIN", 388, 391], ["the material section", "TEST", 143, 163], ["Mechanical model", "TREATMENT", 179, 195], ["The shear strains", "PROBLEM", 195, 212], ["Mechanical model", "TREATMENT", 368, 384], ["The PFR", "TEST", 384, 391], ["shear", "OBSERVATION_MODIFIER", 199, 204], ["strains", "OBSERVATION_MODIFIER", 205, 212], ["stretch", "OBSERVATION_MODIFIER", 318, 325], ["elongation", "OBSERVATION_MODIFIER", 339, 349], ["centerline", "ANATOMY_MODIFIER", 357, 367]]], ["In the remainder we formalize the attachment constraint and we show how the PFR's shear strains and stretch (8) , and thus the flagellar energy (1), are completely determined by the Ax kinematic variables.Mechanical modelFor each s, the PFR cross section centered at r p (s) is in contact with the Ax surface at the point C(s, \u03c6 p ) for for a fixed angle coordinate \u03c6 p , see Figure 1 .", [["Ax surface", "ANATOMY", 298, 308], ["the PFR's shear strains", "TEST", 72, 95], ["Mechanical model", "TREATMENT", 205, 221], ["the PFR cross section", "TREATMENT", 233, 254], ["the Ax surface", "TREATMENT", 294, 308]]], ["The PFR centerline is given byMechanical modelwhere N(s, \u03c6 p ) \u2248 d 1 (s) cos \u03c6 p + d 2 (s) sin \u03c6 p is the outer unit normal to the axonemal surface at C(s, \u03c6 p ).", [["axonemal surface", "ANATOMY", 131, 147], ["axonemal surface", "CELLULAR_COMPONENT", 131, 147], ["The PFR centerline", "TREATMENT", 0, 18], ["the axonemal surface", "TEST", 127, 147]]], ["The normal vector N(s, \u03c6 p ) lies on the plane of the PFR cross section centered at r p (s).", [["the PFR cross section", "TREATMENT", 50, 71], ["normal", "OBSERVATION", 4, 10]]], ["Indeed, we have g 1 (s) = N(s, \u03c6 p ) for the first unit vector of the PFR orthonormal frame.", [["PFR orthonormal frame", "DNA", 70, 91]]], ["Only one more degree of freedom remains, namely g 2 (s), which must be orthogonal to N(s, \u03c6 p ), to fully characterize the orientations of the PFR cross sections.", [["sections", "ANATOMY", 153, 161], ["one", "OBSERVATION_MODIFIER", 5, 8], ["more degree", "OBSERVATION_MODIFIER", 9, 20], ["freedom", "OBSERVATION_MODIFIER", 24, 31]]], ["The bonding links of the PFR cross section centered at r p (s) are attached to three adjacent MTs at the same MTs' arc length s.", [["MTs", "ANATOMY", 94, 97], ["MTs", "ANATOMY", 110, 113], ["MTs", "CELLULAR_COMPONENT", 94, 97], ["PFR", "PROTEIN", 25, 28], ["the PFR cross section", "TREATMENT", 21, 42]]], ["The individual attachments are therefore located on the material section of the Ax at s.", [["individual", "OBSERVATION_MODIFIER", 4, 14], ["attachments", "OBSERVATION_MODIFIER", 15, 26]]], ["Given this, g 2 (s) is imposed to be parallel to \u2202 \u03c6 C(s, \u03c6 p ), the tangent vector to the material section of the Ax at the point of contact C(s, \u03c6 p ), see Figure 4 .", [["Ax", "PROTEIN", 115, 117], ["the tangent vector", "TREATMENT", 65, 83]]], ["This condition critically couples MTs' shear to the orientations of the PFR cross sections, as further demonstrated below.Mechanical modelTo summarize, we have the following formulas for the PFR orthonormal frame vectorsMechanical modeland g 3 (s) = g 1 (s) \u00d7 g 2 (s) .Mechanical modelBy replacing the expression (9)- (10) in (8), we obtain formulas for the shear strains and 8/24Mechanical modelstretch of the PFR in terms of the Ax kinematic parameters.", [["MTs", "ANATOMY", 34, 37], ["sections", "ANATOMY", 82, 90], ["MTs", "CELLULAR_COMPONENT", 34, 37], ["PFR orthonormal frame vectors", "DNA", 191, 220], ["the PFR cross sections", "TEST", 68, 90], ["the PFR orthonormal frame vectors", "TREATMENT", 187, 220], ["Mechanical modeland g", "TREATMENT", 220, 241], ["the shear strains", "TREATMENT", 354, 371], ["Mechanical modelstretch", "TREATMENT", 380, 403], ["the PFR", "TREATMENT", 407, 414], ["the Ax kinematic parameters", "TEST", 427, 454]]], ["Since \u03c1 p is small compared to the length scale L of both PFR and Ax we can neglect these quantities.", [["\u03c1 p", "GENE_OR_GENE_PRODUCT", 6, 9], ["\u03c1 p", "PROTEIN", 6, 9], ["PFR", "PROTEIN", 58, 61], ["Ax", "PROTEIN", 66, 68], ["small", "OBSERVATION_MODIFIER", 13, 18]]], ["The only non-negligible contribution to the PFR energy is thus given by the shear strain V 2 .", [["the PFR energy", "PROBLEM", 40, 54], ["non-negligible", "OBSERVATION_MODIFIER", 9, 23]]], ["After linearization, we have V 2 \u2248 \u2212 sin \u03c6 p \u03b3 1 + cos \u03c6 p \u03b3 2 .", [["\u03b3 1", "PROTEIN", 45, 48], ["\u03b3 2", "PROTEIN", 59, 62], ["linearization", "TEST", 6, 19], ["V", "TEST", 29, 30]]], ["The PFR energy in terms of Ax kinematic parameters is then given byMechanical modelThe shear of axonemal MTs determines the orientation of the PFR cross sections.", [["axonemal MTs", "ANATOMY", 96, 108], ["sections", "ANATOMY", 153, 161], ["axonemal MTs", "CELLULAR_COMPONENT", 96, 108], ["axonemal MTs", "PROTEIN", 96, 108], ["The PFR energy", "PROBLEM", 0, 14], ["Ax kinematic parameters", "TREATMENT", 27, 50], ["byMechanical model", "TREATMENT", 65, 83], ["shear", "OBSERVATION_MODIFIER", 87, 92], ["axonemal MTs", "OBSERVATION", 96, 108]]], ["The Ax is again bent in an arc of a circle on the plane d 1 \u2212 d 3 , with U 1 (s) = 0, U 2 (s) = K, \u03b3 1 (s) = Ks, and \u03b3 2 (s) = 0.", [["U", "TEST", 73, 74], ["U", "TEST", 86, 87], ["K", "TEST", 96, 97], ["Ks", "TEST", 109, 111]]], ["PFR and Ax centerlines run parallel to each other, indeed from (9) we have that \u2202 s r a \u2248 \u2202 s r p for every deformation.", [["PFR", "PROTEIN", 0, 3], ["PFR", "TEST", 0, 3], ["every deformation", "PROBLEM", 102, 119]]], ["The linking bonds impose a rotation of the cross sections of the PFR as we progress from the proximal to the distal end of the flagellum, generating shear strain V 2 (s) = \u2212 sin \u03c6 p \u03b3 1 (s) = \u2212 sin \u03c6 p Ks on the PFR.", [["flagellum", "ANATOMY", 127, 136], ["flagellum", "CELLULAR_COMPONENT", 127, 136], ["PFR", "PROTEIN", 65, 68], ["PFR", "PROTEIN", 212, 215], ["shear strain V", "TEST", 149, 163], ["the PFR", "TEST", 208, 215], ["rotation", "OBSERVATION_MODIFIER", 27, 35], ["proximal", "ANATOMY_MODIFIER", 93, 101], ["distal", "ANATOMY_MODIFIER", 109, 115], ["flagellum", "ANATOMY_MODIFIER", 127, 136], ["shear strain", "OBSERVATION", 149, 161]]], ["This mechanical interplay leads to non-planarity of the euglenid flagellar beat.", [["euglenid", "ANATOMY", 56, 64], ["flagellar beat", "OBSERVATION", 65, 79]]], ["This mechanism is controlled by the offset between the PFR-Ax joining line and the local spontaneous bending plane of the Ax, as further discussed in the Results Section.EquilibriaUnder generic (steady) dynein actuation, i.e. given H 1 and H 2 (not time-dependent), and in the absence of external forces, the flagellum deforms to its equilibrium configuration \u03b4W = 0.", [["Ax", "GENE_OR_GENE_PRODUCT", 122, 124], ["flagellum", "CELLULAR_COMPONENT", 309, 318], ["PFR", "PROTEIN", 55, 58], ["the PFR", "TREATMENT", 51, 58], ["Ax joining line", "TREATMENT", 59, 74], ["the local spontaneous bending plane of the Ax", "TREATMENT", 79, 124], ["dynein actuation", "TEST", 203, 219], ["Ax", "ANATOMY", 122, 124], ["external forces", "OBSERVATION", 288, 303]]], ["Bending strains and twist at equilibrium solve the equationsEquilibriawhere U = (U 1 , U 2 ) is the bending vector, e p = (cos \u03c6 p , sin \u03c6 p ), and H \u22a5 = (\u2212H 2 , H 1 ).", [["H", "CHEMICAL", 148, 149], ["H \u22a5 = (\u2212H 2 , H 1 )", "SIMPLE_CHEMICAL", 148, 167], ["Bending strains", "PROBLEM", 0, 15], ["Equilibriawhere", "TEST", 60, 75], ["U", "TEST", 76, 77], ["the bending vector", "TEST", 96, 114]]], ["We use the symbol a \u2297 b to denote the matrix with components (a \u2297 b) ij = a i b j .", [["matrix", "CELLULAR_COMPONENT", 38, 44], ["the symbol a \u2297 b", "TREATMENT", 7, 23], ["a \u2297 b) ij", "TREATMENT", 62, 71], ["ij", "ANATOMY", 69, 71]]], ["The field equations (12)Equilibriawhere H \u22a5 = (\u2212 H 2 , H 1 ).", [["H", "CHEMICAL", 40, 41], ["The field equations", "TEST", 0, 19], ["Equilibriawhere H \u22a5", "TEST", 24, 43]]], ["Equations (12)-(13) can be interpreted as the torque balance equations of the Ax.", [["Equations", "TEST", 0, 9]]], ["The derivative of the (elastic) bending moment and the internal shear stresses balance the torque per unit length exerted by the PFR on the Ax, which is given by the D p -dependent term appearing in the first equation.", [["PFR", "PROTEIN", 129, 132], ["The derivative of the (elastic) bending moment", "TREATMENT", 0, 46], ["the Ax", "TREATMENT", 136, 142], ["internal shear", "ANATOMY", 55, 69], ["stresses balance", "OBSERVATION", 70, 86]]], ["The torque depends on the integral of the bending vector, making the balance equations non-standard (integrodifferental instead of differential).", [["the bending vector", "TREATMENT", 38, 56], ["the balance equations", "TEST", 65, 86], ["torque", "OBSERVATION_MODIFIER", 4, 10]]], ["This dependency is due to the fact that the torque arises from the shear deformations of the PFR, which are induced by the shear of axonemal MTs, which is, in turn, related to axonemal bending strains via the integral relations (6) .", [["axonemal MTs", "ANATOMY", 132, 144], ["axonemal", "ANATOMY", 176, 184], ["axonemal MTs", "CELLULAR_COMPONENT", 132, 144], ["axonemal", "CELLULAR_COMPONENT", 176, 184], ["the shear deformations of the PFR", "PROBLEM", 63, 96], ["axonemal bending strains", "PROBLEM", 176, 200], ["shear deformations", "OBSERVATION", 67, 85], ["axonemal MTs", "OBSERVATION", 132, 144], ["axonemal bending", "OBSERVATION", 176, 192]]], ["The torque exerted by the PFR on the Ax is sensitive to the direction given by the unit vector e p , hence it depends on the angle \u03c6 p between the Ax-PFR joining line and the unit vector d 1 .HydrodynamicsWe derive here the dynamic equations for a flagellum beating in a viscous fluid.", [["flagellum", "ANATOMY", 248, 257], ["viscous fluid", "ANATOMY", 271, 284], ["PFR", "PROTEIN", 26, 29], ["Ax", "DNA", 37, 39], ["Ax-PFR joining line", "DNA", 147, 166], ["the PFR", "TEST", 22, 29], ["the unit vector e p", "TREATMENT", 79, 98], ["the Ax-PFR joining line", "TREATMENT", 143, 166], ["the unit vector d", "TREATMENT", 171, 188], ["a flagellum beating", "TREATMENT", 246, 265], ["a viscous fluid", "PROBLEM", 269, 284], ["torque", "OBSERVATION_MODIFIER", 4, 10], ["joining line", "OBSERVATION", 154, 166], ["viscous fluid", "OBSERVATION", 271, 284]]], ["We consider the extended functionalHydrodynamics9/24Hydrodynamicswhere \u039b is the Lagrange multiplier vector enforcing the constraint \u2202 s r a = d 3 .", [["the Lagrange multiplier vector", "TREATMENT", 76, 106]]], ["We treat the fluid-flagellum interaction in the local drag approximation of Resistive Force Theory, see e.g. [35] .", [["the fluid-flagellum interaction", "PROBLEM", 9, 40], ["fluid", "OBSERVATION", 13, 18], ["flagellum interaction", "OBSERVATION", 19, 40]]], ["In this approximation, viscous forces and torques depend locally on the translational and rotational velocity of the flagellum, represented here for simplicity by the translational and rotational velocity of the Ax.", [["flagellum", "ANATOMY", 117, 126], ["flagellum", "CELLULAR_COMPONENT", 117, 126], ["viscous forces", "OBSERVATION", 23, 37], ["torques", "OBSERVATION_MODIFIER", 42, 49], ["flagellum", "ANATOMY_MODIFIER", 117, 126]]], ["The external viscous forces F and torques G (per unit length) acting on the flagellum are given byHydrodynamicswhere \u00b5 \u22a5 , \u00b5 || , and \u00b5 r are the normal, parallel, and rotational drag coefficient (respectively), and Id is the identity tensor.", [["flagellum", "ANATOMY", 76, 85], ["flagellum", "CELLULAR_COMPONENT", 76, 85], ["Id", "GENE_OR_GENE_PRODUCT", 216, 218], ["Id", "PROTEIN", 216, 218], ["The external viscous forces F and torques G (per unit length)", "TREATMENT", 0, 61], ["Hydrodynamicswhere", "TEST", 98, 116], ["rotational drag coefficient", "TEST", 168, 195], ["external", "ANATOMY", 4, 12], ["viscous forces", "OBSERVATION", 13, 27], ["normal", "OBSERVATION", 146, 152]]], ["The principle of virtual work imposesHydrodynamicsfor every variation \u03b4r a and \u03b4\u03b8 = \u03b4\u03b8Hydrodynamics, \u03b4\u03b8 2 = (\u03b4d 3 \u00b7 d 1 ), and \u03b4\u03b8 3 = (\u03b4d 1 \u00b7 d 2 ).", [["variation", "TEST", 60, 69], ["Hydrodynamics", "TEST", 86, 99], ["\u03b4\u03b8", "TEST", 101, 103], ["\u03b4\u03b8", "TEST", 127, 129]]], ["Linearizing the force balance equations derived from (16) we obtain the following equations for bending strains and twistHydrodynamicsandHydrodynamicswhich are decoupled from the extra unknown \u039b.", [["the force balance equations", "TEST", 12, 39], ["bending strains", "PROBLEM", 96, 111], ["twistHydrodynamicsandHydrodynamicswhich", "PROBLEM", 116, 155], ["force balance", "OBSERVATION", 16, 29]]], ["Equations (17) and (18) are complemented by the boundary conditionsHydrodynamicsThe details of the derivation of (17)- (19) are provided in Appendix B. Once we solve for U 1 , U 2 , and U 3 either the equilibrium equations (12)- (13) or the dynamic equations (17)- (19) , the shape of the flagellum can be recovered.", [["flagellum", "ANATOMY", 289, 298], ["(17)- (19)", "SIMPLE_CHEMICAL", 113, 123], ["U 2", "GENE_OR_GENE_PRODUCT", 176, 179], ["U 3", "GENE_OR_GENE_PRODUCT", 186, 189], ["flagellum", "CELLULAR_COMPONENT", 289, 298], ["Equations", "TEST", 0, 9], ["the equilibrium equations", "TEST", 197, 222], ["the dynamic equations", "TEST", 237, 258], ["Appendix", "ANATOMY", 140, 148]]], ["In particular, we obtain the orthonormal frame d i with i = 1, 2, 3 by solving while the centerline of the Ax is recovered by integrating \u2202 s r a = d 3 .ResultsWe analyze the geometry of the centerline r a which, due to the slenderness of the flagellar structure, is a close proxy for the shape of the flagellum.ResultsIn general, the shape of a curve is determined by its curvature \u03ba and torsion \u03c4 .", [["flagellum", "ANATOMY", 302, 311], ["flagellum", "CELLULAR_COMPONENT", 302, 311], ["Ax", "DNA", 107, 109], ["the slenderness of the flagellar structure", "PROBLEM", 220, 262], ["a curve", "TEST", 344, 351], ["geometry", "OBSERVATION_MODIFIER", 175, 183], ["centerline", "OBSERVATION_MODIFIER", 191, 201], ["flagellar structure", "OBSERVATION", 243, 262], ["flagellum", "ANATOMY_MODIFIER", 302, 311], ["torsion", "OBSERVATION", 389, 396]]], ["Since r a is parametrized by arc length, the two quantities are given by the formulas \u2202 s t = \u03ban and \u2202 s b = \u2212\u03c4 n, where t = \u2202 s r a , n = \u2202 s t/|\u2202 s t|, and b = t \u00d7 n are the tangent, normal, and binormal vector to the curve r a , respectively.", [["t|", "TEST", 150, 152], ["b", "TEST", 158, 159], ["the tangent", "TEST", 172, 183]]], ["Given \u03ba and \u03c4 , r a is uniquely determined up to rigid motions.ResultsFrom the previous definitions and from (3) we obtain the relations between curvature, torsion, bending, and twist.", [["torsion", "DISEASE", 156, 163], ["the previous definitions", "TEST", 75, 99], ["torsion", "OBSERVATION", 156, 163]]], ["In (20) we introduced the angle \u03c8 that the bending vector U = (U 1 , U 2 ) forms with the line U 2 = 0, see Figure 6 .", [["the bending vector U", "TEST", 39, 59], ["the line U", "TEST", 86, 96]]], ["Now, at equilibrium (12) we haveResults10/24 under any dynein actuation.", [["dynein", "GENE_OR_GENE_PRODUCT", 55, 61], ["dynein", "PROTEIN", 55, 61], ["any dynein actuation", "TREATMENT", 51, 71]]], ["In other words, axonemal deformations are twistless.", [["axonemal", "ANATOMY", 16, 24], ["axonemal deformations", "DISEASE", 16, 37], ["axonemal", "CELLULAR_COMPONENT", 16, 24], ["axonemal deformations", "PROBLEM", 16, 37], ["axonemal deformations", "OBSERVATION", 16, 37]]], ["This is, fundamentally, a consequence of the fact that shear of axonemal MTs and twist are uncoupled (6) .", [["axonemal MTs", "ANATOMY", 64, 76], ["axonemal MTs", "CELLULAR_COMPONENT", 64, 76], ["axonemal MTs", "OBSERVATION", 64, 76]]], ["The torsion of the centerline r a is our main focus, since we are interested in emergent non-planarity.", [["torsion", "OBSERVATION", 4, 11], ["centerline", "OBSERVATION_MODIFIER", 19, 29], ["main", "OBSERVATION_MODIFIER", 41, 45], ["focus", "OBSERVATION", 46, 51]]], ["Combining (20) and (21) we have that torsion can arise only from the rotation rate \u2202 s \u03c8 of the bending vector U along the length of the flagellum.", [["flagellum", "ANATOMY", 137, 146], ["flagellum", "CELLULAR_COMPONENT", 137, 146], ["the rotation rate", "TEST", 65, 82], ["torsion", "OBSERVATION", 37, 44], ["length", "OBSERVATION_MODIFIER", 123, 129], ["flagellum", "ANATOMY_MODIFIER", 137, 146]]], ["This last observation will be important in the following.Dynein actuation induced by sliding inhibitionUnder the assumptions (21) and (23), the flagellar energy (1) can be rewritten asDynein actuation induced by sliding inhibitionare the target bending strains generated by the dynein forces.", [["Dynein", "GENE_OR_GENE_PRODUCT", 57, 63], ["asDynein", "SIMPLE_CHEMICAL", 182, 190], ["dynein", "GENE_OR_GENE_PRODUCT", 278, 284], ["dynein", "PROTEIN", 278, 284], ["Dynein actuation", "TREATMENT", 57, 73], ["asDynein actuation", "TREATMENT", 182, 200], ["dynein forces", "OBSERVATION", 278, 291]]], ["The use of this terminology is clear from (22) .", [["clear", "OBSERVATION", 31, 36]]], ["The effect of dynein actuation at equilibrium (when the energy is minimized) is to bring the bending strains U 1 and U 2 as close as possible to U * 1 and U * 2 , respectively.", [["dynein", "GENE_OR_GENE_PRODUCT", 14, 20], ["U 1", "GENE_OR_GENE_PRODUCT", 109, 112], ["U 2", "GENE_OR_GENE_PRODUCT", 117, 120], ["U * 1", "GENE_OR_GENE_PRODUCT", 145, 150], ["U * 2", "GENE_OR_GENE_PRODUCT", 155, 160], ["dynein", "PROTEIN", 14, 20], ["dynein actuation", "PROBLEM", 14, 30], ["dynein actuation", "OBSERVATION", 14, 30]]], ["The emerging bending strains and the target bending strains might not match due to the interference by the PFR component of the energy (D p = 0).", [["The emerging bending strains", "PROBLEM", 0, 28], ["the target bending strains", "PROBLEM", 33, 59], ["bending strains", "OBSERVATION", 13, 28]]], ["From the formulas for the target bending strains in (22) we can infer the importance of the concentrated shear forces H 1 and H 2 .", [["the target bending strains", "TREATMENT", 22, 48], ["the concentrated shear forces H", "TREATMENT", 88, 119]]], ["Without these forces, admissible spontaneous configurations of the Ax would be ruled out.", [["Ax", "GENE_OR_GENE_PRODUCT", 67, 69], ["the Ax", "TREATMENT", 63, 69], ["forces", "OBSERVATION", 14, 20], ["spontaneous configurations", "OBSERVATION", 33, 59]]], ["If the concentrated shear forces are null, for example, the Ax cannot spontaneously bend into a circular arc.", [["concentrated", "OBSERVATION_MODIFIER", 7, 19], ["shear", "OBSERVATION_MODIFIER", 20, 25], ["forces", "OBSERVATION_MODIFIER", 26, 32], ["circular arc", "OBSERVATION", 96, 108]]], ["Indeed, for a circular arc of radius 1/K on the plane d 1 -d 3 we must have U * 2 = 0 and U * 2 = K. In this case, from (22) we have that \u2212H 1 /B a = \u2202 s U * 2 = 0, which implies H 1 = 0 and H 1 = \u2212B a K, so the concentrated forces must be non zero.Dynein actuation induced by sliding inhibitionAs per our main hypothesis, we suppose that the sliding inhibition exerted by the bonding links let dyneins organize so that the Ax locally bends spontaneously on the plane d 1 (s)-d 3 (s), as shown in Figure 1 .", [["H", "CHEMICAL", 179, 180], ["H", "CHEMICAL", 191, 192], ["K", "CHEMICAL", 202, 203], ["H 1 = \u2212B a K", "SIMPLE_CHEMICAL", 191, 203], ["Dynein", "GENE_OR_GENE_PRODUCT", 249, 255], ["dyneins", "GENE_OR_GENE_PRODUCT", 395, 402], ["dyneins", "PROTEIN", 395, 402], ["Ax", "PROTEIN", 424, 426], ["a circular arc of radius", "TREATMENT", 12, 36], ["the plane d", "TEST", 44, 55], ["U", "TEST", 76, 77], ["H", "TEST", 179, 180], ["H", "TEST", 191, 192], ["\u2212B", "TEST", 197, 199], ["a K", "TEST", 200, 203], ["the concentrated forces", "TEST", 208, 231], ["Dynein actuation", "TREATMENT", 249, 265], ["sliding inhibition", "TREATMENT", 277, 295], ["the sliding inhibition", "TREATMENT", 339, 361]]], ["This is equivalent to require that U * 1 = 0, which leads to the following condition on the shear forcesEmergence of non-planarityWe consider here the equilibrium equations (12) under the hypothesis (23) .", [["the equilibrium equations", "TEST", 147, 172]]], ["We look at the equilibrium configurations for every possible value of the angle \u03c6 p between the Ax-PFR joining line and the spontaneous bending plane of the Ax, even though the value of actual interest for Euglena is \u03c6 p \u2248 \u22122\u03c0/9.", [["Euglena", "CELLULAR_COMPONENT", 206, 213], ["Ax", "PROTEIN", 96, 98], ["PFR", "PROTEIN", 99, 102], ["Ax", "PROTEIN", 157, 159], ["the Ax-PFR joining line", "TREATMENT", 92, 115], ["joining line", "OBSERVATION", 103, 115], ["Ax", "ANATOMY", 157, 159]]], ["We can prove analytically the following statement: if the Ax-PFR joining line is neither parallel nor orthogonal to the spontaneous bending plane of the Ax, then the emergent flagellar shapes are non-planar.", [["flagellar", "ANATOMY", 175, 184], ["Ax", "GENE_OR_GENE_PRODUCT", 153, 155], ["Ax", "DNA", 58, 60], ["Ax", "PROTEIN", 153, 155], ["the Ax-PFR joining line", "TREATMENT", 54, 77], ["joining line", "OBSERVATION", 65, 77], ["flagellar shapes", "OBSERVATION", 175, 191]]], ["From (20) and (21) it follows that the shape of the flagellum is planar \u03c4 = 0 if (and only if) the angle \u03c8 of the bending vector U(s) = (U 1 (s), U 2 (s)) is constant.", [["flagellum", "CELLULAR_COMPONENT", 52, 61], ["U", "TEST", 146, 147]]], ["The bending vector must therefore be confined on a line for every s.", [["The bending vector", "TREATMENT", 0, 18], ["a line", "TREATMENT", 49, 55]]], ["In this case there must be two constants c 1 and c 2 such that U 1 (s) = c 1 U (s) and U 2 (s) = c 2 U (s) for some scalar function U .", [["two constants c", "TEST", 27, 42], ["U (s", "TEST", 77, 81], ["U", "TEST", 87, 88], ["U (s", "TEST", 101, 105], ["some scalar function U", "PROBLEM", 111, 133]]], ["Flagellar non-planarity arising from structural incompatibility.", [["Flagellar non-planarity", "PROBLEM", 0, 23], ["structural incompatibility", "PROBLEM", 37, 63], ["structural incompatibility", "OBSERVATION", 37, 63]]], ["The Ax-PFR mechanical interplay is explained in a three-steps argument (left to right).", [["The Ax-PFR mechanical interplay", "TREATMENT", 0, 31], ["left", "ANATOMY_MODIFIER", 72, 76], ["right", "ANATOMY_MODIFIER", 80, 85]]], ["Consider first the two separated structures in their spontaneous configurations (left).", [["left", "ANATOMY_MODIFIER", 81, 85]]], ["The Ax is bent into a planar arc while the PFR is straight.", [["Ax", "PROTEIN", 4, 6], ["PFR", "DNA", 43, 46], ["a planar arc", "TREATMENT", 20, 32], ["bent", "OBSERVATION", 10, 14], ["planar arc", "OBSERVATION", 22, 32], ["straight", "OBSERVATION_MODIFIER", 50, 58]]], ["Then, the PFR is forced to match to the Ax, while the latter is kept in its spontaneous configuration (middle).", [["Ax", "GENE_OR_GENE_PRODUCT", 40, 42], ["PFR", "PROTEIN", 10, 13], ["Ax", "DNA", 40, 42], ["the PFR", "TREATMENT", 6, 13], ["spontaneous configuration", "OBSERVATION", 76, 101], ["middle", "ANATOMY_MODIFIER", 103, 109]]], ["The attachment constraint induces shear strains in the PFR.", [["shear strains", "PROBLEM", 34, 47], ["shear strains", "OBSERVATION", 34, 47]]], ["When the composite system is released (right), it reaches equilibrium by the relaxation of the PFR shear, which induce additional distortion of the Ax.", [["right", "ANATOMY_MODIFIER", 39, 44], ["PFR shear", "OBSERVATION", 95, 104]]], ["At equilibrium, an optimal energy compromise is reached, which is characterized by an emergent non-planarity.Emergence of non-planaritysolution of (12) then we must haveEmergence of non-planaritywith c 1 U (L) = 0 and c 2 U (L) = \u2212 H 1 /B a .", [["an optimal energy compromise", "PROBLEM", 16, 44], ["an emergent non-planarity", "PROBLEM", 83, 108], ["compromise", "OBSERVATION", 34, 44]]], ["If \u03c6 p = 0, \u03c0/2, \u03c0, 3\u03c0/2 the system of equations (24)- (25) admits no solution.", [["p", "TEST", 5, 6]]], ["If H 1 = 0 then the boundary conditions impose c 1 = 0, but in this case (24) has again U = 0 as a unique solution, which is incompatible with both the boundary conditions and with (25) .", [["a unique solution", "TREATMENT", 97, 114]]], ["For \u03c6 p \u2248 \u22122\u03c0/9, the characteristic value for Euglena, the non-planarity of flagellar shapes is not just possible.", [["Euglena", "CELLULAR_COMPONENT", 46, 53], ["Euglena", "PROBLEM", 46, 53], ["flagellar shapes", "OBSERVATION", 76, 92], ["not just possible", "UNCERTAINTY", 96, 113]]], ["It is the only possible outcome under any non-trivial dynein actuation.Structural incompatibility and torsion with alternating signAlongside the previous analysis there is a less technical way to infer the emergence of non-planarity from our model.", [["dynein", "GENE_OR_GENE_PRODUCT", 54, 60], ["any non-trivial dynein actuation", "TREATMENT", 38, 70], ["Structural incompatibility", "PROBLEM", 71, 97], ["torsion", "PROBLEM", 102, 109], ["the previous analysis", "TEST", 141, 162], ["dynein actuation", "OBSERVATION", 54, 70], ["incompatibility", "OBSERVATION", 82, 97], ["torsion", "OBSERVATION", 102, 109]]], ["We look here more closely to the flagellum energy, and we think in terms of structural incompatibility between Ax and PFR, seen as antagonistic elements of the flagellum assembly, see Figure 5 .Structural incompatibility and torsion with alternating signUnder the assumptions (21) and (23), the flagellar energy is given by with U * 2 as in (22) .", [["flagellum", "ANATOMY", 160, 169], ["Ax", "GENE_OR_GENE_PRODUCT", 111, 113], ["flagellum", "CELLULAR_COMPONENT", 160, 169], ["Ax", "PROTEIN", 111, 113], ["PFR", "PROTEIN", 118, 121], ["structural incompatibility", "PROBLEM", 76, 102], ["Ax and PFR", "TREATMENT", 111, 121], ["Structural incompatibility", "PROBLEM", 194, 220], ["torsion", "PROBLEM", 225, 232], ["incompatibility", "OBSERVATION", 205, 220], ["torsion", "OBSERVATION", 225, 232]]], ["The energy has two components, W a that depends on the Ax bending modulus B a , and W p that depends on the PFR shear modulus D p .", [["two", "OBSERVATION_MODIFIER", 15, 18], ["components", "OBSERVATION_MODIFIER", 19, 29]]], ["We can vary these material parameters and explore what the resulting minima of W, i.e. the equilibrium configurations (12)-(13), must look like.", [["these material parameters", "TEST", 12, 37], ["the equilibrium configurations", "TEST", 87, 117]]], ["We consider the nondimensional parameter \u03bd = D p /(B a L \u22122 ).", [["the nondimensional parameter", "TEST", 12, 40]]], ["In this case, at equilibrium, the bending vector has to be close to the target bending vector U \u2248 (0, U * 2 ).", [["the bending vector", "TREATMENT", 30, 48]]], ["Clearly, if the latter line is different from U 1 = 0, the two extreme regimes \u03bd 1 and \u03bd 1, each of which favours one of the two individual components, aim at two different equilibrium configurations.", [["different", "OBSERVATION_MODIFIER", 163, 172], ["equilibrium configurations", "OBSERVATION", 173, 199]]], ["In other words, Ax and PFR are structurally incompatible.Structural incompatibility and torsion with alternating signWhen neither of the two energy components dominates, the emergence of non-planarity can be intuitively predicted with the following reasoning.", [["Ax", "GENE_OR_GENE_PRODUCT", 16, 18], ["PFR", "PROTEIN", 23, 26], ["Structural incompatibility", "PROBLEM", 57, 83], ["torsion", "PROBLEM", 88, 95], ["structurally", "OBSERVATION_MODIFIER", 31, 43], ["incompatible", "OBSERVATION", 44, 56], ["incompatibility", "OBSERVATION", 68, 83], ["torsion", "OBSERVATION", 88, 95]]], ["In the intermediate case \u03bd \u223c 1 we expect the equilibrium configurations to be a compromise among the two extreme cases, with the bending vector U(s) being \"spread out\" in the region between the two extreme equilibrium lines.", [["extreme equilibrium lines", "CELL_LINE", 198, 223], ["the equilibrium configurations", "PROBLEM", 41, 71], ["region", "ANATOMY_MODIFIER", 175, 181], ["two", "OBSERVATION_MODIFIER", 194, 197], ["extreme", "OBSERVATION_MODIFIER", 198, 205], ["equilibrium lines", "OBSERVATION", 206, 223]]], ["The spreading of the bending vector is aided by the concentrated shear force at the tip, which imposes U(L) = (0, U * 2 (L)) irrespectively of the PFR stiffness.", [["the bending vector", "TREATMENT", 17, 35], ["the PFR stiffness", "PROBLEM", 143, 160], ["tip", "ANATOMY_MODIFIER", 84, 87], ["PFR stiffness", "OBSERVATION", 147, 160]]], ["The bending vector is then \"pinned\" at s = L on the U 1 = 0 line while it gets dragged toward the line generated by e \u22a5 p for large values of \u03bd.", [["The bending vector", "TREATMENT", 0, 18]]], ["Hence the spreading.", [["spreading", "OBSERVATION_MODIFIER", 10, 19]]], ["The bending vector will then span an area and, consequently, undergo rotations.", [["The bending vector", "TREATMENT", 0, 18]]], ["Since torsion is determined by the rotation rate of the bending vector \u03c4 = \u2202 s \u03c8, the resulting flagellar shapes will be non-planar.", [["torsion", "DISEASE", 6, 13], ["\u03c8", "PROTEIN", 79, 80], ["the rotation rate", "TEST", 31, 48], ["the resulting flagellar shapes", "PROBLEM", 82, 112], ["torsion", "OBSERVATION", 6, 13], ["flagellar shapes", "OBSERVATION", 96, 112]]], ["We consider a target bending of the kind U * 2 (s) = A 0 + A 1 sin(2\u03c0s/L)), a fair idealization of the asymmetric shapes of a Chlamydomonas-like flagellar beat [10] .", [["Chlamydomonas", "PROTEIN", 126, 139], ["a Chlamydomonas", "PROBLEM", 124, 139], ["flagellar beat", "PROBLEM", 145, 159], ["asymmetric", "OBSERVATION_MODIFIER", 103, 113], ["shapes", "OBSERVATION_MODIFIER", 114, 120], ["Chlamydomonas", "OBSERVATION", 126, 139], ["flagellar beat", "OBSERVATION", 145, 159]]], ["We take \u03c6 p = \u2212\u03c0/4 (larger than the Euglena value, to obtain clearer graphs).", [["the Euglena value", "TEST", 32, 49]]], ["For \u03bd = 0 the bending vector lies inside the U 1 = 0 line, and its amplitude oscillates.", [["U 1 = 0 line", "CELL_LINE", 45, 57], ["amplitude oscillates", "OBSERVATION", 67, 87]]], ["For positive values of \u03bd, when the PFR stiffness is \"turned on\", the oscillating bending vector is extruded from the U 1 = 0 line.", [["U 1 = 0 line", "CELL_LINE", 117, 129], ["positive values of \u03bd", "PROBLEM", 4, 24], ["the PFR stiffness", "PROBLEM", 31, 48], ["the oscillating bending vector", "TREATMENT", 65, 95]]], ["For large values of \u03bd it gets closer and closer to the line generated by e \u22a5 p .", [["\u03bd", "PROTEIN", 20, 21], ["large", "OBSERVATION_MODIFIER", 4, 9]]], ["The bending vector spans an area and, following the oscillations, it rotates clock-wise and anti-clock-wise generating an alternation in the torsion sign.", [["torsion", "DISEASE", 141, 148], ["The bending vector", "TREATMENT", 0, 18], ["anti-clock", "TREATMENT", 92, 102], ["the torsion sign", "TEST", 137, 153], ["bending", "OBSERVATION_MODIFIER", 4, 11], ["area", "OBSERVATION_MODIFIER", 28, 32], ["torsion", "OBSERVATION", 141, 148]]], ["This is the geometric signature of the spinning lasso.Hydrodynamic simulations and comparison with observationsOur model is able to predict the torsional characteristic of the euglenid flagellum in the static case, and in absence of external forces.", [["euglenid flagellum", "ANATOMY", 176, 194], ["the spinning lasso", "TREATMENT", 35, 53], ["Hydrodynamic simulations", "TEST", 54, 78], ["euglenid flagellum", "ANATOMY", 176, 194], ["external forces", "OBSERVATION", 233, 248]]], ["We test here the model in the more realistic setting of time-dependent dynein actuation in the presence of hydrodynamic interactions.Hydrodynamic simulations and comparison with observationsWe first observe that, as in the static case, the dynamic equations for U and U 3 are decoupled (17)- (18) , and that dynein forces do not affect twist.", [["U 3", "GENE_OR_GENE_PRODUCT", 268, 271], ["time-dependent dynein actuation", "TREATMENT", 56, 87], ["hydrodynamic interactions", "PROBLEM", 107, 132], ["Hydrodynamic simulations", "TEST", 133, 157], ["U and U 3", "TEST", 262, 271], ["dynein actuation", "OBSERVATION", 71, 87], ["hydrodynamic interactions", "OBSERVATION", 107, 132]]], ["We can simply assume (21) for all times, so the torsion of r a is still completely determined by the bending vector.Hydrodynamic simulations and comparison with observationsWe consider a dynein actuation that generates Chlamydomonas-like shapes in a flagellum with no extra-axonemal structures.", [["flagellum", "ANATOMY", 250, 259], ["extra-axonemal structures", "ANATOMY", 268, 293], ["extra-axonemal structures", "TISSUE", 268, 293], ["Hydrodynamic simulations", "TEST", 116, 140], ["a dynein actuation", "TREATMENT", 185, 203], ["Chlamydomonas-like shapes", "PROBLEM", 219, 244], ["extra-axonemal structures", "PROBLEM", 268, 293], ["torsion", "OBSERVATION", 48, 55], ["dynein actuation", "OBSERVATION", 187, 203], ["shapes", "OBSERVATION_MODIFIER", 238, 244]]], ["The shear forces H 1 and H 1 employed in our simulation are shown in Figure 7 .", [["The shear forces H", "TREATMENT", 0, 18], ["shear", "OBSERVATION_MODIFIER", 4, 9], ["forces", "OBSERVATION_MODIFIER", 10, 16]]], ["The same figure also shows the emergent bending strains of a PFR-free flagellum actuated by said forces, beating in a viscous fluid.", [["flagellum", "ANATOMY", 70, 79], ["PFR", "PROTEIN", 61, 64], ["the emergent bending strains", "PROBLEM", 27, 55], ["a PFR-free flagellum", "TREATMENT", 59, 79], ["viscous fluid", "OBSERVATION", 118, 131]]], ["The dynamic equations for this system are simply (17)-(18) with D p = 0.", [["this system", "TEST", 26, 37], ["D p", "TEST", 64, 67]]], ["The resulting bending strains, which generate a planar beat, resembles the experimentally observed Chlamydomonas flagellar curvatures reported in [23] .Hydrodynamic simulations and comparison with observationsFinally, Figure 7 presents the emergent bending strains of the beating euglenid (PFR-bearing) flagellum, together with the corresponding flagellar torsion.", [["flagellum", "ANATOMY", 303, 312], ["PFR", "PROTEIN", 290, 293], ["The resulting bending strains", "PROBLEM", 0, 29], ["the experimentally observed Chlamydomonas flagellar curvatures", "PROBLEM", 71, 133], ["Hydrodynamic simulations", "TEST", 152, 176], ["the emergent bending strains", "PROBLEM", 236, 264], ["the corresponding flagellar torsion", "PROBLEM", 328, 363], ["bending strains", "OBSERVATION", 14, 29], ["flagellar curvatures", "OBSERVATION", 113, 133], ["flagellar torsion", "OBSERVATION", 346, 363]]], ["The spinning lasso torsional signature is clearly present.", [["The spinning lasso torsional signature", "TEST", 0, 38], ["torsional signature", "OBSERVATION", 19, 38]]], ["Indeed, the fluid-structure interaction does not disrupt the Ax-PFR structural incompatibility, which still generates non-planar shapes with travelling waves of torsional peaks with alternating sign and the typical looping-curve outlines, cfr.", [["Ax", "PROTEIN", 61, 63], ["PFR", "PROTEIN", 64, 67], ["cfr", "PROTEIN", 239, 242], ["travelling waves of torsional peaks", "PROBLEM", 141, 176], ["alternating sign", "PROBLEM", 182, 198], ["fluid", "OBSERVATION", 12, 17], ["structural incompatibility", "OBSERVATION", 68, 94], ["non-planar shapes", "OBSERVATION", 118, 135], ["torsional peaks", "OBSERVATION", 161, 176], ["typical", "OBSERVATION_MODIFIER", 207, 214], ["looping", "OBSERVATION", 215, 222]]], ["All the details on the methods and parameters employed in the simulations are given in Appendix C and Appendix D.Discussion and OutlookWe have shown how the origin of the peculiar shapes of the euglenid flagellum can be explained by the mechanical interplay of two antagonistic flagellar components, the Ax and the PFR.", [["euglenid flagellum", "ANATOMY", 194, 212], ["Ax", "GENE_OR_GENE_PRODUCT", 304, 306], ["antagonistic flagellar components", "PROTEIN", 265, 298], ["Ax", "PROTEIN", 304, 306], ["PFR", "PROTEIN", 315, 318], ["the methods", "TEST", 19, 30], ["the PFR", "TREATMENT", 311, 318], ["Appendix", "ANATOMY", 87, 95], ["Appendix", "ANATOMY", 102, 110], ["origin", "ANATOMY_MODIFIER", 157, 163], ["euglenid flagellum", "ANATOMY", 194, 212]]], ["Our conclusions are based mainly on the hypothesis that sliding inhibition by the PFR organizes dynein activity, and localizes the spontaneous bending plane of the Ax as the one that passes from the Ax center through the MTs bonded to the PFR.", [["MTs", "ANATOMY", 221, 224], ["dynein", "GENE_OR_GENE_PRODUCT", 96, 102], ["Ax", "GENE_OR_GENE_PRODUCT", 164, 166], ["MTs", "CELLULAR_COMPONENT", 221, 224], ["PFR", "PROTEIN", 82, 85], ["dynein", "PROTEIN", 96, 102], ["Ax", "PROTEIN", 164, 166], ["MTs", "PROTEIN", 221, 224], ["PFR", "PROTEIN", 239, 242], ["sliding inhibition", "TREATMENT", 56, 74], ["dynein activity", "OBSERVATION", 96, 111]]], ["This is in agreement with the current understanding of the mechanism that generates beat planarity in other PFR-bearing flagellar systems.", [["PFR", "PROTEIN", 108, 111], ["beat planarity", "PROBLEM", 84, 98]]], ["Non-planarity in Euglena can arise because of a marked asymmetry in the Ax-bonding links-PFR complex in the Euglenid flagellum, which is not found in kinetoplastic organisms such as Leishmania [11] or Trypanosoma [22] .", [["Euglenid flagellum", "ANATOMY", 108, 126], ["Euglena", "CELLULAR_COMPONENT", 17, 24], ["Euglenid flagellum", "CELLULAR_COMPONENT", 108, 126], ["Leishmania", "ORGANISM", 182, 192], ["Ax-bonding links-PFR complex", "PROTEIN", 72, 100], ["a marked asymmetry", "PROBLEM", 46, 64], ["PFR complex in the Euglenid flagellum", "PROBLEM", 89, 126], ["kinetoplastic organisms", "PROBLEM", 150, 173], ["Leishmania", "PROBLEM", 182, 192], ["Trypanosoma", "PROBLEM", 201, 212], ["marked", "OBSERVATION_MODIFIER", 48, 54], ["asymmetry", "OBSERVATION", 55, 64], ["Ax", "ANATOMY", 72, 74], ["Euglenid flagellum", "ANATOMY", 108, 126], ["not found", "UNCERTAINTY", 137, 146], ["Leishmania", "OBSERVATION", 182, 192]]], ["In the absence of a precise knowledge of the dynein actuation pattern we tested our mechanical model under shear forces that would, in the absence of extra-axonemal structures, realize a beat similar to those found in model systems like Chlamydomonas.", [["extra-axonemal structures", "ANATOMY", 150, 175], ["dynein", "GENE_OR_GENE_PRODUCT", 45, 51], ["Chlamydomonas.", "ORGANISM", 237, 251], ["dynein", "PROTEIN", 45, 51], ["a beat", "PROBLEM", 185, 191], ["Chlamydomonas", "PROBLEM", 237, 250], ["Chlamydomonas", "OBSERVATION", 237, 250]]], ["We appreciate that the emergent distortion of the Ax, generated by the Ax-PFR interplay, could in principle lead to different actuation patterns, consistently with the hypothesis of dynein actuation via mechanical feedback.", [["Ax", "GENE_OR_GENE_PRODUCT", 50, 52], ["dynein", "GENE_OR_GENE_PRODUCT", 182, 188], ["Ax", "DNA", 50, 52], ["Ax", "PROTEIN", 71, 73], ["PFR", "PROTEIN", 74, 77], ["dynein", "PROTEIN", 182, 188], ["dynein actuation", "TREATMENT", 182, 198], ["mechanical feedback", "TREATMENT", 203, 222]]], ["This question will require further studies.Discussion and OutlookAlong with the mechanism that let the euglenid flagellar shapes emerge, it is worth considering how this characteristic flagellar beat is integrated in the overall behaviour of the organism.", [["further studies", "TEST", 27, 42]]], ["As shown in [25] , the spinning lasso beat produces the typical roto-translational trajectories of swimming euglenas.", [["the spinning lasso beat", "TEST", 19, 42]]], ["Cell body rotation is in turn associated with phototaxis.", [["Cell body", "ANATOMY", 0, 9], ["Cell", "CELL", 0, 4], ["Cell body rotation", "TREATMENT", 0, 18], ["phototaxis", "PROBLEM", 46, 56], ["body rotation", "OBSERVATION", 5, 18]]], ["Indeed, rotation allows cells to \"scan\" the environment, and veer to the light source direction when stimulated (or escape in the opposite direction, when the signal is too strong).", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29]]], ["Here, the key biochemical mechanism could be the one often found in nature, by which periodic signals generated by lighting and shading associated with body rotations are used for navigation, in the sense that the existence of periodicity implies a lack of proper alignment [12] .", [["body", "ANATOMY", 152, 156], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["body rotations", "TREATMENT", 152, 166], ["navigation", "TREATMENT", 180, 190]]], ["It is known that the PFR is directly 15/24 connected with the light-sensing apparatus [24] , and might even be active [21] .", [["PFR", "PROTEIN", 21, 24], ["the PFR", "TEST", 17, 24], ["active", "OBSERVATION_MODIFIER", 111, 117]]], ["Further study on euglenid flagellar motility and phototaxis could lead to a more comprehensive understanding on the role of the PFR.Materials and MethodsStrain SAG 1224-5/27 of Euglena gracilis obtained from the SAG Culture Collection of Algae at the University of G\u00f6ttingen was maintained axenic in liquid culture medium Eg.", [["flagellar", "ANATOMY", 26, 35], ["SAG 1224-5/27", "CHEMICAL", 160, 173], ["Euglena gracilis", "ORGANISM", 177, 193], ["PFR", "PROTEIN", 128, 131], ["Euglena gracilis", "SPECIES", 177, 193], ["Euglena gracilis", "SPECIES", 177, 193], ["Further study", "TEST", 0, 13], ["euglenid flagellar motility", "TREATMENT", 17, 44], ["phototaxis", "TREATMENT", 49, 59], ["the PFR", "TREATMENT", 124, 131], ["Materials", "TEST", 132, 141], ["MethodsStrain SAG", "TEST", 146, 163], ["Euglena gracilis", "PROBLEM", 177, 193], ["the SAG Culture", "TEST", 208, 223]]], ["Cultures were transferred weekly.", [["Cultures", "TEST", 0, 8]]], ["Cells were kept in incubator at 15 \u2022 C at a light:dark cycle of 12:12 h under a cold white LED illumination with an irradiance of about 50 \u00b5mol \u00b7 m \u22122 \u00b7 s \u22121 .Materials and MethodsAn Olympus IX 81 inverted microscope with motorized stage was employed in all the experiments.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["a cold white LED illumination", "PROBLEM", 78, 107], ["an irradiance", "TEST", 113, 126], ["Materials", "TEST", 159, 168], ["MethodsAn Olympus IX", "TREATMENT", 173, 193]]], ["The microscope was equipped with a LCAch 20X Phc objective (NA 0.40) for the imaging of cells trapped at the tip of a glass capillary using transmitted brightfield illumination.", [["cells", "ANATOMY", 88, 93], ["cells", "CELL", 88, 93], ["capillary", "TISSUE", 124, 133], ["The microscope", "TEST", 0, 14], ["NA", "TEST", 60, 62], ["the imaging", "TEST", 73, 84], ["tip", "OBSERVATION_MODIFIER", 109, 112], ["glass capillary", "OBSERVATION", 118, 133], ["brightfield illumination", "OBSERVATION", 152, 176]]], ["The intermediate magnification changer (1.6 X) of the microscope was exploited to achieve higher magnification.", [["the microscope", "TEST", 50, 64], ["intermediate", "OBSERVATION_MODIFIER", 4, 16], ["magnification", "OBSERVATION_MODIFIER", 17, 30]]], ["Micrographs were recorded at a frame rate of 1, 000 fps with a Photron FASTCAM Mini UX100 high-speed digital camera.Materials and MethodsTapered capillaries of circular cross section were obtained from borosilicate glass tubes by employing a micropipette puller and subsequently fire polished.", [["capillaries", "ANATOMY", 145, 156], ["borosilicate", "CHEMICAL", 202, 214], ["capillaries", "TISSUE", 145, 156], ["Micrographs", "TEST", 0, 11], ["a frame rate", "TEST", 29, 41], ["a Photron FASTCAM", "TEST", 61, 78], ["circular cross section", "TREATMENT", 160, 182], ["borosilicate glass tubes", "TREATMENT", 202, 226], ["a micropipette puller", "TREATMENT", 240, 261], ["borosilicate glass tubes", "OBSERVATION", 202, 226]]], ["At each trial observation a glass capillary was filled with a diluted solution of cells and fixed to the microscope stage by means of a custom made, 3d-printed holder.", [["capillary", "ANATOMY", 34, 43], ["cells", "ANATOMY", 82, 87], ["capillary", "TISSUE", 34, 43], ["cells", "CELL", 82, 87], ["a glass capillary", "TREATMENT", 26, 43], ["a diluted solution of cells", "TREATMENT", 60, 87], ["3d-printed holder", "TREATMENT", 149, 166]]], ["The holder allowed for keeping the capillary in place and rotating it about its axis, so as to image a cell specimen from distinct viewpoints.", [["capillary", "ANATOMY", 35, 44], ["cell specimen", "ANATOMY", 103, 116], ["capillary", "TISSUE", 35, 44], ["cell", "CELL", 103, 107], ["The holder", "TREATMENT", 0, 10], ["the capillary in place", "TREATMENT", 31, 53], ["a cell specimen", "TEST", 101, 116]]], ["Cells were immobilized at the tip of the capillary by applying a gentle suction pressure via a syringe connected to the capillary by plastic tubing.A Model detailsThe Ax consists of a bundle of inextensible filaments of length L (MTs) lying on a cylindrical surface of radius \u03c1 a .", [["Cells", "ANATOMY", 0, 5], ["capillary", "ANATOMY", 41, 50], ["capillary", "ANATOMY", 120, 129], ["filaments", "ANATOMY", 207, 216], ["MTs", "ANATOMY", 230, 233], ["surface", "ANATOMY", 258, 265], ["Cells", "CELL", 0, 5], ["capillary", "TISSUE", 41, 50], ["capillary", "TISSUE", 120, 129], ["Ax", "PROTEIN", 167, 169], ["MTs", "PROTEIN", 230, 233], ["a gentle suction pressure", "TREATMENT", 63, 88], ["a syringe", "TREATMENT", 93, 102], ["a cylindrical surface of radius", "TREATMENT", 244, 275], ["tip", "OBSERVATION_MODIFIER", 30, 33], ["capillary", "ANATOMY", 41, 50], ["capillary", "ANATOMY", 120, 129], ["plastic tubing", "OBSERVATION", 133, 147], ["radius", "ANATOMY_MODIFIER", 269, 275]]], ["For simplicity, the model ignores the mechanical effects of radial spokes and the central pair.", [["radial spokes", "ANATOMY", 60, 73], ["radial spokes", "MULTI-TISSUE_STRUCTURE", 60, 73], ["the central pair", "TREATMENT", 78, 94], ["central pair", "OBSERVATION", 82, 94]]], ["The axonemal surface is parametrized by the generalized cylindrical coordinates z and \u03c6 via the mapA Model detailswith r a , d 1 , and d 2 defined as in the main text.", [["axonemal surface", "ANATOMY", 4, 20], ["axonemal surface", "CELLULAR_COMPONENT", 4, 20], ["\u03c6", "DNA", 86, 87], ["axonemal", "OBSERVATION_MODIFIER", 4, 12], ["surface", "OBSERVATION_MODIFIER", 13, 20], ["main text", "ANATOMY", 157, 166]]], ["Following [14] , we suppose that the axonemal constraints confine MTs on the Ax surface at a fixed angular distance \u2206\u03c6 = 2\u03c0/9 between each other.", [["axonemal", "ANATOMY", 37, 45], ["MTs", "ANATOMY", 66, 69], ["Ax surface", "ANATOMY", 77, 87], ["axonemal", "CELLULAR_COMPONENT", 37, 45], ["MTs", "CELLULAR_COMPONENT", 66, 69], ["Ax surface", "CELLULAR_COMPONENT", 77, 87], ["MTs", "PROTEIN", 66, 69]]], ["More formally, for j = 1, . . . , 9, we define the centerline r j of the j-th MT as r j (s) = C(s, \u03c6 j ), whereA Model detailsThe function Z(s, \u03c6) in (28) is defined (implicitly) via the equalityA Model detailsFrom the definitions above follows \u2202 s r j = 1, so MTs are indeed inextensible and s is their arc length.", [["MTs", "ANATOMY", 261, 264], ["MTs", "CELLULAR_COMPONENT", 261, 264], ["The function Z(s", "TEST", 126, 142]]], ["Moreover, the Taylor expansion of C at the first order in \u03c1 a gives the approximated formula (5), with \u03b3 1 and \u03b3 2 given by (6) .", [["Taylor", "OBSERVATION_MODIFIER", 14, 20], ["expansion", "OBSERVATION_MODIFIER", 21, 30]]], ["We associate to the j-th MT an orthonormal frame along r j given by the unit vectorsA Model detailswhere N = cos \u03c6 d 1 (Z) + sin \u03c6 d 2 (Z) is the (outer) unit normal to the cylindrical surface.", [["surface", "ANATOMY", 185, 192], ["surface", "CELLULAR_COMPONENT", 185, 192], ["MT", "DNA", 25, 27], ["orthonormal frame", "DNA", 31, 48], ["Z", "DNA", 136, 137], ["Z", "TEST", 120, 121], ["normal", "OBSERVATION", 159, 165], ["cylindrical", "ANATOMY_MODIFIER", 173, 184], ["surface", "ANATOMY_MODIFIER", 185, 192]]], ["The unit vectors (30) determine MTs' cross section orientations.", [["MTs", "ANATOMY", 32, 35], ["The unit vectors", "TREATMENT", 0, 16], ["MTs' cross section orientations", "TREATMENT", 32, 63]]], ["The unit vectors e j 1 (s) and e j 2 (s) lie on the cross-section centered at r j (s), while e j 3 (s) = \u2202 s r j (s) is orthogonal to it.", [["The unit vectors", "TREATMENT", 0, 16], ["the cross-section", "TREATMENT", 48, 65]]], ["The (passive) elastic energy of the Ax is given by the sum of the MTs' elastic energiesA Model detailsare the strains associated to the j-th MT, while B m and C m are the MTs' bending and twisting moduli (respectively).", [["MTs", "ANATOMY", 66, 69], ["MTs", "ANATOMY", 171, 174], ["MTs", "CELLULAR_COMPONENT", 66, 69], ["B m", "GENE_OR_GENE_PRODUCT", 151, 154], ["C m", "GENE_OR_GENE_PRODUCT", 159, 162], ["the strains", "PROBLEM", 106, 117], ["elastic energiesA", "OBSERVATION", 71, 88], ["twisting moduli", "OBSERVATION", 188, 203]]], ["At the leading order approximation in \u03c1 a we haveA Model detailsFrom (32) and (3) follows that W a pas , as defined in (31), can indeed be approximated by the right hand side of (2), with B a = 9B m and C a = 9C m .A Model detailsWe consider now MT sliding.", [["right hand", "ANATOMY", 159, 169], ["MT sliding", "TREATMENT", 246, 256], ["right", "ANATOMY_MODIFIER", 159, 164]]], ["We then define the sliding \u03c3 j (s) as the difference of the two arc lengths s and \u03a0 j (s).", [["the sliding \u03c3 j (s", "TREATMENT", 15, 33]]], ["Sketch of two MTs' centerlines during deformation.", [["MTs", "ANATOMY", 14, 17], ["two MTs", "OBSERVATION_MODIFIER", 10, 17]]], ["The sliding \u03c3 j (s) is defined as the difference between the arc lengths s and \u03a0 j (s).", [["The sliding \u03c3 j (s)", "TREATMENT", 0, 19], ["arc", "OBSERVATION_MODIFIER", 61, 64], ["lengths", "OBSERVATION_MODIFIER", 65, 72]]], ["The latter is the arc length corresponding to the projection of r j\u22121 (s) on the curve r j .", [["arc", "OBSERVATION_MODIFIER", 18, 21], ["length", "OBSERVATION_MODIFIER", 22, 28]]], ["We have positive sliding when dyneins push the j-th MT towards the distal end of the flagellum and the (j \u2212 1)-th MT toward the proximal end.A Model detailsThe active internal energy of the Ax is defined as minus the total mechanical work of the dyneinsA Model detailswhere F j (s) are the sliding forces on the j-th MT exerted by the dyneins on the (j \u2212 1)-th MT, and F j are the singular sliding forces (on the j-th MT exerted by the dyneins on the (j \u2212 1)-th MT) concentrated at the distal end of the Ax.", [["flagellum", "ANATOMY", 85, 94], ["flagellum", "CELLULAR_COMPONENT", 85, 94], ["F j", "GENE_OR_GENE_PRODUCT", 369, 372], ["proximal end", "DNA", 128, 140], ["dyneins", "PROTEIN", 436, 443], ["the (j \u2212 1)-th MT toward the proximal end", "TREATMENT", 99, 140], ["the sliding forces", "TREATMENT", 286, 304], ["the singular sliding forces", "TREATMENT", 377, 404], ["the j-th MT", "TREATMENT", 409, 420], ["the (j \u2212 1)-th MT", "TREATMENT", 447, 464], ["positive", "OBSERVATION_MODIFIER", 8, 16], ["sliding", "OBSERVATION_MODIFIER", 17, 24], ["distal", "ANATOMY_MODIFIER", 67, 73], ["flagellum", "ANATOMY_MODIFIER", 85, 94], ["proximal", "ANATOMY_MODIFIER", 128, 136], ["active", "OBSERVATION_MODIFIER", 160, 166], ["internal", "OBSERVATION_MODIFIER", 167, 175], ["sliding forces", "OBSERVATION", 390, 404], ["dyneins", "ANATOMY_MODIFIER", 436, 443], ["distal", "ANATOMY_MODIFIER", 486, 492]]], ["From (35) we have that W a act , as defined in (34), is approximated by the right hand side of (4), withA Model details(cos \u03c6 j \u2212 cos \u03c6 j\u22121 )F j (s) , H 2 (s) = \u03c1 a 9 j=1 (sin \u03c6 j \u2212 sin \u03c6 j\u22121 )F j (s) ,A Model detailsIn the remainder we give some details of the derivation of (11) from (7).", [["right hand", "ANATOMY", 76, 86], ["j\u22121", "TEST", 136, 139], ["j", "TEST", 178, 179], ["A Model details", "TEST", 202, 217], ["right", "ANATOMY_MODIFIER", 76, 81]]], ["Expanding (10) at the leading order in \u03c1 p givesA Model detailswith \u03b3 p\u22a5 (s) = \u2212 sin \u03c6 p \u03b3 1 (s) + cos \u03c6 p \u03b3 2 (s).", [["\u03b3 2", "PROTEIN", 107, 110], ["Model", "TEST", 50, 55], ["cos", "TEST", 99, 102]]], ["From (8) and (37), leading order calculations give V 1 , V 3 \u223c \u03c1 p , whereas V 2 \u2248 \u03b3 p\u22a5 / 1 + \u03b3 2 p\u22a5 .", [["p\u22a5", "PROTEIN", 98, 100], ["calculations", "TEST", 33, 45], ["V", "TEST", 77, 78], ["p\u22a5", "TEST", 85, 87]]], ["Linearizing in \u03b3 p\u22a5 we have V 2 \u2248 \u03b3 p , from which follows (11).B Dynamical equationsTo derive equations (17)- (19) it is convenient to introduce the quantities M 1 , M 2 , and M 3 defined via the following variational equalityB Dynamical equationswhere \u03b3 p\u22a5 (s) = \u2212 sin \u03c6 p \u03b3 1 (s) + cos \u03c6 p \u03b3 2 (s), as in the previous section.", [["cos", "TEST", 285, 288], ["the previous section", "TREATMENT", 308, 328], ["Dynamical equations", "OBSERVATION", 66, 85]]], ["We then write the variations \u03b4U i in terms of \u03b4\u03b8 i (defined in the main text) obtaining \uf8f1 \uf8f4 \uf8f2 \uf8f4 \uf8f3B Dynamical equationsCombining (38) In the calculations above we took variations with \u03b4r a (0) = \u03b4\u03b8(0) = 0, since we consider a flagellum with a clamped end at s = 0.", [["a flagellum", "TREATMENT", 223, 234]]], ["The principle of virtual work (16) gives us then the following force and torque balance equationsB Dynamical equationswith \u039b(L) = 0 , and M(L) = 0 .B Dynamical equationsEquations (17)- (19) are derived from (42) and (43), after some extra formal manipulations that we explain in the reminder.", [["torque balance", "TEST", 73, 87], ["Dynamical", "TEST", 99, 108], ["Dynamical equationsEquations", "TEST", 150, 178], ["some extra formal manipulations", "TREATMENT", 228, 259]]], ["We first introduce the local angular velocitiesB Dynamical equationswhich are related to the strains via the following compatibility equations \uf8f1 \uf8f2B Dynamical equationsEquations (45) follow from the identities \u2202 s \u2202 t d i = \u2202 t \u2202 s d i , with i = 1, 2, 3.", [["the strains", "PROBLEM", 89, 100], ["equations", "TEST", 133, 142], ["Dynamical equationsEquations", "TEST", 148, 176], ["the identities", "TEST", 194, 208]]], ["We then rewrite the external forces and torques (15) in compact form asB Dynamical equationsWe rewrite the force balance equation as \u2202 t r a = V [d 3 ] \u22121 \u2202 s \u039b and, after differentiating both sides with respect to s and then scalar multiplying by d 1 , d 2 , and d 3 , we haveB Dynamical equationsFrom (40), (45), and (48) we obtain (18) by first differentiating with respect to s both sides of (48), and then by linearizing the resulting equation.", [["the force balance equation", "TEST", 103, 129], ["scalar", "TEST", 226, 232], ["Dynamical equations", "TEST", 279, 298], ["external forces", "ANATOMY", 20, 35], ["Dynamical equations", "OBSERVATION", 73, 92], ["resulting equation", "OBSERVATION", 430, 448]]], ["Boundary conditions (19) follow from (43) andB Dynamical equationswhich follows from the fixed end condition r a (0, t) = 0.", [["(43) andB", "CHEMICAL", 37, 46]]], ["Given U 1 , U 2 , and U 3 the orthonormal frame d 1 , d 2 , and d 3 can be recovered by integrating the system of equationsB Dynamical equationswhich is derived from (3).", [["U 1", "GENE_OR_GENE_PRODUCT", 6, 9], ["U 2", "GENE_OR_GENE_PRODUCT", 12, 15], ["U 3", "GENE_OR_GENE_PRODUCT", 22, 25], ["U 1 , U 2", "DNA", 6, 15], ["U 3", "DNA", 22, 25], ["orthonormal frame d 1 , d 2", "DNA", 30, 57]]], ["The PFR centerline r p and the orthonormal frame g 1 , g 2 , and g 3 follow from (9) and (10).C NumericsWe define the nondimensional variables for arc length x, time y, strains u i , shear forces h i , and concentrated shear forces\u0125 i as follows x = s/L , y = t/T , u i = U i /L \u22121 , h i = H i /B a L \u22122 , and\u0125 i = H i /B a L \u22121 .C NumericsThe equilibrium equations (12) , with (21) and (23), are solved by seeking for a minimizer of the energy (26) in the adimensional formC NumericsIn the formula above u = (u 1 , u 2 ) is the adimensional bending vector and u * 2 = U * 2 /L \u22121 is the adimensional target bending.", [["C", "CHEMICAL", 94, 95], ["The PFR", "TEST", 0, 7], ["the orthonormal frame g", "TEST", 27, 50], ["g", "TEST", 55, 56], ["i", "TEST", 233, 234], ["B", "TEST", 320, 321], ["Numerics", "TEST", 332, 340], ["The equilibrium equations", "TEST", 340, 365], ["the adimensional bending vector", "TEST", 525, 556], ["the adimensional target bending", "PROBLEM", 584, 615], ["centerline", "OBSERVATION_MODIFIER", 8, 18], ["target bending", "OBSERVATION", 601, 615]]], ["We find the minimizer using the gradient descend method u n+1 = u n \u2212 \u03b1 \u03b4w \u03b4u22/24and \u03b1 is a conveniently chosen step size.", [["\u03b4u22", "PROTEIN", 75, 79], ["\u03b1", "PROTEIN", 86, 87], ["u n", "TEST", 64, 67], ["size", "OBSERVATION_MODIFIER", 118, 122]]], ["We initiate the algorithm with u 0 = (0, u * 2 ), and then we iterate (54) until u n+1 \u2212 u n falls below a pre-set tolerance parameter.22/24The dynamic equations (17) are recast, and then solved, in terms of the shear vector \u03b3 = (\u03b3 1 , \u03b3 2 ) where \u03b3 1 (x) = x 0 u 2 , and \u03b3 2 (x) = \u2212 x 0 u 1 .22/24(55)", [["The dynamic equations", "TEST", 140, 161], ["the shear vector", "TEST", 208, 224], ["u", "TEST", 262, 263], ["\u03b3", "TEST", 272, 273], ["\u2212", "TEST", 282, 283], ["u", "TEST", 288, 289]]]], "PMC7225211": [["To the Editor\u2014 Named SARS-CoV-2 by the International Committee on Taxonomy of Viruses, this novel coronavirus attacks the lower respiratory tract of patients infected with cryptogenic organizing pneumonia.1 The infectious disease it causes was named COVID-19 by the World Health Organization.", [["lower respiratory tract", "ANATOMY", 122, 145], ["coronavirus", "DISEASE", 98, 109], ["pneumonia", "DISEASE", 195, 204], ["infectious disease", "DISEASE", 211, 229], ["coronavirus", "ORGANISM", 98, 109], ["lower", "ORGANISM_SUBDIVISION", 122, 127], ["respiratory tract", "ORGANISM_SUBDIVISION", 128, 145], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Viruses", "TREATMENT", 78, 85], ["this novel coronavirus attacks the lower respiratory tract", "PROBLEM", 87, 145], ["cryptogenic organizing pneumonia", "PROBLEM", 172, 204], ["Viruses", "OBSERVATION", 78, 85], ["coronavirus", "OBSERVATION", 98, 109], ["lower", "ANATOMY_MODIFIER", 122, 127], ["respiratory tract", "ANATOMY", 128, 145], ["cryptogenic", "OBSERVATION_MODIFIER", 172, 183], ["organizing", "OBSERVATION_MODIFIER", 184, 194], ["pneumonia", "OBSERVATION", 195, 204], ["infectious", "OBSERVATION", 211, 221]]], ["Coronaviruses comprise a large family of viruses that cause illness ranging from the common cold to more severe diseases like pneumonia, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS).", [["illness", "DISEASE", 60, 67], ["pneumonia", "DISEASE", 126, 135], ["Middle East respiratory syndrome", "DISEASE", 137, 169], ["MERS", "DISEASE", 171, 175], ["acute respiratory syndrome", "DISEASE", 189, 215], ["SARS", "DISEASE", 217, 221], ["Middle East respiratory syndrome (MERS)", "SPECIES", 137, 176], ["Coronaviruses", "PROBLEM", 0, 13], ["illness", "PROBLEM", 60, 67], ["more severe diseases", "PROBLEM", 100, 120], ["pneumonia", "PROBLEM", 126, 135], ["Middle East respiratory syndrome", "PROBLEM", 137, 169], ["severe acute respiratory syndrome", "PROBLEM", 182, 215], ["large", "OBSERVATION_MODIFIER", 25, 30], ["viruses", "OBSERVATION", 41, 48], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["diseases", "OBSERVATION", 112, 120], ["pneumonia", "OBSERVATION", 126, 135], ["Middle", "ANATOMY_MODIFIER", 137, 143], ["respiratory syndrome", "OBSERVATION", 149, 169], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["respiratory syndrome", "OBSERVATION", 195, 215]]], ["Most people are vulnerable to SARS-CoV-2, and this novel coronavirus can affect people with low or normal immunity.2 People with low immunity, such as the elderly, pregnant women, and patients with chronic diseases, are prone to severe acute symptoms after contracting COVID-19.", [["SARS", "DISEASE", 30, 34], ["coronavirus", "DISEASE", 57, 68], ["chronic diseases", "DISEASE", 198, 214], ["COVID-19", "CHEMICAL", 269, 277], ["people", "ORGANISM", 5, 11], ["SARS-CoV-2", "ORGANISM", 30, 40], ["coronavirus", "ORGANISM", 57, 68], ["people", "ORGANISM", 80, 86], ["People", "ORGANISM", 117, 123], ["women", "ORGANISM", 173, 178], ["patients", "ORGANISM", 184, 192], ["people", "SPECIES", 5, 11], ["coronavirus", "SPECIES", 57, 68], ["people", "SPECIES", 80, 86], ["People", "SPECIES", 117, 123], ["women", "SPECIES", 173, 178], ["patients", "SPECIES", 184, 192], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["this novel coronavirus", "PROBLEM", 46, 68], ["chronic diseases", "PROBLEM", 198, 214], ["severe acute symptoms", "PROBLEM", 229, 250], ["contracting COVID", "TEST", 257, 274], ["low immunity", "OBSERVATION_MODIFIER", 129, 141], ["chronic", "OBSERVATION_MODIFIER", 198, 205], ["diseases", "OBSERVATION", 206, 214], ["severe", "OBSERVATION_MODIFIER", 229, 235], ["acute", "OBSERVATION_MODIFIER", 236, 241]]], ["SARS-CoV-2 is mainly transmitted via droplets, touching (including self-infection caused by contaminated hands), and short-distance transmission of respiratory aerosols of different sizes.", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 72, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["hands", "ORGANISM_SUBDIVISION", 105, 110], ["self-infection", "PROBLEM", 67, 81], ["respiratory aerosols", "OBSERVATION", 148, 168], ["different", "OBSERVATION_MODIFIER", 172, 181], ["sizes", "OBSERVATION_MODIFIER", 182, 187]]], ["Currently, SARS-CoV-2 is mainly spread via droplets.", [["SARS", "DISEASE", 11, 15], ["SARS-CoV-2", "ORGANISM", 11, 21], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "TEST", 11, 15], ["CoV", "TEST", 16, 19]]], ["At first, this virus was transferred from bats to humans; it falls into a specific category of bat viruses.", [["humans", "ORGANISM", 50, 56], ["bat viruses", "ORGANISM", 95, 106], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["this virus", "PROBLEM", 10, 20], ["bat", "ANATOMY", 95, 98], ["viruses", "OBSERVATION", 99, 106]]], ["Different coronaviruses persist on surfaces for various lengths of time.", [["coronaviruses", "ORGANISM", 10, 23], ["Different coronaviruses", "PROBLEM", 0, 23], ["coronaviruses", "OBSERVATION", 10, 23], ["surfaces", "OBSERVATION_MODIFIER", 35, 43]]]], "PMC7150853": [], "83263b1c3aa6f156aef5edc952a10b1d8e8546e0": [["IntroductionTo date different platforms are used for production of recombinant proteins ranging from bacteria, yeast and fungi to insect-, plant-, and mammalian cells (Andersson et al., 2001; Bao and Fukuhara, 2001; Boedeker, 2001; Cai, 2001; Chen et al., 2001; Friehs and Reardon, 1993; James and Lee, 2001; J\u00f8nson and Johnsen, 2001; Konishi et al., 2002; Lazaris et al., 2002; Levy et al., 2001; Mattes, 2001; Massaer et al., 2001; McQuillan et al., 2001; Menassa et al., 2004; Sarkar and Sen, 1998) .", [["cells", "ANATOMY", 161, 166], ["mammalian cells", "CELL", 151, 166], ["recombinant proteins", "PROTEIN", 67, 87], ["mammalian cells", "CELL_TYPE", 151, 166], ["yeast", "SPECIES", 111, 116], ["yeast", "SPECIES", 111, 116], ["Andersson et al., 2001; Bao and Fukuhara, 2001; Boedeker, 2001; Cai, 2001; Chen et al., 2001; Friehs and Reardon, 1993; James and Lee, 2001; J\u00f8nson", "SPECIES", 168, 315], ["recombinant proteins", "PROBLEM", 67, 87], ["bacteria", "PROBLEM", 101, 109], ["yeast", "PROBLEM", 111, 116], ["fungi", "PROBLEM", 121, 126]]], ["Given the importance of human type posttranslational and peri-translational processing for protein half-life, biological activity, secretion, and protein yields (Berg et al., 1993; Breitbach and Jarvis, 2001; Fussenegger et al., 1999; Jenkins et al., 1998; Kawashima et al., 1993; Lawrence et al., 2001; Lee et al., 1989; Marchal et al., 2001; Mosser et al., 1994; Seo et al., 2001) , either human derived cell lines or non-human systems adapted to express human enzymes involved in post-transcriptional modification of proteins, are preferred (C\u00f4 t\u00e9 et al., 1998; Lawrence et al., 2001; Marchal et al., 2001; Seo et al., 2001) .", [["cell lines", "ANATOMY", 406, 416], ["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 392, 397], ["cell lines", "CELL", 406, 416], ["non-human", "ORGANISM", 420, 429], ["human", "ORGANISM", 457, 462], ["human derived cell lines", "CELL_LINE", 392, 416], ["human enzymes", "PROTEIN", 457, 470], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 392, 397], ["human", "SPECIES", 457, 462], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 392, 397], ["human", "SPECIES", 457, 462], ["human type posttranslational", "TREATMENT", 24, 52], ["peri-translational processing", "TREATMENT", 57, 86], ["protein half-life", "TREATMENT", 91, 108], ["non-human systems", "TREATMENT", 420, 437], ["human enzymes", "TEST", 457, 470], ["cell lines", "OBSERVATION", 406, 416]]], ["However, mammalian cell-based protein production is time-consuming since it requires stable cell line generation, sub-cloning, screening, and cell clone-selection.", [["cell", "ANATOMY", 19, 23], ["cell line", "ANATOMY", 92, 101], ["cell", "ANATOMY", 142, 146], ["mammalian cell", "CELL", 9, 23], ["cell line", "CELL", 92, 101], ["cell clone", "CELL", 142, 152], ["mammalian cell", "PROBLEM", 9, 23], ["stable cell line generation", "TREATMENT", 85, 112], ["screening", "TEST", 127, 136], ["cell clone-selection", "TREATMENT", 142, 162], ["mammalian cell", "OBSERVATION", 9, 23], ["protein production", "OBSERVATION", 30, 48], ["stable cell line", "OBSERVATION", 85, 101]]], ["Moreover, this process is costly due to the required safety testing of both candidate products as well as cell banks.", [["cell", "ANATOMY", 106, 110], ["cell", "CELL", 106, 110], ["safety testing", "TEST", 53, 67], ["both candidate products", "TREATMENT", 71, 94]]], ["As such this process does not allow for the rapid production of high quality recombinant protein batches required for candidate protein selection or rapid evaluation of a candidate protein in a clinical setting.", [["high quality recombinant protein batches", "TREATMENT", 64, 104], ["protein selection", "TEST", 128, 145], ["rapid evaluation", "TEST", 149, 165]]], ["Because of these limitations, research attention focuses on novel systems and technology for transient production of high quality protein.", [["high quality protein", "PROTEIN", 117, 137], ["high quality protein", "PROBLEM", 117, 137]]], ["Although predominantly large-scale DNA transfection is being investigated (Baldi et al., 2007; Derouazi et al., 2004; Tait et al., 2004) adenoviral vectors are being considered as well (Andersen and Krummen, 2002; C\u00f4 t\u00e9 et al., 1998; Garnier et al., 1994; Gossen et al., 1994; Massie et al., 1995; Sarkar et al., 2001; Tom et al., 1995; Wu et al., 1996) .", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["adenoviral", "ORGANISM", 137, 147], ["predominantly large-scale DNA transfection", "PROBLEM", 9, 51], ["adenoviral vectors", "TREATMENT", 137, 155], ["predominantly", "OBSERVATION_MODIFIER", 9, 22], ["large", "OBSERVATION_MODIFIER", 23, 28], ["-scale", "OBSERVATION_MODIFIER", 28, 34], ["DNA transfection", "OBSERVATION", 35, 51]]], ["Attractive features of the adenoviral vector approach for transient protein production include (i) the ability of adenovirus to actively bind to cells growing in suspension, (ii) the high efficiency of vector internalization, and (iii) the high efficiency of nuclear transport of the adenovirus genome coding for a gene of interest.", [["cells", "ANATOMY", 145, 150], ["nuclear", "ANATOMY", 259, 266], ["adenoviral", "ORGANISM", 27, 37], ["adenovirus", "ORGANISM", 114, 124], ["cells", "CELL", 145, 150], ["nuclear", "CELLULAR_COMPONENT", 259, 266], ["adenovirus", "ORGANISM", 284, 294], ["adenovirus genome", "DNA", 284, 301], ["the adenoviral vector approach", "TREATMENT", 23, 53], ["transient protein production", "PROBLEM", 58, 86], ["adenovirus", "PROBLEM", 114, 124], ["the high efficiency of vector internalization", "PROBLEM", 179, 224], ["the adenovirus genome", "TREATMENT", 280, 301], ["adenoviral vector", "OBSERVATION", 27, 44], ["high efficiency", "OBSERVATION_MODIFIER", 183, 198], ["high efficiency", "OBSERVATION_MODIFIER", 240, 255]]], ["Because of these features it can be envisioned that the use of adenoviral vectors results in higher protein yields derived from mammalian cells cultured in suspension as compared to current DNA transfection protocols for which processes at scale like cell uptake and nuclear localization, present major technical hurdles.IntroductionHowever, the use of an adenoviral vector based transient protein production system raises several safety issues, which need to be addressed thoroughly.", [["cells", "ANATOMY", 138, 143], ["cell", "ANATOMY", 251, 255], ["nuclear", "ANATOMY", 267, 274], ["adenoviral", "ORGANISM", 63, 73], ["mammalian cells", "CELL", 128, 143], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["cell", "CELL", 251, 255], ["nuclear", "CELLULAR_COMPONENT", 267, 274], ["adenoviral", "ORGANISM", 356, 366], ["mammalian cells", "CELL_TYPE", 128, 143], ["adenoviral vectors", "TREATMENT", 63, 81], ["higher protein yields", "PROBLEM", 93, 114], ["mammalian cells", "TREATMENT", 128, 143], ["current DNA transfection protocols", "TREATMENT", 182, 216], ["cell uptake", "TEST", 251, 262], ["nuclear localization", "TEST", 267, 287], ["an adenoviral vector", "TREATMENT", 353, 373], ["transient protein production system", "PROBLEM", 380, 415], ["mammalian cells", "OBSERVATION", 128, 143], ["cell uptake", "OBSERVATION", 251, 262]]], ["Most importantly, absence of replication competent adenovirus (RCA) as well as replication deficient (DE1) virus needs to be demonstrated.", [["adenovirus", "ORGANISM", 51, 61], ["RCA", "GENE_OR_GENE_PRODUCT", 63, 66], ["DE1) virus", "ORGANISM", 102, 112], ["replication competent adenovirus (RCA)", "PROBLEM", 29, 67], ["replication deficient (DE1) virus", "PROBLEM", 79, 112]]], ["Besides these critical parameters, production of proteins derived from the viral backbone is undesired as it may interfere with cell proliferation and viability and could impact on protein purification protocols (Ladisch et al., 1979) .", [["cell", "ANATOMY", 128, 132], ["cell", "CELL", 128, 132], ["production of proteins", "PROBLEM", 35, 57], ["the viral backbone", "PROBLEM", 71, 89], ["cell proliferation", "PROBLEM", 128, 146], ["protein purification protocols", "TREATMENT", 181, 211], ["viral backbone", "OBSERVATION", 75, 89], ["cell proliferation", "OBSERVATION", 128, 146]]], ["Finally, the transient production of protein should be scalable and ideally be performed in absence of any serum components to circumvent transmissible spongiform encephalopathies (TSE) and further facilitate protein purification.IntroductionHere we show that DE1/DE2A Ad5 vectors, produced on PER.E2A cells, are unable to replicate on PER.C6 cells and do not express adenoviral capsid proteins in human indicator cells.", [["serum", "ANATOMY", 107, 112], ["cells", "ANATOMY", 302, 307], ["C6 cells", "ANATOMY", 340, 348], ["cells", "ANATOMY", 414, 419], ["transmissible spongiform encephalopathies", "DISEASE", 138, 179], ["TSE", "DISEASE", 181, 184], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["DE1", "GENE_OR_GENE_PRODUCT", 260, 263], ["DE2A", "GENE_OR_GENE_PRODUCT", 264, 268], ["E2A", "GENE_OR_GENE_PRODUCT", 298, 301], ["C6 cells", "CELL", 340, 348], ["adenoviral", "ORGANISM", 368, 378], ["human", "ORGANISM", 398, 403], ["cells", "CELL", 414, 419], ["DE1/DE2A Ad5 vectors", "DNA", 260, 280], ["PER", "PROTEIN", 294, 297], ["E2A cells", "CELL_LINE", 298, 307], ["PER", "PROTEIN", 336, 339], ["C6 cells", "CELL_LINE", 340, 348], ["adenoviral capsid proteins", "PROTEIN", 368, 394], ["human indicator cells", "CELL_TYPE", 398, 419], ["human", "SPECIES", 398, 403], ["Ad5", "SPECIES", 269, 272], ["human", "SPECIES", 398, 403], ["the transient production of protein", "PROBLEM", 9, 44], ["any serum components", "PROBLEM", 103, 123], ["transmissible spongiform encephalopathies", "PROBLEM", 138, 179], ["protein purification", "TREATMENT", 209, 229], ["DE1/DE2A Ad5 vectors", "TREATMENT", 260, 280], ["C6 cells", "PROBLEM", 340, 348], ["adenoviral capsid proteins in human indicator cells", "PROBLEM", 368, 419], ["human indicator cells", "OBSERVATION", 398, 419]]], ["We further demonstrate that exposure of PER.C6 cells to a DE1/DE2A vector carrying the gene coding for SARS-CoV spike protein, the cellular SARS receptor (ACE2) or a SARS-AB results in high yield protein (up to 600 mg/L).", [["PER.C6 cells", "ANATOMY", 40, 52], ["cellular", "ANATOMY", 131, 139], ["DE1", "CHEMICAL", 58, 61], ["SARS", "DISEASE", 166, 170], ["PER.C6 cells", "CELL", 40, 52], ["DE1", "GENE_OR_GENE_PRODUCT", 58, 61], ["DE2A", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["cellular SARS receptor", "GENE_OR_GENE_PRODUCT", 131, 153], ["ACE2", "GENE_OR_GENE_PRODUCT", 155, 159], ["PER.C6 cells", "CELL_LINE", 40, 52], ["DE1/DE2A vector", "DNA", 58, 73], ["SARS-CoV spike protein", "PROTEIN", 103, 125], ["cellular SARS receptor", "PROTEIN", 131, 153], ["ACE2", "PROTEIN", 155, 159], ["SARS-CoV", "SPECIES", 103, 111], ["a DE1/DE2A vector", "TREATMENT", 56, 73], ["SARS", "PROBLEM", 103, 107], ["CoV spike protein", "PROBLEM", 108, 125], ["the cellular SARS receptor", "PROBLEM", 127, 153], ["a SARS", "TEST", 164, 170], ["AB results", "TEST", 171, 181]]], ["Finally, by performing FACS and ELISA analyses we demonstrate that proteins produced using this transient production platform are biologically active.", [["ELISA analyses", "TEST", 32, 46], ["this transient production platform", "TREATMENT", 91, 125]]], ["We thus present a new platform that ensures rapid and high yield production of different classes of proteins.", [["rapid", "OBSERVATION_MODIFIER", 44, 49]]], ["Production can be performed in a virus-and serum-free environment, is suitable for scaling to large bioreactors, and thus provides a promising alternative for established protein production systems.Materials and MethodsGeneration of PER.E2A Cell Line and Cell CultureMaterials and MethodsThe complete ts125E2A-coding region was PCR-amplified from DNA isolated from the temperature sensitive adenovirus mutant H5ts125 (Ensinger et al., 1972; Vliet and Sussenbach, 1975; with primers DBPpcr1 and DBPpcr2 using the Expand TM Long Template PCR system according to the standard protocol of the supplier (Boeringer, Mannheim, Germany).", [["serum", "ANATOMY", 43, 48], ["Cell", "ANATOMY", 241, 245], ["Cell", "ANATOMY", 255, 259], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["Cell", "CELL", 255, 259], ["DNA", "CELLULAR_COMPONENT", 347, 350], ["adenovirus", "ORGANISM", 391, 401], ["E2A", "PROTEIN", 237, 240], ["ts125E2A-coding region", "DNA", 301, 323], ["primers DBPpcr1", "DNA", 474, 489], ["a virus", "TEST", 31, 38], ["large bioreactors", "TREATMENT", 94, 111], ["established protein production systems", "TREATMENT", 159, 197], ["E2A Cell Line", "TREATMENT", 237, 250], ["Cell CultureMaterials", "TEST", 255, 276], ["Methods", "TREATMENT", 281, 288], ["The complete ts", "TEST", 288, 303], ["PCR", "TEST", 328, 331], ["DNA", "PROBLEM", 347, 350], ["the temperature", "TEST", 365, 380], ["Sussenbach", "TEST", 451, 461], ["primers DBPpcr1", "TREATMENT", 474, 489], ["DBPpcr2", "TREATMENT", 494, 501], ["the Expand TM Long Template PCR system", "TREATMENT", 508, 546], ["large", "OBSERVATION_MODIFIER", 94, 99], ["bioreactors", "OBSERVATION", 100, 111], ["Cell Line", "OBSERVATION", 241, 250], ["Cell CultureMaterials", "OBSERVATION", 255, 276]]], ["The primer DBPpcr1: CGG GAT CCG CCA CC A TGG CCA GTC GGG AAG AGG AG (5 0 -3 0 ) contained a unique BamHI restriction site (underlined) 5 0 of the Kozak sequence (italic) and start codon of the E2A coding sequence (bold).", [["BamHI", "GENE_OR_GENE_PRODUCT", 99, 104], ["E2A", "GENE_OR_GENE_PRODUCT", 193, 196], ["primer DBPpcr1", "DNA", 4, 18], ["5 0 -3 0", "DNA", 69, 77], ["BamHI restriction site", "DNA", 99, 121], ["Kozak sequence", "DNA", 146, 160], ["start codon", "DNA", 174, 185], ["E2A coding sequence", "DNA", 193, 212], ["The primer DBPpcr1", "TEST", 0, 18], ["CGG", "TEST", 20, 23], ["CCG", "TEST", 28, 31], ["CCA", "TEST", 32, 35], ["CC", "TEST", 36, 38], ["A", "TEST", 39, 40], ["TGG", "TEST", 41, 44], ["CCA", "TEST", 45, 48], ["GTC", "TEST", 49, 52], ["GGG AAG AGG AG", "TEST", 53, 67], ["a unique BamHI restriction site", "TREATMENT", 90, 121], ["the Kozak sequence", "TEST", 142, 160]]], ["The primer DBPpcr2: CGG AAT TCT TAA AAA TCA AAG GGG TTC TGC CGC (5 0 -3 0 ) contained a unique EcoRI restriction site (underlined) 3 0 and the stop codon of the E2A coding sequence (bold).", [["EcoRI", "GENE_OR_GENE_PRODUCT", 95, 100], ["E2A", "GENE_OR_GENE_PRODUCT", 161, 164], ["primer DBPpcr2", "DNA", 4, 18], ["EcoRI restriction site", "DNA", 95, 117], ["underlined) 3 0", "DNA", 119, 134], ["E2A coding sequence", "DNA", 161, 180], ["The primer DBPpcr2", "TEST", 0, 18], ["CGG", "TEST", 20, 23], ["TCT", "TEST", 28, 31], ["TAA", "TEST", 32, 35], ["AAA", "TEST", 36, 39], ["TCA", "TEST", 40, 43], ["AAG", "TEST", 44, 47], ["GGG", "TEST", 48, 51], ["TTC", "TEST", 52, 55], ["CGC", "TEST", 60, 63], ["a unique EcoRI restriction site", "TREATMENT", 86, 117]]], ["The PCR fragment was digested with BamHI/EcoRI and cloned into plasmid pcDNA3 (Invitrogen, Breda, The Netherlands) and sequenced giving rise to pcDNA3tsE2A.", [["BamHI", "GENE_OR_GENE_PRODUCT", 35, 40], ["EcoRI", "GENE_OR_GENE_PRODUCT", 41, 46], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 71, 77], ["pcDNA3tsE2A", "GENE_OR_GENE_PRODUCT", 144, 155], ["PCR fragment", "DNA", 4, 16], ["BamHI", "DNA", 35, 40], ["EcoRI", "DNA", 41, 46], ["plasmid pcDNA3", "DNA", 63, 77], ["pcDNA3tsE2A", "DNA", 144, 155], ["The PCR fragment", "PROBLEM", 0, 16], ["BamHI/EcoRI", "TREATMENT", 35, 46], ["plasmid pcDNA3", "TREATMENT", 63, 77], ["fragment", "OBSERVATION_MODIFIER", 8, 16]]], ["For transfer of the E2A region, PER.C6 cells were transfected with 5 mg pcDNA3 plasmid containing no insert, wild type E2A, or ts125E2A using the lipofectAMINE Plus reagent kit according to the protocol supplied (Invitrogen).", [["C6 cells", "ANATOMY", 36, 44], ["E2A", "GENE_OR_GENE_PRODUCT", 20, 23], ["C6 cells", "CELL", 36, 44], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 72, 78], ["E2A", "GENE_OR_GENE_PRODUCT", 119, 122], ["E2A region", "DNA", 20, 30], ["PER", "PROTEIN", 32, 35], ["C6 cells", "CELL_LINE", 36, 44], ["pcDNA3 plasmid", "DNA", 72, 86], ["wild type E2A", "PROTEIN", 109, 122], ["ts125E2A", "DNA", 127, 135], ["C6 cells", "PROBLEM", 36, 44], ["5 mg pcDNA3 plasmid", "TREATMENT", 67, 86], ["AMINE Plus reagent kit", "TREATMENT", 154, 176], ["the protocol", "TREATMENT", 190, 202]]], ["Seventy-two hours after transfection, cells were seeded in DMEM/10% FBS/10 mM MgCl 2 , supplemented with 0.25 mg/mL G418 to select for transfectants.", [["cells", "ANATOMY", 38, 43], ["transfectants", "ANATOMY", 135, 148], ["MgCl 2", "CHEMICAL", 78, 84], ["G418", "CHEMICAL", 116, 120], ["MgCl 2", "CHEMICAL", 78, 84], ["G418", "CHEMICAL", 116, 120], ["cells", "CELL", 38, 43], ["FBS", "ORGANISM_SUBSTANCE", 68, 71], ["MgCl 2", "SIMPLE_CHEMICAL", 78, 84], ["transfectants", "CELL", 135, 148], ["transfectants", "PROBLEM", 135, 148]]], ["Stable transfected clones were routinely maintained in the same medium, however the G418 selection was withdrawn from the cultures at the moment DE1/DE2 viruses were produced.", [["clones", "ANATOMY", 19, 25], ["cultures", "ANATOMY", 122, 130], ["G418", "CHEMICAL", 84, 88], ["clones", "CELL", 19, 25], ["DE2 viruses", "ORGANISM", 149, 160], ["Stable transfected clones", "PROBLEM", 0, 25], ["the G418 selection", "TREATMENT", 80, 98], ["the cultures", "TEST", 118, 130], ["transfected clones", "OBSERVATION", 7, 25]]], ["The E2A expression levels in different cell clones were determined by Western blotting using monoclonal antibody B6 (Reich et al., 1983) and horseradish-peroxidase-conjugated-goat anti mouse antibody (BioRad, Hercules, CA) as first and second antibody, respectively.", [["cell clones", "ANATOMY", 39, 50], ["E2A", "GENE_OR_GENE_PRODUCT", 4, 7], ["cell clones", "CELL", 39, 50], ["horseradish-peroxidase", "SIMPLE_CHEMICAL", 141, 163], ["mouse", "ORGANISM", 185, 190], ["CA", "GENE_OR_GENE_PRODUCT", 219, 221], ["E2A", "PROTEIN", 4, 7], ["cell clones", "CELL_LINE", 39, 50], ["monoclonal antibody B6", "PROTEIN", 93, 115], ["horseradish-peroxidase-conjugated-goat anti mouse antibody", "PROTEIN", 141, 199], ["BioRad, Hercules, CA) as first and second antibody", "PROTEIN", 201, 251], ["horseradish", "SPECIES", 141, 152], ["goat", "SPECIES", 175, 179], ["mouse", "SPECIES", 185, 190], ["mouse", "SPECIES", 185, 190], ["The E2A expression levels", "TEST", 0, 25], ["different cell clones", "TEST", 29, 50], ["Western blotting", "TEST", 70, 86], ["monoclonal antibody", "TEST", 93, 112], ["horseradish", "TEST", 141, 152], ["peroxidase", "TEST", 153, 163], ["goat anti mouse antibody", "TEST", 175, 199], ["BioRad", "TEST", 201, 207], ["Hercules", "TEST", 209, 217], ["cell clones", "OBSERVATION", 39, 50]]], ["Western blotting procedure and incubations were performed according to the protocol provided by Millipore (Billerica, MA).", [["Western blotting procedure", "TREATMENT", 0, 26], ["incubations", "TREATMENT", 31, 42]]], ["The complexes were visualized with the ECL detection system according to the manufacturer's protocol (Amersham, Piscataway, NJ).", [["the manufacturer's protocol", "TREATMENT", 73, 100]]], ["In addition, the selected cell lines were tested for their ability to complement the deleted E2A gene function of adenovirus Ad5.d1802 (Rice and Klessig, 1985) by demonstrating the appearance of cytopathic effect (CPE) upon infection at 328C.", [["cell lines", "ANATOMY", 26, 36], ["infection", "DISEASE", 224, 233], ["cell lines", "CELL", 26, 36], ["E2A", "GENE_OR_GENE_PRODUCT", 93, 96], ["adenovirus", "ORGANISM", 114, 124], ["Ad5.d1802", "ORGANISM", 125, 134], ["cell lines", "CELL_LINE", 26, 36], ["E2A gene", "DNA", 93, 101], ["adenovirus Ad5.d1802 (Rice and Klessig, 1985)", "SPECIES", 114, 159], ["the selected cell lines", "TREATMENT", 13, 36], ["cytopathic effect (CPE", "PROBLEM", 195, 217], ["infection", "PROBLEM", 224, 233], ["cell lines", "OBSERVATION", 26, 36], ["cytopathic effect", "OBSERVATION", 195, 212], ["infection", "OBSERVATION", 224, 233]]], ["To obtain cells growing in suspension, one selected PER.E2A cell line was cultured at 398C and 10% CO 2 in a 175 cm 2 tissue culture flask in DMEM, supplemented with 10% FBS and 10 mM MgCl 2 .", [["cells", "ANATOMY", 10, 15], ["cell line", "ANATOMY", 60, 69], ["CO 2", "CHEMICAL", 99, 103], ["MgCl 2", "CHEMICAL", 184, 190], ["cells", "CELL", 10, 15], ["E2A cell line", "CELL", 56, 69], ["FBS", "ORGANISM_SUBSTANCE", 170, 173], ["E2A cell line", "CELL_LINE", 56, 69], ["cells", "TEST", 10, 15], ["E2A cell line", "TREATMENT", 56, 69], ["10% FBS", "TREATMENT", 166, 173], ["suspension", "OBSERVATION_MODIFIER", 27, 37], ["cell line", "OBSERVATION", 60, 69]]], ["At 70-80% confluency cells were washed with PBS (NPBI) and the medium was replaced by 25 mL serum-free suspension medium SFM consisting of Ex-cell TM 525 (JRH) supplemented with 1\u00c2 L-glutamine (Gibco BRL).", [["cells", "ANATOMY", 21, 26], ["serum", "ANATOMY", 92, 97], ["cell", "ANATOMY", 142, 146], ["Ex-cell TM 525", "CHEMICAL", 139, 153], ["JRH", "CHEMICAL", 155, 158], ["L-glutamine", "CHEMICAL", 181, 192], ["BRL", "CHEMICAL", 200, 203], ["L-glutamine", "CHEMICAL", 181, 192], ["cells", "CELL", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["Ex-cell", "CELL", 139, 146], ["L-glutamine", "SIMPLE_CHEMICAL", 181, 192], ["PBS (NPBI", "TREATMENT", 44, 53], ["serum-free suspension medium SFM", "TREATMENT", 92, 124], ["Ex-cell TM", "TEST", 139, 149], ["JRH", "TEST", 155, 158], ["1\u00c2 L-glutamine", "TREATMENT", 178, 192]]], ["Two days later, cells were detached from the flask by flicking and the cells were centrifuged at 1,000 rpm for 5 min.", [["cells", "ANATOMY", 16, 21], ["cells", "ANATOMY", 71, 76], ["cells", "CELL", 16, 21], ["cells", "CELL", 71, 76]]], ["The cell pellet was re-suspended in 5 mL SFM and 0.5 mL cell suspension was transferred to an 80 cm 2 tissue culture flask, together with 12 mL fresh SFM.", [["cell pellet", "ANATOMY", 4, 15], ["cell", "ANATOMY", 56, 60], ["cell", "CELL", 4, 8], ["cell", "CELL", 56, 60], ["The cell pellet", "TREATMENT", 0, 15], ["0.5 mL cell suspension", "TREATMENT", 49, 71], ["tissue culture flask", "TEST", 102, 122], ["cell pellet", "OBSERVATION", 4, 15]]], ["After 2 days, cells were harvested.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["harvested", "OBSERVATION", 25, 34]]], ["Next cells were seeded in a 125 mL tissue culture Erlenmeyer (Corning, Corning, NY) at a seeding density of 3 \u00c2 10 5 cells/mL in a total volume of 20 mL SFM.", [["cells", "ANATOMY", 5, 10], ["cells", "ANATOMY", 117, 122], ["cells", "CELL", 5, 10], ["cells", "CELL", 117, 122], ["Next cells", "PROBLEM", 0, 10], ["seeding density", "OBSERVATION_MODIFIER", 89, 104]]], ["Cells were further cultured at 125 rpm on an orbital shaker at 398C, 10% CO 2 .", [["Cells", "ANATOMY", 0, 5], ["CO", "CHEMICAL", 73, 75], ["Cells", "CELL", 0, 5], ["orbital", "ANATOMY", 45, 52]]], ["Cells were counted at days 1-6 in a Burker cell counter.", [["Cells", "ANATOMY", 0, 5], ["Burker cell", "ANATOMY", 36, 47], ["Cells", "CELL", 0, 5], ["Burker cell", "CELL", 36, 47], ["Cells", "TEST", 0, 5]]], ["Human PER.C6 1 cells are routinely maintained in a humidified 378C environment in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10 mM MgCl 2 , either in the presence or absence of fetal bovine serum (FBS).", [["PER.C6 1 cells", "ANATOMY", 6, 20], ["fetal bovine serum", "ANATOMY", 192, 210], ["FBS", "ANATOMY", 212, 215], ["MgCl 2", "CHEMICAL", 146, 152], ["MgCl 2", "CHEMICAL", 146, 152], ["Human", "ORGANISM", 0, 5], ["PER.C6 1 cells", "CELL", 6, 20], ["bovine", "ORGANISM", 198, 204], ["serum", "ORGANISM_SUBSTANCE", 205, 210], ["FBS", "ORGANISM_SUBSTANCE", 212, 215], ["Human PER.C6 1 cells", "CELL_LINE", 0, 20], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 198, 204], ["Human PER.C6 1", "SPECIES", 0, 14], ["bovine", "SPECIES", 198, 204], ["a humidified 378C environment", "TREATMENT", 49, 78], ["Dulbecco's Modified Eagle medium (DMEM)", "TREATMENT", 82, 121], ["10 mM MgCl 2", "TREATMENT", 140, 152], ["fetal bovine serum", "TEST", 192, 210]]], ["Human A549-cells were obtained from the American Type Culture Collection (ATCC, Mannasas, VA) and were maintained in DMEM/10% FBS.", [["A549-cells", "ANATOMY", 6, 16], ["FBS", "ANATOMY", 126, 129], ["Human", "ORGANISM", 0, 5], ["A549-cells", "CELL", 6, 16], ["FBS", "ORGANISM_SUBSTANCE", 126, 129], ["Human A549-cells", "CELL_LINE", 0, 16], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["ATCC", "SPECIES", 74, 78]]], ["For infection, PER.C6 cells were seeded in roller bottles (100 mL volume) at 0.3 \u00c2 10 6 cells/mL in AEM medium (Invitrogen) supplemented with L-glutamine.", [["C6 cells", "ANATOMY", 19, 27], ["cells", "ANATOMY", 88, 93], ["infection", "DISEASE", 4, 13], ["L-glutamine", "CHEMICAL", 142, 153], ["L-glutamine", "CHEMICAL", 142, 153], ["C6 cells", "CELL", 19, 27], ["L-glutamine", "SIMPLE_CHEMICAL", 142, 153], ["C6 cells", "CELL_LINE", 19, 27], ["infection", "PROBLEM", 4, 13], ["C6 cells", "PROBLEM", 19, 27], ["AEM medium (Invitrogen)", "TREATMENT", 100, 123], ["L-glutamine", "TREATMENT", 142, 153], ["infection", "OBSERVATION", 4, 13]]], ["Cells were cultured in roller bottles (2 rpm) in a 378C incubator at 10% CO 2 .", [["Cells", "ANATOMY", 0, 5], ["CO", "CHEMICAL", 73, 75], ["Cells", "CELL", 0, 5]]], ["When cell concentrations reached 2 \u00c2 10 6 cells/ mL, cultures were centrifuged for 10 min at 500g and pellets were re-suspended in 100 mL fresh AEM/L-glutamine at a final cell concentration of 2.5 \u00c2 10 6 cells/mL.", [["cell", "ANATOMY", 5, 9], ["cells", "ANATOMY", 42, 47], ["cultures", "ANATOMY", 53, 61], ["cell", "ANATOMY", 171, 175], ["cells", "ANATOMY", 204, 209], ["AEM", "CHEMICAL", 144, 147], ["L-glutamine", "CHEMICAL", 148, 159], ["L-glutamine", "CHEMICAL", 148, 159], ["cell", "CELL", 5, 9], ["cells", "CELL", 42, 47], ["AEM", "SIMPLE_CHEMICAL", 144, 147], ["L-glutamine", "SIMPLE_CHEMICAL", 148, 159], ["cell", "CELL", 171, 175], ["cell concentrations", "PROBLEM", 5, 24], ["cultures", "TEST", 53, 61], ["glutamine", "TREATMENT", 150, 159]]], ["The next day cells were counted using a Casey counter (Sch\u00e4rfe system) and virus was added to the roller bottles corresponding to the desired MOI.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["a Casey counter (Sch\u00e4rfe system", "TREATMENT", 38, 69], ["virus", "TREATMENT", 75, 80], ["the roller bottles", "TREATMENT", 94, 112], ["the desired MOI", "PROBLEM", 130, 145]]], ["For infection of PER.C6 cells in shaker flasks (25 mL culture volume) cells cultured in roller bottles were counted, centrifuged and cell pellets were re-suspended in fresh AEM/L-glutamine at 2.5 \u00c2 10 6 cells/mL after which virus was added at the desired MOI.", [["C6 cells", "ANATOMY", 21, 29], ["cells", "ANATOMY", 70, 75], ["cell", "ANATOMY", 133, 137], ["cells", "ANATOMY", 203, 208], ["infection", "DISEASE", 4, 13], ["AEM/L-glutamine", "CHEMICAL", 173, 188], ["L-glutamine", "CHEMICAL", 177, 188], ["C6 cells", "CELL", 21, 29], ["cells", "CELL", 70, 75], ["cell", "CELL", 133, 137], ["AEM", "SIMPLE_CHEMICAL", 173, 176], ["L-glutamine", "SIMPLE_CHEMICAL", 177, 188], ["cells", "CELL", 203, 208], ["C6 cells", "CELL_LINE", 21, 29], ["infection", "PROBLEM", 4, 13], ["C6 cells", "PROBLEM", 21, 29], ["shaker flasks", "TEST", 33, 46], ["culture volume) cells", "TEST", 54, 75], ["cell pellets", "TEST", 133, 145], ["glutamine", "TREATMENT", 179, 188], ["virus", "PROBLEM", 224, 229], ["infection", "OBSERVATION", 4, 13]]], ["Cells were cultured in shaker flasks at 75 rpm, 378C, 10% CO 2 .", [["Cells", "ANATOMY", 0, 5], ["CO", "CHEMICAL", 58, 60], ["Cells", "CELL", 0, 5]]], ["Harvest of medium was done between day 3 and 14, depending on the type of experiment and the protein expressed.Construction of DE1/DE2 Plasmid System and Vector GenerationRecombinant DE1/DE2 viruses were generated by a homologous recombination procedure using an identical plasmid-based system as previously described for the production of E1-deleted vectors (Havenga et al., 2001) with the exception that a modified cosmid (pWE/Ad.AflII-rITR.DE2A) lacking the E2A gene was used.", [["DE1", "GENE_OR_GENE_PRODUCT", 127, 130], ["DE2", "GENE_OR_GENE_PRODUCT", 131, 134], ["Vector GenerationRecombinant DE1/DE2 viruses", "ORGANISM", 154, 198], ["E1", "GENE_OR_GENE_PRODUCT", 340, 342], ["AflII-rITR.DE2A", "GENE_OR_GENE_PRODUCT", 432, 447], ["E2A", "GENE_OR_GENE_PRODUCT", 461, 464], ["DE1", "DNA", 127, 130], ["plasmid", "DNA", 273, 280], ["E1", "DNA", 340, 342], ["modified cosmid", "DNA", 408, 423], ["pWE", "DNA", 425, 428], ["AflII", "DNA", 432, 437], ["rITR.DE2A", "DNA", 438, 447], ["E2A gene", "DNA", 461, 469], ["DE1/DE2 Plasmid System", "TREATMENT", 127, 149], ["Vector GenerationRecombinant DE1/DE2 viruses", "TREATMENT", 154, 198], ["a homologous recombination procedure", "TREATMENT", 217, 253], ["an identical plasmid-based system", "TREATMENT", 260, 293], ["E1-deleted vectors", "TREATMENT", 340, 358], ["a modified cosmid (pWE/Ad", "TREATMENT", 406, 431], ["lacking the E2A gene", "TREATMENT", 449, 469], ["medium", "OBSERVATION_MODIFIER", 11, 17]]], ["To remove the E2A from the adenoviral backbone assembly PCR amplification and standard molecular cloning techniques were used.", [["E2A", "GENE_OR_GENE_PRODUCT", 14, 17], ["adenoviral", "ORGANISM", 27, 37], ["E2A", "PROTEIN", 14, 17], ["the E2A", "TREATMENT", 10, 17], ["the adenoviral backbone", "TREATMENT", 23, 46], ["PCR amplification", "TREATMENT", 56, 73], ["standard molecular cloning techniques", "TREATMENT", 78, 115]]], ["Co-transfection into mammalian cells of this cosmid with an expression plasmid encoding the left 5 kb of the adenoviral genome (pAdapt), results in homologous recombination leading to a complete Ad5 genome.", [["mammalian cells", "ANATOMY", 21, 36], ["plasmid", "ANATOMY", 71, 78], ["mammalian cells", "CELL", 21, 36], ["adenoviral", "ORGANISM", 109, 119], ["pAdapt", "GENE_OR_GENE_PRODUCT", 128, 134], ["Ad5", "ORGANISM", 195, 198], ["mammalian cells", "CELL_TYPE", 21, 36], ["cosmid", "DNA", 45, 51], ["expression plasmid", "DNA", 60, 78], ["adenoviral genome", "DNA", 109, 126], ["pAdapt", "DNA", 128, 134], ["Ad5 genome", "DNA", 195, 205], ["Ad5", "SPECIES", 195, 198], ["this cosmid", "TREATMENT", 40, 51], ["an expression plasmid", "TREATMENT", 57, 78], ["homologous recombination", "TREATMENT", 148, 172], ["mammalian cells", "OBSERVATION", 21, 36], ["left", "ANATOMY_MODIFIER", 92, 96], ["adenoviral genome", "OBSERVATION", 109, 126], ["Ad5 genome", "OBSERVATION", 195, 205]]], ["The cDNA (3,767 bp) coding for full-length SARS-CoV S1-spike (Brink et al., 2005) was cloned into the expression cassette of pAdapt whereas also the 1,695 bp fragment of S1-spike obtained through restriction analyses was cloned into the expression cassette of pAdapt in order to obtain a 'secreted' or 'soluble' form of S1-spike (pAdapt.S565).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 43, 51], ["pAdapt", "GENE_OR_GENE_PRODUCT", 125, 131], ["S1", "GENE_OR_GENE_PRODUCT", 170, 172], ["pAdapt", "GENE_OR_GENE_PRODUCT", 260, 266], ["S1", "GENE_OR_GENE_PRODUCT", 320, 322], ["S565", "GENE_OR_GENE_PRODUCT", 337, 341], ["cDNA", "DNA", 4, 8], ["expression cassette", "DNA", 102, 121], ["pAdapt", "DNA", 125, 131], ["1,695 bp fragment", "DNA", 149, 166], ["S1", "DNA", 170, 172], ["expression cassette", "DNA", 237, 256], ["pAdapt", "PROTEIN", 260, 266], ["S1", "PROTEIN", 320, 322], ["pAdapt", "PROTEIN", 330, 336], ["S565", "PROTEIN", 337, 341], ["SARS-CoV", "SPECIES", 43, 51], ["The cDNA", "TEST", 0, 8], ["bp", "TEST", 16, 18], ["full-length SARS", "TEST", 31, 47], ["spike", "PROBLEM", 55, 60], ["a 'secreted'", "TREATMENT", 286, 298]]], ["Likewise, the 2417 bp fragment coding for complete ACE2 (Genbank sequence AF291820) and a truncated version (sACE2) lacking the trans-membrane region (aa residues 741-805 of ACE2) were cloned into pAdapt.", [["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 174, 178], ["pAdapt", "GENE_OR_GENE_PRODUCT", 197, 203], ["2417 bp fragment", "DNA", 14, 30], ["ACE2", "PROTEIN", 51, 55], ["Genbank sequence AF291820", "DNA", 57, 82], ["ACE2", "PROTEIN", 110, 114], ["trans-membrane region", "PROTEIN", 128, 149], ["ACE2", "PROTEIN", 174, 178], ["pAdapt", "PROTEIN", 197, 203], ["complete ACE2", "TEST", 42, 55], ["a truncated version (sACE2)", "TREATMENT", 88, 115], ["the trans-membrane region", "TREATMENT", 124, 149], ["aa residues", "TEST", 151, 162], ["ACE2", "TEST", 174, 178]]], ["Both soluble proteins (S565 and sACE2) were fused in frame and upstream of a Myc-His tag to enable simple purification and detection of these expressed proteins.", [["S565", "GENE_OR_GENE_PRODUCT", 23, 27], ["sACE2", "GENE_OR_GENE_PRODUCT", 32, 37], ["Myc", "GENE_OR_GENE_PRODUCT", 77, 80], ["soluble proteins", "PROTEIN", 5, 21], ["S565", "PROTEIN", 23, 27], ["sACE2", "PROTEIN", 32, 37], ["Myc", "PROTEIN", 77, 80], ["expressed proteins", "PROTEIN", 142, 160], ["Both soluble proteins", "TREATMENT", 0, 21], ["His tag", "TREATMENT", 81, 88], ["simple purification", "TREATMENT", 99, 118], ["these expressed proteins", "PROBLEM", 136, 160]]], ["To create a DE1/DE2 vector carrying the light chain (LC) and heavy chain (HC) coding for a SARS-CoV neutralizing antibody (Meulen et al., 2004) the LC and HC genes were subcloned into plasmids that already contained appropriate leader sequences and either the constant CH1, CH2, and CH3 regions of the HC or C kappa, the constant region of the LC.", [["plasmids", "ANATOMY", 184, 192], ["CH2", "CHEMICAL", 274, 277], ["heavy chain", "GENE_OR_GENE_PRODUCT", 61, 72], ["C kappa", "GENE_OR_GENE_PRODUCT", 308, 315], ["DE1/DE2 vector", "DNA", 12, 26], ["light chain", "PROTEIN", 40, 51], ["LC", "PROTEIN", 53, 55], ["heavy chain", "PROTEIN", 61, 72], ["HC", "PROTEIN", 74, 76], ["SARS-CoV neutralizing antibody", "PROTEIN", 91, 121], ["LC and HC genes", "DNA", 148, 163], ["plasmids", "DNA", 184, 192], ["leader sequences", "DNA", 228, 244], ["CH1, CH2, and CH3 regions", "DNA", 269, 294], ["C kappa", "PROTEIN", 308, 315], ["SARS-CoV", "SPECIES", 91, 99], ["a DE1/DE2 vector", "TREATMENT", 10, 26], ["a SARS", "TEST", 89, 95], ["CoV neutralizing antibody", "TEST", 96, 121], ["the LC", "TEST", 144, 150], ["the constant CH1", "PROBLEM", 256, 272], ["LC", "ANATOMY", 148, 150], ["LC", "ANATOMY", 344, 346]]], ["To enable translation of HC and LC from one transcript, a Internal Ribosome Entry Site sequence derived from the EncephaloMyocarditis Virus (Jackson et al., 1990) was inserted in between HC and LC and cloned in the expression cassette of pAdapt.", [["HC", "CELL", 25, 27], ["EncephaloMyocarditis Virus", "ORGANISM", 113, 139], ["pAdapt", "GENE_OR_GENE_PRODUCT", 238, 244], ["Internal Ribosome Entry Site sequence", "DNA", 58, 95], ["expression cassette", "DNA", 215, 234], ["pAdapt", "DNA", 238, 244], ["the EncephaloMyocarditis Virus", "PROBLEM", 109, 139], ["EncephaloMyocarditis Virus", "OBSERVATION", 113, 139], ["LC", "ANATOMY", 194, 196]]], ["Generation of recombinant DE1/DE2 adenovirus batches was accomplished at 328C on adherent PER.E2A cells using Lipofectamine2000 transfection of pAdapt carrying various transgenes and cosmid (pWE/AflII-rITRdE2A) according to instructions provided by the manufacturer (Invitrogen).", [["cells", "ANATOMY", 98, 103], ["Lipofectamine2000", "CHEMICAL", 110, 127], ["Lipofectamine2000", "CHEMICAL", 110, 127], ["DE1", "GENE_OR_GENE_PRODUCT", 26, 29], ["DE2 adenovirus", "ORGANISM", 30, 44], ["E2A", "GENE_OR_GENE_PRODUCT", 94, 97], ["Lipofectamine2000", "SIMPLE_CHEMICAL", 110, 127], ["pAdapt", "GENE_OR_GENE_PRODUCT", 144, 150], ["E2A cells", "CELL_LINE", 94, 103], ["pAdapt", "DNA", 144, 150], ["transgenes", "DNA", 168, 178], ["cosmid", "DNA", 183, 189], ["pWE", "DNA", 191, 194], ["AflII", "DNA", 195, 200], ["rITRdE2A", "DNA", 201, 209], ["recombinant DE1/DE2 adenovirus batches", "TREATMENT", 14, 52], ["E2A cells", "TREATMENT", 94, 103], ["Lipofectamine2000 transfection", "TREATMENT", 110, 140], ["pAdapt carrying various transgenes", "TREATMENT", 144, 178], ["cosmid (pWE/AflII-rITRdE2A", "TREATMENT", 183, 209]]], ["Homologous recombination between sequences shared between pAdapt and pWE/AflII-rITRdE2A resulted in formation of DE1/DE2 vector visible by the onset and progression of CPE.", [["CPE", "DISEASE", 168, 171], ["pAdapt", "GENE_OR_GENE_PRODUCT", 58, 64], ["pWE", "GENE_OR_GENE_PRODUCT", 69, 72], ["AflII-rITRdE2A", "GENE_OR_GENE_PRODUCT", 73, 87], ["pAdapt", "DNA", 58, 64], ["pWE", "DNA", 69, 72], ["AflII", "DNA", 73, 78], ["rITRdE2A", "DNA", 79, 87], ["DE1/DE2 vector", "DNA", 113, 127], ["Homologous recombination between sequences", "PROBLEM", 0, 42], ["pAdapt", "TEST", 58, 64], ["rITRdE2A", "TREATMENT", 79, 87], ["DE1/DE2 vector", "TREATMENT", 113, 127], ["CPE", "PROBLEM", 168, 171], ["progression", "OBSERVATION_MODIFIER", 153, 164], ["CPE", "OBSERVATION", 168, 171]]], ["Purified virus stocks were obtained using standard two-step CsClgradient banding and the isolated virus was dialyzed in three steps to a final formulation in PBS/5% (w/v) sucrose.", [["sucrose", "CHEMICAL", 171, 178], ["sucrose", "CHEMICAL", 171, 178], ["/v) sucrose", "SIMPLE_CHEMICAL", 167, 178], ["Purified virus stocks", "PROBLEM", 0, 21], ["standard two-step CsClgradient banding", "TREATMENT", 42, 80], ["the isolated virus", "PROBLEM", 85, 103], ["a final formulation in PBS", "TREATMENT", 135, 161], ["sucrose", "TREATMENT", 171, 178], ["virus stocks", "OBSERVATION", 9, 21], ["virus", "OBSERVATION", 98, 103]]], ["Virus concentrations were determined based on optical density method (Maizel et al., 1968) in the presence of 1% (w/v) SDS.", [["Virus", "ORGANISM", 0, 5], ["Virus concentrations", "PROBLEM", 0, 20], ["SDS", "PROBLEM", 119, 122]]], ["Infectivity was measured by TCID 50 assay on PER.E2A cells (3 weeks post-infection) as described previously (Fallaux et al., 1996) .Protein and DNA analysesDetection of adenoviral proteins in infected cells and DBP protein in PER.E2A cells was performed by Western blot analysis.", [["E2A cells", "ANATOMY", 49, 58], ["cells", "ANATOMY", 201, 206], ["E2A cells", "ANATOMY", 230, 239], ["infection", "DISEASE", 73, 82], ["E2A", "GENE_OR_GENE_PRODUCT", 49, 52], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["adenoviral", "ORGANISM", 169, 179], ["cells", "CELL", 201, 206], ["DBP", "GENE_OR_GENE_PRODUCT", 211, 214], ["E2A", "GENE_OR_GENE_PRODUCT", 230, 233], ["E2A cells", "CELL_LINE", 49, 58], ["adenoviral proteins", "PROTEIN", 169, 188], ["infected cells", "CELL_TYPE", 192, 206], ["DBP protein", "PROTEIN", 211, 222], ["PER", "PROTEIN", 226, 229], ["E2A cells", "CELL_LINE", 230, 239], ["E2A cells", "PROBLEM", 49, 58], ["infection", "PROBLEM", 73, 82], ["Protein", "TEST", 132, 139], ["DNA analyses", "TEST", 144, 156], ["adenoviral proteins in infected cells", "PROBLEM", 169, 206], ["DBP protein", "TEST", 211, 222], ["E2A cells", "PROBLEM", 230, 239], ["blot analysis", "TEST", 265, 278], ["infection", "OBSERVATION", 73, 82], ["infected cells", "OBSERVATION", 192, 206]]], ["Hereto, 20 mg of total cellular protein was loaded on a polyacrylamide gel.", [["cellular", "ANATOMY", 23, 31], ["polyacrylamide", "CHEMICAL", 56, 70], ["cellular", "CELL", 23, 31], ["total cellular protein", "PROTEIN", 17, 39], ["total cellular protein", "TREATMENT", 17, 39], ["a polyacrylamide gel", "TREATMENT", 54, 74]]], ["To visualize DBP, fiber, penton, the pTP/TP proteins, or the E4-orf6 protein, antibodies B6-mouse (A kind gift from N. Reich, New York, USA; Reich et al., 1983) , E641/3-rabbit (a kind gift from R. Gerard, Leuven, Belgium), Pb571-rabbit (a kind gift from P. Boulanger, Montpellier, France), pTP-396-rabbit (a kind gift from P. van Vliet, Utrecht, the Netherlands), RSA-3mouse (a kind gift from P. Branton, Montreal, Canada), were used at dilutions of 1/1,000, 1/1,000, 1/1,000, 1/750, and 1/377, respectively.", [["DBP", "GENE_OR_GENE_PRODUCT", 13, 16], ["fiber", "CELLULAR_COMPONENT", 18, 23], ["pTP", "GENE_OR_GENE_PRODUCT", 37, 40], ["TP", "GENE_OR_GENE_PRODUCT", 41, 43], ["E4-orf6", "GENE_OR_GENE_PRODUCT", 61, 68], ["mouse", "ORGANISM", 92, 97], ["rabbit", "ORGANISM", 170, 176], ["Pb571-rabbit", "ORGANISM", 224, 236], ["rabbit", "ORGANISM", 299, 305], ["DBP", "PROTEIN", 13, 16], ["pTP", "PROTEIN", 37, 40], ["TP proteins", "PROTEIN", 41, 52], ["E4", "PROTEIN", 61, 63], ["orf6 protein", "PROTEIN", 64, 76], ["antibodies B6", "PROTEIN", 78, 91], ["mouse", "SPECIES", 92, 97], ["rabbit", "SPECIES", 170, 176], ["rabbit", "SPECIES", 230, 236], ["rabbit", "SPECIES", 299, 305], ["mouse", "SPECIES", 92, 97], ["rabbit", "SPECIES", 170, 176], ["rabbit", "SPECIES", 230, 236], ["rabbit", "SPECIES", 299, 305], ["P. van Vliet", "SPECIES", 324, 336], ["DBP", "TEST", 13, 16], ["the pTP/TP proteins", "TEST", 33, 52], ["the E4", "TEST", 57, 63], ["antibodies", "TEST", 78, 88], ["pTP", "TEST", 291, 294]]], ["Primary antibody binding was visualized utilizing a second antibody (ECL detection kit), that is Goat-anti-mouse, IgG, H \u00fe L, (BioRad) or Goat-antirabbit, IgG H \u00fe L, both at a dilution of 1/7,500.", [["mouse", "ORGANISM", 107, 112], ["IgG", "GENE_OR_GENE_PRODUCT", 114, 117], ["H \u00fe L", "SIMPLE_CHEMICAL", 119, 124], ["BioRad", "GENE_OR_GENE_PRODUCT", 127, 133], ["Goat-antirabbit", "SIMPLE_CHEMICAL", 138, 153], ["ECL detection kit", "PROTEIN", 69, 86], ["Goat", "PROTEIN", 97, 101], ["anti", "PROTEIN", 102, 106], ["IgG", "PROTEIN", 114, 117], ["H \u00fe L", "PROTEIN", 119, 124], ["BioRad", "PROTEIN", 127, 133], ["Goat", "PROTEIN", 138, 142], ["antirabbit", "PROTEIN", 143, 153], ["IgG H", "PROTEIN", 155, 160], ["Goat", "SPECIES", 97, 101], ["mouse", "SPECIES", 107, 112], ["Goat", "SPECIES", 138, 142], ["mouse", "SPECIES", 107, 112], ["Primary antibody binding", "PROBLEM", 0, 24], ["a second antibody", "TEST", 50, 67], ["ECL detection kit", "TEST", 69, 86], ["Goat", "TEST", 97, 101], ["IgG", "TEST", 114, 117], ["BioRad", "TEST", 127, 133], ["Goat", "TEST", 138, 142], ["antibody binding", "OBSERVATION", 8, 24]]], ["For Southern blot analyses, viral DNA was isolated from infected cells as described previously (Zhang et al., 1995) .", [["cells", "ANATOMY", 65, 70], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["cells", "CELL", 65, 70], ["viral DNA", "DNA", 28, 37], ["infected cells", "CELL_TYPE", 56, 70], ["Southern blot analyses", "TEST", 4, 26], ["viral DNA", "PROBLEM", 28, 37], ["infected cells", "PROBLEM", 56, 70], ["viral DNA", "OBSERVATION", 28, 37], ["infected cells", "OBSERVATION", 56, 70]]], ["Viral DNA was digested with EcoRI, liberating the LacZ coding domain from the adenoviral backbone.", [["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["EcoRI", "GENE_OR_GENE_PRODUCT", 28, 33], ["LacZ", "GENE_OR_GENE_PRODUCT", 50, 54], ["adenoviral", "ORGANISM", 78, 88], ["Viral DNA", "DNA", 0, 9], ["EcoRI", "DNA", 28, 33], ["LacZ coding domain", "DNA", 50, 68], ["Viral DNA", "PROBLEM", 0, 9], ["EcoRI", "TREATMENT", 28, 33], ["the LacZ coding domain", "TREATMENT", 46, 68], ["the adenoviral backbone", "TREATMENT", 74, 97], ["adenoviral backbone", "ANATOMY", 78, 97]]], ["Blots were probed with a 32 P-labeled EcoRI fragment of the LacZ cDNA.", [["EcoRI", "GENE_OR_GENE_PRODUCT", 38, 43], ["LacZ", "GENE_OR_GENE_PRODUCT", 60, 64], ["32 P-labeled EcoRI fragment", "DNA", 25, 52], ["LacZ cDNA", "DNA", 60, 69], ["Blots", "TEST", 0, 5], ["a 32 P-labeled EcoRI fragment", "TREATMENT", 23, 52], ["the LacZ cDNA", "TREATMENT", 56, 69]]], ["Purified S565; sACE2 and SARS-AB were fractionated by SDS-PAGE on 10% Bis-Tris gels and ran in MOPS running buffer (Invitrogen) and stained using Collodial blue staining (Invitrogen) according to the supplier protocol.", [["Bis-Tris", "CHEMICAL", 70, 78], ["Collodial blue", "CHEMICAL", 146, 160], ["S565", "GENE_OR_GENE_PRODUCT", 9, 13], ["sACE2", "GENE_OR_GENE_PRODUCT", 15, 20], ["SARS-AB", "ORGANISM", 25, 32], ["Bis-Tris gels", "SIMPLE_CHEMICAL", 70, 83], ["sACE2", "PROTEIN", 15, 20], ["sACE2", "TEST", 15, 20], ["SARS", "PROBLEM", 25, 29], ["SDS", "TEST", 54, 57], ["Bis", "TEST", 70, 73], ["Tris gels", "TREATMENT", 74, 83], ["MOPS running buffer", "TREATMENT", 95, 114], ["Collodial blue staining", "TREATMENT", 146, 169], ["the supplier protocol", "TREATMENT", 196, 217]]], ["For Western blot analysis, fractionated proteins were transferred onto Immobilon-P membranes (Millipore) and incubated with (1:10,000) HRP-conjugated donkey-a-human Mab (Jackson ImmunoResearch, Suffolk, UK) in case of SARS-AB and with anti-c-Myc-HRP (1:10,000) for both S565 and sACE2.", [["Immobilon-P membranes", "ANATOMY", 71, 92], ["HRP", "SIMPLE_CHEMICAL", 135, 138], ["anti-c-Myc", "GENE_OR_GENE_PRODUCT", 235, 245], ["HRP", "GENE_OR_GENE_PRODUCT", 246, 249], ["S565", "GENE_OR_GENE_PRODUCT", 270, 274], ["sACE2", "GENE_OR_GENE_PRODUCT", 279, 284], ["fractionated proteins", "PROTEIN", 27, 48], ["HRP", "PROTEIN", 135, 138], ["conjugated donkey", "PROTEIN", 139, 156], ["a-human Mab", "PROTEIN", 157, 168], ["anti-c", "PROTEIN", 235, 241], ["Myc", "PROTEIN", 242, 245], ["HRP", "PROTEIN", 246, 249], ["S565", "PROTEIN", 270, 274], ["sACE2", "PROTEIN", 279, 284], ["donkey", "SPECIES", 150, 156], ["Western blot analysis", "TEST", 4, 25], ["fractionated proteins", "TEST", 27, 48], ["HRP", "TEST", 135, 138], ["SARS", "PROBLEM", 218, 222], ["AB", "TREATMENT", 223, 225], ["anti-c", "TEST", 235, 241]]], ["Efficiency of gene transfer was typically assessed 48 h after virus addition by determination of LacZ transgene expression either by staining the intact cells as described previously (Havenga et al., 2001) or by preparing a cell lysate of the cells and measuring b-galactosidase activity in the total cell lysate using a b-galactosidase activity kit (Promega, Madsion WI).", [["cells", "ANATOMY", 153, 158], ["cell lysate", "ANATOMY", 224, 235], ["cells", "ANATOMY", 243, 248], ["cell lysate", "ANATOMY", 301, 312], ["LacZ", "GENE_OR_GENE_PRODUCT", 97, 101], ["cells", "CELL", 153, 158], ["cell", "CELL", 224, 228], ["cells", "CELL", 243, 248], ["b-galactosidase", "GENE_OR_GENE_PRODUCT", 263, 278], ["cell", "CELL", 301, 305], ["LacZ transgene", "DNA", 97, 111], ["intact cells", "CELL_TYPE", 146, 158], ["b-galactosidase", "PROTEIN", 263, 278], ["LacZ transgene expression", "TREATMENT", 97, 122], ["a cell lysate of the cells", "TREATMENT", 222, 248], ["measuring b-galactosidase activity", "TREATMENT", 253, 287], ["the total cell lysate", "TREATMENT", 291, 312], ["a b-galactosidase activity kit", "TREATMENT", 319, 349], ["intact cells", "OBSERVATION", 146, 158]]], ["Transfection experiments were performed with 5 mg of plasmid DNA purified via Qiagen columns (Westburg, The Netherlands).", [["plasmid", "ANATOMY", 53, 60], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["plasmid DNA", "DNA", 53, 64], ["Transfection experiments", "TEST", 0, 24], ["plasmid DNA", "TREATMENT", 53, 64]]], ["Both soluble (Myc-His tagged) proteins S565 and sACE2 as well as the SARS-AB were produced in 100 mL roller bottles, medium was collected and centrifuged at 500g and filtered using a 0.22 mm bottle top filter.", [["Myc", "GENE_OR_GENE_PRODUCT", 14, 17], ["S565", "GENE_OR_GENE_PRODUCT", 39, 43], ["sACE2", "GENE_OR_GENE_PRODUCT", 48, 53], ["SARS-AB", "GENE_OR_GENE_PRODUCT", 69, 76], ["soluble (Myc-His tagged) proteins", "PROTEIN", 5, 38], ["S565", "PROTEIN", 39, 43], ["sACE2", "PROTEIN", 48, 53], ["SARS-AB", "PROTEIN", 69, 76], ["His tagged) proteins", "TEST", 18, 38], ["sACE2", "TEST", 48, 53], ["the SARS-AB", "TREATMENT", 65, 76], ["a 0.22 mm bottle top filter", "TREATMENT", 181, 208], ["filter", "OBSERVATION", 202, 208]]], ["S565 and sACE2 proteins were purified on an AKTA explorer (GE Healthcare, Brussels, Belgium) using HisTrap HP (1 mL) affinity and HiTrap desalting (5 mL) columns (GE Healthcare) using the appropriate buffers as recommended by the supplier.", [["S565", "GENE_OR_GENE_PRODUCT", 0, 4], ["sACE2", "GENE_OR_GENE_PRODUCT", 9, 14], ["S565", "PROTEIN", 0, 4], ["sACE2 proteins", "PROTEIN", 9, 23], ["an AKTA explorer (GE Healthcare", "TREATMENT", 41, 72], ["HisTrap HP (1 mL) affinity", "TREATMENT", 99, 125], ["HiTrap desalting (5 mL) columns (GE Healthcare", "TREATMENT", 130, 176], ["the appropriate buffers", "TREATMENT", 184, 207]]], ["Total protein concentration in culture harvests was determined using the Micro BCA TM protein assay (Pierce; The Netherlands) according to instructions provided by the manufacturer.", [["Total protein concentration", "TREATMENT", 0, 27], ["culture harvests", "TREATMENT", 31, 47], ["concentration", "OBSERVATION_MODIFIER", 14, 27], ["culture harvests", "OBSERVATION", 31, 47]]], ["Samples of the harvests were also serial diluted and separated on SDS-PAGE gels, after colloid blue staining the gel was optically scanned and all single products (in the linear sample range) present in the individual lanes were digitally integrated and converted to integrated optical density (IOD) values using Gel-Pro analyzer developed by Media Cybernetics, Inc. (Bethesda, MD).", [["Samples", "ANATOMY", 0, 7], ["the harvests", "TREATMENT", 11, 23], ["colloid blue staining", "TEST", 87, 108], ["harvests", "OBSERVATION", 15, 23]]], ["Subsequently, the amount of produced S565 and sACE2 was calculated by multiplication of the purity by the total amount of protein.", [["S565", "GENE_OR_GENE_PRODUCT", 37, 41], ["sACE2", "GENE_OR_GENE_PRODUCT", 46, 51], ["S565", "PROTEIN", 37, 41], ["sACE2", "PROTEIN", 46, 51], ["amount", "OBSERVATION_MODIFIER", 18, 24]]], ["The SARS virus neutralizing antibody, present in culture medium was purified by HPLC using HiTrap rProtein A protA and HiPrep 26/10 affinity and desalting columns (GE Healthcare) and quantified by optical density measurements at 280 nm.", [["SARS virus", "ORGANISM", 4, 14], ["protA", "SIMPLE_CHEMICAL", 109, 114], ["SARS virus neutralizing antibody", "PROTEIN", 4, 36], ["SARS virus", "SPECIES", 4, 14], ["The SARS virus neutralizing antibody", "TEST", 0, 36], ["culture medium", "TEST", 49, 63], ["HPLC", "TEST", 80, 84], ["HiTrap rProtein", "TREATMENT", 91, 106], ["HiPrep", "TREATMENT", 119, 125], ["desalting columns (GE Healthcare", "TREATMENT", 145, 177]]], ["Detection of ACE2 on PER.C6 cells was performed by exposure of PER.C6 cells to a DE1/DE2 vector carrying the ACE2 coding domain.", [["C6 cells", "ANATOMY", 25, 33], ["C6 cells", "ANATOMY", 67, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["C6 cells", "CELL", 25, 33], ["C6 cells", "CELL", 67, 75], ["DE2", "GENE_OR_GENE_PRODUCT", 85, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["ACE2", "PROTEIN", 13, 17], ["PER", "PROTEIN", 21, 24], ["C6 cells", "CELL_LINE", 25, 33], ["C6 cells", "CELL_LINE", 67, 75], ["DE1/DE2 vector", "DNA", 81, 95], ["ACE2 coding domain", "DNA", 109, 127], ["C6 cells", "PROBLEM", 25, 33], ["C6 cells", "PROBLEM", 67, 75], ["a DE1/DE2 vector", "TREATMENT", 79, 95]]], ["After 48 h, transiently expressed ACE2 on PER.C6 cell membranes was detected by FACS analysis after cell staining with goat-anti human ACE2 ectodomain polyclonal (0.4 mg/mL; R&D Systems, Oxford, UK) and PE-conjugated (1:100) Donkey anti-goat IgG (Jackson ImmunoResearch) .", [["C6 cell membranes", "ANATOMY", 46, 63], ["cell", "ANATOMY", 100, 104], ["PE", "CHEMICAL", 203, 205], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["C6 cell", "CELL", 46, 53], ["cell", "CELL", 100, 104], ["human", "ORGANISM", 129, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["PE-conjugated", "SIMPLE_CHEMICAL", 203, 216], ["ACE2", "PROTEIN", 34, 38], ["PER", "PROTEIN", 42, 45], ["goat-anti human ACE2 ectodomain", "PROTEIN", 119, 150], ["conjugated (1:100) Donkey anti-goat IgG", "PROTEIN", 206, 245], ["Jackson ImmunoResearch", "PROTEIN", 247, 269], ["goat", "SPECIES", 119, 123], ["human", "SPECIES", 129, 134], ["anti-goat", "SPECIES", 232, 241], ["human", "SPECIES", 129, 134], ["C6 cell membranes", "PROBLEM", 46, 63], ["FACS analysis", "TEST", 80, 93], ["cell staining", "TEST", 100, 113], ["goat", "TEST", 119, 123], ["anti human ACE2 ectodomain polyclonal", "TREATMENT", 124, 161], ["PE", "PROBLEM", 203, 205], ["cell membranes", "OBSERVATION", 49, 63], ["PE", "OBSERVATION", 203, 205]]], ["For the detection of proper binding of sACE2 to S1-spike, PER.C6 cells were infected with a DE1/DE2 vector carrying the S1-spike and after 48 h cells were incubated with transiently produced and purified sACE2 (40 mg/mL) and subsequently with mouse-anti-c-Myc (9E10) FITC (6 mg/ mL; Santa Cruz Biotechnologies, Inc., Santa Cruz, Calif.).", [["C6 cells", "ANATOMY", 62, 70], ["cells", "ANATOMY", 144, 149], ["sACE2", "CHEMICAL", 204, 209], ["FITC", "CHEMICAL", 267, 271], ["sACE2", "GENE_OR_GENE_PRODUCT", 39, 44], ["C6 cells", "CELL", 62, 70], ["DE2", "GENE_OR_GENE_PRODUCT", 96, 99], ["cells", "CELL", 144, 149], ["sACE2", "SIMPLE_CHEMICAL", 204, 209], ["mouse", "ORGANISM", 243, 248], ["-c-Myc", "GENE_OR_GENE_PRODUCT", 253, 259], ["FITC", "SIMPLE_CHEMICAL", 267, 271], ["sACE2", "PROTEIN", 39, 44], ["S1", "PROTEIN", 48, 50], ["PER", "PROTEIN", 58, 61], ["C6 cells", "CELL_LINE", 62, 70], ["DE1/DE2 vector", "DNA", 92, 106], ["S1", "PROTEIN", 120, 122], ["Myc (9E10) FITC", "PROTEIN", 256, 271], ["mouse", "SPECIES", 243, 248], ["mouse", "SPECIES", 243, 248], ["C6 cells", "PROBLEM", 62, 70], ["a DE1/DE2 vector", "TREATMENT", 90, 106], ["mouse-anti-c-Myc (9E10) FITC", "TREATMENT", 243, 271]]], ["All incubations and washes were performed at 48C in PBS supplemented with 1% BSA.", [["BSA", "SIMPLE_CHEMICAL", 77, 80], ["All incubations", "TREATMENT", 0, 15], ["washes", "TREATMENT", 20, 26]]], ["Cells were analyzed on a FACSCalibur with CELLQuest Pro software (Becton Dickinson, Franklin Lakes, NJ).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["To determine functionality of the SARS virus neutralizing antibody, microtiter plates (Nunc, Roskilde, Denmark) were coated overnight with anti-Myc antibody (5 mg/mL PBS, pH 7.4) followed by incubation with purified Myc-tagged S565 (2 mg/well).", [["SARS", "DISEASE", 34, 38], ["S565", "GENE_OR_GENE_PRODUCT", 227, 231], ["SARS virus neutralizing antibody", "PROTEIN", 34, 66], ["anti-Myc antibody", "PROTEIN", 139, 156], ["Myc-tagged S565", "PROTEIN", 216, 231], ["SARS virus", "SPECIES", 34, 44], ["the SARS virus neutralizing antibody", "TEST", 30, 66], ["microtiter plates", "TEST", 68, 85], ["anti-Myc antibody", "TREATMENT", 139, 156], ["pH", "TEST", 171, 173]]], ["Concentrations of a transiently or stably produced SARS virus neutralizing antibody range (0.18-370 ng/mL) were added and incubated with (2,000 times diluted) PEconjugated donkey anti-Human IgG (H \u00fe L; Jackson ImmunoResearch).", [["SARS virus", "ORGANISM", 51, 61], ["donkey", "ORGANISM", 172, 178], ["PEconjugated donkey", "PROTEIN", 159, 178], ["anti-Human IgG", "PROTEIN", 179, 193], ["H \u00fe L; Jackson ImmunoResearch", "PROTEIN", 195, 224], ["donkey", "SPECIES", 172, 178], ["SARS virus", "SPECIES", 51, 61], ["H \u00fe L; Jackson ImmunoResearch", "SPECIES", 195, 224], ["stably produced SARS virus neutralizing antibody range", "PROBLEM", 35, 89]]], ["The assay was further developed using O-phenylenediamine substrate and stopped by the addition of 1 M H 2 SO 4 .", [["O-phenylenediamine", "CHEMICAL", 38, 56], ["O-phenylenediamine", "CHEMICAL", 38, 56], ["H 2 SO 4", "CHEMICAL", 102, 110], ["O-phenylenediamine", "SIMPLE_CHEMICAL", 38, 56], ["The assay", "TEST", 0, 9], ["O-phenylenediamine substrate", "TREATMENT", 38, 66]]], ["The absorbance was measured at 492 nm.ResultsGeneration of the PER.E2A Cell Line and Production of DE1/DE2A Vector Transfection in PER.C6 cells of a plasmid containing a Neomycine resistance (G418 R ) gene and the E2A coding domain (Vliet and Sussenbach, 1975) under the regulation of the CMV-promoter, resulted in >100 G418 R colonies from which 45 clones were further tested resulting in 37 established cell lines.", [["Cell", "ANATOMY", 71, 75], ["C6 cells", "ANATOMY", 135, 143], ["plasmid", "ANATOMY", 149, 156], ["colonies", "ANATOMY", 327, 335], ["cell lines", "ANATOMY", 405, 415], ["Neomycine", "CHEMICAL", 170, 179], ["E2A", "GENE_OR_GENE_PRODUCT", 67, 70], ["C6 cells", "CELL", 135, 143], ["Neomycine", "GENE_OR_GENE_PRODUCT", 170, 179], ["G418 R", "GENE_OR_GENE_PRODUCT", 192, 198], ["E2A", "GENE_OR_GENE_PRODUCT", 214, 217], ["CMV", "ORGANISM", 289, 292], ["clones", "CELL", 350, 356], ["cell lines", "CELL", 405, 415], ["PER", "PROTEIN", 63, 66], ["E2A", "PROTEIN", 67, 70], ["DE1", "PROTEIN", 99, 102], ["DE2A", "PROTEIN", 103, 107], ["PER", "PROTEIN", 131, 134], ["C6 cells", "CELL_LINE", 135, 143], ["Neomycine resistance (G418 R ) gene", "DNA", 170, 205], ["E2A coding domain", "DNA", 214, 231], ["CMV-promoter", "DNA", 289, 301], ["cell lines", "CELL_LINE", 405, 415], ["The absorbance", "TEST", 0, 14], ["E2A Cell Line", "TREATMENT", 67, 80], ["DE1/DE2A Vector Transfection", "TREATMENT", 99, 127], ["C6 cells", "PROBLEM", 135, 143], ["a plasmid", "TREATMENT", 147, 156], ["a Neomycine resistance", "TREATMENT", 168, 190], ["the CMV-promoter", "TREATMENT", 285, 301], ["absorbance", "OBSERVATION_MODIFIER", 4, 14], ["Cell Line", "OBSERVATION", 71, 80], ["Neomycine resistance", "OBSERVATION", 170, 190], ["cell lines", "OBSERVATION", 405, 415]]], ["Each cell line produced high levels of DNA binding protein (DBP) driven from the E2A gene as determined by Western analysis (data not shown).", [["cell line", "ANATOMY", 5, 14], ["cell line", "CELL", 5, 14], ["DNA binding protein", "GENE_OR_GENE_PRODUCT", 39, 58], ["DBP", "GENE_OR_GENE_PRODUCT", 60, 63], ["E2A", "GENE_OR_GENE_PRODUCT", 81, 84], ["cell line", "CELL_LINE", 5, 14], ["DNA binding protein", "PROTEIN", 39, 58], ["DBP", "PROTEIN", 60, 63], ["E2A gene", "DNA", 81, 89], ["Each cell line", "TEST", 0, 14], ["DNA binding protein", "PROBLEM", 39, 58], ["DBP", "TEST", 60, 63], ["cell line", "OBSERVATION", 5, 14], ["high", "OBSERVATION_MODIFIER", 24, 28]]], ["From the 37 cell lines the PER.E2A cell line was selected based on the capability of the cells to stably express the E2A gene in the absence of G418 and the ability to grow in suspension in the absence of animal serum.", [["cell lines", "ANATOMY", 12, 22], ["PER.E2A cell line", "ANATOMY", 27, 44], ["cells", "ANATOMY", 89, 94], ["serum", "ANATOMY", 212, 217], ["G418", "CHEMICAL", 144, 148], ["G418", "CHEMICAL", 144, 148], ["cell lines", "CELL", 12, 22], ["PER.E2A cell line", "CELL", 27, 44], ["cells", "CELL", 89, 94], ["E2A", "GENE_OR_GENE_PRODUCT", 117, 120], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["37 cell lines", "CELL_LINE", 9, 22], ["PER.E2A cell line", "CELL_LINE", 27, 44], ["E2A gene", "DNA", 117, 125], ["the 37 cell lines", "TREATMENT", 5, 22], ["the PER.E2A cell line", "TREATMENT", 23, 44], ["G418", "TREATMENT", 144, 148], ["37 cell lines", "OBSERVATION", 9, 22], ["cell line", "OBSERVATION", 35, 44]]], ["The PER.E2A cell line was compared to PER.C6 cells showing that during a 10 days culture period at 398C the proliferation kinetics of the two cell lines were identical (data not shown).", [["PER.E2A cell line", "ANATOMY", 4, 21], ["C6 cells", "ANATOMY", 42, 50], ["cell lines", "ANATOMY", 142, 152], ["PER.E2A cell line", "CELL", 4, 21], ["C6 cells", "CELL", 42, 50], ["cell lines", "CELL", 142, 152], ["PER.E2A cell line", "CELL_LINE", 4, 21], ["PER", "PROTEIN", 38, 41], ["C6 cells", "CELL_LINE", 42, 50], ["cell lines", "CELL_LINE", 142, 152], ["The PER.E2A cell line", "TREATMENT", 0, 21], ["C6 cells", "PROBLEM", 42, 50], ["the proliferation kinetics", "PROBLEM", 104, 130], ["cell line", "OBSERVATION", 12, 21], ["two cell lines", "OBSERVATION", 138, 152]]], ["At 328C, both cell lines behaved identical until after approximately 5 days in culture when the cell viability of the PER.E2A cell line started to decrease as a result of E2A toxicity (data not shown) thus providing a 5-day time frame for virus replication and progeny formation of DE1/DE2A adenoviral vectors.", [["cell lines", "ANATOMY", 14, 24], ["cell", "ANATOMY", 96, 100], ["cell line", "ANATOMY", 126, 135], ["toxicity", "DISEASE", 175, 183], ["cell lines", "CELL", 14, 24], ["cell", "CELL", 96, 100], ["E2A", "GENE_OR_GENE_PRODUCT", 122, 125], ["E2A", "GENE_OR_GENE_PRODUCT", 171, 174], ["DE1", "GENE_OR_GENE_PRODUCT", 282, 285], ["DE2A", "GENE_OR_GENE_PRODUCT", 286, 290], ["adenoviral", "ORGANISM", 291, 301], ["cell lines", "CELL_LINE", 14, 24], ["E2A cell line", "CELL_LINE", 122, 135], ["E2A", "PROTEIN", 171, 174], ["both cell lines", "TREATMENT", 9, 24], ["culture", "TEST", 79, 86], ["E2A cell line", "TREATMENT", 122, 135], ["E2A toxicity", "PROBLEM", 171, 183], ["virus replication", "TREATMENT", 239, 256], ["DE1/DE2A adenoviral vectors", "TREATMENT", 282, 309], ["cell lines", "OBSERVATION", 14, 24], ["cell line", "OBSERVATION", 126, 135]]], ["Next, the efficiency of DE1/DE2A recombinant vector generation on PER.E2A cells in relation to cell culture temperature was established.", [["cells", "ANATOMY", 74, 79], ["cell", "ANATOMY", 95, 99], ["DE1", "GENE_OR_GENE_PRODUCT", 24, 27], ["DE2A", "GENE_OR_GENE_PRODUCT", 28, 32], ["E2A", "GENE_OR_GENE_PRODUCT", 70, 73], ["cell", "CELL", 95, 99], ["DE1", "PROTEIN", 24, 27], ["DE2A", "PROTEIN", 28, 32], ["PER", "PROTEIN", 66, 69], ["E2A cells", "CELL_LINE", 70, 79], ["DE1/DE2A recombinant vector generation", "TREATMENT", 24, 62], ["E2A cells", "PROBLEM", 70, 79], ["cell culture temperature", "TEST", 95, 119]]], ["Hereto, an DE1/DE2A vector and as control an DE1 virus, both carrying the LacZ reporter gene, were generated on PER.E2A and PER.C6 respectively and purified.", [["DE1", "GENE_OR_GENE_PRODUCT", 11, 14], ["DE2A", "GENE_OR_GENE_PRODUCT", 15, 19], ["DE1 virus", "ORGANISM", 45, 54], ["LacZ", "GENE_OR_GENE_PRODUCT", 74, 78], ["E2A", "GENE_OR_GENE_PRODUCT", 116, 119], ["PER", "GENE_OR_GENE_PRODUCT", 124, 127], ["DE1/DE2A vector", "DNA", 11, 26], ["LacZ reporter gene", "DNA", 74, 92], ["E2A", "PROTEIN", 116, 119], ["PER", "PROTEIN", 124, 127], ["C6", "CELL_LINE", 128, 130], ["DE1 virus", "SPECIES", 45, 54], ["an DE1/DE2A vector", "TREATMENT", 8, 26], ["an DE1 virus", "TREATMENT", 42, 54]]], ["These vector stocks were used to transduce both PER.C6 and PER.E2A cells at a concentration of 100 virus particles per cell after which cells were cultured at different temperatures.", [["cells", "ANATOMY", 67, 72], ["cell", "ANATOMY", 119, 123], ["cells", "ANATOMY", 136, 141], ["E2A", "GENE_OR_GENE_PRODUCT", 63, 66], ["cell", "CELL", 119, 123], ["cells", "CELL", 136, 141], ["PER", "PROTEIN", 48, 51], ["PER", "PROTEIN", 59, 62], ["E2A cells", "CELL_LINE", 63, 72], ["These vector stocks", "TREATMENT", 0, 19], ["E2A cells", "PROBLEM", 63, 72], ["vector stocks", "OBSERVATION", 6, 19]]], ["Forty-eight hours later, the amount of infectious virus particles formed was determined by exposing human A549 indicator cells to 100 mL of cleared supernatant and subsequently counting the number of LacZ positive cells obtained.", [["A549", "ANATOMY", 106, 110], ["cells", "ANATOMY", 121, 126], ["supernatant", "ANATOMY", 148, 159], ["cells", "ANATOMY", 214, 219], ["human", "ORGANISM", 100, 105], ["A549", "CELL", 106, 110], ["cells", "CELL", 121, 126], ["LacZ", "GENE_OR_GENE_PRODUCT", 200, 204], ["cells", "CELL", 214, 219], ["human A549 indicator cells", "CELL_LINE", 100, 126], ["LacZ positive cells", "CELL_LINE", 200, 219], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["infectious virus particles", "PROBLEM", 39, 65], ["LacZ positive cells", "PROBLEM", 200, 219], ["amount", "OBSERVATION_MODIFIER", 29, 35], ["infectious", "OBSERVATION_MODIFIER", 39, 49], ["virus particles", "OBSERVATION", 50, 65]]], ["As shown in Figure 1A , an DE1 vector can be produced both on PER.C6 as well as PER.E2A cells whereas an DE1/DE2A vector can be produced only on PER.E2A cells.", [["cells", "ANATOMY", 88, 93], ["E2A cells", "ANATOMY", 149, 158], ["DE1", "GENE_OR_GENE_PRODUCT", 27, 30], ["E2A", "GENE_OR_GENE_PRODUCT", 84, 87], ["DE1", "GENE_OR_GENE_PRODUCT", 105, 108], ["DE2A", "GENE_OR_GENE_PRODUCT", 109, 113], ["E2A", "GENE_OR_GENE_PRODUCT", 149, 152], ["DE1 vector", "DNA", 27, 37], ["PER", "PROTEIN", 80, 83], ["E2A cells", "CELL_LINE", 84, 93], ["DE1/DE2A vector", "DNA", 105, 120], ["E2A cells", "CELL_LINE", 149, 158], ["an DE1 vector", "TREATMENT", 24, 37], ["E2A cells", "PROBLEM", 84, 93], ["an DE1/DE2A vector", "TREATMENT", 102, 120]]], ["Moreover, a temperature of 348C proved optimal for production of an DE1/DE2A vector on PER.E2A.", [["348C", "CHEMICAL", 27, 31], ["DE1", "GENE_OR_GENE_PRODUCT", 68, 71], ["DE2A", "GENE_OR_GENE_PRODUCT", 72, 76], ["E2A", "GENE_OR_GENE_PRODUCT", 91, 94], ["DE1/DE2A vector", "DNA", 68, 83], ["E2A", "PROTEIN", 91, 94], ["a temperature", "TEST", 10, 23], ["an DE1/DE2A vector", "TREATMENT", 65, 83]]], ["A subsequent time-course experiment whereby supernatant was harvested at 24, 48, 72, or 120 h after virus exposure demonstrated that the highest titer of DE1/DE2A vector could be obtained at 72 h post-virus exposure (data not shown).ResultsUsing these parameters, more than 25 batches of recombinant DE1/DE2A viruses carrying different transgenes have since been produced and purified on PER.E2A cells with averaged yield of 4.7 \u00c2 10 11 virus articles per milliliter and a virus particle per infectious unit ratio (VP/IU) of 22.4 AE 17.9 (average AE SD).", [["supernatant", "ANATOMY", 44, 55], ["cells", "ANATOMY", 396, 401], ["DE1", "GENE_OR_GENE_PRODUCT", 154, 157], ["DE2A", "GENE_OR_GENE_PRODUCT", 158, 162], ["recombinant", "ORGANISM", 288, 299], ["DE1/DE2A viruses", "ORGANISM", 300, 316], ["E2A", "GENE_OR_GENE_PRODUCT", 392, 395], ["DE1/DE2A vector", "DNA", 154, 169], ["E2A cells", "CELL_LINE", 392, 401], ["virus exposure", "TEST", 100, 114], ["DE1/DE2A vector", "TREATMENT", 154, 169], ["these parameters", "TEST", 246, 262], ["recombinant DE1/DE2A viruses", "TREATMENT", 288, 316], ["E2A cells", "TEST", 392, 401], ["a virus particle", "TEST", 471, 487], ["infectious unit ratio", "TEST", 492, 513], ["VP/IU)", "TEST", 515, 521], ["AE", "TEST", 530, 532]]], ["These production data are similar to data as established for DE1 adenoviral vectors production on PER.C6 cells.", [["C6 cells", "ANATOMY", 102, 110], ["DE1", "ORGANISM", 61, 64], ["adenoviral", "ORGANISM", 65, 75], ["C6 cells", "CELL", 102, 110], ["C6 cells", "CELL_LINE", 102, 110], ["DE1", "SPECIES", 61, 64], ["These production data", "TEST", 0, 21], ["DE1 adenoviral vectors production", "TREATMENT", 61, 94], ["C6 cells", "PROBLEM", 102, 110]]], ["A sensitive PCR analyses, discriminating between E2A \u00fe and E2A \u00c0 virus, performed on purified virus batches indicated that reversion, that is homologous recombination between E2A DNA in the cell and the viral genome, possibly leading to E2A \u00fe virus does not occur (data not shown).Replication Specificity and Viral Gene Expression of an DE1/DE2A VectorTo investigate the replication potential of an DE1/DE2A and as control DE1 recombinant vector in PER.C6 and PER.E2A in relation to cell culture temperature, both cell types were cultured at different temperatures and subsequently transduced with either a DE1 or an DE1/DE2A vector.", [["cell", "ANATOMY", 190, 194], ["cell", "ANATOMY", 483, 487], ["cell", "ANATOMY", 514, 518], ["E2A", "GENE_OR_GENE_PRODUCT", 49, 52], ["E2A", "GENE_OR_GENE_PRODUCT", 59, 62], ["E2A", "GENE_OR_GENE_PRODUCT", 175, 178], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["cell", "CELL", 190, 194], ["E2A", "GENE_OR_GENE_PRODUCT", 237, 240], ["DE2A", "GENE_OR_GENE_PRODUCT", 403, 407], ["E2A", "GENE_OR_GENE_PRODUCT", 464, 467], ["cell", "CELL", 483, 487], ["cell", "CELL", 514, 518], ["DE1", "GENE_OR_GENE_PRODUCT", 617, 620], ["DE2A", "GENE_OR_GENE_PRODUCT", 621, 625], ["E2A", "PROTEIN", 49, 52], ["E2A", "PROTEIN", 59, 62], ["E2A DNA", "DNA", 175, 182], ["viral genome", "DNA", 203, 215], ["E2A", "PROTEIN", 237, 240], ["DE1", "PROTEIN", 337, 340], ["DE2A VectorTo", "PROTEIN", 341, 354], ["DE1", "DNA", 399, 402], ["DE2A", "DNA", 403, 407], ["DE1 recombinant vector", "DNA", 423, 445], ["PER", "PROTEIN", 460, 463], ["E2A", "PROTEIN", 464, 467], ["DE1 or an DE1/DE2A vector", "DNA", 607, 632], ["E2A \u00c0 virus", "SPECIES", 59, 70], ["DE1", "SPECIES", 423, 426], ["A sensitive PCR analyses", "TEST", 0, 24], ["E2A \u00c0 virus", "PROBLEM", 59, 70], ["purified virus batches", "TREATMENT", 85, 107], ["E2A DNA", "PROBLEM", 175, 182], ["the viral genome", "PROBLEM", 199, 215], ["E2A \u00fe virus", "PROBLEM", 237, 248], ["an DE1/DE2A VectorTo", "TREATMENT", 334, 354], ["an DE1/DE2A", "TREATMENT", 396, 407], ["cell culture temperature", "TEST", 483, 507], ["both cell types", "PROBLEM", 509, 524], ["a DE1", "TREATMENT", 605, 610], ["an DE1/DE2A vector", "TREATMENT", 614, 632], ["viral genome", "OBSERVATION", 203, 215]]], ["Forty-eight hours after vector exposure, viral DNA was isolated and Southern analysis was performed.", [["DNA", "CELLULAR_COMPONENT", 47, 50], ["viral DNA", "DNA", 41, 50], ["vector exposure", "TREATMENT", 24, 39], ["viral DNA", "PROBLEM", 41, 50], ["Southern analysis", "TEST", 68, 85]]], ["From the results, shown in Figure 1B , the following conclusions were drawn: (i) at 32, 34, and 378C both an DE1 and DE1/DE2A vector can efficiently replicate in PER.E2A cells resulting in the clear detection of viral DNA copies at 48 post-virus exposure, (ii) at 398C the replication efficiency of an DE1/ DE2A vector is significantly reduced due to the absence of functional E2A protein, (iii) an DE1/DE2A vector exposure to PER.C6 cells did not result in detection of viral copies indicative for the absence of viral replication.", [["cells", "ANATOMY", 170, 175], ["C6 cells", "ANATOMY", 431, 439], ["E2A", "GENE_OR_GENE_PRODUCT", 166, 169], ["DNA", "CELLULAR_COMPONENT", 218, 221], ["DE1", "GENE_OR_GENE_PRODUCT", 302, 305], ["DE2A", "GENE_OR_GENE_PRODUCT", 307, 311], ["E2A", "GENE_OR_GENE_PRODUCT", 377, 380], ["C6 cells", "CELL", 431, 439], ["DE1 and DE1/DE2A vector", "DNA", 109, 132], ["PER", "PROTEIN", 162, 165], ["E2A cells", "CELL_LINE", 166, 175], ["viral DNA copies", "DNA", 212, 228], ["DE1/ DE2A vector", "DNA", 302, 318], ["E2A protein", "PROTEIN", 377, 388], ["PER", "PROTEIN", 427, 430], ["C6 cells", "CELL_LINE", 431, 439], ["an DE1 and DE1/DE2A vector", "TREATMENT", 106, 132], ["E2A cells", "PROBLEM", 166, 175], ["viral DNA copies", "PROBLEM", 212, 228], ["an DE1/ DE2A vector", "TREATMENT", 299, 318], ["an DE1/DE2A vector exposure", "TREATMENT", 396, 423], ["C6 cells", "PROBLEM", 431, 439], ["viral copies", "PROBLEM", 471, 483], ["viral replication", "PROBLEM", 514, 531], ["viral replication", "OBSERVATION", 514, 531]]], ["Since E2A is indirectly involved in activation of the viral major late promoter (MLP), responsible for driving late gene expression (structural proteins), deletion of this region from the adenoviral genome should result in absence of viral capsid proteins in transduced cells.", [["cells", "ANATOMY", 270, 275], ["E2A", "GENE_OR_GENE_PRODUCT", 6, 9], ["MLP", "GENE_OR_GENE_PRODUCT", 81, 84], ["adenoviral", "ORGANISM", 188, 198], ["cells", "CELL", 270, 275], ["E2A", "PROTEIN", 6, 9], ["viral major late promoter", "DNA", 54, 79], ["MLP", "DNA", 81, 84], ["structural proteins", "PROTEIN", 133, 152], ["adenoviral genome", "DNA", 188, 205], ["viral capsid proteins", "PROTEIN", 234, 255], ["transduced cells", "CELL_LINE", 259, 275], ["deletion of this region", "PROBLEM", 155, 178], ["the adenoviral genome", "TREATMENT", 184, 205], ["viral capsid proteins in transduced cells", "PROBLEM", 234, 275], ["adenoviral genome", "OBSERVATION", 188, 205], ["viral capsid proteins", "OBSERVATION", 234, 255], ["transduced cells", "OBSERVATION", 259, 275]]], ["To investigate capsid protein expression, human A549 indicator cells were exposed to an increasing concentration of DE1 or DE1/DE2A vector and Western analyses on protein lysates was performed.", [["A549", "ANATOMY", 48, 52], ["cells", "ANATOMY", 63, 68], ["lysates", "ANATOMY", 171, 178], ["DE1", "CHEMICAL", 116, 119], ["DE1", "CHEMICAL", 123, 126], ["DE1", "CHEMICAL", 116, 119], ["human", "ORGANISM", 42, 47], ["A549 indicator cells", "CELL", 48, 68], ["DE1", "SIMPLE_CHEMICAL", 116, 119], ["DE1", "SIMPLE_CHEMICAL", 123, 126], ["capsid protein", "PROTEIN", 15, 29], ["human A549 indicator cells", "CELL_LINE", 42, 68], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["capsid protein expression", "TREATMENT", 15, 40], ["human A549 indicator cells", "TREATMENT", 42, 68], ["an increasing concentration of DE1", "TREATMENT", 85, 119], ["DE1/DE2A vector", "TREATMENT", 123, 138], ["protein lysates", "TEST", 163, 178], ["protein expression", "OBSERVATION", 22, 40]]], ["As shown in Figure 1C , even at 10,000 virus particles per cell no expression could be observed from either penton or fiber capsid at 48 h after DE1/DE2A vector exposure.", [["cell", "ANATOMY", 59, 63], ["DE1", "CHEMICAL", 145, 148], ["DE2A", "CHEMICAL", 149, 153], ["cell", "CELL", 59, 63], ["penton", "CELLULAR_COMPONENT", 108, 114], ["fiber capsid", "CELLULAR_COMPONENT", 118, 130], ["fiber capsid", "TREATMENT", 118, 130], ["DE1/DE2A vector exposure", "TREATMENT", 145, 169]]], ["In contrast, expression of both penton and fiber capsid proteins could be detected after exposure of 1,000 virus particles per cell using a DE1 vector.", [["cell", "ANATOMY", 127, 131], ["penton", "GENE_OR_GENE_PRODUCT", 32, 38], ["cell", "CELL", 127, 131], ["penton and fiber capsid proteins", "PROTEIN", 32, 64], ["DE1 vector", "DNA", 140, 150], ["both penton and fiber capsid proteins", "PROBLEM", 27, 64], ["a DE1 vector", "TREATMENT", 138, 150], ["both penton", "OBSERVATION", 27, 38]]], ["Expression of pre-terminal protein (pTP) and terminal protein (TP) derived from the viral E2B region, involved exclusively in promoting viral DNA replication in the PER.E2A cell line, as well as E4 derived orf-6 protein (E4) involved in trans-activation of the CMV promoter driving expression of the gene encoding for the protein of interest (Gorziglia et al., 1999; Lusky et al., 1998) could still be detected.", [["cell line", "ANATOMY", 173, 182], ["pre-terminal protein", "GENE_OR_GENE_PRODUCT", 14, 34], ["pTP", "GENE_OR_GENE_PRODUCT", 36, 39], ["terminal protein", "GENE_OR_GENE_PRODUCT", 45, 61], ["TP", "GENE_OR_GENE_PRODUCT", 63, 65], ["E2B", "GENE_OR_GENE_PRODUCT", 90, 93], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["E2A", "GENE_OR_GENE_PRODUCT", 169, 172], ["E4", "GENE_OR_GENE_PRODUCT", 195, 197], ["orf-6", "GENE_OR_GENE_PRODUCT", 206, 211], ["E4", "GENE_OR_GENE_PRODUCT", 221, 223], ["CMV", "ORGANISM", 261, 264], ["pre-terminal protein", "PROTEIN", 14, 34], ["pTP", "PROTEIN", 36, 39], ["terminal protein", "PROTEIN", 45, 61], ["TP", "PROTEIN", 63, 65], ["viral E2B region", "DNA", 84, 100], ["E2A cell line", "CELL_LINE", 169, 182], ["E4 derived orf-6 protein", "PROTEIN", 195, 219], ["E4", "PROTEIN", 221, 223], ["CMV promoter", "DNA", 261, 273], ["pre-terminal protein (pTP)", "PROBLEM", 14, 40], ["terminal protein (TP)", "PROBLEM", 45, 66], ["the viral E2B region", "TREATMENT", 80, 100], ["viral DNA replication", "TREATMENT", 136, 157], ["E2A cell line", "TREATMENT", 169, 182], ["E4 derived orf", "TEST", 195, 209], ["the CMV promoter", "TREATMENT", 257, 273], ["viral E2B", "OBSERVATION", 84, 93], ["viral DNA replication", "OBSERVATION", 136, 157], ["cell line", "OBSERVATION", 173, 182]]], ["Finally, we determined whether equal levels of expression from an inserted transgene could be obtained using an DE1/DE2A as compared to a DE1 recombinant virus.", [["DE1", "GENE_OR_GENE_PRODUCT", 112, 115], ["DE2A", "GENE_OR_GENE_PRODUCT", 116, 120], ["DE1 recombinant virus", "ORGANISM", 138, 159], ["DE1", "PROTEIN", 112, 115], ["DE2A", "PROTEIN", 116, 120], ["an inserted transgene", "TREATMENT", 63, 84], ["an DE1/DE2A", "TREATMENT", 109, 120], ["a DE1 recombinant virus", "TREATMENT", 136, 159]]], ["Hereto, human A549 indicator cells were transduced with equal doses of vector carrying the LacZ marker gene.", [["A549 indicator cells", "ANATOMY", 14, 34], ["human", "ORGANISM", 8, 13], ["A549 indicator cells", "CELL", 14, 34], ["LacZ", "GENE_OR_GENE_PRODUCT", 91, 95], ["human A549 indicator cells", "CELL_LINE", 8, 34], ["LacZ marker gene", "DNA", 91, 107], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["human A549 indicator cells", "TREATMENT", 8, 34], ["vector", "TREATMENT", 71, 77], ["the LacZ marker gene", "TREATMENT", 87, 107]]], ["Since levels of reporter gene expression proved not (black bar).", [["reporter gene", "DNA", 16, 29]]], ["Forty-eight hours later cleared supernatant (100 mL) was added to human A549 cells and 48 h post-inoculation the number of LacZ positive cells was determined.", [["supernatant", "ANATOMY", 32, 43], ["A549 cells", "ANATOMY", 72, 82], ["cells", "ANATOMY", 137, 142], ["human", "ORGANISM", 66, 71], ["A549 cells", "CELL", 72, 82], ["LacZ", "GENE_OR_GENE_PRODUCT", 123, 127], ["cells", "CELL", 137, 142], ["human A549 cells", "CELL_LINE", 66, 82], ["LacZ positive cells", "CELL_LINE", 123, 142], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["human A549 cells", "TREATMENT", 66, 82], ["LacZ positive cells", "PROBLEM", 123, 142], ["positive cells", "OBSERVATION", 128, 142]]], ["B: PER.C6 and PER.E2A cells were infected with 10 virus particles per cell of an DE1 or DE1/E2A virus carrying the LacZ transgene.", [["cells", "ANATOMY", 22, 27], ["cell", "ANATOMY", 70, 74], ["DE1", "ANATOMY", 81, 84], ["PER.C6", "GENE_OR_GENE_PRODUCT", 3, 9], ["E2A", "GENE_OR_GENE_PRODUCT", 18, 21], ["cell", "CELL", 70, 74], ["DE1", "CANCER", 81, 84], ["DE1", "GENE_OR_GENE_PRODUCT", 88, 91], ["E2A", "GENE_OR_GENE_PRODUCT", 92, 95], ["LacZ", "GENE_OR_GENE_PRODUCT", 115, 119], ["PER.C6", "PROTEIN", 3, 9], ["PER", "PROTEIN", 14, 17], ["E2A cells", "CELL_LINE", 18, 27], ["LacZ transgene", "DNA", 115, 129], ["DE1", "SPECIES", 81, 84], ["E2A cells", "PROBLEM", 18, 27], ["an DE1", "TREATMENT", 78, 84], ["DE1/E2A virus", "TREATMENT", 88, 101], ["the LacZ transgene", "TREATMENT", 111, 129]]], ["Cells were subsequently cultured at 32, 34, 37, and 398C for 48 h prior to cell harvest and viral DNA isolation.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 75, 79], ["Cells", "CELL", 0, 5], ["cell", "CELL", 75, 79], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["Cells", "TEST", 0, 5], ["cell harvest", "TREATMENT", 75, 87], ["viral DNA isolation", "TREATMENT", 92, 111], ["cell harvest", "OBSERVATION", 75, 87], ["viral DNA isolation", "OBSERVATION", 92, 111]]], ["Southern analysis using a 32 P labeled probe (708 bp of LacZ gene) was performed with as a positive control, 2 \u00c2 10 8 virus genomes derived from a purified virus batch (\u00fe) and as a negative control, genomic DNA of the cell line (\u00c0).", [["cell line", "ANATOMY", 218, 227], ["LacZ", "GENE_OR_GENE_PRODUCT", 56, 60], ["DNA", "CELLULAR_COMPONENT", 207, 210], ["cell line", "CELL", 218, 227], ["\u00c0", "CELL", 229, 230], ["32 P labeled probe", "DNA", 26, 44], ["LacZ gene", "DNA", 56, 65], ["\u00c2 10 8 virus genomes", "DNA", 111, 131], ["genomic DNA", "DNA", 199, 210], ["cell line", "CELL_LINE", 218, 227], ["\u00c0", "CELL_LINE", 229, 230], ["Southern analysis", "TEST", 0, 17], ["a 32 P labeled probe", "TREATMENT", 24, 44], ["bp of LacZ gene", "TREATMENT", 50, 65], ["a positive control", "TREATMENT", 89, 107], ["a purified virus batch", "TREATMENT", 145, 167], ["cell line", "OBSERVATION", 218, 227]]], ["C: Human A549 cells were exposed to 100, 1000, or 10,000 vp/cell of either an DE1 or an DE1/E2A vector.", [["A549 cells", "ANATOMY", 9, 19], ["cell", "ANATOMY", 60, 64], ["Human", "ORGANISM", 3, 8], ["A549 cells", "CELL", 9, 19], ["cell", "CELL", 60, 64], ["DE1", "GENE_OR_GENE_PRODUCT", 88, 91], ["E2A", "GENE_OR_GENE_PRODUCT", 92, 95], ["Human A549 cells", "CELL_LINE", 3, 19], ["DE1/E2A vector", "DNA", 88, 102], ["Human", "SPECIES", 3, 8], ["Human A549 cells", "TREATMENT", 3, 19], ["an DE1/E2A vector", "TREATMENT", 85, 102], ["A549 cells", "OBSERVATION", 9, 19]]], ["Forty-eight hours later cells were harvested and protein lysate prepared.", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["protein lysate", "TREATMENT", 49, 63]]], ["Twenty microgram of total cellular protein was loaded for Western analysis and probed with antibodies against DBP (E2A), late genes encoding for fiber or penton, and pTP and TP, or the orf6 protein derived from the E4 region.", [["cellular", "ANATOMY", 26, 34], ["cellular", "CELL", 26, 34], ["DBP", "GENE_OR_GENE_PRODUCT", 110, 113], ["E2A", "GENE_OR_GENE_PRODUCT", 115, 118], ["fiber", "CELLULAR_COMPONENT", 145, 150], ["penton", "CELLULAR_COMPONENT", 154, 160], ["pTP", "GENE_OR_GENE_PRODUCT", 166, 169], ["TP", "GENE_OR_GENE_PRODUCT", 174, 176], ["orf6", "GENE_OR_GENE_PRODUCT", 185, 189], ["E4", "GENE_OR_GENE_PRODUCT", 215, 217], ["total cellular protein", "PROTEIN", 20, 42], ["antibodies", "PROTEIN", 91, 101], ["DBP", "PROTEIN", 110, 113], ["E2A", "PROTEIN", 115, 118], ["penton", "PROTEIN", 154, 160], ["pTP", "PROTEIN", 166, 169], ["TP", "PROTEIN", 174, 176], ["orf6 protein", "PROTEIN", 185, 197], ["E4 region", "DNA", 215, 224], ["total cellular protein", "TEST", 20, 42], ["Western analysis", "TEST", 58, 74], ["antibodies", "TEST", 91, 101], ["DBP", "TEST", 110, 113], ["fiber or penton", "TREATMENT", 145, 160], ["pTP", "TEST", 166, 169], ["TP", "TEST", 174, 176], ["the orf6 protein", "TEST", 181, 197]]], ["As a positive control (\u00fe), 20 mg of total cellular protein was loaded derived from PER.C6 cells infected with an DE1-LacZ virus.", [["cellular", "ANATOMY", 42, 50], ["C6 cells", "ANATOMY", 87, 95], ["cellular", "CELL", 42, 50], ["C6 cells", "CELL", 87, 95], ["DE1", "GENE_OR_GENE_PRODUCT", 113, 116], ["LacZ", "GENE_OR_GENE_PRODUCT", 117, 121], ["cellular protein", "PROTEIN", 42, 58], ["C6 cells", "CELL_LINE", 87, 95], ["DE1-LacZ virus", "SPECIES", 113, 127], ["total cellular protein", "TREATMENT", 36, 58], ["C6 cells", "PROBLEM", 87, 95], ["an DE1-LacZ virus", "PROBLEM", 110, 127], ["LacZ virus", "OBSERVATION", 117, 127]]], ["As negative control (\u00c0), A549 cell lysate was used.", [["A549 cell lysate", "ANATOMY", 25, 41], ["A549 cell", "CELL", 25, 34], ["A549 cell", "CELL_LINE", 25, 34], ["A549 cell lysate", "TREATMENT", 25, 41], ["A549 cell lysate", "OBSERVATION", 25, 41]]], ["D: Human A549 cells were exposed to 0, 100, 1,000, or 10,000 virus particles per cell of an DE1 (triangle) or an DE1/E2 (square) vector carrying LacZ.", [["A549 cells", "ANATOMY", 9, 19], ["cell", "ANATOMY", 81, 85], ["E2", "CHEMICAL", 117, 119], ["Human", "ORGANISM", 3, 8], ["A549 cells", "CELL", 9, 19], ["cell", "CELL", 81, 85], ["LacZ", "GENE_OR_GENE_PRODUCT", 145, 149], ["Human A549 cells", "CELL_LINE", 3, 19], ["LacZ", "PROTEIN", 145, 149], ["Human", "SPECIES", 3, 8], ["Human A549 cells", "TREATMENT", 3, 19], ["an DE1 (triangle", "TREATMENT", 89, 105], ["an DE1/E2 (square) vector carrying LacZ", "TREATMENT", 110, 149]]], ["Forty-eight hours after infection cells were analyzed for the amount of LacZ activity, expressed in relative LacZ activity per milligram protein.Replication Specificity and Viral Gene Expression of an DE1/DE2A Vectorsignificantly different using either LacZ (Fig. 1D) it was concluded that the vectors are comparable with regard to transduction capacity, capsid stability, and CMV-mediated protein expression.", [["cells", "ANATOMY", 34, 39], ["infection", "DISEASE", 24, 33], ["cells", "CELL", 34, 39], ["LacZ", "GENE_OR_GENE_PRODUCT", 72, 76], ["LacZ", "GENE_OR_GENE_PRODUCT", 109, 113], ["LacZ", "GENE_OR_GENE_PRODUCT", 253, 257], ["CMV", "ORGANISM", 377, 380], ["LacZ", "PROTEIN", 72, 76], ["LacZ", "PROTEIN", 109, 113], ["DE1", "DNA", 201, 204], ["DE2A", "DNA", 205, 209], ["LacZ", "DNA", 253, 257], ["infection cells", "PROBLEM", 24, 39], ["LacZ activity", "PROBLEM", 72, 85], ["an DE1/DE2A", "TREATMENT", 198, 209], ["LacZ (Fig. 1D", "TREATMENT", 253, 266], ["the vectors", "TREATMENT", 290, 301], ["transduction capacity", "TEST", 332, 353], ["capsid stability", "TEST", 355, 371], ["CMV", "TEST", 377, 380], ["LacZ activity", "OBSERVATION", 72, 85]]], ["Based on the data obtained thus far it was concluded that an DE1/DE2A adenoviral vector can be efficiently produced at 348C on PER.E2A cells and can subsequently serve as a tranducing agent for PER.C6 cells without inducing viral backbone replication or high level viral capsid protein expression in human A549 indicator cells.DE1/DE2A Vector Mediated Protein Production in PER.C6Taking advantage of the observation that DE1/DE2 vectors do not replicate on PER.C6 cells we were interested to investigate if recombinant protein could be efficiently expressed in PER.C6 cells using this vector.", [["E2A cells", "ANATOMY", 131, 140], ["C6 cells", "ANATOMY", 198, 206], ["A549 indicator cells", "ANATOMY", 306, 326], ["C6 cells", "ANATOMY", 461, 469], ["C6 cells", "ANATOMY", 565, 573], ["DE1", "GENE_OR_GENE_PRODUCT", 61, 64], ["DE2A", "GENE_OR_GENE_PRODUCT", 65, 69], ["adenoviral", "ORGANISM", 70, 80], ["E2A", "GENE_OR_GENE_PRODUCT", 131, 134], ["C6 cells", "CELL", 198, 206], ["human", "ORGANISM", 300, 305], ["A549 indicator cells", "CELL", 306, 326], ["DE2A Vector", "GENE_OR_GENE_PRODUCT", 331, 342], ["DE1", "GENE_OR_GENE_PRODUCT", 421, 424], ["DE2", "GENE_OR_GENE_PRODUCT", 425, 428], ["C6 cells", "CELL", 461, 469], ["C6 cells", "CELL", 565, 573], ["DE1/DE2A adenoviral vector", "DNA", 61, 87], ["E2A cells", "CELL_LINE", 131, 140], ["C6 cells", "CELL_LINE", 198, 206], ["viral capsid protein", "PROTEIN", 265, 285], ["human A549 indicator cells", "CELL_LINE", 300, 326], ["DE1", "PROTEIN", 327, 330], ["DE2A", "PROTEIN", 331, 335], ["DE1/DE2 vectors", "DNA", 421, 436], ["PER", "PROTEIN", 457, 460], ["C6 cells", "CELL_LINE", 461, 469], ["recombinant protein", "PROTEIN", 507, 526], ["PER", "PROTEIN", 561, 564], ["C6 cells", "CELL_LINE", 565, 573], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 300, 305], ["the data", "TEST", 9, 17], ["an DE1/DE2A adenoviral vector", "TREATMENT", 58, 87], ["a tranducing agent", "TREATMENT", 171, 189], ["C6 cells", "PROBLEM", 198, 206], ["inducing viral backbone replication", "PROBLEM", 215, 250], ["high level viral capsid protein expression in human A549 indicator cells", "PROBLEM", 254, 326], ["DE1/DE2 vectors", "TREATMENT", 421, 436], ["C6 cells", "PROBLEM", 461, 469], ["recombinant protein", "PROBLEM", 507, 526], ["this vector", "TREATMENT", 580, 591], ["without", "UNCERTAINTY", 207, 214], ["high", "OBSERVATION_MODIFIER", 254, 258], ["viral capsid protein expression", "OBSERVATION", 265, 296], ["A549 indicator cells", "OBSERVATION", 306, 326]]], ["To investigate yield, five DE1/DE2 vectors were generated and purified, one carrying the SARS-CoV soluble spike protein (S565), one carrying the complete SARS-CoA Spike protein (S1-spike), one carrying the soluble SARS virus receptor (sACE2), one carrying the complete ACE2 cellular receptor, and one carrying the heavy and LC coding for an SARS virus neutralizing antibody (ter Meulen et al., 2004) .", [["cellular", "ANATOMY", 274, 282], ["DE2", "GENE_OR_GENE_PRODUCT", 31, 34], ["SARS-CoA Spike", "GENE_OR_GENE_PRODUCT", 154, 168], ["SARS virus receptor", "GENE_OR_GENE_PRODUCT", 214, 233], ["ACE2", "GENE_OR_GENE_PRODUCT", 236, 240], ["ACE2 cellular receptor", "GENE_OR_GENE_PRODUCT", 269, 291], ["SARS virus", "ORGANISM", 341, 351], ["DE1/DE2 vectors", "DNA", 27, 42], ["SARS-CoV soluble spike protein", "PROTEIN", 89, 119], ["S565", "PROTEIN", 121, 125], ["SARS-CoA Spike protein", "PROTEIN", 154, 176], ["S1", "PROTEIN", 178, 180], ["soluble SARS virus receptor", "PROTEIN", 206, 233], ["ACE2", "PROTEIN", 236, 240], ["ACE2 cellular receptor", "PROTEIN", 269, 291], ["SARS virus neutralizing antibody", "PROTEIN", 341, 373], ["SARS-CoV", "SPECIES", 89, 97], ["SARS virus", "SPECIES", 214, 224], ["SARS virus", "SPECIES", 341, 351], ["five DE1/DE2 vectors", "TREATMENT", 22, 42], ["the SARS", "TEST", 85, 93], ["CoV soluble spike protein", "TEST", 94, 119], ["the complete SARS", "TEST", 141, 158], ["CoA Spike protein (S1-spike", "PROBLEM", 159, 186], ["the soluble SARS virus receptor", "TREATMENT", 202, 233], ["an SARS virus neutralizing antibody", "PROBLEM", 338, 373]]], ["These proteins were chosen since they represent different classes of proteins and to determine bioactivity of the proteins in binding assays (SARS-AB binds S1-spike and both S1-spike and S565 bind to the ACE2 receptor).", [["SARS-AB", "GENE_OR_GENE_PRODUCT", 142, 149], ["S1", "GENE_OR_GENE_PRODUCT", 156, 158], ["S565", "GENE_OR_GENE_PRODUCT", 187, 191], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 204, 217], ["S1", "PROTEIN", 156, 158], ["S1", "PROTEIN", 174, 176], ["S565", "PROTEIN", 187, 191], ["ACE2 receptor", "PROTEIN", 204, 217], ["These proteins", "TEST", 0, 14], ["binding assays", "TEST", 126, 140], ["SARS", "TEST", 142, 146], ["spike", "PROBLEM", 159, 164]]], ["The DE1/DE2 vector coding for complete ACE2 protein was subsequently used to transduce PER.C6 suspension cells cultured in 100 mL roller bottles at increasing concentrations of virus particles per cell.", [["PER.C6 suspension cells", "ANATOMY", 87, 110], ["cell", "ANATOMY", 197, 201], ["DE1", "GENE_OR_GENE_PRODUCT", 4, 7], ["DE2", "GENE_OR_GENE_PRODUCT", 8, 11], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["PER.C6 suspension cells", "CELL", 87, 110], ["cell", "CELL", 197, 201], ["DE1/DE2 vector", "DNA", 4, 18], ["ACE2 protein", "PROTEIN", 39, 51], ["PER.C6 suspension cells", "CELL_LINE", 87, 110], ["The DE1/DE2 vector", "TREATMENT", 0, 18], ["complete ACE2 protein", "TREATMENT", 30, 51], ["PER.C6 suspension cells", "TREATMENT", 87, 110], ["increasing concentrations of virus particles", "PROBLEM", 148, 192], ["virus particles", "OBSERVATION", 177, 192]]], ["Staining of the cells, 48 h after vector exposure, with a commercially available anti-ACE2 antibody demonstrated that approximately 90% of cells growing in suspension clearly produced the ACE2 protein using as little as 30 virus particles per cell as inoculation dose ( Fig. 2A) .", [["cells", "ANATOMY", 16, 21], ["cells", "ANATOMY", 139, 144], ["cell", "ANATOMY", 243, 247], ["cells", "CELL", 16, 21], ["anti-ACE2", "GENE_OR_GENE_PRODUCT", 81, 90], ["cells", "CELL", 139, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 188, 192], ["cell", "CELL", 243, 247], ["anti-ACE2 antibody", "PROTEIN", 81, 99], ["ACE2 protein", "PROTEIN", 188, 200], ["Staining of the cells", "PROBLEM", 0, 21], ["a commercially available anti-ACE2 antibody", "TEST", 56, 99], ["the ACE2 protein", "TEST", 184, 200], ["cells", "ANATOMY", 16, 21]]], ["In a subsequent experiment, shaker flasks (25 mL, 2.5 \u00c2 10 6 cells/mL) were inoculated with 10, 30, or 100 virus particles per cell using the DE1/DE2 vector expressing the SARS-AB.", [["cells", "ANATOMY", 61, 66], ["cell", "ANATOMY", 127, 131], ["SARS", "DISEASE", 172, 176], ["cell", "CELL", 127, 131], ["the DE1/DE2 vector", "TREATMENT", 138, 156]]], ["As shown in Figure 2B the antibody yield increased with increasing inoculation dose up to 60 mg/mL (at 100 VP/cell) over an 8-day batch production protocol.", [["cell", "ANATOMY", 110, 114], ["cell", "CELL", 110, 114], ["increasing inoculation dose", "TREATMENT", 56, 83], ["an 8-day batch production protocol", "TREATMENT", 121, 155], ["increased", "OBSERVATION_MODIFIER", 41, 50]]], ["Although the highest antibody concentration was obtained with the highest virus particle per cell concentration, 30 virus particles per cell was chosen as inoculation dose for the remainder of the experiments.", [["cell", "ANATOMY", 93, 97], ["cell", "ANATOMY", 136, 140], ["cell", "CELL", 93, 97], ["cell", "CELL", 136, 140], ["the highest antibody concentration", "TEST", 9, 43], ["the highest virus particle per cell concentration", "TREATMENT", 62, 111], ["inoculation dose", "TREATMENT", 155, 171]]], ["Experiments performed thus far used caesium chloride purified DE1/DE2 vectors (Fang et al., 1996; Goldman et al., 1995; O'Neal et al., 1998) .", [["caesium chloride", "CHEMICAL", 36, 52], ["caesium chloride", "CHEMICAL", 36, 52], ["caesium chloride", "SIMPLE_CHEMICAL", 36, 52], ["DE1", "SIMPLE_CHEMICAL", 62, 65], ["DE2", "GENE_OR_GENE_PRODUCT", 66, 69], ["caesium chloride", "TREATMENT", 36, 52]]], ["Clearly, timelines required to produce protein could be significantly reduced if PER.C6 cells could be inoculated with non-purified vector stocks produced on the PER.E2A cell line.", [["C6 cells", "ANATOMY", 85, 93], ["cell line", "ANATOMY", 170, 179], ["C6 cells", "CELL", 85, 93], ["E2A", "GENE_OR_GENE_PRODUCT", 166, 169], ["C6 cells", "CELL_LINE", 85, 93], ["E2A cell line", "CELL_LINE", 166, 179], ["C6 cells", "PROBLEM", 85, 93], ["non-purified vector stocks", "TREATMENT", 119, 145], ["E2A cell line", "TREATMENT", 166, 179], ["inoculated", "OBSERVATION_MODIFIER", 103, 113], ["vector stocks", "OBSERVATION", 132, 145], ["cell line", "OBSERVATION", 170, 179]]], ["Therefore a head-to-head comparison was performed whereby four infectious units per cell of either non-purified (cleared vector stock) or purified vector stock (caesium chloride gradient purified) was used to inoculate PER.C6 cells.", [["head", "ANATOMY", 12, 16], ["cell", "ANATOMY", 84, 88], ["PER.C6 cells", "ANATOMY", 219, 231], ["caesium chloride", "CHEMICAL", 161, 177], ["caesium chloride", "CHEMICAL", 161, 177], ["head", "ORGANISM_SUBDIVISION", 12, 16], ["cell", "CELL", 84, 88], ["caesium chloride", "SIMPLE_CHEMICAL", 161, 177], ["PER.C6 cells", "CELL", 219, 231], ["PER.C6 cells", "CELL_LINE", 219, 231], ["a head-to-head comparison", "TEST", 10, 35], ["purified vector stock (caesium chloride gradient", "TREATMENT", 138, 186], ["head", "ANATOMY", 12, 16]]], ["As shown in Figure 2C the yield of SARS anti-body produced did not significantly differ demonstrating that cleared vector stock directly harvested from he PER.E2A cell line can be used for production of recombinant protein without compromising yield.DE1/DE2A Vector Mediated Protein Production in PER.C6Next, roller bottles containing 2.5 \u00c2 10 6 PER.C6 cells/mL (100 mL) growing in suspension in absence of serum were inoculated with 30 virus particles per cell using the DE1/DE2 vector carrying the sACE2 receptor.", [["cell line", "ANATOMY", 163, 172], ["C6 cells", "ANATOMY", 350, 358], ["serum", "ANATOMY", 407, 412], ["cell", "ANATOMY", 457, 461], ["SARS", "DISEASE", 35, 39], ["E2A cell line", "CELL", 159, 172], ["DE2A Vector", "GENE_OR_GENE_PRODUCT", 254, 265], ["C6 cells", "CELL", 350, 358], ["serum", "ORGANISM_SUBSTANCE", 407, 412], ["cell", "CELL", 457, 461], ["DE2", "GENE_OR_GENE_PRODUCT", 476, 479], ["sACE2 receptor", "GENE_OR_GENE_PRODUCT", 500, 514], ["E2A cell line", "CELL_LINE", 159, 172], ["recombinant protein", "PROTEIN", 203, 222], ["DE1", "PROTEIN", 250, 253], ["DE2A", "PROTEIN", 254, 258], ["PER", "PROTEIN", 297, 300], ["C6 cells", "CELL_LINE", 350, 358], ["DE1/DE2 vector", "DNA", 472, 486], ["sACE2 receptor", "PROTEIN", 500, 514], ["SARS anti-body", "PROBLEM", 35, 49], ["E2A cell line", "TREATMENT", 159, 172], ["production of recombinant protein", "TREATMENT", 189, 222], ["C6 cells/mL", "PROBLEM", 350, 361], ["serum", "TEST", 407, 412], ["the DE1/DE2 vector", "TREATMENT", 468, 486], ["cell line", "OBSERVATION", 163, 172], ["suspension", "OBSERVATION_MODIFIER", 382, 392]]], ["Four days postinoculation cells were harvested demonstrating that the total cell count had not increased nor decreased over the 4-day vector exposure period.", [["cells", "ANATOMY", 26, 31], ["cell", "ANATOMY", 76, 80], ["cells", "CELL", 26, 31], ["cell", "CELL", 76, 80], ["the total cell count", "TEST", 66, 86], ["postinoculation cells", "OBSERVATION", 10, 31], ["total", "OBSERVATION_MODIFIER", 70, 75], ["cell count", "OBSERVATION", 76, 86], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["decreased", "OBSERVATION_MODIFIER", 109, 118]]], ["A volumetric productivity of 611 mg/mL and specific productivity of 61 pg/cell/day (611/4 days/2.5 million cells) was obtained using this production protocol.", [["cell", "ANATOMY", 74, 78], ["cells", "ANATOMY", 107, 112], ["cells", "CELL", 107, 112], ["A volumetric productivity", "TEST", 0, 25], ["this production protocol", "TREATMENT", 133, 157]]], ["Inoculation of roller bottles with 30 virus particles per cell of the DE1/DE2 vector coding for S565 resulted in a volumetric productivity of 370 mg/mL or specific productivity of 37 pg/cell/day.", [["cell", "ANATOMY", 58, 62], ["cell", "ANATOMY", 186, 190], ["S565", "CHEMICAL", 96, 100], ["cell", "CELL", 58, 62], ["DE2", "GENE_OR_GENE_PRODUCT", 74, 77], ["DE1/DE2 vector", "DNA", 70, 84], ["Inoculation of roller bottles", "TREATMENT", 0, 29], ["the DE1/DE2 vector", "TREATMENT", 66, 84]]], ["The SARS antibody yielded 140 mg/mL or specific productivity of 7 pg/cell/day during a 8 day batch production protocol.DE1/DE2A Vector Mediated Protein Production in PER.C6Since the sACE2 and S565 were generated carrying a Myc-His tag they could be easily purified using a commercially available (Nickel-based) HisTrap HP column that has affinity for the included histidine residues, whereas the SARS antibody was purified using HPLC as described in the Material and Method Section.", [["cell", "ANATOMY", 69, 73], ["SARS", "DISEASE", 4, 8], ["Nickel", "CHEMICAL", 297, 303], ["histidine", "CHEMICAL", 364, 373], ["His", "CHEMICAL", 227, 230], ["Nickel", "CHEMICAL", 297, 303], ["histidine", "CHEMICAL", 364, 373], ["DE2A Vector", "GENE_OR_GENE_PRODUCT", 123, 134], ["sACE2", "GENE_OR_GENE_PRODUCT", 182, 187], ["S565", "GENE_OR_GENE_PRODUCT", 192, 196], ["Myc", "GENE_OR_GENE_PRODUCT", 223, 226], ["SARS antibody", "PROTEIN", 4, 17], ["DE1", "PROTEIN", 119, 122], ["DE2A", "PROTEIN", 123, 127], ["PER", "PROTEIN", 166, 169], ["C6Since", "PROTEIN", 170, 177], ["sACE2", "DNA", 182, 187], ["S565", "DNA", 192, 196], ["Myc", "PROTEIN", 223, 226], ["SARS antibody", "PROTEIN", 396, 409], ["The SARS antibody", "TEST", 0, 17], ["a 8 day batch production protocol", "TREATMENT", 85, 118], ["a commercially available (Nickel-based) HisTrap HP column", "TREATMENT", 271, 328], ["histidine residues", "PROBLEM", 364, 382], ["the SARS antibody", "TEST", 392, 409], ["HPLC", "TEST", 429, 433]]], ["Purified proteins were run on SDS-PAGE gel and visualized either by whole protein staining (Collodial blue staining) or Western Blot analyses (Fig. 3 panels A and B , respectively) demonstrating protein integrity of transiently produced proteins without apparent aberrant protein being formed.DE1/DE2A Vector Mediated Protein Production in PER.C6To assess the bioactivity of the produced proteins two sets of experiments were performed.", [["DE2A Vector", "GENE_OR_GENE_PRODUCT", 297, 308], ["transiently produced proteins", "PROTEIN", 216, 245], ["DE1", "PROTEIN", 293, 296], ["DE2A", "PROTEIN", 297, 301], ["PER", "PROTEIN", 340, 343], ["C6To", "PROTEIN", 344, 348], ["Purified proteins", "PROBLEM", 0, 17], ["SDS", "TEST", 30, 33], ["whole protein staining", "TEST", 68, 90], ["Collodial blue staining", "TEST", 92, 115], ["Western Blot analyses", "TEST", 120, 141], ["protein integrity", "TEST", 195, 212], ["apparent aberrant protein", "PROBLEM", 254, 279], ["protein", "OBSERVATION", 272, 279]]], ["In the first set of experiments PER.C6 cells transiently expressing complete S1-spike protein were incubated with purified sACE2 protein and subsequently stained with anti-c-Myc (9E10) FITC labeled antibody.", [["C6 cells", "ANATOMY", 36, 44], ["FITC", "CHEMICAL", 185, 189], ["C6 cells", "CELL", 36, 44], ["sACE2", "GENE_OR_GENE_PRODUCT", 123, 128], ["anti-c-Myc", "GENE_OR_GENE_PRODUCT", 167, 177], ["9E10", "GENE_OR_GENE_PRODUCT", 179, 183], ["FITC", "GENE_OR_GENE_PRODUCT", 185, 189], ["C6 cells", "CELL_LINE", 36, 44], ["S1", "PROTEIN", 77, 79], ["spike protein", "PROTEIN", 80, 93], ["sACE2 protein", "PROTEIN", 123, 136], ["anti-c-Myc (9E10) FITC labeled antibody", "PROTEIN", 167, 206], ["C6 cells", "PROBLEM", 36, 44], ["purified sACE2 protein", "TEST", 114, 136], ["anti-c", "TEST", 167, 173], ["Myc", "TEST", 174, 177], ["FITC labeled antibody", "TEST", 185, 206]]], ["As shown in Figure 4A almost all cells expressed on their membrane the S1-spike protein resulting in clear binding of the sACE2 protein as witnessed by high mean fluorescence upon staining with the anti-c-Myc antibody.", [["cells", "ANATOMY", 33, 38], ["membrane", "ANATOMY", 58, 66], ["cells", "CELL", 33, 38], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["sACE2", "GENE_OR_GENE_PRODUCT", 122, 127], ["anti-c-Myc", "GENE_OR_GENE_PRODUCT", 198, 208], ["S1-spike protein", "PROTEIN", 71, 87], ["sACE2 protein", "PROTEIN", 122, 135], ["anti-c-Myc antibody", "PROTEIN", 198, 217], ["spike protein", "PROBLEM", 74, 87], ["clear binding of the sACE2 protein", "PROBLEM", 101, 135], ["high mean fluorescence", "PROBLEM", 152, 174], ["the anti-c", "TEST", 194, 204], ["clear binding", "OBSERVATION", 101, 114], ["Myc antibody", "OBSERVATION", 205, 217]]], ["In the second set of experiments, plates were coated with anti-Myc to capture S565 protein, which in turn was used to capture the SARS-AB.", [["SARS", "DISEASE", 130, 134], ["anti-Myc", "GENE_OR_GENE_PRODUCT", 58, 66], ["S565", "GENE_OR_GENE_PRODUCT", 78, 82], ["anti-Myc", "PROTEIN", 58, 66], ["S565 protein", "PROTEIN", 78, 90], ["anti-Myc", "TREATMENT", 58, 66]]], ["The ELISA was performed using an antibody dose titration and head-tohead comparison of the transiently produced antibody versus the SARS-AB produced and purified from PER.C6 cells that stably expresses this antibody (specific activity 14 pg/cell/day).", [["C6 cells", "ANATOMY", 171, 179], ["cell", "ANATOMY", 241, 245], ["C6 cells", "CELL", 171, 179], ["transiently produced antibody", "PROTEIN", 91, 120], ["C6 cells", "CELL_LINE", 171, 179], ["The ELISA", "TEST", 0, 9], ["an antibody dose titration", "TREATMENT", 30, 56], ["head-tohead comparison", "TEST", 61, 83], ["the transiently produced antibody", "PROBLEM", 87, 120], ["the SARS", "PROBLEM", 128, 136], ["C6 cells", "PROBLEM", 171, 179], ["this antibody", "TEST", 202, 215]]], ["As shown in Figure 4B no significant difference in binding affinity of the antibody could be observed using transient produced antibody as compared to the antibody produced from a stable cell line.DE1/DE2A Vector Mediated Protein Production in PER.C6Collectively the data obtained demonstrate that (i) DE1/ DE2 vectors are suitable for the production of different classes of proteins, that is, viral protein, cellular protein or antibody, (ii) a inoculation dose of 30 virus particles per cell suffices for significant protein yield without the need to purify vector inoculation stocks and is eligible for further optimization, and (iii) proteins produced and purified demonstrate proper integrity and bioactivity as witnessed in binding assays and compared to protein produced in stable cell lines.", [["cell line", "ANATOMY", 187, 196], ["cellular", "ANATOMY", 409, 417], ["cell", "ANATOMY", 489, 493], ["cell lines", "ANATOMY", 788, 798], ["cell line", "CELL", 187, 196], ["DE2A Vector", "GENE_OR_GENE_PRODUCT", 201, 212], ["DE2", "GENE_OR_GENE_PRODUCT", 307, 310], ["cellular", "CELL", 409, 417], ["cell", "CELL", 489, 493], ["cell lines", "CELL", 788, 798], ["transient produced antibody", "PROTEIN", 108, 135], ["stable cell line", "CELL_LINE", 180, 196], ["DE1", "PROTEIN", 197, 200], ["DE2A", "PROTEIN", 201, 205], ["PER", "PROTEIN", 244, 247], ["viral protein", "PROTEIN", 394, 407], ["cellular protein", "PROTEIN", 409, 425], ["antibody", "PROTEIN", 429, 437], ["stable cell lines", "CELL_LINE", 781, 798], ["significant difference in binding affinity", "PROBLEM", 25, 67], ["the antibody", "TEST", 71, 83], ["transient produced antibody", "PROBLEM", 108, 135], ["the antibody", "TEST", 151, 163], ["a stable cell line", "TREATMENT", 178, 196], ["DE1/ DE2 vectors", "TREATMENT", 302, 318], ["viral protein", "TEST", 394, 407], ["cellular protein", "TEST", 409, 425], ["antibody", "TEST", 429, 437], ["a inoculation dose of 30 virus particles", "TREATMENT", 444, 484], ["significant protein yield", "PROBLEM", 507, 532], ["vector inoculation stocks", "TREATMENT", 560, 585], ["further optimization", "TEST", 606, 626], ["binding assays", "TEST", 730, 744], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["difference", "OBSERVATION", 37, 47], ["binding affinity", "OBSERVATION", 51, 67], ["stable cell line", "OBSERVATION", 180, 196], ["stable cell lines", "OBSERVATION", 781, 798]]], ["As such, this platform could deliver high yield recombinant protein batches within approximately 30 working days (see projection in Fig. 5 ) although clearly further optimization is currently required to achieve vector generation and titration within approximately 4 weeks in order to perform large scale protein production.DiscussionSeveral reports have previously described the use of a replication deficient adenovirus in combination with adenovirus production cells (HEK293) with the aim to produce recombinant protein (Andersen and Krummen, 2002; C\u00f4 t\u00e9 et al., 1998; Garnier et al., 1994; Lamarche et al., 1990; Massie et al., 1995 Massie et al., , 1998 .", [["cells", "ANATOMY", 464, 469], ["HEK293", "ANATOMY", 471, 477], ["adenovirus", "ORGANISM", 411, 421], ["adenovirus", "ORGANISM", 442, 452], ["cells", "CELL", 464, 469], ["HEK293", "CELL", 471, 477], ["adenovirus production cells", "CELL_TYPE", 442, 469], ["HEK293", "CELL_LINE", 471, 477], ["recombinant protein", "PROTEIN", 503, 522], ["adenovirus", "SPECIES", 442, 452], ["high yield recombinant protein batches", "TREATMENT", 37, 75], ["vector generation", "TREATMENT", 212, 229], ["titration", "TREATMENT", 234, 243], ["large scale protein production", "PROBLEM", 293, 323], ["a replication deficient adenovirus", "TREATMENT", 387, 421], ["adenovirus production cells", "TREATMENT", 442, 469], ["large", "OBSERVATION_MODIFIER", 293, 298], ["scale protein production", "OBSERVATION", 299, 323]]], ["In these studies, the E1-deleted vector was allowed to replicate in HEK293 cells, in the process yielding high amounts (4-20% total cell protein) of the protein of interest.", [["HEK293 cells", "ANATOMY", 68, 80], ["cell", "ANATOMY", 132, 136], ["E1", "GENE_OR_GENE_PRODUCT", 22, 24], ["HEK293 cells", "CELL", 68, 80], ["cell", "CELL", 132, 136], ["E1-deleted vector", "DNA", 22, 39], ["HEK293 cells", "CELL_LINE", 68, 80], ["these studies", "TEST", 3, 16], ["the E1-deleted vector", "TREATMENT", 18, 39], ["HEK293 cells", "OBSERVATION", 68, 80], ["high", "OBSERVATION_MODIFIER", 106, 110], ["amounts", "OBSERVATION_MODIFIER", 111, 118]]], ["However, besides the formation of replication incompetent vectors during production it has been demonstrated that homologous recombination can occur in HEK293 cells between vector and cell line sequences resulting in the formation of RCA (Imler et al., 1995; Lochm\u00fcller et al., 1994) .", [["HEK293 cells", "ANATOMY", 152, 164], ["cell line", "ANATOMY", 184, 193], ["HEK293 cells", "CELL", 152, 164], ["cell line", "CELL", 184, 193], ["HEK293 cells", "CELL_LINE", 152, 164], ["replication incompetent vectors", "PROBLEM", 34, 65], ["homologous recombination", "PROBLEM", 114, 138], ["vector and cell line sequences", "TREATMENT", 173, 203], ["replication", "OBSERVATION_MODIFIER", 34, 45], ["incompetent", "OBSERVATION", 46, 57], ["cell line", "OBSERVATION", 184, 193], ["RCA", "ANATOMY", 234, 237]]], ["Another disadvantage of the reported systems is the relative short time frame allowed for protein production given the fact that the adenovirus lyses the cells that produce the protein of interest within days.DiscussionTo improve upon the existing systems, PER.C6 cells were chosen as a starting point for the generation of a transient protein production platform (Fallaux et al., 1998) .", [["cells", "ANATOMY", 154, 159], ["C6 cells", "ANATOMY", 261, 269], ["adenovirus", "ORGANISM", 133, 143], ["cells", "CELL", 154, 159], ["C6 cells", "CELL", 261, 269], ["C6 cells", "CELL_LINE", 261, 269], ["adenovirus", "SPECIES", 133, 143], ["protein production", "PROBLEM", 90, 108], ["the adenovirus lyses the cells", "PROBLEM", 129, 159], ["C6 cells", "PROBLEM", 261, 269], ["a transient protein production platform", "PROBLEM", 324, 363]]], ["This cell line has been extensively documented, cell banks meet all pertinent US and EEC regulatory requirements, cells can be cultured in suspension without the aid of micro-carriers to high cell densities (>10 7 cells/mL), cells can be cultured in suspension in the absence of any serum components, and cultures can be scaled to large bioreactors.", [["cell line", "ANATOMY", 5, 14], ["cell", "ANATOMY", 48, 52], ["cells", "ANATOMY", 114, 119], ["cell", "ANATOMY", 192, 196], ["cells", "ANATOMY", 214, 219], ["cells", "ANATOMY", 225, 230], ["serum", "ANATOMY", 283, 288], ["cell line", "CELL", 5, 14], ["cell", "CELL", 48, 52], ["cells", "CELL", 114, 119], ["cell", "CELL", 192, 196], ["cells", "CELL", 225, 230], ["serum", "ORGANISM_SUBSTANCE", 283, 288], ["cell line", "CELL_LINE", 5, 14], ["This cell line", "TREATMENT", 0, 14], ["all pertinent US", "TEST", 64, 80], ["EEC regulatory requirements", "PROBLEM", 85, 112], ["micro-carriers", "PROBLEM", 169, 183], ["high cell densities", "PROBLEM", 187, 206], ["cells", "PROBLEM", 225, 230], ["any serum components", "PROBLEM", 279, 299], ["cultures", "TEST", 305, 313], ["large bioreactors", "TREATMENT", 331, 348], ["cell line", "OBSERVATION", 5, 14], ["cell banks", "OBSERVATION", 48, 58], ["high cell densities", "OBSERVATION", 187, 206]]], ["In addition, the formation of RCA vectors has never been reported.", [["RCA", "GENE_OR_GENE_PRODUCT", 30, 33], ["RCA vectors", "DNA", 30, 41], ["RCA vectors", "TREATMENT", 30, 41], ["RCA", "OBSERVATION", 30, 33]]], ["To meet other criteria, that is absence of replication deficient virus particles and de novo synthesis of viral capsid proteins that could negatively influence cell viability and proliferation, an adenovirus deleted in its genome for both the E1/E2A regions was generated.", [["cell", "ANATOMY", 160, 164], ["cell", "CELL", 160, 164], ["adenovirus", "ORGANISM", 197, 207], ["E1", "GENE_OR_GENE_PRODUCT", 243, 245], ["E2A", "GENE_OR_GENE_PRODUCT", 246, 249], ["viral capsid proteins", "PROTEIN", 106, 127], ["E1/E2A regions", "DNA", 243, 257], ["replication deficient virus particles", "PROBLEM", 43, 80], ["viral capsid proteins", "PROBLEM", 106, 127], ["an adenovirus", "PROBLEM", 194, 207], ["E2A", "ANATOMY", 246, 249]]], ["Deletion of these regions has been previously shown to result in absence of almost all viral gene expression (Gorziglia et al., 1999; Lusky et al., 1998; O'Neal Figure 2 .", [["Deletion of these regions", "PROBLEM", 0, 25], ["viral gene expression", "OBSERVATION", 87, 108]]], ["A: Shaker flasks were inoculated in parallel with MOI 0, 30, 60 and 120 vp/cell of a DE1/DE2 vector carrying the complete ACE2 coding region.", [["cell", "ANATOMY", 75, 79], ["cell", "CELL", 75, 79], ["DE2", "GENE_OR_GENE_PRODUCT", 89, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 122, 126], ["DE1/DE2 vector", "DNA", 85, 99], ["ACE2 coding region", "DNA", 122, 140], ["a DE1/DE2 vector", "TREATMENT", 83, 99]]], ["Forty-eight hours later the percentage of cells positive for ACE2 protein was determined with FACS by staining cells with goat anti-ACE2 and PE-conjugated Donkey anti-human IgG (100-fold dilution).", [["cells", "ANATOMY", 42, 47], ["cells", "ANATOMY", 111, 116], ["cells", "CELL", 42, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["cells", "CELL", 111, 116], ["goat", "ORGANISM", 122, 126], ["anti-ACE2", "SIMPLE_CHEMICAL", 127, 136], ["PE", "SIMPLE_CHEMICAL", 141, 143], ["ACE2 protein", "PROTEIN", 61, 73], ["goat anti-ACE2 and PE-conjugated Donkey anti-human IgG", "PROTEIN", 122, 176], ["goat", "SPECIES", 122, 126], ["goat", "SPECIES", 122, 126], ["ACE2 protein", "TEST", 61, 73], ["staining cells", "TEST", 102, 116], ["goat anti-ACE2", "TEST", 122, 136], ["PE", "TEST", 141, 143], ["conjugated Donkey anti-human IgG", "TREATMENT", 144, 176], ["PE", "OBSERVATION", 141, 143]]], ["Parental PER.C6 stained with goat anti-ACE2 and PE-conjugated Donkey anti-human IgG served as negative control.", [["PE", "CHEMICAL", 48, 50], ["goat", "ORGANISM", 29, 33], ["anti-ACE2", "GENE_OR_GENE_PRODUCT", 34, 43], ["PE", "SIMPLE_CHEMICAL", 48, 50], ["PER.C6", "PROTEIN", 9, 15], ["goat anti-ACE2", "PROTEIN", 29, 43], ["PE-conjugated Donkey anti-human IgG", "PROTEIN", 48, 83], ["goat", "SPECIES", 29, 33], ["goat", "SPECIES", 29, 33], ["goat anti-ACE2", "TREATMENT", 29, 43], ["PE", "PROBLEM", 48, 50], ["conjugated Donkey anti-human IgG", "TREATMENT", 51, 83], ["PE", "OBSERVATION", 48, 50]]], ["B: Shaker flasks were inoculated in parallel with 30 (diamond), 60 (square) and 100 (triangle) vp/cell of a DE1/DE2 vector carrying the SARS-AB coding regions.", [["cell", "ANATOMY", 98, 102], ["DE2", "GENE_OR_GENE_PRODUCT", 112, 115], ["DE1/DE2 vector", "DNA", 108, 122], ["SARS-AB coding regions", "DNA", 136, 158], ["Shaker flasks", "PROBLEM", 3, 16], ["a DE1/DE2 vector", "TREATMENT", 106, 122], ["the SARS", "PROBLEM", 132, 140]]], ["The concentration of the antibody produced was determined in medium samples using HPLC-protA column chromatography standardized for IgG quantity measurement.", [["samples", "ANATOMY", 68, 75], ["IgG", "PROTEIN", 132, 135], ["the antibody", "TREATMENT", 21, 33], ["HPLC", "TEST", 82, 86], ["protA column chromatography", "TEST", 87, 114], ["IgG quantity measurement", "TEST", 132, 156]]], ["C: Shaker flasks were inoculated in parallel with 1 \u00c2 10 9 infectious virus particles (4 IU/cell) of either CsCL-purified vector (triangles) or with cleared crude lysate (squares).", [["cell", "ANATOMY", 92, 96], ["lysate", "ANATOMY", 163, 169], ["cell", "CELL", 92, 96], ["Shaker flasks", "PROBLEM", 3, 16], ["9 infectious virus particles", "PROBLEM", 57, 85]]], ["The concentration of the antibody produced was determined in medium samples using HPLC-protA column chromatography standardized for IgG quantity measurement.", [["samples", "ANATOMY", 68, 75], ["IgG", "PROTEIN", 132, 135], ["the antibody", "TREATMENT", 21, 33], ["HPLC", "TEST", 82, 86], ["protA column chromatography", "TEST", 87, 114], ["IgG quantity measurement", "TEST", 132, 156]]], ["[Color figure can be seen in the online version of this article, available at www.interscience.wiley.com.] et al., 1998) without compromising CMV promoter activity driving foreign gene expression (Gorziglia et al., 1999; Lusky et al., 1998) .", [["CMV", "ORGANISM", 142, 145], ["CMV promoter", "DNA", 142, 154]]], ["This report demonstrates that a DE1/DE2A vector is unable to replicate in PER.C6 cells and does not express viral capsid proteins even after high dose inoculation of susceptible human A549 cells.DiscussionWe therefore postulated that this vector could provide a safe reagent to introduce DNA into PER.C6 cells growing in suspension for scalable transient protein production purposes.", [["C6 cells", "ANATOMY", 78, 86], ["A549 cells", "ANATOMY", 184, 194], ["C6 cells", "ANATOMY", 301, 309], ["DE1", "GENE_OR_GENE_PRODUCT", 32, 35], ["DE2A", "GENE_OR_GENE_PRODUCT", 36, 40], ["C6 cells", "CELL", 78, 86], ["human", "ORGANISM", 178, 183], ["A549 cells", "CELL", 184, 194], ["DNA", "CELLULAR_COMPONENT", 288, 291], ["C6 cells", "CELL", 301, 309], ["DE1/DE2A vector", "DNA", 32, 47], ["PER", "PROTEIN", 74, 77], ["C6 cells", "CELL_LINE", 78, 86], ["viral capsid proteins", "PROTEIN", 108, 129], ["susceptible human A549 cells", "CELL_LINE", 166, 194], ["PER", "PROTEIN", 297, 300], ["C6 cells", "CELL_LINE", 301, 309], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["a DE1/DE2A vector", "TREATMENT", 30, 47], ["C6 cells", "PROBLEM", 78, 86], ["viral capsid proteins", "PROBLEM", 108, 129], ["high dose inoculation of susceptible human A549 cells", "TREATMENT", 141, 194], ["this vector", "TREATMENT", 234, 245], ["a safe reagent", "TREATMENT", 260, 274], ["C6 cells", "PROBLEM", 301, 309], ["scalable transient protein production purposes", "PROBLEM", 336, 382], ["A549 cells", "OBSERVATION", 184, 194], ["transient", "OBSERVATION_MODIFIER", 345, 354], ["protein production", "OBSERVATION", 355, 373]]], ["In order to produce high-titer DE1/DE2A vector we established the PER.E2A cell line.", [["cell line", "ANATOMY", 74, 83], ["E2A", "GENE_OR_GENE_PRODUCT", 70, 73], ["DE1", "PROTEIN", 31, 34], ["DE2A vector", "DNA", 35, 46], ["PER", "PROTEIN", 66, 69], ["E2A cell line", "CELL_LINE", 70, 83], ["high-titer DE1/DE2A vector", "TREATMENT", 20, 46], ["E2A cell line", "TREATMENT", 70, 83], ["cell line", "OBSERVATION", 74, 83]]], ["Hereto, a temperature sensitive mutant E2A gene (Vliet and Sussenbach, 1975) was employed since wild type E2A protein expression is known to be toxic to cells (Klessig et al., 1984) .", [["cells", "ANATOMY", 153, 158], ["E2A", "GENE_OR_GENE_PRODUCT", 39, 42], ["E2A", "GENE_OR_GENE_PRODUCT", 106, 109], ["cells", "CELL", 153, 158], ["temperature sensitive mutant E2A gene", "DNA", 10, 47], ["E2A protein", "PROTEIN", 106, 117], ["wild type E2A protein expression", "PROBLEM", 96, 128], ["toxic to cells", "PROBLEM", 144, 158]]], ["The temperature sensitive mutant carries a mutation in codon 413 of the DNA binding protein transcribed from the E2A region of adenovirus serotype 5 (Kruijer et al., 1981) , which results in functional E2A protein at 328C but not at 398C.", [["DNA", "CELLULAR_COMPONENT", 72, 75], ["E2A", "GENE_OR_GENE_PRODUCT", 113, 116], ["adenovirus serotype 5", "ORGANISM", 127, 148], ["E2A", "GENE_OR_GENE_PRODUCT", 202, 205], ["codon 413", "DNA", 55, 64], ["DNA binding protein", "PROTEIN", 72, 91], ["E2A region", "DNA", 113, 123], ["E2A protein", "PROTEIN", 202, 213], ["328C", "PROTEIN", 217, 221], ["The temperature", "TEST", 0, 15], ["a mutation in codon", "PROBLEM", 41, 60], ["the DNA binding protein", "TREATMENT", 68, 91], ["adenovirus serotype", "TREATMENT", 127, 146], ["functional E2A protein", "TEST", 191, 213]]], ["This allowed the establishment of a stable E2A expressing cell line that could be cultured without apparent growth deficit or viability loss at 398C as compared to parental PER.C6 cells.", [["cell line", "ANATOMY", 58, 67], ["PER.C6 cells", "ANATOMY", 173, 185], ["E2A", "GENE_OR_GENE_PRODUCT", 43, 46], ["cell line", "CELL", 58, 67], ["PER.C6 cells", "CELL", 173, 185], ["E2A expressing cell line", "CELL_LINE", 43, 67], ["PER.C6 cells", "CELL_LINE", 173, 185], ["a stable E2A expressing cell line", "TREATMENT", 34, 67], ["apparent growth deficit", "PROBLEM", 99, 122], ["viability loss", "PROBLEM", 126, 140], ["stable", "OBSERVATION_MODIFIER", 36, 42], ["cell line", "OBSERVATION", 58, 67]]], ["For production of the DE1/DE2 vector the PER.E2A cells were switched to a temperature of 328C, which allowed a 5 day time window for vector production before cell viability started to decrease due to E2A expression.", [["PER.E2A cells", "ANATOMY", 41, 54], ["cell", "ANATOMY", 158, 162], ["DE1", "GENE_OR_GENE_PRODUCT", 22, 25], ["DE2", "GENE_OR_GENE_PRODUCT", 26, 29], ["PER.E2A cells", "CELL", 41, 54], ["cell", "CELL", 158, 162], ["E2A", "GENE_OR_GENE_PRODUCT", 200, 203], ["DE1/DE2 vector", "DNA", 22, 36], ["PER.E2A cells", "CELL_LINE", 41, 54], ["E2A", "PROTEIN", 200, 203], ["the DE1/DE2 vector", "TREATMENT", 18, 36], ["a temperature", "TEST", 72, 85], ["vector production", "TREATMENT", 133, 150], ["cell viability", "TREATMENT", 158, 172]]], ["To ensure scalability of the platform the PER.E2A cells were adapted to grow in suspension, in the absence of serum components.DiscussionThis report thus describes for the first time a transient protein production system that can be as safe as the use of naked DNA for large scale transient protein production but solves the current technological bottlenecks associated with PER.C6 cells were exposed to 30 vp/cell of an DE1/DE2 vector carrying the S1-spike coding domain.", [["PER.E2A cells", "ANATOMY", 42, 55], ["serum", "ANATOMY", 110, 115], ["C6 cells", "ANATOMY", 379, 387], ["cell", "ANATOMY", 410, 414], ["PER.E2A cells", "CELL", 42, 55], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["DNA", "CELLULAR_COMPONENT", 261, 264], ["C6 cells", "CELL", 379, 387], ["cell", "CELL", 410, 414], ["DE1", "GENE_OR_GENE_PRODUCT", 421, 424], ["DE2", "GENE_OR_GENE_PRODUCT", 425, 428], ["PER.E2A cells", "CELL_LINE", 42, 55], ["PER", "PROTEIN", 375, 378], ["C6 cells", "CELL_LINE", 379, 387], ["DE1/DE2 vector", "DNA", 421, 435], ["S1-spike coding domain", "DNA", 449, 471], ["serum components", "PROBLEM", 110, 126], ["a transient protein production system", "PROBLEM", 183, 220], ["naked DNA", "PROBLEM", 255, 264], ["large scale transient protein production", "PROBLEM", 269, 309], ["C6 cells", "PROBLEM", 379, 387], ["an DE1/DE2 vector", "TREATMENT", 418, 435], ["scalability", "OBSERVATION_MODIFIER", 10, 21], ["protein production", "OBSERVATION", 291, 309], ["S1", "ANATOMY", 449, 451]]], ["Forty-eight hours post-exposure cells were harvested and stained with 40 mg/mL transiently produced sACE2.", [["cells", "ANATOMY", 32, 37], ["cells", "CELL", 32, 37], ["sACE2", "GENE_OR_GENE_PRODUCT", 100, 105], ["sACE2", "PROTEIN", 100, 105]]], ["To visualize sACE2 binding to S1-spike cells were further incubated with mouse-anti-c-myc-FITC.", [["S1-spike cells", "ANATOMY", 30, 44], ["FITC", "CHEMICAL", 90, 94], ["sACE2", "GENE_OR_GENE_PRODUCT", 13, 18], ["cells", "CELL", 39, 44], ["mouse", "ORGANISM", 73, 78], ["anti-c-myc", "GENE_OR_GENE_PRODUCT", 79, 89], ["FITC", "GENE_OR_GENE_PRODUCT", 90, 94], ["sACE2", "PROTEIN", 13, 18], ["S1-spike cells", "CELL_LINE", 30, 44], ["mouse-anti-c-myc-FITC", "PROTEIN", 73, 94], ["mouse", "SPECIES", 73, 78], ["mouse", "SPECIES", 73, 78], ["spike cells", "PROBLEM", 33, 44], ["mouse", "TEST", 73, 78], ["S1", "ANATOMY", 30, 32]]], ["Unstained infected PER.C6 cells were used to set back ground cell staining at 1%.", [["C6 cells", "ANATOMY", 23, 31], ["back ground cell", "ANATOMY", 49, 65], ["C6 cells", "CELL", 23, 31], ["cell", "CELL", 61, 65], ["C6 cells", "CELL_LINE", 23, 31], ["C6 cells", "PROBLEM", 23, 31], ["infected", "OBSERVATION", 10, 18]]], ["B: The SARS virus neutralizing antibody produced transiently using a DE1/DE2 vector (triangles) was compared to the identical antibody produced on PER.C6 cells stably expressing this antibody (diamonds) via ELISA.", [["C6 cells", "ANATOMY", 151, 159], ["SARS virus", "ORGANISM", 7, 17], ["DE2", "GENE_OR_GENE_PRODUCT", 73, 76], ["C6 cells", "CELL", 151, 159], ["SARS virus neutralizing antibody", "PROTEIN", 7, 39], ["DE1/DE2 vector", "DNA", 69, 83], ["C6 cells", "CELL_LINE", 151, 159], ["SARS virus", "SPECIES", 7, 17], ["The SARS virus neutralizing antibody", "TEST", 3, 39], ["a DE1/DE2 vector", "TREATMENT", 67, 83], ["C6 cells", "PROBLEM", 151, 159], ["ELISA", "TEST", 207, 212]]], ["Binding of the SARS-AB to S565 in a dose dependent manner was detected using peroxidase-conjugated AffiniPure donkey anti-human IgG (Jackson Immuno Research) . the use of naked DNA transfection, that is, limited internalization of plasmid DNA into mammalian cells and limited transport of plasmid DNA to the nucleus.", [["plasmid", "ANATOMY", 231, 238], ["mammalian cells", "ANATOMY", 248, 263], ["plasmid", "ANATOMY", 289, 296], ["nucleus", "ANATOMY", 308, 315], ["SARS", "DISEASE", 15, 19], ["S565", "CHEMICAL", 26, 30], ["SARS-AB", "GENE_OR_GENE_PRODUCT", 15, 22], ["S565", "GENE_OR_GENE_PRODUCT", 26, 30], ["peroxidase", "SIMPLE_CHEMICAL", 77, 87], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["mammalian cells", "CELL", 248, 263], ["plasmid", "CELLULAR_COMPONENT", 289, 296], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["nucleus", "CELLULAR_COMPONENT", 308, 315], ["S565", "DNA", 26, 30], ["peroxidase", "PROTEIN", 77, 87], ["AffiniPure donkey anti-human IgG", "PROTEIN", 99, 131], ["Jackson", "PROTEIN", 133, 140], ["plasmid DNA", "DNA", 231, 242], ["mammalian cells", "CELL_TYPE", 248, 263], ["plasmid DNA", "DNA", 289, 300], ["donkey", "SPECIES", 110, 116], ["the SARS", "TEST", 11, 19], ["peroxidase-conjugated AffiniPure donkey anti-human IgG", "TREATMENT", 77, 131], ["naked DNA transfection", "TREATMENT", 171, 193], ["plasmid DNA into mammalian cells", "TREATMENT", 231, 263], ["mammalian cells", "OBSERVATION", 248, 263], ["nucleus", "ANATOMY", 308, 315]]], ["Several improvements to this system that will be investigated next include the set-up of a fast and reliable RT-PCR or FACS-based virus titration assay, needed to replace the laborious TCID 50 assay.", [["PCR", "TEST", 112, 115], ["FACS", "TEST", 119, 123], ["the laborious TCID", "TREATMENT", 171, 189]]], ["Also, analyses need to be performed regarding the quality of protein produced using this novel system to investigate proper post-translational modification.", [["this novel system", "TREATMENT", 84, 101], ["proper post-translational modification", "TREATMENT", 117, 155]]], ["Regardless of these points of consideration, the data obtained thus far warrant further investigations into the robustness and safety aspects of this transient protein production system given that there is an increasing demand for high quality, high yield recombinant protein to facilitate pre-clinical and clinical pilot studies.DiscussionEssentially the process described in Figure 5 is not limited by scale given the calculations demonstrating that at 1,000 liter scale (PER.C6 cell density at 2 \u00c2 10 6 cells/ mL \u00bc 2 \u00c2 10 12 cells) a vector inoculation dose (50 IU/cell) of 1 \u00c2 10 14 IU would be required.", [["C6 cell", "ANATOMY", 478, 485], ["cells", "ANATOMY", 506, 511], ["cells", "ANATOMY", 528, 533], ["cell", "ANATOMY", 568, 572], ["C6 cell", "CELL", 478, 485], ["cells", "CELL", 506, 511], ["cells", "CELL", 528, 533], ["recombinant protein", "PROTEIN", 256, 275], ["the data", "TEST", 45, 53], ["further investigations", "TEST", 80, 102], ["this transient protein production system", "PROBLEM", 145, 185], ["an increasing demand", "PROBLEM", 206, 226], ["high yield recombinant protein", "PROBLEM", 245, 275], ["clinical pilot studies", "TEST", 307, 329], ["the calculations", "TEST", 416, 432], ["C6 cell density", "TEST", 478, 493], ["cells/ mL \u00bc", "TEST", 506, 517], ["a vector inoculation dose", "TREATMENT", 535, 560], ["increasing", "OBSERVATION_MODIFIER", 209, 219], ["cell density", "OBSERVATION", 481, 493]]], ["This amount of virus can easily be generated due to the efficient virus amplification using the suspension PER.E2A cell line cultured at 2 \u00c2 10 6 cells per mL in a 10 liter bioreactor within the timeframe of 4 weeks.", [["cell line", "ANATOMY", 115, 124], ["cells", "ANATOMY", 146, 151], ["E2A cell line", "CELL", 111, 124], ["cells", "CELL", 146, 151], ["E2A cell line", "CELL_LINE", 111, 124], ["virus", "PROBLEM", 15, 20], ["the efficient virus amplification", "TREATMENT", 52, 85], ["E2A cell line", "TREATMENT", 111, 124], ["a 10 liter bioreactor", "TREATMENT", 162, 183], ["virus", "OBSERVATION", 15, 20], ["virus", "OBSERVATION", 66, 71], ["cell line", "OBSERVATION", 115, 124]]]], "PMC7305927": [["1.1 Energy demand and neural networks ::: IntroductionWith increasing energy demands and fluctuations, modeling, and forecasting of energy gain increasing importance.", [["neural networks", "ANATOMY", 22, 37], ["neural networks", "MULTI-TISSUE_STRUCTURE", 22, 37], ["increasing energy demands", "PROBLEM", 59, 84], ["energy demands", "OBSERVATION", 70, 84]]], ["The mining and consumption of fossil fuels directly influence phenomena such as air pollution in metropolitan areas.", [["fossil fuels", "TREATMENT", 30, 42], ["influence phenomena", "PROBLEM", 52, 71], ["air pollution in metropolitan areas", "PROBLEM", 80, 115], ["fossil fuels", "OBSERVATION", 30, 42], ["air pollution", "OBSERVATION", 80, 93]]], ["Different methods and tools are used to analyze energy demand and determine the effect of various factors.", [["Different methods", "TREATMENT", 0, 17]]], ["Most of the researches conducted was to estimate petroleum and electricity demand through linear function and econometric methods [8].", [["petroleum", "SIMPLE_CHEMICAL", 49, 58], ["econometric methods", "TREATMENT", 110, 129]]], ["However, since the variables affecting energy carrier demand are volatile over the studied time series period, nonlinear methods can provide better estimates for energy consumption [9].1.1 Energy demand and neural networks ::: IntroductionCompletely nonlinear trends such as oil and electricity consumption are highly complex and are influenced by various factors, each of which exhibiting complicated behavior.", [["neural networks", "ANATOMY", 207, 222], ["neural networks", "MULTI-TISSUE_STRUCTURE", 207, 222], ["oil", "ORGANISM_SUBSTANCE", 275, 278], ["nonlinear methods", "TREATMENT", 111, 128]]], ["For this reason, modeling through the analysis method is practically impossible for these phenomena.", [["the analysis method", "TEST", 34, 53], ["these phenomena", "PROBLEM", 84, 99], ["phenomena", "OBSERVATION", 90, 99]]], ["For modeling such phenomena, traditionally, statistical techniques and regression modeling, and recently, methods based on artificial intelligence, such as Artificial Neural Networks (ANNs) or nonlinear Regression and other hybrid models, are used.", [["modeling such phenomena", "PROBLEM", 4, 27], ["regression modeling", "TEST", 71, 90], ["artificial intelligence", "TREATMENT", 123, 146], ["Artificial Neural Networks", "TREATMENT", 156, 182], ["nonlinear Regression and other hybrid models", "PROBLEM", 193, 237]]], ["The advantage of using neural networks is in their ability to identify and determine the relationship between input and output variables without the need to acquire a comprehensive knowledge of phenomenal physics [10], and the advantage of the regression is its simplicity and more precise results which can be implemented in the structural relations.1.1 Energy demand and neural networks ::: IntroductionSeveral studies have reported better efficiency and lower error of the neural networks in comparison with traditional methods [19], [20], [21], [22].", [["neural networks", "ANATOMY", 23, 38], ["neural networks", "ANATOMY", 373, 388], ["neural networks", "ANATOMY", 476, 491], ["neural networks", "MULTI-TISSUE_STRUCTURE", 23, 38], ["neural networks", "MULTI-TISSUE_STRUCTURE", 373, 388], ["neural networks", "MULTI-TISSUE_STRUCTURE", 476, 491], ["IntroductionSeveral studies", "TEST", 393, 420], ["lower error", "OBSERVATION", 457, 468], ["neural networks", "OBSERVATION", 476, 491]]], ["In this study, a multi-layer feedforward perceptron neural network is used with a hidden layer to provide an oil and electricity consumption model in the economic sectors of China, such as industry, residential, agriculture, services (please refer to the methodology section for a complete breakdown of variables).", [["oil", "ANATOMY", 109, 112], ["neural network", "MULTI-TISSUE_STRUCTURE", 52, 66], ["oil", "ORGANISM_SUBSTANCE", 109, 112], ["this study", "TEST", 3, 13], ["a multi-layer feedforward perceptron neural network", "TREATMENT", 15, 66], ["neural network", "OBSERVATION", 52, 66]]], ["Due to the increasing growth of infections in world and challenges in providing energy demand as well as the significant contribution of the oil and electricity sector in the economic status of countries, analysis of oil and electricity consumption in the economic sectors and evaluation of factors affecting it have caught the attention of many researchers.", [["oil", "ANATOMY", 141, 144], ["infections", "DISEASE", 32, 42], ["oil", "ORGANISM_SUBSTANCE", 141, 144], ["oil", "ORGANISM_SUBSTANCE", 217, 220], ["the increasing growth of infections", "PROBLEM", 7, 42], ["evaluation", "TEST", 277, 287], ["increasing", "OBSERVATION_MODIFIER", 11, 21], ["growth", "OBSERVATION_MODIFIER", 22, 28], ["infections", "OBSERVATION", 32, 42]]], ["Many researchers estimated, forecasted, and investigated energy demand in economic sectors of China using models with linear equations, quadratic and exponential equations, and based on conventional criteria.1.1 Energy demand and neural networks ::: IntroductionArtificial neural networks are presented as one of the most used modeling and predictive tools of energy consumption and are compared with other modeling techniques [23], [24].", [["neural networks", "ANATOMY", 230, 245], ["neural networks", "ANATOMY", 273, 288], ["neural networks", "MULTI-TISSUE_STRUCTURE", 230, 245], ["neural networks", "MULTI-TISSUE_STRUCTURE", 273, 288], ["energy demand", "OBSERVATION", 57, 70], ["exponential equations", "OBSERVATION", 150, 171], ["neural networks", "OBSERVATION", 273, 288]]], ["A paper published in 2015 has predicted Thailand's energy demand in the transportation sector through artificial neural networks and nonlinear regression models for the next twenty years [25].", [["neural", "ANATOMY", 113, 119], ["neural networks", "MULTI-TISSUE_STRUCTURE", 113, 128], ["artificial neural networks", "TREATMENT", 102, 128]]], ["Another reference from 2003 has modeled the energy consumption of the transportation sector in Jordan and predicted it through the neuro-fuzzy neural network [26].", [["neural network", "MULTI-TISSUE_STRUCTURE", 143, 157]]], ["Energy demand is that South Korea has been modeled and predicted using artificial neural networks with a similar structure to the method presented in this study [25].1.1 Energy demand and neural networks ::: IntroductionThe ability of artificial neural networks to estimate the complex nonlinear functions has made them a useful tool for complex modeling phenomena.", [["neural networks", "ANATOMY", 82, 97], ["neural networks", "ANATOMY", 188, 203], ["neural networks", "ANATOMY", 246, 261], ["neural networks", "MULTI-TISSUE_STRUCTURE", 82, 97], ["neural networks", "MULTI-TISSUE_STRUCTURE", 188, 203], ["neural networks", "MULTI-TISSUE_STRUCTURE", 246, 261], ["artificial neural networks", "TREATMENT", 71, 97], ["this study", "TEST", 150, 160], ["artificial neural networks", "TREATMENT", 235, 261], ["complex modeling phenomena", "PROBLEM", 338, 364]]], ["In recent years neural networks have been applied for various energy forecasting studies, ranging from forecasting the fluctuation of wind power in various timescales [27], energy consumption in buildings [28], to prices, and supply and demand in energy systems [29], [30].1.2 The present study ::: IntroductionThis paper aims to investigate the relationship between the macroeconomic parameters (especially the petroleum and electricity demand) in the time of a pandemic situation.", [["neural networks", "ANATOMY", 16, 31], ["neural networks", "MULTI-TISSUE_STRUCTURE", 16, 31], ["various energy forecasting studies", "TEST", 54, 88], ["the macroeconomic parameters", "TEST", 367, 395], ["petroleum", "OBSERVATION_MODIFIER", 412, 421]]], ["The first global pandemic in the 21st century.", [["global", "OBSERVATION_MODIFIER", 10, 16], ["pandemic", "OBSERVATION", 17, 25]]], ["It uses an auto-regressive elasticity and neural network-based sensitivity analysis to determine the structural correlative coefficients, which governs the relationship between the specified parameters.", [["neural", "ANATOMY", 42, 48], ["an auto-regressive elasticity", "TREATMENT", 8, 37], ["neural network", "TEST", 42, 56], ["sensitivity analysis", "TEST", 63, 83]]], ["This model is the main contribution of this paper to the field of energy and economic decision-making body in the time of the pandemic outbreak.1.2 The present study ::: IntroductionAdditionally, the novelty of this paper lies in the use of descriptive variables of the model that are extensively linked to the novel COVID-19 pandemic.", [["body", "ANATOMY", 102, 106], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["the pandemic outbreak", "PROBLEM", 122, 143], ["the novel COVID", "TEST", 307, 322], ["pandemic", "PROBLEM", 326, 334], ["main", "OBSERVATION_MODIFIER", 18, 22], ["pandemic", "OBSERVATION", 126, 134]]], ["Exploring the energy consumption sensitivity from variables such as GDP and Labour performance index is a novel aspect in literature [9], [10].", [["GDP", "CHEMICAL", 68, 71], ["GDP", "SIMPLE_CHEMICAL", 68, 71], ["the energy consumption sensitivity", "TEST", 10, 44], ["GDP and Labour performance index", "TEST", 68, 100]]], ["The timeliness and data resolution of this study is also unique; as previous case studies on energy demand analysis in China, the data are measured on an annual basis, whereas the time interval in this paper is more detailed being analyzed monthly.", [["this study", "TEST", 38, 48], ["previous case studies", "TEST", 68, 89], ["energy demand analysis", "TEST", 93, 115], ["the data", "TEST", 126, 134]]], ["This issue, besides the enlargement of the data, can lead to the improvement of the efficiency of the neural network and regression.", [["neural network", "ANATOMY", 102, 116], ["neural network", "MULTI-TISSUE_STRUCTURE", 102, 116], ["the enlargement of the data", "PROBLEM", 20, 47], ["the efficiency of the neural network", "PROBLEM", 80, 116], ["enlargement", "OBSERVATION", 24, 35], ["efficiency", "OBSERVATION_MODIFIER", 84, 94], ["neural network", "OBSERVATION", 102, 116]]], ["The use of an energy consumption neural network model in China for sensitivity analysis is also a novel attribute of this paper, as it is implemented to estimate the impact of the novel coronavirus pandemic on the electricity and oil demand.1.2 The present study ::: IntroductionOverall, this paper contributes to decision-makers to better predict the responses of the demand and supply side of the markets, guiding the management of the impacts of economic stagnation during and after a pandemic.", [["oil", "ANATOMY", 230, 233], ["coronavirus", "DISEASE", 186, 197], ["neural network", "MULTI-TISSUE_STRUCTURE", 33, 47], ["coronavirus", "ORGANISM", 186, 197], ["oil", "ORGANISM_SUBSTANCE", 230, 233], ["an energy consumption", "TREATMENT", 11, 32], ["sensitivity analysis", "TEST", 67, 87], ["the management", "TREATMENT", 416, 430], ["economic stagnation", "PROBLEM", 449, 468], ["a pandemic", "PROBLEM", 486, 496], ["economic stagnation", "OBSERVATION", 449, 468]]], ["The suggested guidelines of this study also aim to support future studies in the field of energy policy, when developing adaptive econometric models for severe and multi-dimensional social problems.Method selection ::: MethodologyAccurate prediction of economic outcomes is integral to successful decision making.", [["this study", "TEST", 28, 38], ["future studies", "TEST", 59, 73], ["severe and multi-dimensional social problems", "PROBLEM", 153, 197]]], ["It can lead to better government policies and planning, although economic forecasts and foresight models might prove valuable, its a challenge for econometric researchers, who must develop the framework of an accurate model [8].", [["foresight models", "TREATMENT", 88, 104]]], ["The accuracy of the econometric methods varies with different problems, and although these models are useful in illustrating the future of the different parameters and their trends, they can be biased and lead to systematic errors [9].Method selection ::: MethodologyIn this matter, the models can assist in processing a large number of parameters and filling the gap between risk factors and estimations.", [["the econometric methods", "TEST", 16, 39], ["different problems", "PROBLEM", 52, 70], ["systematic errors", "PROBLEM", 213, 230], ["filling the gap between risk factors", "PROBLEM", 352, 388], ["large", "OBSERVATION_MODIFIER", 321, 326], ["number", "OBSERVATION_MODIFIER", 327, 333]]], ["The regression, which is a statistical method, is widely used in the economic and social fields of study, and the methodology is mature and well-established, and coefficients can have intuitive economic and social interpretations.", [["study", "TEST", 99, 104], ["regression", "OBSERVATION_MODIFIER", 4, 14]]], ["Neural network and Bayesian networks are nature-based models consisting of nodes and interconnections [11].", [["Neural network", "ANATOMY", 0, 14], ["Neural network", "MULTI-TISSUE_STRUCTURE", 0, 14], ["nodes", "OBSERVATION", 75, 80]]], ["Although they are similar in type, they are intrinsically different in the term of the process and mathematical model.", [["similar", "OBSERVATION_MODIFIER", 18, 25], ["type", "OBSERVATION_MODIFIER", 29, 33], ["intrinsically", "OBSERVATION_MODIFIER", 44, 57], ["different", "OBSERVATION_MODIFIER", 58, 67]]], ["The Bayesian model's interconnections (arcs) illustrate the conditional dependence relationships between the variables as defined with probability theory, and each node of the graph represents the variable of interest.", [["The Bayesian model's interconnections (arcs)", "TREATMENT", 0, 44], ["node", "OBSERVATION", 164, 168]]], ["In the neural network (ANN) arcs and nodes are not representing a predefined relationship, and the values are discovered during the training analysis, and the interpretations are made according to the model defined relationships [12].", [["neural network", "ANATOMY", 7, 21], ["nodes", "ANATOMY", 37, 42], ["neural network", "MULTI-TISSUE_STRUCTURE", 7, 21], ["the training analysis", "TEST", 128, 149], ["neural", "ANATOMY_MODIFIER", 7, 13], ["nodes", "OBSERVATION", 37, 42], ["not representing", "UNCERTAINTY", 47, 63]]], ["The ANN is more complicated, with more nodes and a more comprehensive process and relationships.", [["more nodes", "PROBLEM", 34, 44], ["more complicated", "OBSERVATION_MODIFIER", 11, 27], ["more", "OBSERVATION_MODIFIER", 34, 38], ["nodes", "OBSERVATION", 39, 44]]], ["The process begins with environmental scanning to determine the possible effective driving variables, then the main variables are being selected, and the data is gathered for them, and then the data is processed and analyzed through two different methods to provide us with an accurate comparative model [37].Data ::: MethodologyIn recent years, the use of cointegration analysis to estimate energy demand patterns has grown widely [8], [22].", [["environmental scanning", "TEST", 24, 46], ["cointegration analysis", "TEST", 357, 379]]], ["Cointegration analysis is commonly used to test the long-term and short-term characteristics of energy demand [8].", [["Cointegration analysis", "TEST", 0, 22]]], ["One method of cointegration analysis that has been widely used in recent years is the autoregressive approach with distributed interruptions, which yields unbiased estimates of long-run coefficients.", [["cointegration analysis", "TEST", 14, 36]]], ["The variables used to model the coronavirus effect on economic status, and energy demand is summarized in Table 1, Table 2[37]:Regressive model ::: MethodologyIn this paper, the conventional least squares, fully adjusted least squares, cointegration analysis, and ARDL approach was used to estimate China's energy and electricity demand pattern in the time of critical epidemic or pandemic conditions.", [["coronavirus", "DISEASE", 32, 43], ["the coronavirus effect", "PROBLEM", 28, 50], ["cointegration analysis", "TEST", 236, 258], ["ARDL approach", "TREATMENT", 264, 277], ["pandemic conditions", "PROBLEM", 381, 400], ["coronavirus", "OBSERVATION", 32, 43]]], ["Two tests of Engel-Granger and Johansson-Yuselius were used for the coagulation test [23].", [["Two tests", "TEST", 0, 9], ["Engel", "TEST", 13, 18], ["Johansson-Yuselius", "TREATMENT", 31, 49], ["the coagulation test", "TEST", 64, 84]]], ["Halisiagoglu and Bakertasch's model also used the two-step Engel-Granger method to model the relationship between energy, economic activity, and price [47].Regressive model ::: MethodologyThe model introduced by Shane and Boys also argues that time series must all be in the form of Eqs.", [["Halisiagoglu", "TREATMENT", 0, 12], ["Bakertasch's model", "TREATMENT", 17, 35]]], ["(1), (2) to use this approach effectively.", [["this approach", "TREATMENT", 16, 29]]], ["The suggested pattern is shown below:Regressive model ::: MethodologyFor Oil Demand(1)LnDemandoil=B1GDP+B2LnDemandelectricity+B3LnEpidemic\u221710+B4LnPopulationinfected+B5LnPMI+B6LnExports+B7LnFDI+B8LnStocks+B9LnPindustry+B10", [["B7LnFDI", "CHEMICAL", 185, 192], ["B1GDP+B2Ln", "SIMPLE_CHEMICAL", 98, 108], ["B5LnPMI+B6LnExports", "SIMPLE_CHEMICAL", 165, 184], ["B7LnFDI+B8LnStocks", "SIMPLE_CHEMICAL", 185, 203], ["B9LnPindustry", "PROTEIN", 204, 217], ["LnDemandoil", "TEST", 86, 97], ["B1GDP", "TEST", 98, 103], ["Demandelectricity", "TEST", 108, 125], ["B3LnEpidemic", "TEST", 126, 138], ["B4LnPopulationinfected", "TEST", 142, 164], ["PMI", "TEST", 169, 172], ["B6LnExports", "TEST", 173, 184], ["B7LnFDI", "TEST", 185, 192], ["B8LnStocks", "TEST", 193, 203], ["B9LnPindustry", "TEST", 204, 217], ["B10", "ANATOMY", 218, 221]]]], "94943b2fe8a76fe18759ee052d5681c108b2ef3a": [["PACIENTES Y M\u00c9TODO: estudio retrospectivo observacional de pacientes consecutivos ingresados con infecci\u00f3n por SARS-CoV-2 confirmada, con neumon\u00eda por estudio radiol\u00f3gico o tomograf\u00eda de t\u00f3rax, que cumpl\u00edan criterios de STC y que recibieron tratamiento.", [["CoV", "TEST", 116, 119]]], ["Clasificamos a los pacientes en los que recibieron s\u00f3lo pulsos de glucocorticoides (GC), o pulsos de GC y tocilizumab.", [["GC y tocilizumab", "TREATMENT", 101, 117]]], ["Determinamos niveles s\u00e9ricos de ferritina, PCR y d\u00edmeros-D.", [["Determinamos", "TEST", 0, 12]]], ["La variable final fue la supervivencia.", [["fue la supervivencia", "OBSERVATION", 18, 38]]]], "6f025ef45d6f3eb64da32be2e59269131e948894": [["Health control in international migration has historically been driven by the concern of receiving states to screen newcomers for disease in the interest of protecting their citizens from health risks.", [["disease", "PROBLEM", 130, 137]]], ["In recent years the global campaign for the right to health as a fundamental human right has opened the way for civil society organizations and scholars to develop and establish an approach to the health needs of labour migrants which enables their voices to be heard and properly addressed (WHO 2010) .", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["right", "ANATOMY_MODIFIER", 44, 49], ["right", "ANATOMY_MODIFIER", 83, 88]]], ["The fragmented understanding of sexuality in health matters calls for more creative cooperation between health research and migration research to steer policy agendas towards providing more appropriate responses to the SRH needs of labour migrants.", [["fragmented", "OBSERVATION_MODIFIER", 4, 14]]]], "44b1fa51d84a9d4954102b4b1dcdb6e6474789a3": [], "PMC7094688": [["IntroductionRespiratory complications (RC) are common and often a major cause of mortality in hematopoietic stem cell transplantation (HSCT) recipients.1, 2, 3, 4 In a recent series published by our group, almost 30% of patients undergoing an HSCT suffered at least one significant RC in the first year after transplantation, with an associated mortality of 23%.5 In these patients, obtaining an early diagnosis is essential for prescribing a specific treatment that may improve prognosis.6 However, this is a difficult task as the range of potential complications, both infectious and non-infectious, is considerable and the clinical and radiologic presentation is often similar.", [["hematopoietic stem cell", "ANATOMY", 94, 117], ["IntroductionRespiratory complications", "DISEASE", 0, 37], ["hematopoietic stem cell", "CELL", 94, 117], ["recipients", "ORGANISM", 141, 151], ["patients", "ORGANISM", 220, 228], ["patients", "ORGANISM", 373, 381], ["patients", "SPECIES", 220, 228], ["patients", "SPECIES", 373, 381], ["IntroductionRespiratory complications", "PROBLEM", 0, 37], ["hematopoietic stem cell transplantation", "TREATMENT", 94, 133], ["HSCT) recipients", "TREATMENT", 135, 151], ["an HSCT", "TEST", 240, 247], ["transplantation", "TREATMENT", 309, 324], ["a specific treatment", "TREATMENT", 441, 461], ["potential complications", "PROBLEM", 541, 564], ["infectious", "PROBLEM", 571, 581], ["non-infectious", "PROBLEM", 586, 600], ["hematopoietic stem cell transplantation", "OBSERVATION", 94, 133], ["significant", "OBSERVATION_MODIFIER", 270, 281], ["RC", "OBSERVATION", 282, 284], ["complications", "OBSERVATION", 551, 564], ["infectious", "OBSERVATION_MODIFIER", 571, 581], ["non-infectious", "OBSERVATION_MODIFIER", 586, 600]]], ["These RC are thus often treated with different empirical drugs and often unnecessary, potentially toxic and expensive therapies, which can lead to antimicrobial resistance.", [["different empirical drugs", "TREATMENT", 37, 62], ["expensive therapies", "TREATMENT", 108, 127], ["antimicrobial resistance", "PROBLEM", 147, 171], ["antimicrobial resistance", "OBSERVATION", 147, 171]]], ["The availability of new biomarkers with high sensitivity and specificity for infections may facilitate the clinical management of RC in HSCT recipients.", [["infections", "DISEASE", 77, 87], ["new biomarkers", "TEST", 20, 34], ["high sensitivity", "PROBLEM", 40, 56], ["infections", "PROBLEM", 77, 87], ["RC in HSCT recipients", "TREATMENT", 130, 151]]], ["C-reactive protein (CRP) is an acute phase protein produced by the liver, which has been widely used as a biochemical inflammatory marker.7, 8 More recently, researchers have been focussing on procalcitonin (PCT) and proadrenomedullin (proADM), two peptides derived from the calcitonin gene family, with distinct functions and properties.9, 10, 11 Although these biomarkers have proved useful for the management of systemic infections in immunocompetent patients, their value in HSCT recipients is still the subject of debate.12, 13 Thus, it has been shown that patients with GvHD may exhibit PCT positivity.", [["liver", "ANATOMY", 67, 72], ["calcitonin", "CHEMICAL", 275, 285], ["systemic infections", "DISEASE", 415, 434], ["GvHD", "DISEASE", 576, 580], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["liver", "ORGAN", 67, 72], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 193, 206], ["PCT", "GENE_OR_GENE_PRODUCT", 208, 211], ["proadrenomedullin", "SIMPLE_CHEMICAL", 217, 234], ["proADM", "SIMPLE_CHEMICAL", 236, 242], ["calcitonin", "GENE_OR_GENE_PRODUCT", 275, 285], ["patients", "ORGANISM", 454, 462], ["recipients", "ORGANISM", 484, 494], ["patients", "ORGANISM", 562, 570], ["PCT", "GENE_OR_GENE_PRODUCT", 593, 596], ["C-reactive protein", "PROTEIN", 0, 18], ["CRP", "PROTEIN", 20, 23], ["acute phase protein", "PROTEIN", 31, 50], ["procalcitonin", "PROTEIN", 193, 206], ["PCT", "PROTEIN", 208, 211], ["proadrenomedullin", "PROTEIN", 217, 234], ["proADM", "PROTEIN", 236, 242], ["calcitonin gene family", "PROTEIN", 275, 297], ["PCT", "PROTEIN", 593, 596], ["patients", "SPECIES", 454, 462], ["patients", "SPECIES", 562, 570], ["C-reactive protein", "TEST", 0, 18], ["CRP", "TEST", 20, 23], ["an acute phase protein", "PROBLEM", 28, 50], ["a biochemical inflammatory marker", "TEST", 104, 137], ["procalcitonin (PCT)", "TREATMENT", 193, 212], ["proadrenomedullin (proADM)", "TREATMENT", 217, 243], ["the calcitonin gene family", "TREATMENT", 271, 297], ["these biomarkers", "TEST", 357, 373], ["systemic infections", "PROBLEM", 415, 434], ["HSCT recipients", "TREATMENT", 479, 494], ["GvHD", "PROBLEM", 576, 580], ["PCT positivity", "PROBLEM", 593, 607], ["reactive protein", "OBSERVATION", 2, 18], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["phase", "OBSERVATION_MODIFIER", 37, 42], ["protein", "OBSERVATION", 43, 50], ["liver", "ANATOMY", 67, 72], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["systemic", "OBSERVATION_MODIFIER", 415, 423], ["infections", "OBSERVATION", 424, 434]]], ["Furthermore, different inflammatory non-infectious RC related to transplantation may cause an increase in different cytokines and inflammatory mediators, potentially diminishing the usefulness of biomarkers in clinical practice.14 Most series published in immunocompromised patients are retrospective and include a heterogeneous population of oncologic patients.", [["patients", "ORGANISM", 274, 282], ["patients", "ORGANISM", 353, 361], ["cytokines", "PROTEIN", 116, 125], ["inflammatory mediators", "PROTEIN", 130, 152], ["patients", "SPECIES", 274, 282], ["patients", "SPECIES", 353, 361], ["different inflammatory non-infectious RC", "PROBLEM", 13, 53], ["transplantation", "TREATMENT", 65, 80], ["an increase in different cytokines and inflammatory mediators", "PROBLEM", 91, 152], ["different", "OBSERVATION_MODIFIER", 13, 22], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35], ["non-infectious", "OBSERVATION", 36, 50], ["transplantation", "OBSERVATION", 65, 80], ["increase", "OBSERVATION_MODIFIER", 94, 102], ["different cytokines", "OBSERVATION", 106, 125], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142], ["heterogeneous", "OBSERVATION_MODIFIER", 315, 328], ["oncologic patients", "OBSERVATION", 343, 361]]], ["Moreover, the episodes evaluated do not always have a specific etiology or do not have a pulmonary origin.15, 16 Finally, most series do not include a control group of HSCT recipients without RC.", [["pulmonary", "ANATOMY", 89, 98], ["pulmonary", "ORGAN", 89, 98], ["recipients", "ORGANISM", 173, 183], ["the episodes", "PROBLEM", 10, 22], ["HSCT recipients", "TREATMENT", 168, 183], ["RC", "PROBLEM", 192, 194], ["pulmonary", "ANATOMY", 89, 98], ["origin", "ANATOMY_MODIFIER", 99, 105]]], ["Although we neither have a control group, in this study we have tried to circumvent other aforementioned shortcomings.", [["this study", "TEST", 45, 55]]], ["Thus, our cohort of HSCT recipients has been prospectively evaluated for one year.5 Also, only respiratory infections (RI) with an identified microorganism have been included.", [["respiratory", "ANATOMY", 95, 106], ["respiratory infections", "DISEASE", 95, 117], ["HSCT", "CANCER", 20, 24], ["recipients", "ORGANISM", 25, 35], ["HSCT recipients", "TREATMENT", 20, 35], ["respiratory infections", "PROBLEM", 95, 117], ["an identified microorganism", "PROBLEM", 128, 155], ["respiratory", "ANATOMY", 95, 106], ["infections", "OBSERVATION", 107, 117], ["microorganism", "OBSERVATION", 142, 155]]], ["Finally, to avoid confounding information, mixed RI, a common occurrence in HSCT recipients, have been excluded.5IntroductionThe aim of this study was to determine the role of different relevant biomarkers in identifying the type and severity of RC in HSCT recipients.Patients and transplantation procedure ::: Materials and methodsThe information provided in this manuscript comes from a prospective interventional study to evaluate RC in a cohort of consecutive HSCT recipients followed-up for 1 year.", [["RC", "DISEASE", 246, 248], ["Patients", "ORGANISM", 268, 276], ["recipients", "ORGANISM", 469, 479], ["Patients", "SPECIES", 268, 276], ["HSCT recipients", "TREATMENT", 76, 91], ["this study", "TEST", 136, 146], ["HSCT recipients", "TREATMENT", 252, 267], ["transplantation procedure", "TREATMENT", 281, 306], ["a prospective interventional study", "TEST", 387, 421], ["consecutive HSCT recipients", "TREATMENT", 452, 479]]], ["Details of this protocol have been published elsewhere5 and are provided in the Supplementary Information.Data collection ::: Materials and methodsData collected included demographic and clinical information, underlying hematologic or non-hematologic disease status, and transplantation characteristics.5Data collection ::: Materials and methodsPatients with respiratory symptoms, fever and/or radiologic signs (new infiltrates on the chest X-ray or chest-computed tomography) suggestive of RC were submitted to a series of non-invasive procedures (sputum cultures, nasopharyngeal swab, urinary Ag tests and blood samples for basic biochemistry, serology and cytokine determinations).", [["hematologic", "ANATOMY", 220, 231], ["respiratory", "ANATOMY", 359, 370], ["sputum", "ANATOMY", 549, 555], ["nasopharyngeal swab", "ANATOMY", 566, 585], ["urinary", "ANATOMY", 587, 594], ["blood samples", "ANATOMY", 608, 621], ["respiratory symptoms", "DISEASE", 359, 379], ["fever", "DISEASE", 381, 386], ["Ag", "CHEMICAL", 595, 597], ["Patients", "ORGANISM", 345, 353], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 566, 585], ["blood samples", "ORGANISM_SUBSTANCE", 608, 621], ["cytokine", "PROTEIN", 659, 667], ["Patients", "SPECIES", 345, 353], ["this protocol", "TREATMENT", 11, 24], ["methodsData", "TEST", 140, 151], ["underlying hematologic or non-hematologic disease status", "PROBLEM", 209, 265], ["respiratory symptoms", "PROBLEM", 359, 379], ["fever", "PROBLEM", 381, 386], ["radiologic signs", "PROBLEM", 394, 410], ["new infiltrates", "PROBLEM", 412, 427], ["the chest X-ray", "TEST", 431, 446], ["chest-computed tomography", "TEST", 450, 475], ["RC", "PROBLEM", 491, 493], ["non-invasive procedures", "TEST", 524, 547], ["sputum cultures", "TEST", 549, 564], ["nasopharyngeal swab", "TEST", 566, 585], ["urinary Ag tests", "TEST", 587, 603], ["blood samples", "TEST", 608, 621], ["basic biochemistry", "TEST", 626, 644], ["serology", "TEST", 646, 654], ["cytokine determinations", "TEST", 659, 682], ["new", "OBSERVATION_MODIFIER", 412, 415], ["infiltrates", "OBSERVATION", 416, 427], ["chest", "ANATOMY", 435, 440], ["chest", "ANATOMY", 450, 455], ["urinary", "ANATOMY", 587, 594]]], ["The indications to perform computed tomography and/or fiberoptic bronchoscopy have been described elsewere5 (Supplementary information).Sample processing ::: Materials and methodsSpecific primers for influenza viruses types A, B and C, respiratory syncytial viruses types A and B, and adenovirus in one real time-PCR; and specific primers for parainfluenza viruses 1, 2, 3 and 4, coronaviruses 229E, and for generic detection of rhinoviruses and enteroviruses in another real time-PCR were carried out in BAL and nasopharyngeal swab when they were clinically indicated.Sample processing ::: Materials and methodsThe methodology for obtaining culture samples, diagnostic tests for Legionella pneumophila and Streptococcus pneumoniae Ag and detection of CMV and aspergillus galactomannan Ag has been described elsewhere.5Definitions ::: Materials and methodsAs explained in our previous study,5 all episodes of RC were carefully recorded and were further divided into infectious, non-infectious or undetermined.", [["BAL", "ANATOMY", 505, 508], ["nasopharyngeal swab", "ANATOMY", 513, 532], ["culture samples", "ANATOMY", 642, 657], ["influenza viruses", "DISEASE", 200, 217], ["respiratory syncytial viruses", "DISEASE", 236, 265], ["parainfluenza viruses", "DISEASE", 343, 364], ["Legionella pneumophila", "DISEASE", 680, 702], ["Ag", "CHEMICAL", 786, 788], ["Ag", "CHEMICAL", 786, 788], ["influenza viruses", "ORGANISM", 200, 217], ["B and C", "ORGANISM", 227, 234], ["respiratory syncytial viruses", "ORGANISM", 236, 265], ["B", "GENE_OR_GENE_PRODUCT", 278, 279], ["adenovirus", "ORGANISM", 285, 295], ["parainfluenza viruses 1", "ORGANISM", 343, 366], ["2", "GENE_OR_GENE_PRODUCT", 368, 369], ["3", "GENE_OR_GENE_PRODUCT", 371, 372], ["4", "GENE_OR_GENE_PRODUCT", 377, 378], ["coronaviruses", "ORGANISM", 380, 393], ["229E", "ORGANISM", 394, 398], ["rhinoviruses", "ORGANISM", 429, 441], ["BAL", "ORGANISM_SUBSTANCE", 505, 508], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 513, 532], ["Legionella pneumophila", "ORGANISM", 680, 702], ["Streptococcus pneumoniae", "ORGANISM", 707, 731], ["Ag", "ORGANISM", 732, 734], ["CMV", "ORGANISM", 752, 755], ["Ag", "GENE_OR_GENE_PRODUCT", 786, 788], ["Streptococcus pneumoniae Ag", "PROTEIN", 707, 734], ["Ag", "PROTEIN", 786, 788], ["parainfluenza", "SPECIES", 343, 356], ["Legionella pneumophila", "SPECIES", 680, 702], ["Streptococcus pneumoniae", "SPECIES", 707, 731], ["adenovirus", "SPECIES", 285, 295], ["parainfluenza viruses", "SPECIES", 343, 364], ["Legionella pneumophila", "SPECIES", 680, 702], ["Streptococcus pneumoniae", "SPECIES", 707, 731], ["CMV", "SPECIES", 752, 755], ["computed tomography", "TEST", 27, 46], ["fiberoptic bronchoscopy", "TEST", 54, 77], ["Specific primers", "TEST", 179, 195], ["influenza viruses types A, B and C, respiratory syncytial viruses types A and B", "PROBLEM", 200, 279], ["adenovirus", "PROBLEM", 285, 295], ["PCR", "TEST", 313, 316], ["specific primers", "TEST", 322, 338], ["parainfluenza viruses", "PROBLEM", 343, 364], ["coronaviruses 229E", "TEST", 380, 398], ["rhinoviruses", "PROBLEM", 429, 441], ["enteroviruses", "PROBLEM", 446, 459], ["PCR", "TEST", 481, 484], ["BAL", "TEST", 505, 508], ["nasopharyngeal swab", "TEST", 513, 532], ["obtaining culture samples", "TEST", 632, 657], ["diagnostic tests", "TEST", 659, 675], ["Legionella pneumophila", "PROBLEM", 680, 702], ["Streptococcus pneumoniae Ag", "TEST", 707, 734], ["CMV", "PROBLEM", 752, 755], ["aspergillus galactomannan", "TEST", 760, 785], ["our previous study", "TEST", 872, 890], ["RC", "PROBLEM", 909, 911], ["non-infectious", "PROBLEM", 978, 992], ["respiratory syncytial", "ANATOMY", 236, 257], ["rhinoviruses", "OBSERVATION", 429, 441], ["nasopharyngeal", "ANATOMY", 513, 527], ["infectious", "OBSERVATION", 966, 976], ["non-infectious", "OBSERVATION_MODIFIER", 978, 992]]], ["Among patients who presented more than one complication, each episode was recorded and considered independently.Definitions ::: Materials and methodsRespiratory infections were diagnosed when clinical data suggested an infectious etiology, microbiological agents were isolated in any processed sample, and the clinical course and response to treatment were in accordance with an infectious etiology.", [["sample", "ANATOMY", 294, 300], ["Respiratory infections", "DISEASE", 149, 171], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["methodsRespiratory infections", "PROBLEM", 142, 171], ["clinical data", "TEST", 192, 205], ["an infectious etiology", "PROBLEM", 216, 238], ["microbiological agents", "TREATMENT", 240, 262], ["treatment", "TREATMENT", 342, 351], ["Respiratory", "ANATOMY", 149, 160], ["infections", "OBSERVATION", 161, 171], ["infectious", "OBSERVATION_MODIFIER", 219, 229], ["infectious", "OBSERVATION", 379, 389]]], ["One or more microbiologically documented bacteria in association with one or more viruses were considered a mixed infection.", [["infection", "DISEASE", 114, 123], ["more microbiologically documented bacteria", "PROBLEM", 7, 49], ["more viruses", "PROBLEM", 77, 89], ["a mixed infection", "PROBLEM", 106, 123], ["more", "OBSERVATION_MODIFIER", 7, 11], ["microbiologically documented", "OBSERVATION_MODIFIER", 12, 40], ["bacteria", "OBSERVATION", 41, 49], ["viruses", "OBSERVATION", 82, 89], ["mixed", "OBSERVATION_MODIFIER", 108, 113], ["infection", "OBSERVATION", 114, 123]]], ["Pneumonia was diagnosed in cases with fever (\u2a7e38 \u00baC), cough, dyspnea and/or purulent expectoration and new or progressive pulmonary infiltrate not explained by any other non-infectious cause.17 As noted above, microbiological agent isolation from respiratory samples was required for inclusion in the study.Definitions ::: Materials and methodsCriteria for diagnosis of non-infectious RC are described in the Supplementary Information and published elsewhere.5Definitions ::: Materials and methodsNeutropenia was defined as an ANC of <0.5 \u00d7 109 cells/L.Definitions ::: Materials and methodsIn accordance with Koya et al.,18 we further classified RI in two groups: bacterial\u2013fungal infections and intracellular infection that included virus and tuberculosis.Biomarker measurements ::: Materials and methodsBlood samples were centrifuged, aliquoted and frozen at \u221280 \u00b0C for subsequent analyses.", [["pulmonary", "ANATOMY", 122, 131], ["respiratory samples", "ANATOMY", 247, 266], ["cells", "ANATOMY", 545, 550], ["intracellular", "ANATOMY", 696, 709], ["Blood samples", "ANATOMY", 805, 818], ["Pneumonia", "DISEASE", 0, 9], ["fever", "DISEASE", 38, 43], ["cough", "DISEASE", 54, 59], ["dyspnea", "DISEASE", 61, 68], ["expectoration", "DISEASE", 85, 98], ["Neutropenia", "DISEASE", 497, 508], ["bacterial\u2013fungal infections", "DISEASE", 664, 691], ["intracellular infection", "DISEASE", 696, 719], ["tuberculosis", "DISEASE", 744, 756], ["pulmonary", "ORGAN", 122, 131], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 696, 709], ["Blood samples", "ORGANISM_SUBSTANCE", 805, 818], ["Pneumonia", "PROBLEM", 0, 9], ["fever", "PROBLEM", 38, 43], ["cough", "PROBLEM", 54, 59], ["dyspnea", "PROBLEM", 61, 68], ["purulent expectoration", "PROBLEM", 76, 98], ["new or progressive pulmonary infiltrate", "PROBLEM", 103, 142], ["any other non-infectious cause", "PROBLEM", 160, 190], ["microbiological agent isolation", "TREATMENT", 210, 241], ["respiratory samples", "TEST", 247, 266], ["the study", "TEST", 297, 306], ["non-infectious RC", "PROBLEM", 370, 387], ["methodsNeutropenia", "PROBLEM", 490, 508], ["an ANC", "TEST", 524, 530], ["bacterial\u2013fungal infections", "PROBLEM", 664, 691], ["intracellular infection", "PROBLEM", 696, 719], ["virus", "PROBLEM", 734, 739], ["tuberculosis", "PROBLEM", 744, 756], ["Biomarker measurements", "TEST", 757, 779], ["Blood samples", "TEST", 805, 818], ["purulent", "OBSERVATION_MODIFIER", 76, 84], ["expectoration", "OBSERVATION", 85, 98], ["new", "OBSERVATION_MODIFIER", 103, 106], ["progressive", "OBSERVATION_MODIFIER", 110, 121], ["pulmonary", "ANATOMY", 122, 131], ["infiltrate", "OBSERVATION", 132, 142], ["non-infectious", "OBSERVATION", 170, 184], ["non-infectious", "OBSERVATION", 370, 384], ["bacterial\u2013fungal", "ANATOMY", 664, 680], ["infections", "OBSERVATION", 681, 691], ["intracellular", "OBSERVATION_MODIFIER", 696, 709], ["infection", "OBSERVATION", 710, 719], ["tuberculosis", "OBSERVATION", 744, 756]]], ["Levels of CRP, proADM and PCT were measured using plasma samples within the first 24\u201348 h after identification of the RC (day 0) and on days 3 and 7 thereafter.", [["plasma samples", "ANATOMY", 50, 64], ["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["proADM", "GENE_OR_GENE_PRODUCT", 15, 21], ["PCT", "GENE_OR_GENE_PRODUCT", 26, 29], ["plasma samples", "ORGANISM_SUBSTANCE", 50, 64], ["CRP", "PROTEIN", 10, 13], ["proADM", "PROTEIN", 15, 21], ["PCT", "PROTEIN", 26, 29], ["Levels", "TEST", 0, 6], ["CRP", "TEST", 10, 13], ["proADM", "TEST", 15, 21], ["PCT", "TEST", 26, 29], ["plasma samples", "TEST", 50, 64], ["the RC", "TEST", 114, 120]]], ["Concentrations of PCT and proADM were determined using sandwich immunoassays and time-resolved amplified cryptate emission (TRACE) technology (PCT sensitive KRYPTOR and proADM KRYPTOR; BRAHMS; Hennigsdorf, Germany).", [["proADM", "CHEMICAL", 26, 32], ["PCT", "SIMPLE_CHEMICAL", 18, 21], ["proADM", "SIMPLE_CHEMICAL", 26, 32], ["cryptate", "SIMPLE_CHEMICAL", 105, 113], ["PCT", "PROTEIN", 18, 21], ["PCT", "TEST", 18, 21], ["proADM", "TREATMENT", 26, 32], ["sandwich immunoassays", "TEST", 55, 76], ["PCT", "TEST", 143, 146]]], ["C-reactive protein was measured using a commercially available immunoturbidimetric method (Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA).Biomarker measurements ::: Materials and methodsThe minimum detection level was 0.02 ng/mL for PCT; 0.23 nmol/L for proADM and 0.1 mg/dL for CRP.", [["proADM", "CHEMICAL", 266, 272], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["CRP", "GENE_OR_GENE_PRODUCT", 291, 294], ["C-reactive protein", "PROTEIN", 0, 18], ["CRP", "PROTEIN", 291, 294], ["C-reactive protein", "PROBLEM", 0, 18], ["Biomarker measurements", "TEST", 150, 172], ["The minimum detection level", "TEST", 198, 225], ["PCT", "TEST", 245, 248], ["proADM", "TREATMENT", 266, 272], ["CRP", "TEST", 291, 294], ["reactive protein", "OBSERVATION", 2, 18]]], ["The cutoff value was 0.50 ng/mL for PCT; 0.55 nmol/L for proADM and 1 mg/dL for CRP.Cytokine measurements ::: Materials and methodsDetermination of TNF-\u03b1, interleukin (IL)-1\u03b2, IL-6, IL-8 and IL-10 ultrasensitive (US) was performed in serum samples on the first day.", [["serum samples", "ANATOMY", 234, 247], ["CRP", "GENE_OR_GENE_PRODUCT", 80, 83], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 148, 153], ["interleukin (IL)-1\u03b2", "GENE_OR_GENE_PRODUCT", 155, 174], ["IL-6", "GENE_OR_GENE_PRODUCT", 176, 180], ["IL-8", "GENE_OR_GENE_PRODUCT", 182, 186], ["IL-10", "GENE_OR_GENE_PRODUCT", 191, 196], ["serum samples", "ORGANISM_SUBSTANCE", 234, 247], ["CRP", "PROTEIN", 80, 83], ["Cytokine", "PROTEIN", 84, 92], ["TNF", "PROTEIN", 148, 151], ["interleukin (IL)-1\u03b2", "PROTEIN", 155, 174], ["IL", "PROTEIN", 191, 193], ["The cutoff value", "TEST", 0, 16], ["PCT", "TEST", 36, 39], ["proADM", "TREATMENT", 57, 63], ["CRP", "TEST", 80, 83], ["Cytokine measurements", "TEST", 84, 105], ["methodsDetermination", "TEST", 124, 144], ["TNF", "TEST", 148, 151], ["interleukin (IL)", "TEST", 155, 171], ["IL", "TEST", 176, 178], ["IL", "TEST", 182, 184], ["IL", "TEST", 191, 193], ["serum samples", "TEST", 234, 247]]], ["Cytokine levels were measured by enzyme linked immunoassay (Diasource Inmunoassays, Louvain-la-Neuve, Belgium) and IL-10 US with an ultrasensitive assay (Invitrogen Coorporation, Camarillo, CA, USA).", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-10", "GENE_OR_GENE_PRODUCT", 115, 120], ["Cytokine", "PROTEIN", 0, 8], ["IL", "PROTEIN", 115, 117], ["Cytokine levels", "TEST", 0, 15], ["enzyme linked immunoassay", "TEST", 33, 58], ["Diasource", "TEST", 60, 69], ["Inmunoassays", "TEST", 70, 82], ["Louvain", "TEST", 84, 91], ["an ultrasensitive assay", "TEST", 129, 152]]], ["Detection limits were 0.7 pg/mL for TNF-\u03b1; 0.2 pg/mL for IL-10 US and 2 pg/mL for IL-1\u03b2, IL-6 and IL-8.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-10", "GENE_OR_GENE_PRODUCT", 57, 62], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 82, 87], ["IL-6", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-8", "GENE_OR_GENE_PRODUCT", 98, 102], ["TNF", "PROTEIN", 36, 39], ["IL", "PROTEIN", 57, 59], ["IL-8", "PROTEIN", 98, 102], ["TNF", "TEST", 36, 39], ["IL", "TEST", 57, 59], ["IL", "TEST", 82, 84], ["IL", "TEST", 89, 91], ["IL", "TEST", 98, 100]]], ["The values taken as the upper limits were 10 pg/mL for TNF-\u03b1; 5 pg/mL for IL-6; 8.2 pg/mL for IL-10 US and 15 pg/mL for IL-1\u03b2 and IL-8.Statistical analysis ::: Materials and methodsContinuous variables were summarized as mean\u00b1s.d. or median (interquartile range) and compared using the t-test or the non-parametric Mann\u2013Whitney test, respectively.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-6", "GENE_OR_GENE_PRODUCT", 74, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-8", "GENE_OR_GENE_PRODUCT", 130, 134], ["TNF", "PROTEIN", 55, 58], ["IL", "PROTEIN", 74, 76], ["IL", "PROTEIN", 94, 96], ["IL", "PROTEIN", 120, 122], ["IL-8", "PROTEIN", 130, 134], ["The values", "TEST", 0, 10], ["TNF", "TEST", 55, 58], ["IL", "TEST", 74, 76], ["IL", "TEST", 94, 96], ["IL", "TEST", 120, 122], ["IL", "TEST", 130, 132], ["the t-test", "TEST", 282, 292], ["the non-parametric Mann\u2013Whitney test", "TEST", 296, 332]]], ["Categorical variables were expressed as n (%) and compared using the \u03c72-test or the Fisher exact test when appropriate.", [["Categorical variables", "TEST", 0, 21], ["the \u03c72-test", "TEST", 65, 76], ["the Fisher exact test", "TEST", 80, 101]]], ["In order to establish the predictive value of biomarkers for the different RC, the area under the curve in the receiver operating characteristic analysis was calculated.Statistical analysis ::: Materials and methodsUnivariate analyses that included clinical variables associated with an increased risk of mortality identified in our previous study5 and concentrations of the different biomarkers and cytokines studied on day 0 were performed.", [["cytokines", "PROTEIN", 400, 409], ["the different RC", "TREATMENT", 61, 77], ["methodsUnivariate analyses", "TEST", 208, 234], ["clinical variables", "PROBLEM", 249, 267], ["an increased risk of mortality", "PROBLEM", 284, 314], ["our previous study5", "TEST", 329, 348], ["the different biomarkers", "TEST", 371, 395], ["increased", "OBSERVATION_MODIFIER", 287, 296], ["mortality", "OBSERVATION", 305, 314]]], ["Variables that showed a significant result in the univariate analysis (P<0.1) were included in the initial Cox proportional hazards model.19 A manual backward stepwise selection was used to determine factors associated with 1-year mortality.", [["the univariate analysis", "TEST", 46, 69], ["A manual backward stepwise selection", "TREATMENT", 141, 177], ["significant", "OBSERVATION_MODIFIER", 24, 35]]], ["The hazard ratio and 95% confidence interval (CI) were calculated.", [["The hazard ratio", "TEST", 0, 16], ["CI", "TEST", 46, 48]]], ["Proportional hazards assumptions were tested using log-minus-log plots.", [["Proportional hazards assumptions", "PROBLEM", 0, 32]]], ["To investigate the lack of fit of our final model we evaluated the deviance residuals.", [["the deviance residuals", "PROBLEM", 63, 85]]], ["All statistical analyses were done using IBM SPSS Statistics version 20.0 (Armonk, New York, USA).Biomarkers and cytokines in infectious and non-infectious respiratory complications ::: ResultsTable 3 shows biomarker and cytokine levels at different times in the population evaluated.", [["respiratory", "ANATOMY", 156, 167], ["respiratory complications", "DISEASE", 156, 181], ["cytokines", "PROTEIN", 113, 122], ["cytokine", "PROTEIN", 221, 229], ["All statistical analyses", "TEST", 0, 24], ["Biomarkers", "TEST", 98, 108], ["cytokines in infectious and non-infectious respiratory complications", "PROBLEM", 113, 181], ["biomarker", "TEST", 207, 216], ["cytokine levels", "TEST", 221, 236], ["cytokines", "OBSERVATION", 113, 122], ["infectious", "OBSERVATION_MODIFIER", 126, 136], ["non-infectious", "OBSERVATION_MODIFIER", 141, 155], ["respiratory complications", "OBSERVATION", 156, 181], ["cytokine levels", "OBSERVATION", 221, 236]]], ["There were no significant differences in leukocytes or neutrophil counts between infectious and non-infectious RC.", [["leukocytes", "ANATOMY", 41, 51], ["neutrophil", "ANATOMY", 55, 65], ["infectious and non-infectious RC", "DISEASE", 81, 113], ["leukocytes", "CELL", 41, 51], ["neutrophil", "CELL", 55, 65], ["leukocytes", "CELL_TYPE", 41, 51], ["neutrophil", "CELL_TYPE", 55, 65], ["significant differences in leukocytes", "PROBLEM", 14, 51], ["neutrophil counts between infectious and non-infectious RC", "PROBLEM", 55, 113], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["leukocytes", "OBSERVATION", 41, 51], ["neutrophil counts", "OBSERVATION", 55, 72], ["infectious", "OBSERVATION_MODIFIER", 81, 91], ["non-infectious", "OBSERVATION_MODIFIER", 96, 110], ["RC", "OBSERVATION_MODIFIER", 111, 113]]], ["A significant increase was observed in levels of CRP and proADM on day 0 in the non-infectious group (P=0.005 and P=0.03; respectively).", [["CRP", "GENE_OR_GENE_PRODUCT", 49, 52], ["CRP", "PROTEIN", 49, 52], ["proADM", "PROTEIN", 57, 63], ["A significant increase", "PROBLEM", 0, 22], ["CRP", "TEST", 49, 52], ["P", "TEST", 102, 103], ["P", "TEST", 114, 115], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["non-infectious", "OBSERVATION", 80, 94]]], ["By contrast, between-group cytokine levels were similar, except IL-6 on day 0, which was significantly higher in non-infectious complications (P=0.04).Biomarkers and cytokines in infectious and non-infectious respiratory complications ::: ResultsA good correlation was observed between levels of PCT, CRP (P<0.001) and proADM (P<0.01).Biomarkers and cytokines in infectious and non-infectious respiratory complications ::: ResultsBiomarker/cytokine levels did not differ between patients with and without neutropenia for both groups of complications.Biomarkers and cytokines in respiratory infections ::: ResultsLevels of CRP, PCT and proADM on day 0 were higher in bacterial\u2013fungal infections compared with viral infections (CRP, 10.46\u00b18.49 mg/dL vs 6.52\u00b18.15 mg/dL (P=0.02); PCT, 11.39\u00b122 ng/mL vs 0.47\u00b10.49 ng/mL (P=0.04); proADM, 3.62\u00b13.30 nmol/L vs 1.65\u00b11.03 nmol/L (P<0.01)).", [["respiratory", "ANATOMY", 209, 220], ["respiratory", "ANATOMY", 393, 404], ["respiratory", "ANATOMY", 578, 589], ["respiratory complications", "DISEASE", 209, 234], ["respiratory complications", "DISEASE", 393, 418], ["neutropenia", "DISEASE", 505, 516], ["respiratory infections", "DISEASE", 578, 600], ["infections", "DISEASE", 683, 693], ["viral infections", "DISEASE", 708, 724], ["IL-6", "GENE_OR_GENE_PRODUCT", 64, 68], ["PCT", "GENE_OR_GENE_PRODUCT", 296, 299], ["CRP", "GENE_OR_GENE_PRODUCT", 301, 304], ["patients", "ORGANISM", 479, 487], ["CRP", "GENE_OR_GENE_PRODUCT", 622, 625], ["proADM", "SIMPLE_CHEMICAL", 635, 641], ["CRP", "GENE_OR_GENE_PRODUCT", 726, 729], ["cytokine", "PROTEIN", 27, 35], ["IL", "PROTEIN", 64, 66], ["cytokines", "PROTEIN", 166, 175], ["PCT", "PROTEIN", 296, 299], ["CRP", "PROTEIN", 301, 304], ["cytokines", "PROTEIN", 350, 359], ["cytokine", "PROTEIN", 440, 448], ["cytokines", "PROTEIN", 565, 574], ["CRP", "PROTEIN", 622, 625], ["PCT", "PROTEIN", 627, 630], ["proADM", "PROTEIN", 635, 641], ["CRP", "PROTEIN", 726, 729], ["patients", "SPECIES", 479, 487], ["group cytokine levels", "TEST", 21, 42], ["IL", "TEST", 64, 66], ["non-infectious complications", "PROBLEM", 113, 141], ["P", "TEST", 143, 144], ["Biomarkers", "TEST", 151, 161], ["cytokines in infectious and non-infectious respiratory complications", "PROBLEM", 166, 234], ["PCT", "TEST", 296, 299], ["CRP", "TEST", 301, 304], ["P", "TEST", 306, 307], ["proADM", "TEST", 319, 325], ["Biomarkers", "TEST", 335, 345], ["cytokines in infectious and non-infectious respiratory complications", "PROBLEM", 350, 418], ["ResultsBiomarker/cytokine levels", "TEST", 423, 455], ["neutropenia", "PROBLEM", 505, 516], ["complications", "PROBLEM", 536, 549], ["Biomarkers", "TEST", 550, 560], ["cytokines in respiratory infections", "PROBLEM", 565, 600], ["CRP", "TEST", 622, 625], ["PCT", "TEST", 627, 630], ["bacterial\u2013fungal infections", "PROBLEM", 666, 693], ["viral infections", "PROBLEM", 708, 724], ["CRP", "TEST", 726, 729], ["dL vs", "TEST", 745, 750], ["P", "TEST", 768, 769], ["PCT", "TEST", 777, 780], ["ng", "TEST", 791, 793], ["vs", "TEST", 797, 799], ["ng", "TEST", 810, 812], ["P", "TEST", 817, 818], ["proADM", "TEST", 826, 832], ["nmol", "TEST", 844, 848], ["L vs", "TEST", 849, 853], ["nmol", "TEST", 864, 868], ["P", "TEST", 872, 873], ["significantly", "OBSERVATION_MODIFIER", 89, 102], ["higher", "OBSERVATION_MODIFIER", 103, 109], ["non-infectious", "OBSERVATION_MODIFIER", 113, 127], ["cytokines", "OBSERVATION", 166, 175], ["infectious", "OBSERVATION_MODIFIER", 179, 189], ["non-infectious", "OBSERVATION_MODIFIER", 194, 208], ["respiratory complications", "OBSERVATION", 209, 234], ["cytokines", "OBSERVATION", 350, 359], ["infectious", "OBSERVATION_MODIFIER", 363, 373], ["non-infectious", "OBSERVATION_MODIFIER", 378, 392], ["respiratory complications", "OBSERVATION", 393, 418], ["complications", "OBSERVATION", 536, 549], ["respiratory", "ANATOMY", 578, 589], ["infections", "OBSERVATION", 590, 600], ["infections", "OBSERVATION", 683, 693]]], ["As shown in Figure 2, levels of CRP, PCT and proADM tended to decrease over time (days 0, 3 and 7) in bacterial\u2013fungal RI, whereas they were persistently low in viral infections.", [["viral infections", "DISEASE", 161, 177], ["CRP", "GENE_OR_GENE_PRODUCT", 32, 35], ["PCT", "GENE_OR_GENE_PRODUCT", 37, 40], ["proADM", "SIMPLE_CHEMICAL", 45, 51], ["CRP", "PROTEIN", 32, 35], ["PCT", "PROTEIN", 37, 40], ["proADM", "PROTEIN", 45, 51], ["CRP", "TEST", 32, 35], ["PCT", "TEST", 37, 40], ["bacterial\u2013fungal RI", "PROBLEM", 102, 121], ["viral infections", "PROBLEM", 161, 177], ["decrease", "OBSERVATION_MODIFIER", 62, 70], ["persistently", "OBSERVATION_MODIFIER", 141, 153], ["low", "OBSERVATION_MODIFIER", 154, 157], ["viral infections", "OBSERVATION", 161, 177]]], ["To analyze the discriminatory power of biomarkers for the detection of bacterial\u2013fungal RI, a receiver operating characteristic curve analysis was calculated for each biomarker (Figure 3).", [["bacterial\u2013fungal RI", "PROTEIN", 71, 90], ["bacterial\u2013fungal RI", "PROBLEM", 71, 90], ["curve analysis", "TEST", 128, 142]]], ["ProADM had the highest area under the curve (0.75, 95% CI 0.60\u20130.91; P<0.01).", [["ProADM", "CHEMICAL", 0, 6], ["ProADM", "SIMPLE_CHEMICAL", 0, 6], ["CI", "TEST", 55, 57], ["P", "TEST", 69, 70], ["highest", "OBSERVATION_MODIFIER", 15, 22]]], ["A value \u2a7e2.125 nmol/L of proADM on day 0 was associated with bacterial\u2013fungal RI with a sensitivity of 61%, a specificity of 83%, a positive predictive value (PPV) of 79%, and an negative predictive value (NPV) of 68%.", [["A value", "TEST", 0, 7], ["bacterial\u2013fungal RI", "PROBLEM", 61, 80], ["PPV", "TEST", 159, 162], ["NPV", "TEST", 206, 209]]], ["We also tested whether persistently low biomarkers values could rule out bacterial\u2013fungal RI.", [["bacterial\u2013fungal RI", "PROTEIN", 73, 92], ["persistently low biomarkers values", "PROBLEM", 23, 57], ["bacterial\u2013fungal RI", "PROBLEM", 73, 92], ["bacterial\u2013fungal RI", "OBSERVATION", 73, 92]]], ["For various cutoff levels of the maximum value obtained on days 0, 3 and 7, we calculated, for each biomarker, sensitivity, specificity, PPV and NPV for precluding systemic bacterial\u2013fungal infection.", [["bacterial\u2013fungal infection", "DISEASE", 173, 199], ["various cutoff levels", "TEST", 4, 25], ["the maximum value", "TEST", 29, 46], ["each biomarker", "TEST", 95, 109], ["sensitivity", "TEST", 111, 122], ["specificity", "TEST", 124, 135], ["PPV", "TEST", 137, 140], ["NPV", "TEST", 145, 148], ["systemic bacterial\u2013fungal infection", "PROBLEM", 164, 199], ["infection", "OBSERVATION", 190, 199]]], ["The results show that persistently lower levels (for the first 7 days) of CRP and proADM can be very specific in ruling out bacterial\u2013fungal infections.", [["infections", "DISEASE", 141, 151], ["CRP", "GENE_OR_GENE_PRODUCT", 74, 77], ["proADM", "GENE_OR_GENE_PRODUCT", 82, 88], ["CRP", "PROTEIN", 74, 77], ["proADM", "PROTEIN", 82, 88], ["persistently lower levels", "PROBLEM", 22, 47], ["CRP", "TEST", 74, 77], ["bacterial\u2013fungal infections", "PROBLEM", 124, 151], ["persistently", "OBSERVATION_MODIFIER", 22, 34], ["lower levels", "OBSERVATION_MODIFIER", 35, 47], ["bacterial\u2013fungal", "OBSERVATION_MODIFIER", 124, 140], ["infections", "OBSERVATION", 141, 151]]], ["In particular, levels of CRP below 4.07 mg/dL had a sensitivity of 46%, a specificity of 94% and a PPV of 92% and levels of proADM below 0.91 had a sensitivity of 28%, a specificity and a PPV of 100% (Table 4).", [["CRP", "GENE_OR_GENE_PRODUCT", 25, 28], ["CRP", "PROTEIN", 25, 28], ["CRP", "TEST", 25, 28], ["a sensitivity", "TEST", 50, 63], ["a specificity", "TEST", 72, 85], ["a PPV", "TEST", 97, 102], ["levels", "TEST", 114, 120], ["a PPV", "TEST", 186, 191]]], ["A combination of PCT (\u2a7e1.695 ng/mL) and proADM (\u2a7e2.245 nmol/L) confirmed a bacterial\u2013fungal infection with a sensitivity of 28%, a specificity of 100%, a PPV of 100%, and an NPV of 58%.Biomarkers and cytokines in respiratory infections ::: ResultsBaseline levels of cytokines evaluated did not differ among the different RI.Biomarkers and cytokines and clinical characteristics ::: ResultsClinical variables such as type of transplantation (allogeneic vs autologous), intensity of conditioning, and GvHD did not influence biomarker/cytokine levels for either non-infectious or infectious PC (Tables 1, 2 and 3 of Supplementary Information).Outcome ::: ResultsOverall 1-year mortality was 33% (17 out of 51 patients).", [["bacterial\u2013fungal", "ANATOMY", 75, 91], ["respiratory", "ANATOMY", 213, 224], ["bacterial\u2013fungal infection", "DISEASE", 75, 101], ["respiratory infections", "DISEASE", 213, 235], ["GvHD", "DISEASE", 499, 503], ["non-infectious or infectious PC", "DISEASE", 559, 590], ["proADM", "SIMPLE_CHEMICAL", 40, 46], ["patients", "ORGANISM", 706, 714], ["cytokines", "PROTEIN", 200, 209], ["cytokines", "PROTEIN", 266, 275], ["cytokines", "PROTEIN", 339, 348], ["cytokine", "PROTEIN", 532, 540], ["patients", "SPECIES", 706, 714], ["PCT", "TEST", 17, 20], ["proADM", "TREATMENT", 40, 46], ["a bacterial\u2013fungal infection", "PROBLEM", 73, 101], ["a PPV", "TEST", 152, 157], ["an NPV", "TEST", 171, 177], ["Biomarkers", "TEST", 185, 195], ["cytokines in respiratory infections", "PROBLEM", 200, 235], ["cytokines", "TEST", 266, 275], ["Biomarkers", "TEST", 324, 334], ["transplantation (allogeneic vs autologous)", "TREATMENT", 424, 466], ["GvHD", "PROBLEM", 499, 503], ["biomarker/cytokine levels", "TEST", 522, 547], ["non-infectious", "PROBLEM", 559, 573], ["infection", "OBSERVATION", 92, 101], ["respiratory", "ANATOMY", 213, 224], ["infections", "OBSERVATION", 225, 235]]], ["Sixty-five per cent of all cause mortality was due to RC (11 out of 17 cases).", [["RC", "TEST", 54, 56]]], ["Procalcitonin and proADM levels on day 0 were significantly higher in patients who died compared with survivors (Figure 4).", [["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["proADM", "SIMPLE_CHEMICAL", 18, 24], ["patients", "ORGANISM", 70, 78], ["proADM", "PROTEIN", 18, 24], ["patients", "SPECIES", 70, 78], ["Procalcitonin and proADM levels", "TEST", 0, 31]]], ["In addition, CRP values showed a significant decrease over time (days 0, 3 and 7) in survivors compared with deceased patients (P=0.001).Outcome ::: ResultsUnivariate analysis showed that Max-PCT (+1 mg/mL, P=0.012), Max-proADM (+1 mg/mL, P=0.002), Max-CRP (+1 mg/dL, P=0.010), GvHD (P=0.019) and infection of bacterial\u2013fungal etiology (P=0.021) were risk factors associated with 1-year mortality.", [["GvHD", "DISEASE", 278, 282], ["infection", "DISEASE", 297, 306], ["CRP", "GENE_OR_GENE_PRODUCT", 13, 16], ["patients", "ORGANISM", 118, 126], ["CRP", "PROTEIN", 13, 16], ["patients", "SPECIES", 118, 126], ["CRP values", "TEST", 13, 23], ["ResultsUnivariate analysis", "TEST", 149, 175], ["PCT", "TEST", 192, 195], ["P", "TEST", 207, 208], ["Max-proADM", "TEST", 217, 227], ["P", "TEST", 239, 240], ["Max-CRP", "TEST", 249, 256], ["P", "TEST", 268, 269], ["GvHD", "PROBLEM", 278, 282], ["infection of bacterial\u2013fungal etiology", "PROBLEM", 297, 335], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["decrease", "OBSERVATION_MODIFIER", 45, 53]]], ["Of these variables, infection of bacterial\u2013fungal etiology (hazard ratio 6.24, 95% CI 1.32\u201329.47; P=0.021) was the only variable associated with 1-year mortality in the multivariate analysis.DiscussionThe results of this prospective study show that although biomarkers cannot differentiate between infectious and non-infectious complications in HSCT recipients, they still can be useful from a clinical standpoint.", [["infection", "DISEASE", 20, 29], ["infection of bacterial\u2013fungal etiology", "PROBLEM", 20, 58], ["hazard ratio", "TEST", 60, 72], ["CI", "TEST", 83, 85], ["P", "TEST", 98, 99], ["the multivariate analysis", "TEST", 165, 190], ["this prospective study", "TEST", 216, 238], ["biomarkers", "TEST", 258, 268], ["infectious and non-infectious complications", "PROBLEM", 298, 341], ["HSCT recipients", "TREATMENT", 345, 360], ["infection", "OBSERVATION", 20, 29], ["infectious", "OBSERVATION", 298, 308], ["non-infectious", "OBSERVATION_MODIFIER", 313, 327]]], ["Levels of CRP, PCT and proADM on day 0 reflect the severity of the RC and have prognostic relevance.", [["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["PCT", "GENE_OR_GENE_PRODUCT", 15, 18], ["CRP", "PROTEIN", 10, 13], ["PCT", "PROTEIN", 15, 18], ["proADM", "PROTEIN", 23, 29], ["Levels", "TEST", 0, 6], ["CRP", "TEST", 10, 13], ["PCT", "TEST", 15, 18]]], ["Moreover, persistent low levels of these biomarkers suggest a viral infection and may help to tailor the therapeutic regime.DiscussionIn immunocompetent patients, biomarkers such as PCT and proADM are helpful in the diagnosis and management of severe bacterial infections.20, 21 Also, in febrile neutropenic patients, high serum PCT and proADM levels have been associated with the diagnosis and the severity of bacterial\u2013fungal infection.22, 23 It has been speculated that in HSCT recipients, biomarkers might be of particularly utility due to the range of potential complications, both infectious and non-infectious, that these patients may suffer.", [["serum", "ANATOMY", 323, 328], ["viral infection", "DISEASE", 62, 77], ["bacterial infections", "DISEASE", 251, 271], ["neutropenic", "DISEASE", 296, 307], ["bacterial\u2013fungal infection", "DISEASE", 411, 437], ["patients", "ORGANISM", 153, 161], ["proADM", "SIMPLE_CHEMICAL", 190, 196], ["patients", "ORGANISM", 308, 316], ["serum", "ORGANISM_SUBSTANCE", 323, 328], ["PCT", "GENE_OR_GENE_PRODUCT", 329, 332], ["proADM", "GENE_OR_GENE_PRODUCT", 337, 343], ["patients", "ORGANISM", 629, 637], ["proADM", "PROTEIN", 337, 343], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 308, 316], ["patients", "SPECIES", 629, 637], ["persistent low levels", "PROBLEM", 10, 31], ["these biomarkers", "TEST", 35, 51], ["a viral infection", "PROBLEM", 60, 77], ["the therapeutic regime", "TREATMENT", 101, 123], ["PCT", "TEST", 182, 185], ["proADM", "TREATMENT", 190, 196], ["management", "TREATMENT", 230, 240], ["severe bacterial infections", "PROBLEM", 244, 271], ["febrile neutropenic patients", "PROBLEM", 288, 316], ["high serum PCT", "PROBLEM", 318, 332], ["proADM levels", "TEST", 337, 350], ["bacterial\u2013fungal infection", "PROBLEM", 411, 437], ["HSCT recipients", "TREATMENT", 476, 491], ["biomarkers", "TEST", 493, 503], ["potential complications", "PROBLEM", 557, 580], ["infectious", "PROBLEM", 587, 597], ["non-infectious", "PROBLEM", 602, 616], ["persistent", "OBSERVATION_MODIFIER", 10, 20], ["low levels", "OBSERVATION_MODIFIER", 21, 31], ["viral", "OBSERVATION_MODIFIER", 62, 67], ["infection", "OBSERVATION", 68, 77], ["severe", "OBSERVATION_MODIFIER", 244, 250], ["bacterial", "OBSERVATION_MODIFIER", 251, 260], ["infections", "OBSERVATION", 261, 271], ["febrile", "OBSERVATION_MODIFIER", 288, 295], ["neutropenic", "OBSERVATION", 296, 307], ["bacterial\u2013fungal", "OBSERVATION_MODIFIER", 411, 427], ["infection", "OBSERVATION", 428, 437], ["complications", "OBSERVATION", 567, 580], ["infectious", "OBSERVATION_MODIFIER", 587, 597], ["non-infectious", "OBSERVATION_MODIFIER", 602, 616]]], ["Previous studies evaluating different biomarkers in this setting have been controversial.15, 24, 25, 26, 27 Pihusch et al.24 evidenced that CRP, PCT and IL-6 levels increase in both infectious and non-infectious complications.", [["CRP", "GENE_OR_GENE_PRODUCT", 140, 143], ["IL-6", "GENE_OR_GENE_PRODUCT", 153, 157], ["CRP", "PROTEIN", 140, 143], ["PCT", "PROTEIN", 145, 148], ["Previous studies", "TEST", 0, 16], ["different biomarkers", "TEST", 28, 48], ["CRP", "TEST", 140, 143], ["PCT", "TEST", 145, 148], ["IL", "TEST", 153, 155], ["both infectious and non-infectious complications", "PROBLEM", 177, 225], ["increase", "OBSERVATION_MODIFIER", 165, 173], ["both", "OBSERVATION_MODIFIER", 177, 181], ["infectious", "OBSERVATION", 182, 192], ["non-infectious", "OBSERVATION_MODIFIER", 197, 211]]], ["Furthermore, these authors showed that plasma levels of PCT were useful for differentiating between infection and other transplant-related complications, although, no details were given on the etiology and localization of the infection, making it difficult to draw comparisons with our own series.", [["plasma", "ANATOMY", 39, 45], ["infection", "DISEASE", 100, 109], ["infection", "DISEASE", 226, 235], ["plasma", "ORGANISM_SUBSTANCE", 39, 45], ["PCT", "GENE_OR_GENE_PRODUCT", 56, 59], ["PCT", "PROTEIN", 56, 59], ["plasma levels", "TEST", 39, 52], ["PCT", "TEST", 56, 59], ["infection", "PROBLEM", 100, 109], ["related complications", "PROBLEM", 131, 152], ["the infection", "PROBLEM", 222, 235], ["our own series", "TEST", 282, 296], ["infection", "OBSERVATION", 100, 109], ["infection", "OBSERVATION", 226, 235]]], ["By contrast, a meta-analysis that included six different studies and a total of 1344 episodes of suspected systemic infection in the immediate post-transplant period demonstrated that CRP and PCT were neither sensitive nor specific enough for discriminating systemic infection from other inflammatory complications.26 However, variations in clinical criteria used to define severe systemic infection across studies and the different etiology of fever among the groups compared were an evident source of heterogeneity.28 The present study confirms the poor discriminative value of these biomarkers for diagnosing RI in this cohort of patients.", [["systemic infection", "DISEASE", 107, 125], ["infection", "DISEASE", 267, 276], ["systemic infection", "DISEASE", 381, 399], ["fever", "DISEASE", 445, 450], ["CRP", "GENE_OR_GENE_PRODUCT", 184, 187], ["patients", "ORGANISM", 633, 641], ["CRP", "PROTEIN", 184, 187], ["patients", "SPECIES", 633, 641], ["a meta-analysis", "TEST", 13, 28], ["six different studies", "TEST", 43, 64], ["systemic infection", "PROBLEM", 107, 125], ["CRP", "TEST", 184, 187], ["PCT", "TEST", 192, 195], ["discriminating systemic infection", "PROBLEM", 243, 276], ["other inflammatory complications", "PROBLEM", 282, 314], ["severe systemic infection across studies", "PROBLEM", 374, 414], ["fever", "PROBLEM", 445, 450], ["heterogeneity", "PROBLEM", 503, 516], ["The present study", "TEST", 520, 537], ["these biomarkers", "TEST", 580, 596], ["systemic", "OBSERVATION_MODIFIER", 107, 115], ["infection", "OBSERVATION", 116, 125], ["systemic", "OBSERVATION_MODIFIER", 258, 266], ["infection", "OBSERVATION", 267, 276], ["inflammatory", "OBSERVATION_MODIFIER", 288, 300], ["severe", "OBSERVATION_MODIFIER", 374, 380], ["systemic", "OBSERVATION_MODIFIER", 381, 389], ["infection", "OBSERVATION", 390, 399], ["different", "OBSERVATION_MODIFIER", 423, 432], ["fever", "OBSERVATION", 445, 450], ["heterogeneity", "OBSERVATION", 503, 516]]], ["In fact, the highest values of some of these biomarkers were found in patients with non-infectious RC.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["these biomarkers", "TEST", 39, 55], ["non-infectious RC", "PROBLEM", 84, 101], ["non-infectious", "OBSERVATION", 84, 98]]], ["These findings are relevant as one of the strengths of the present study is that, contrary to other series, the episodes have been collected prospectively during a 1 year follow-up from a specific cohort of HSCT recipients.", [["recipients", "ORGANISM", 212, 222], ["the episodes", "PROBLEM", 108, 120], ["HSCT recipients", "TREATMENT", 207, 222]]], ["Furthermore, we have included only patients with RC and a specific etiology.DiscussionIn this sense, a valid concern with the published trials involving both immunocompetent and immunosuppressed patients is the paucity of data that associate the microbiologic etiology of respiratory tract infections with biomarker levels.29DiscussionIn this series, patients with non-infectious complications had significantly higher levels of CRP, proADM and IL-6 than patients with RI.", [["respiratory tract", "ANATOMY", 272, 289], ["respiratory tract infections", "DISEASE", 272, 300], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 195, 203], ["respiratory tract", "ORGANISM_SUBDIVISION", 272, 289], ["patients", "ORGANISM", 351, 359], ["CRP", "GENE_OR_GENE_PRODUCT", 429, 432], ["proADM", "GENE_OR_GENE_PRODUCT", 434, 440], ["IL-6", "GENE_OR_GENE_PRODUCT", 445, 449], ["patients", "ORGANISM", 455, 463], ["CRP", "PROTEIN", 429, 432], ["proADM", "PROTEIN", 434, 440], ["IL-6", "PROTEIN", 445, 449], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 351, 359], ["patients", "SPECIES", 455, 463], ["RC", "TREATMENT", 49, 51], ["respiratory tract infections", "PROBLEM", 272, 300], ["biomarker levels", "TEST", 306, 322], ["non-infectious complications", "PROBLEM", 365, 393], ["CRP", "TEST", 429, 432], ["RI", "PROBLEM", 469, 471], ["respiratory tract", "ANATOMY", 272, 289], ["non-infectious", "OBSERVATION_MODIFIER", 365, 379]]], ["A potential reason for this is that pathways that cause the secretion of biomarkers after infection can also be activated by other inflammatory conditions.", [["infection", "DISEASE", 90, 99], ["the secretion of biomarkers", "PROBLEM", 56, 83], ["infection", "PROBLEM", 90, 99], ["other inflammatory conditions", "PROBLEM", 125, 154], ["inflammatory", "OBSERVATION", 131, 143]]], ["Hematopoietic SCT recipients with GvHD can exhibit PCT positivity due to gastrointestinal damage causing translocation of lipopolysaccharide and secondary production of inflammatory cytokines.15, 26 Moreover, engraftment syndrome, an inflammatory condition occurring during granulocyte recovery in HSCT and characterized by fever without an identifiable infectious source and manifestations of vascular leak, is associated with elevated concentrations of several cytokines and CRP.30, 31, 32, 33 In our series, 26% of the non-infectious RC was due to the engraftment syndrome, a situation that could partially explain the high levels of biomarkers found in these patients.15DiscussionWhen considering only RI, our results confirm previous findings that biomarkers were significantly increased in bacterial\u2013fungal RI compared with viral etiology.16DiscussionA possible application of biomarkers in clinical practice is their potential high NPV when measured repetitively to rule out specific infections.", [["Hematopoietic", "ANATOMY", 0, 13], ["gastrointestinal", "ANATOMY", 73, 89], ["granulocyte", "ANATOMY", 274, 285], ["vascular", "ANATOMY", 394, 402], ["GvHD", "DISEASE", 34, 38], ["gastrointestinal damage", "DISEASE", 73, 96], ["lipopolysaccharide", "CHEMICAL", 122, 140], ["engraftment syndrome", "DISEASE", 209, 229], ["fever", "DISEASE", 324, 329], ["vascular leak", "DISEASE", 394, 407], ["RC", "DISEASE", 537, 539], ["engraftment syndrome", "DISEASE", 555, 575], ["infections", "DISEASE", 991, 1001], ["recipients", "ORGANISM", 18, 28], ["gastrointestinal", "ORGAN", 73, 89], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 122, 140], ["granulocyte", "CELL", 274, 285], ["vascular", "MULTI-TISSUE_STRUCTURE", 394, 402], ["patients", "ORGANISM", 663, 671], ["inflammatory cytokines", "PROTEIN", 169, 191], ["cytokines", "PROTEIN", 463, 472], ["patients", "SPECIES", 663, 671], ["Hematopoietic SCT recipients", "TREATMENT", 0, 28], ["GvHD", "PROBLEM", 34, 38], ["PCT positivity", "PROBLEM", 51, 65], ["gastrointestinal damage", "PROBLEM", 73, 96], ["translocation of lipopolysaccharide", "PROBLEM", 105, 140], ["inflammatory cytokines", "PROBLEM", 169, 191], ["engraftment syndrome", "PROBLEM", 209, 229], ["an inflammatory condition", "PROBLEM", 231, 256], ["fever", "PROBLEM", 324, 329], ["an identifiable infectious source", "PROBLEM", 338, 371], ["vascular leak", "PROBLEM", 394, 407], ["elevated concentrations", "PROBLEM", 428, 451], ["several cytokines", "TEST", 455, 472], ["CRP.30", "TEST", 477, 483], ["the non-infectious RC", "PROBLEM", 518, 539], ["the engraftment syndrome", "PROBLEM", 551, 575], ["the high levels of biomarkers", "PROBLEM", 618, 647], ["biomarkers", "TEST", 753, 763], ["bacterial\u2013fungal RI", "PROBLEM", 796, 815], ["high NPV", "PROBLEM", 934, 942], ["specific infections", "PROBLEM", 982, 1001], ["GvHD", "OBSERVATION", 34, 38], ["gastrointestinal", "ANATOMY", 73, 89], ["damage", "OBSERVATION", 90, 96], ["lipopolysaccharide", "OBSERVATION_MODIFIER", 122, 140], ["inflammatory cytokines", "OBSERVATION", 169, 191], ["engraftment syndrome", "OBSERVATION", 209, 229], ["inflammatory", "OBSERVATION_MODIFIER", 234, 246], ["fever", "OBSERVATION", 324, 329], ["infectious", "OBSERVATION", 354, 364], ["vascular", "ANATOMY", 394, 402], ["leak", "OBSERVATION", 403, 407], ["elevated", "OBSERVATION_MODIFIER", 428, 436], ["concentrations", "OBSERVATION_MODIFIER", 437, 451], ["several", "OBSERVATION_MODIFIER", 455, 462], ["cytokines", "OBSERVATION", 463, 472], ["non-infectious", "OBSERVATION", 522, 536], ["engraftment syndrome", "OBSERVATION", 555, 575], ["increased", "OBSERVATION_MODIFIER", 783, 792], ["infections", "OBSERVATION", 991, 1001]]], ["In this regard, our results confirm those obtained by Koya et al.18 in a small series of 28 patients, demonstrating that persistent low values of biomarkers, particularly CRP and proADM, almost certainly rule out a bacterial\u2013fungal infection as the etiologic agent of the RI in these patients, information that may encourage the physician in charge to withhold specific antibiotic prescriptions with potential serious adverse effects.34 Other authors have found that levels of PCT allow for discrimination between episodes of fever caused by bacteria, fungi and parasites from fever of viral etiologies.35 Reasons for the absence of elevation of these biomarkers in viral infections are not well understood, but it has been shown that, by secreting interferon-gamma, viruses induce an inhibitory effect on PCT gene transcription.36 Thus, the combination of aggressive attempts at pathogen detection together with determination of biomarker levels would enhance antibiotic stewardship, particularly considering the high prevalence of viral pulmonary infections in HSCT recipients.29DiscussionAnother potential utility of biomarkers in clinical management is the assessment of the severity of the complication.18, 25, 37, 38 In the present study, levels of PCT and proADM were significantly higher in patients who died during RC compared with survivors.", [["pulmonary", "ANATOMY", 1039, 1048], ["infection", "DISEASE", 232, 241], ["fever", "DISEASE", 526, 531], ["fever", "DISEASE", 577, 582], ["viral infections", "DISEASE", 666, 682], ["viral pulmonary infections", "DISEASE", 1033, 1059], ["patients", "ORGANISM", 92, 100], ["CRP", "GENE_OR_GENE_PRODUCT", 171, 174], ["patients", "ORGANISM", 284, 292], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 749, 765], ["PCT", "GENE_OR_GENE_PRODUCT", 806, 809], ["pulmonary", "ORGAN", 1039, 1048], ["PCT", "GENE_OR_GENE_PRODUCT", 1255, 1258], ["proADM", "SIMPLE_CHEMICAL", 1263, 1269], ["patients", "ORGANISM", 1299, 1307], ["CRP", "PROTEIN", 171, 174], ["proADM", "PROTEIN", 179, 185], ["PCT", "PROTEIN", 477, 480], ["interferon-gamma", "PROTEIN", 749, 765], ["PCT gene", "DNA", 806, 814], ["PCT", "PROTEIN", 1255, 1258], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 284, 292], ["patients", "SPECIES", 1299, 1307], ["persistent low values of biomarkers", "PROBLEM", 121, 156], ["CRP", "TEST", 171, 174], ["a bacterial\u2013fungal infection", "PROBLEM", 213, 241], ["specific antibiotic prescriptions", "TREATMENT", 361, 394], ["potential serious adverse effects", "PROBLEM", 400, 433], ["PCT", "TEST", 477, 480], ["fever", "PROBLEM", 526, 531], ["bacteria", "PROBLEM", 542, 550], ["fungi", "PROBLEM", 552, 557], ["parasites", "PROBLEM", 562, 571], ["fever", "PROBLEM", 577, 582], ["viral etiologies", "PROBLEM", 586, 602], ["elevation of these biomarkers", "PROBLEM", 633, 662], ["viral infections", "PROBLEM", 666, 682], ["viruses", "PROBLEM", 767, 774], ["PCT gene transcription", "TREATMENT", 806, 828], ["pathogen detection", "TEST", 880, 898], ["biomarker levels", "TEST", 930, 946], ["antibiotic stewardship", "TREATMENT", 961, 983], ["viral pulmonary infections", "PROBLEM", 1033, 1059], ["HSCT recipients", "TREATMENT", 1063, 1078], ["clinical management", "TREATMENT", 1134, 1153], ["the assessment", "TEST", 1157, 1171], ["the complication", "PROBLEM", 1191, 1207], ["the present study", "TEST", 1226, 1243], ["PCT", "TEST", 1255, 1258], ["persistent", "OBSERVATION_MODIFIER", 121, 131], ["low values", "OBSERVATION_MODIFIER", 132, 142], ["bacterial\u2013fungal", "OBSERVATION_MODIFIER", 215, 231], ["infection", "OBSERVATION", 232, 241], ["fever", "OBSERVATION", 526, 531], ["elevation", "OBSERVATION_MODIFIER", 633, 642], ["viral infections", "OBSERVATION", 666, 682], ["viral", "OBSERVATION_MODIFIER", 1033, 1038], ["pulmonary", "ANATOMY", 1039, 1048], ["infections", "OBSERVATION", 1049, 1059], ["complication", "OBSERVATION", 1195, 1207]]], ["Other authors have also found an association between levels of PCT and mortality in critically ill patients.38, 39 Koya et al.18 also identified this association in a small series of HSCT recipients.", [["critically ill", "DISEASE", 84, 98], ["patients", "ORGANISM", 99, 107], ["HSCT", "CANCER", 183, 187], ["recipients", "ORGANISM", 188, 198], ["patients", "SPECIES", 99, 107], ["PCT", "TEST", 63, 66], ["HSCT recipients", "TREATMENT", 183, 198], ["small", "OBSERVATION_MODIFIER", 167, 172]]], ["This information can be very useful when making decisions about intensive care unit admission and monitoring of the patients.DiscussionDifferent limitations must be considered for the proper evaluation of this study.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["the proper evaluation", "TEST", 180, 201], ["this study", "TEST", 205, 215]]], ["First, the lack of a control group of HSCT recipients without RC is a flaw.", [["HSCT", "CANCER", 38, 42], ["recipients", "ORGANISM", 43, 53], ["HSCT recipients", "TREATMENT", 38, 53]]], ["Certainly, HSCT recipients undergo different stages (aplastic phase, recovery phase), and suffer some conditions (acute and/or chronic graft) or complications (presence of mucositis) that may potentially influence biomarker levels.", [["graft", "ANATOMY", 135, 140], ["mucositis", "DISEASE", 172, 181], ["recipients", "ORGANISM", 16, 26], ["graft", "TISSUE", 135, 140], ["different stages (aplastic phase", "PROBLEM", 35, 67], ["some conditions", "PROBLEM", 97, 112], ["chronic graft)", "PROBLEM", 127, 141], ["complications", "PROBLEM", 145, 158], ["mucositis", "PROBLEM", 172, 181], ["biomarker levels", "TEST", 214, 230], ["different stages", "OBSERVATION_MODIFIER", 35, 51], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["chronic", "OBSERVATION_MODIFIER", 127, 134], ["graft", "OBSERVATION", 135, 140], ["mucositis", "OBSERVATION", 172, 181]]], ["Nevertheless, the demonstration of significant differences between the different types of complications confirm that the use of biomarkers can be useful, as a complementary tool in the management of RC in HSCT recipients.", [["RC in HSCT recipients", "TREATMENT", 199, 220], ["significant", "OBSERVATION_MODIFIER", 35, 46]]], ["Second, we decided to apply rigorous exclusion criteria and include only those cases with microbiologically documented RI.", [["rigorous exclusion criteria", "TEST", 28, 55]]], ["The authors are aware of the relatively small number of patients included, which was mainly due to the numerous dropouts of the primary cohort owing to the lack of identification of the causal microorganism or, conversely, owing to the identification of a mixed infection (caused by several microorganisms).", [["infection", "DISEASE", 262, 271], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["the causal microorganism", "PROBLEM", 182, 206], ["a mixed infection", "PROBLEM", 254, 271], ["several microorganisms", "PROBLEM", 283, 305], ["small", "OBSERVATION_MODIFIER", 40, 45], ["mixed", "OBSERVATION_MODIFIER", 256, 261], ["infection", "OBSERVATION", 262, 271]]], ["Most of the studies published on this topic include patients with both clinical and microbiological diagnosis of infection.", [["infection", "DISEASE", 113, 122], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["the studies", "TEST", 8, 19], ["infection", "PROBLEM", 113, 122], ["infection", "OBSERVATION", 113, 122]]], ["This fact represents a potential bias, since RI may be produced by different microorganisms or by a combination of them, thus making it impossible to correlate a specific microorganism with biomarker levels.18 Third, in our study we divided, as other authors did, extracellular from intracellular infections.", [["extracellular", "ANATOMY", 264, 277], ["intracellular", "ANATOMY", 283, 296], ["infections", "DISEASE", 297, 307], ["RI", "GENE_OR_GENE_PRODUCT", 45, 47], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 264, 277], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 283, 296], ["a potential bias", "PROBLEM", 21, 37], ["RI", "PROBLEM", 45, 47], ["different microorganisms", "PROBLEM", 67, 91], ["biomarker levels", "TEST", 190, 206], ["our study", "TEST", 220, 229], ["intracellular infections", "PROBLEM", 283, 307], ["bias", "OBSERVATION", 33, 37], ["may be", "UNCERTAINTY", 48, 54], ["different", "OBSERVATION_MODIFIER", 67, 76], ["microorganisms", "OBSERVATION", 77, 91], ["intracellular", "OBSERVATION_MODIFIER", 283, 296], ["infections", "OBSERVATION", 297, 307]]], ["We are aware of the conflicting results obtained by different authors regarding the biomarkers behavior in fungal diseases.", [["fungal diseases", "DISEASE", 107, 122], ["fungal diseases", "PROBLEM", 107, 122], ["fungal diseases", "OBSERVATION", 107, 122]]], ["Although controversial, it is possible that biomarker levels may differ between fungal and bacterial pulmonary infections and further studies are needed on this issue.", [["pulmonary", "ANATOMY", 101, 110], ["fungal and bacterial pulmonary infections", "DISEASE", 80, 121], ["pulmonary", "ORGAN", 101, 110], ["biomarker levels", "TEST", 44, 60], ["fungal and bacterial pulmonary infections", "PROBLEM", 80, 121], ["further studies", "TEST", 126, 141], ["bacterial", "OBSERVATION_MODIFIER", 91, 100], ["pulmonary", "ANATOMY", 101, 110], ["infections", "OBSERVATION", 111, 121]]], ["Finally, most of the patients included in this study were receiving antibiotic and/or immunosuppressive therapy when biomarker values were measured, and we cannot therefore assess the potential influence of these variables on biomarker concentrations.DiscussionIn summary, in HSCT recipients, CRP, PCT and proADM cannot differentiate between infectious and non-infectious RC.", [["infectious and non-infectious RC", "DISEASE", 342, 374], ["patients", "ORGANISM", 21, 29], ["recipients", "ORGANISM", 281, 291], ["CRP", "GENE_OR_GENE_PRODUCT", 293, 296], ["proADM", "SIMPLE_CHEMICAL", 306, 312], ["CRP", "PROTEIN", 293, 296], ["PCT", "PROTEIN", 298, 301], ["patients", "SPECIES", 21, 29], ["this study", "TEST", 42, 52], ["antibiotic", "TREATMENT", 68, 78], ["immunosuppressive therapy", "TREATMENT", 86, 111], ["biomarker values", "TEST", 117, 133], ["biomarker concentrations", "TEST", 226, 250], ["CRP", "TEST", 293, 296], ["PCT", "TEST", 298, 301], ["infectious and non-infectious RC", "PROBLEM", 342, 374], ["infectious", "OBSERVATION", 342, 352], ["non-infectious", "OBSERVATION", 357, 371]]], ["However, these biomarkers can estimate the severity of infection.", [["infection", "DISEASE", 55, 64], ["these biomarkers", "TEST", 9, 25], ["infection", "PROBLEM", 55, 64], ["infection", "OBSERVATION", 55, 64]]], ["Persistently low values of these biomarkers militate against a bacterial\u2013fungal infection, and an alternative diagnosis such as viral infections should be considered in the appropriate clinical setting.", [["bacterial\u2013fungal infection", "DISEASE", 63, 89], ["viral infections", "DISEASE", 128, 144], ["Persistently low values", "PROBLEM", 0, 23], ["these biomarkers", "TEST", 27, 43], ["a bacterial\u2013fungal infection", "PROBLEM", 61, 89], ["viral infections", "PROBLEM", 128, 144], ["low values", "OBSERVATION_MODIFIER", 13, 23], ["bacterial\u2013fungal", "OBSERVATION_MODIFIER", 63, 79], ["infection", "OBSERVATION", 80, 89], ["viral", "OBSERVATION_MODIFIER", 128, 133], ["infections", "OBSERVATION", 134, 144]]]], "PMC7309273": [["IntroductionInfectious diseases pose a serious threat to public health due to its high infectivity and potentially high mortality.", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["IntroductionInfectious diseases", "PROBLEM", 0, 31], ["its high infectivity", "PROBLEM", 78, 98], ["high mortality", "OBSERVATION", 115, 129]]], ["Over the last few decades, infectious diseases have caused several regional and worldwide pandemics, resulting in many infections and deaths.", [["infectious diseases", "DISEASE", 27, 46], ["infections", "DISEASE", 119, 129], ["deaths", "DISEASE", 134, 140], ["infectious diseases", "PROBLEM", 27, 46], ["several regional and worldwide pandemics", "PROBLEM", 59, 99], ["many infections", "PROBLEM", 114, 129], ["infectious", "OBSERVATION", 27, 37], ["several", "OBSERVATION_MODIFIER", 59, 66], ["regional", "OBSERVATION_MODIFIER", 67, 75], ["worldwide", "OBSERVATION_MODIFIER", 80, 89], ["pandemics", "OBSERVATION", 90, 99], ["many", "OBSERVATION_MODIFIER", 114, 118], ["infections", "OBSERVATION", 119, 129]]], ["For example, during H1N1 pandemic in 2009, more than 600,000 cases were lab-confirmed and more than 14,000 were dead all over the world [1].", [["H1N1 pandemic", "DISEASE", 20, 33]]], ["According to World Health Organization (WHO), the epidemic of Ebola in 2014 has caused significant mortality in many West African countries, with a reported case with fatality rate of 70% [2].", [["Ebola", "DISEASE", 62, 67], ["Ebola", "ORGANISM", 62, 67], ["fatality rate", "TEST", 167, 180], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["mortality", "OBSERVATION", 99, 108]]], ["Even for a seasonal influenza, it is estimated to affect 5% to 15% of the global population and cause 3 to 5 million cases of severe infections and 250,000 to 500,000 deaths worldwide each year [3].IntroductionTo prevent infectious diseases, one of the most effective ways is to vaccinate the susceptible individuals.", [["influenza", "DISEASE", 20, 29], ["infections", "DISEASE", 133, 143], ["deaths", "DISEASE", 167, 173], ["infectious diseases", "DISEASE", 221, 240], ["a seasonal influenza", "PROBLEM", 9, 29], ["severe infections", "PROBLEM", 126, 143], ["infectious diseases", "PROBLEM", 221, 240], ["influenza", "OBSERVATION", 20, 29], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["infections", "OBSERVATION", 133, 143], ["infectious", "OBSERVATION", 221, 231]]], ["However, due to resource constraints such as the limited vaccine supply, in many cases, it may not be practical to vaccinate all the susceptible individuals, especially when a new infectious disease outbreaks.", [["resource constraints", "TREATMENT", 16, 36], ["the limited vaccine supply", "TREATMENT", 45, 71], ["a new infectious disease outbreaks", "PROBLEM", 174, 208], ["new", "OBSERVATION_MODIFIER", 176, 179], ["infectious", "OBSERVATION", 180, 190]]], ["Therefore, targeted vaccination, which vaccinates a small group of people in a community, is an alternative approach to contain infectious diseases.", [["infectious diseases", "DISEASE", 128, 147], ["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73], ["targeted vaccination", "TREATMENT", 11, 31], ["an alternative approach", "TREATMENT", 93, 116], ["infectious diseases", "PROBLEM", 128, 147], ["small", "OBSERVATION_MODIFIER", 52, 57], ["infectious", "OBSERVATION", 128, 138]]], ["The challenge is how to find the group of people whose vaccination will averagely result in the maximum reduction of disease spread.IntroductionTargeted vaccination has been studied in some previous works [4]\u2013[7].", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["disease spread", "PROBLEM", 117, 131], ["IntroductionTargeted vaccination", "TREATMENT", 132, 164], ["maximum", "OBSERVATION_MODIFIER", 96, 103], ["reduction", "OBSERVATION_MODIFIER", 104, 113], ["disease", "OBSERVATION", 117, 124]]], ["However, these works are limited to theoretical analysis based on synthetic networks such as random, homogeneous or scale-free network, which may not reflect the real contact patterns among people in different scenarios.", [["people", "ORGANISM", 190, 196], ["people", "SPECIES", 190, 196], ["theoretical analysis", "TEST", 36, 56], ["may not reflect", "UNCERTAINTY", 142, 157]]], ["For example, based on the contact traces collected from high school students, where each student carries a sensor node to record the contacts with others by sending and receiving packets (details shown in Section III), we show in Figure 1 that the distributions of the number of nodes\u2019 contacts (i.e., the number of packets received from other nodes) and neighbors (i.e., the number of nodes from which packets are received) are different from the power-law distributions.", [["nodes\u2019 contacts", "ANATOMY", 279, 294], ["sensor node", "MULTI-TISSUE_STRUCTURE", 107, 118], ["a sensor node", "PROBLEM", 105, 118], ["node", "OBSERVATION", 114, 118], ["nodes", "OBSERVATION", 279, 284], ["nodes", "OBSERVATION", 344, 349], ["nodes", "OBSERVATION", 386, 391], ["law distributions", "OBSERVATION", 454, 471]]], ["Since students in the high school spend most of their time in classes and students in the same class may have contacts with each other, most of the nodes in the network will have similar number of neighbors and contacts.", [["nodes", "MULTI-TISSUE_STRUCTURE", 148, 153], ["nodes", "OBSERVATION", 148, 153]]], ["As observed from our collected trace, the number of nodes\u2019 neighbors and the number of nodes\u2019 contacts are more likely to follow normal distributions rather than power-law distributions.", [["nodes\u2019 contacts", "ANATOMY", 87, 102], ["trace", "OBSERVATION_MODIFIER", 31, 36], ["number", "OBSERVATION_MODIFIER", 42, 48], ["nodes", "OBSERVATION", 52, 57], ["number", "OBSERVATION_MODIFIER", 77, 83], ["nodes", "OBSERVATION", 87, 92], ["more likely", "UNCERTAINTY", 107, 118], ["law distributions", "OBSERVATION", 168, 185]]]], "PMC7381917": [], "90b2bda4ec15c4846949f7b2dad066ee0ee6f7c3": [["(PIV)1-4, human CoV (including subtypes OC43 and NL63), human bocavirus (BoV) and parechovirus (PEV) are the most common viruses detected in respiratory samples worldwide.", [["respiratory samples", "ANATOMY", 141, 160], ["(PIV)1-4", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 10, 15], ["CoV", "ORGANISM", 16, 19], ["OC43", "GENE_OR_GENE_PRODUCT", 40, 44], ["NL63", "GENE_OR_GENE_PRODUCT", 49, 53], ["human", "ORGANISM", 56, 61], ["bocavirus", "GENE_OR_GENE_PRODUCT", 62, 71], ["BoV", "GENE_OR_GENE_PRODUCT", 73, 76], ["parechovirus (PEV", "ORGANISM", 82, 99], ["respiratory samples", "CANCER", 141, 160], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 56, 61], ["human CoV", "SPECIES", 10, 19], ["human bocavirus", "SPECIES", 56, 71], ["BoV", "SPECIES", 73, 76], ["PEV", "SPECIES", 96, 99], ["PIV", "TEST", 1, 4], ["human CoV", "TEST", 10, 19], ["subtypes OC43", "TEST", 31, 44], ["NL63", "TEST", 49, 53], ["human bocavirus (BoV)", "TEST", 56, 77], ["parechovirus", "PROBLEM", 82, 94], ["the most common viruses", "PROBLEM", 105, 128], ["most common", "OBSERVATION_MODIFIER", 109, 120], ["viruses", "OBSERVATION", 121, 128], ["respiratory samples", "OBSERVATION", 141, 160]]], ["[3] [4] [5] [6] [7] [8] [9] Of these, influenza A virus, influenza B virus, and CoV have been reported as the most common viruses detected in people over 5 years old, [10] [11] [12] [13] while RSV and PIVs have been regarded as the leading causes of respiratory infections in children under 5 years old in South East Asia.", [["respiratory", "ANATOMY", 250, 261], ["[3] [4] [5] [6] [7] [8] [9", "CHEMICAL", 0, 26], ["influenza A", "DISEASE", 38, 49], ["influenza B", "DISEASE", 57, 68], ["[10] [11] [12] [13]", "CHEMICAL", 167, 186], ["respiratory infections", "DISEASE", 250, 272], ["[3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 27], ["influenza A virus", "ORGANISM", 38, 55], ["influenza B virus", "ORGANISM", 57, 74], ["CoV", "ORGANISM", 80, 83], ["people", "ORGANISM", 142, 148], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 167, 186], ["RSV", "ORGANISM", 193, 196], ["PIVs", "GENE_OR_GENE_PRODUCT", 201, 205], ["children", "ORGANISM", 276, 284], ["influenza A virus", "SPECIES", 38, 55], ["influenza B virus", "SPECIES", 57, 74], ["people", "SPECIES", 142, 148], ["children", "SPECIES", 276, 284], ["influenza A virus", "SPECIES", 38, 55], ["influenza B virus", "SPECIES", 57, 74], ["RSV", "SPECIES", 193, 196], ["[3] [4] [5] [6] [7] [8", "TEST", 0, 22], ["influenza A virus", "PROBLEM", 38, 55], ["influenza B virus", "PROBLEM", 57, 74], ["CoV", "PROBLEM", 80, 83], ["RSV", "TREATMENT", 193, 196], ["PIVs", "TREATMENT", 201, 205], ["respiratory infections", "PROBLEM", 250, 272], ["respiratory", "ANATOMY", 250, 261], ["infections", "OBSERVATION", 262, 272]]], ["3, 14, 15 Zoonotic infections are of global concern, and approximately 60% of known infectious diseases in humans are of zoonotic origin.", [["Zoonotic infections", "DISEASE", 10, 29], ["infectious diseases", "DISEASE", 84, 103], ["humans", "ORGANISM", 107, 113], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["Zoonotic infections", "PROBLEM", 10, 29], ["known infectious diseases", "PROBLEM", 78, 103], ["Zoonotic", "OBSERVATION_MODIFIER", 10, 18], ["infections", "OBSERVATION", 19, 29], ["global", "OBSERVATION_MODIFIER", 37, 43], ["infectious", "OBSERVATION", 84, 94], ["zoonotic", "OBSERVATION_MODIFIER", 121, 129]]], ["16 In addition, Southeast Asia, including Vietnam, is one of the hotspots of emerging infectious diseases.", [["infectious diseases", "DISEASE", 86, 105], ["emerging infectious diseases", "PROBLEM", 77, 105], ["infectious", "OBSERVATION", 86, 96]]], ["Indeed, many of the recent respiratory outbreaks are linked with zoonotic viruses as SARS-CoV, 17 avian influenza A virus H5N1, 18pandemic influenzaA virus subtype H1N1, 19 and more recently MERS-CoV, 20 and community-based studies, was conducted across Vietnam.", [["respiratory outbreaks", "DISEASE", 27, 48], ["zoonotic viruses", "DISEASE", 65, 81], ["SARS-CoV", "DISEASE", 85, 93], ["influenza A virus H5N1", "DISEASE", 104, 126], ["influenzaA", "DISEASE", 139, 149], ["H1N1", "DISEASE", 164, 168], ["SARS-CoV", "ORGANISM", 85, 93], ["17", "ORGANISM", 95, 97], ["avian influenza A virus H5N1", "ORGANISM", 98, 126], ["18pandemic", "ORGANISM", 128, 138], ["influenzaA virus subtype H1N1", "ORGANISM", 139, 168], ["MERS-CoV", "ORGANISM", 191, 199], ["avian influenza", "SPECIES", 98, 113], ["A virus H5N1", "SPECIES", 114, 126], ["pandemic influenzaA virus subtype H1N1", "SPECIES", 130, 168], ["SARS-CoV", "SPECIES", 85, 93], ["MERS-CoV", "SPECIES", 191, 199], ["the recent respiratory outbreaks", "PROBLEM", 16, 48], ["zoonotic viruses", "PROBLEM", 65, 81], ["SARS", "PROBLEM", 85, 89], ["CoV", "TEST", 90, 93], ["avian influenza A virus H5N1", "PROBLEM", 98, 126], ["18pandemic influenzaA virus subtype H1N1", "PROBLEM", 128, 168], ["CoV", "TEST", 196, 199], ["community-based studies", "TEST", 208, 231], ["respiratory", "ANATOMY", 27, 38], ["outbreaks", "OBSERVATION", 39, 48]]], ["21, 22 Herein, we focus our analysis on a community-based study, which was designed to capture the cross-species transmission events of zoonotic viruses among individuals with a high risk of zoonotic infections in southern and highland Vietnam.", [["zoonotic viruses", "DISEASE", 136, 152], ["zoonotic infections", "DISEASE", 191, 210], ["our analysis", "TEST", 24, 36], ["a community-based study", "TEST", 40, 63], ["zoonotic viruses", "PROBLEM", 136, 152], ["zoonotic infections", "PROBLEM", 191, 210], ["zoonotic viruses", "OBSERVATION", 136, 152], ["zoonotic", "OBSERVATION_MODIFIER", 191, 199], ["infections", "OBSERVATION", 200, 210]]], ["In this study, our aim was to describe the frequency of common respiratory viruses in clinical samples collected from these individuals, later called cohort members, at baseline and when a respiratory disease episode was reported during the study period.| Study design and inclusion criteriaThis study was a part of the High-Risk Sentinel Cohort (HRSC) study which was a community-based component of the VIZIONS project.", [["samples", "ANATOMY", 95, 102], ["respiratory", "ANATOMY", 189, 200], ["respiratory viruses", "DISEASE", 63, 82], ["respiratory disease", "DISEASE", 189, 208], ["this study", "TEST", 3, 13], ["common respiratory viruses", "PROBLEM", 56, 82], ["a respiratory disease episode", "PROBLEM", 187, 216], ["inclusion criteria", "TEST", 273, 291], ["This study", "TEST", 291, 301], ["the VIZIONS project", "TREATMENT", 400, 419], ["respiratory viruses", "OBSERVATION", 63, 82], ["respiratory", "ANATOMY", 189, 200], ["disease", "OBSERVATION", 201, 208]]], ["21 The HRSC study was first commenced in June 2013 in Dong Thap and then in February 2014 in Dak Lak.", [["The HRSC study", "TEST", 3, 17]]], ["These are provinces located in southern and highland of Vietnam, respectively, representing two different geographic areas in Vietnam.| Study design and inclusion criteriaAnimal-raising farmers, animal health workers, and slaughterers were eligible to be enrolled in the study since these are common occupations in rural Vietnam with frequent occupational exposure to animals.", [["Study design", "TEST", 136, 148], ["the study", "TEST", 267, 276], ["provinces", "OBSERVATION_MODIFIER", 10, 19], ["southern", "OBSERVATION_MODIFIER", 31, 39], ["highland", "OBSERVATION_MODIFIER", 44, 52], ["two", "OBSERVATION_MODIFIER", 92, 95], ["different", "OBSERVATION_MODIFIER", 96, 105], ["geographic", "OBSERVATION_MODIFIER", 106, 116], ["areas", "OBSERVATION_MODIFIER", 117, 122]]], ["Rat traders in Dong Thap were additionally recruited due to the commonality of this occupation in this locality.", [["Rat", "SPECIES", 0, 3]]], ["The animal-raising farmers accounted for about twothird of the population with occupational exposure to animals in these study provinces.| Study design and inclusion criteriaOn the basis of the animal farm census, letters were sent out to invite potential participants to attend an introductory meeting.", [["participants", "SPECIES", 256, 268], ["Study design", "TEST", 139, 151]]], ["The consent forms were then obtained from those who were willing to join the HRSC study.", [["the HRSC study", "TEST", 73, 87]]], ["The slaughterers were recruited from all local central abattoirs or slaughter points.", [["central abattoirs", "OBSERVATION", 47, 64]]], ["The animalhealth workers and rat traders were selected by convenience.", [["rat", "ORGANISM", 29, 32], ["rat", "SPECIES", 29, 32], ["rat", "SPECIES", 29, 32]]], ["Consequently, a total of 581 individuals (median age in year, 38; range, 2-89), including 415 (71.4%) animal-raising farmers, 100 (11.7%) slaughterers, 61 (10.5%) animal-health workers, and 5 (1.8%) rat-traders, were recruited.", [["rat", "ORGANISM", 199, 202], ["rat", "SPECIES", 199, 202], ["slaughterers", "TEST", 138, 150]]], ["Each cohort members were followed up annually for up 3 years since recruitment.| Data collectionAnnually, to establish the baseline data (ie, no disease episode reported), the cohort members were interviewed, and clinical specimens, including rectal, pooled nasal, and throat swabs and blood were also collected from each interviewee.", [["specimens", "ANATOMY", 222, 231], ["rectal", "ANATOMY", 243, 249], ["nasal", "ANATOMY", 258, 263], ["throat swabs", "ANATOMY", 269, 281], ["blood", "ANATOMY", 286, 291], ["rectal", "ORGANISM_SUBDIVISION", 243, 249], ["nasal", "ORGANISM_SUBDIVISION", 258, 263], ["throat swabs", "ORGANISM_SUBSTANCE", 269, 281], ["blood", "ORGANISM_SUBSTANCE", 286, 291], ["Data collection", "TEST", 81, 96], ["the baseline data", "TEST", 119, 136], ["disease episode", "PROBLEM", 145, 160], ["clinical specimens", "TEST", 213, 231], ["rectal, pooled nasal, and throat swabs", "TEST", 243, 281], ["rectal", "ANATOMY", 243, 249], ["nasal", "ANATOMY", 258, 263], ["throat", "ANATOMY", 269, 275]]], ["These baseline data were collected from all cohort members, except for the farmers, for which only one person mostly working with animals per household was interviewed and sampled.| Data collectionDuring the study period, whenever getting illness (diarrhea and respiratory infection) defined as any signs/symptoms of respiratory tract infections (eg, sneezing, coughing or sore throat), plus fever (\u226538\u00b0C), the cohort members informed the local study teams.", [["respiratory", "ANATOMY", 261, 272], ["respiratory tract", "ANATOMY", 317, 334], ["illness", "DISEASE", 239, 246], ["diarrhea", "DISEASE", 248, 256], ["respiratory infection", "DISEASE", 261, 282], ["respiratory tract infections", "DISEASE", 317, 345], ["sneezing", "DISEASE", 351, 359], ["coughing", "DISEASE", 361, 369], ["sore throat", "DISEASE", 373, 384], ["fever", "DISEASE", 392, 397], ["respiratory tract", "ORGANISM_SUBDIVISION", 317, 334], ["person", "SPECIES", 103, 109], ["the study", "TEST", 204, 213], ["illness", "PROBLEM", 239, 246], ["diarrhea", "PROBLEM", 248, 256], ["respiratory infection", "PROBLEM", 261, 282], ["symptoms", "PROBLEM", 305, 313], ["respiratory tract infections", "PROBLEM", 317, 345], ["sneezing", "PROBLEM", 351, 359], ["coughing", "PROBLEM", 361, 369], ["sore throat", "PROBLEM", 373, 384], ["fever", "PROBLEM", 392, 397], ["respiratory", "ANATOMY", 261, 272], ["infection", "OBSERVATION", 273, 282], ["respiratory tract", "ANATOMY", 317, 334]]], ["Within 48 hours, the site study doctors made a visit to the participant houses and collected information about animal exposures, associated symptoms, and medication.", [["associated symptoms", "PROBLEM", 129, 148], ["medication", "TREATMENT", 154, 164]]], ["In addition, clinical specimens, including blood, and (when relevant) rectal-or pooled nasal and throat swabs were collected.", [["specimens", "ANATOMY", 22, 31], ["blood", "ANATOMY", 43, 48], ["rectal", "ANATOMY", 70, 76], ["nasal", "ANATOMY", 87, 92], ["throat swabs", "ANATOMY", 97, 109], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["rectal", "ORGANISM_SUBDIVISION", 70, 76], ["nasal", "ORGANISM_SUBDIVISION", 87, 92], ["throat swabs", "ORGANISM_SUBSTANCE", 97, 109], ["clinical specimens", "TEST", 13, 31], ["blood", "TEST", 43, 48], ["rectal", "TEST", 70, 76], ["pooled nasal and throat swabs", "PROBLEM", 80, 109], ["rectal", "ANATOMY", 70, 76], ["nasal", "ANATOMY", 87, 92], ["throat", "ANATOMY", 97, 103]]], ["All the specimens were stored at \u221280\u00b0C until analysis.", [["specimens", "ANATOMY", 8, 17], ["specimens", "CANCER", 8, 17], ["All the specimens", "TEST", 0, 17], ["analysis", "TEST", 45, 53]]], ["Here, we focused on respiratory episodes.", [["respiratory", "ANATOMY", 20, 31], ["respiratory episodes", "DISEASE", 20, 40], ["respiratory episodes", "PROBLEM", 20, 40], ["respiratory episodes", "OBSERVATION", 20, 40]]], ["As such, only pooled nasal-throat swabs of each individual were analyzed.| Respiratory virus detections by real-time polymerase chain reaction analysisTo detect common respiratory viruses in pooled nasal and throat swabs, we first isolated total nucleic acid (NA) from patient samples Table S2 ).", [["nasal", "ANATOMY", 21, 26], ["nasal", "ANATOMY", 198, 203], ["throat swabs", "ANATOMY", 208, 220], ["respiratory viruses", "DISEASE", 168, 187], ["nucleic acid", "CHEMICAL", 246, 258], ["NA", "CHEMICAL", 260, 262], ["nasal", "ORGANISM_SUBDIVISION", 21, 26], ["nasal", "ORGANISM_SUBDIVISION", 198, 203], ["throat swabs", "ORGANISM_SUBSTANCE", 208, 220], ["patient", "ORGANISM", 269, 276], ["patient", "SPECIES", 269, 276], ["pooled nasal-throat swabs", "TEST", 14, 39], ["Respiratory virus detections", "TEST", 75, 103], ["reaction analysis", "TEST", 134, 151], ["common respiratory viruses", "PROBLEM", 161, 187], ["pooled nasal and throat swabs", "PROBLEM", 191, 220], ["throat", "ANATOMY", 27, 33], ["common", "ANATOMY", 161, 167], ["respiratory viruses", "OBSERVATION", 168, 187], ["nasal", "ANATOMY", 198, 203], ["throat", "ANATOMY", 208, 214]]], ["All the RT-PCR reactions were carried in a LightCycler 480 Instrument II (96-wells) (Roche Molecular Systems, Inc).| Data analysisThe data were analyzed by STATA software, version 12.0.", [["All the RT-PCR reactions", "TEST", 0, 24], ["Instrument II", "TEST", 59, 72], ["Data analysis", "TEST", 117, 130], ["The data", "TEST", 130, 138], ["version", "TEST", 172, 179], ["RT", "ANATOMY", 8, 10]]], ["27 The pairwise comparisons of categorical variables were calculated by Pearson's \u03c7 2 test (or Fisher exact test when the sample size was less than five in any of the cells of a contingency table) or two-sample t test with equal variances.| Data analysisThe errors of multiple comparisons were corrected by the Bonferroni method.", [["cells", "ANATOMY", 167, 172], ["cells", "CELL", 167, 172], ["Fisher exact test", "TEST", 95, 112], ["the sample size", "TEST", 118, 133], ["sample t test", "TEST", 204, 217], ["Data analysis", "TEST", 241, 254]]], ["EpiTools 29 were used to calculate 95% confidence intervals for the odds ratio.", [["EpiTools", "TREATMENT", 0, 8], ["the odds ratio", "TEST", 64, 78]]], ["The rat traders (n = 5) were excluded from these tests because of an insufficient sample size.", [["rat", "ORGANISM", 4, 7], ["rat", "SPECIES", 4, 7], ["The rat traders", "TEST", 0, 15], ["these tests", "TEST", 43, 54], ["an insufficient sample size", "PROBLEM", 66, 93], ["insufficient", "OBSERVATION", 69, 81], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["In addition, mixed infections were recorded in 2 (0.3%) and 7 (0.9%) samples collected at baseline and disease episodes, respectively (Table 2) .| EthicsOf the detected viruses, EVs, HRV and influenza A virus were the most common viruses detected in samples collected at both baseline and disease episodes, followed by ADV and CoV ( Table 3 ).", [["samples", "ANATOMY", 69, 76], ["EVs", "ANATOMY", 178, 181], ["samples", "ANATOMY", 250, 257], ["infections", "DISEASE", 19, 29], ["influenza A virus", "DISEASE", 191, 208], ["EVs", "CELL", 178, 181], ["HRV", "ORGANISM", 183, 186], ["influenza A virus", "ORGANISM", 191, 208], ["samples", "CANCER", 250, 257], ["influenza A virus", "SPECIES", 191, 208], ["influenza A virus", "SPECIES", 191, 208], ["ADV", "SPECIES", 319, 322], ["mixed infections", "PROBLEM", 13, 29], ["samples", "TEST", 69, 76], ["disease episodes", "PROBLEM", 103, 119], ["EVs", "TEST", 178, 181], ["HRV", "PROBLEM", 183, 186], ["influenza A virus", "PROBLEM", 191, 208], ["disease episodes", "PROBLEM", 289, 305], ["mixed", "OBSERVATION_MODIFIER", 13, 18], ["infections", "OBSERVATION", 19, 29], ["viruses", "OBSERVATION", 169, 176]]], ["In addition, gastrointestinal symptoms were recorded in 7.3% (56 of 770), but watery diarrhea was more often recorded in cohort members without a virus detected than in those with a positive finding, 52 of 634 (8.2%) vs 4 of 136 (2.9%), P = .029 (Table 3) .| Clinical signs/symptoms of cohort members in acute respiratory diseases with the detected virusesOf the virus-positive cases, watery diarrhea was only recorded in those positive for EVs and HRV, whilst sore throat was predominantly recorded in those positive for influenza A virus.| Clinical signs/symptoms of cohort members in acute respiratory diseases with the detected virusesOtherwise, there were considerable similarities in age and clinical presentations of cohort-member groups who were positive for different viruses (Table 3) .| The frequency of respiratory viruses detected by provincesTo assess the differences in the frequencies of respiratory viruses under investigation between Dong Thap and Dak Lak, which represent the two distinct geographic localities in Vietnam, we stratified the data for these two individual provinces ( were significantly more often detected in samples collected at disease episode than at baseline; P < .001 for both EVs and HRV.", [["gastrointestinal", "ANATOMY", 13, 29], ["respiratory", "ANATOMY", 310, 321], ["EVs", "ANATOMY", 441, 444], ["respiratory", "ANATOMY", 593, 604], ["samples", "ANATOMY", 1144, 1151], ["EVs", "ANATOMY", 1217, 1220], ["gastrointestinal symptoms", "DISEASE", 13, 38], ["diarrhea", "DISEASE", 85, 93], ["respiratory diseases", "DISEASE", 310, 330], ["diarrhea", "DISEASE", 392, 400], ["sore throat", "DISEASE", 461, 472], ["influenza A virus", "DISEASE", 522, 539], ["acute respiratory diseases", "DISEASE", 587, 613], ["respiratory viruses", "DISEASE", 815, 834], ["respiratory viruses", "DISEASE", 904, 923], ["gastrointestinal", "ORGAN", 13, 29], ["EVs", "MULTI-TISSUE_STRUCTURE", 441, 444], ["influenza A virus", "ORGANISM", 522, 539], ["influenza A virus", "SPECIES", 522, 539], ["HRV", "SPECIES", 449, 452], ["influenza A virus", "SPECIES", 522, 539], ["gastrointestinal symptoms", "PROBLEM", 13, 38], ["watery diarrhea", "PROBLEM", 78, 93], ["a virus", "PROBLEM", 144, 151], ["P", "TEST", 237, 238], ["Clinical signs/symptoms", "PROBLEM", 259, 282], ["acute respiratory diseases", "PROBLEM", 304, 330], ["the detected viruses", "PROBLEM", 336, 356], ["the virus-positive cases", "PROBLEM", 359, 383], ["watery diarrhea", "PROBLEM", 385, 400], ["EVs", "TEST", 441, 444], ["HRV", "PROBLEM", 449, 452], ["whilst sore throat", "PROBLEM", 454, 472], ["influenza A virus", "PROBLEM", 522, 539], ["Clinical signs/symptoms", "PROBLEM", 542, 565], ["acute respiratory diseases", "PROBLEM", 587, 613], ["the detected viruses", "PROBLEM", 619, 639], ["respiratory viruses", "PROBLEM", 815, 834], ["respiratory viruses", "PROBLEM", 904, 923], ["Dak Lak", "TREATMENT", 966, 973], ["P", "TEST", 1199, 1200], ["gastrointestinal", "ANATOMY", 13, 29], ["virus", "OBSERVATION", 146, 151], ["acute", "OBSERVATION_MODIFIER", 304, 309], ["respiratory diseases", "OBSERVATION", 310, 330], ["viruses", "OBSERVATION", 349, 356], ["virus", "OBSERVATION", 363, 368], ["positive cases", "OBSERVATION_MODIFIER", 369, 383], ["acute", "OBSERVATION_MODIFIER", 587, 592], ["respiratory diseases", "OBSERVATION", 593, 613], ["viruses", "OBSERVATION", 632, 639], ["respiratory viruses", "OBSERVATION", 815, 834], ["respiratory", "ANATOMY", 904, 915], ["viruses", "OBSERVATION", 916, 923], ["distinct", "OBSERVATION_MODIFIER", 999, 1007], ["geographic", "OBSERVATION_MODIFIER", 1008, 1018], ["localities", "OBSERVATION", 1019, 1029]]], ["In Dak Lak, no significant differences were found (Table 4 ).| Temporal and seasonal differences in the frequency of detection of respiratory virusesThere were some fluctuations in the detection of the most common viruses (especially EVs and HRV; In terms of seasonality, overall, there were some clear trends| Animal exposureOverall, the cohort members were exposed to a wide range of animals, including 11 types of exotic animals and 11 types of domestic animals, within \u22641 month prior to the disease episode (n = 770) (Table S1) The antibiotic use of the patients from the first symptoms to the incidence interview/sampling.", [["EVs", "ANATOMY", 234, 237], ["respiratory viruses", "DISEASE", 130, 149], ["EVs", "MULTI-TISSUE_STRUCTURE", 234, 237], ["patients", "ORGANISM", 558, 566], ["Dak Lak", "CELL_LINE", 3, 10], ["patients", "SPECIES", 558, 566], ["Temporal and seasonal differences", "PROBLEM", 63, 96], ["respiratory viruses", "PROBLEM", 130, 149], ["some fluctuations", "PROBLEM", 160, 177], ["the detection", "TEST", 181, 194], ["the most common viruses", "PROBLEM", 198, 221], ["HRV", "PROBLEM", 242, 245], ["the disease episode", "PROBLEM", 491, 510], ["The antibiotic use", "TREATMENT", 532, 550], ["the first symptoms", "PROBLEM", 572, 590], ["no", "UNCERTAINTY", 12, 14], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["seasonal", "OBSERVATION_MODIFIER", 76, 84], ["differences", "OBSERVATION_MODIFIER", 85, 96], ["respiratory viruses", "OBSERVATION", 130, 149], ["some", "OBSERVATION_MODIFIER", 160, 164], ["fluctuations", "OBSERVATION_MODIFIER", 165, 177], ["most common", "OBSERVATION_MODIFIER", 202, 213], ["viruses", "OBSERVATION", 214, 221]]], ["Note: Other viral pathogens were not showed as they were detected in less than 10 samples.", [["samples", "ANATOMY", 82, 89], ["Other viral pathogens", "TEST", 6, 27]]], ["P values were calculated by Pearson's HRV and ADV, our report supports previous findings.", [["P", "DNA", 0, 1], ["ADV", "SPECIES", 46, 49], ["P values", "TEST", 0, 8]]], ["[39] [40] [41] [42] [43] Our overall RT-PCR yield of 17.7% of viral agents in respiratory samples of the cohort members with the majority age from 16 years or above is in agreement with the diagnostic yields of previous studies.", [["respiratory samples", "ANATOMY", 78, 97], ["[39] [40] [41] [42", "CHEMICAL", 0, 18], ["[39] [40] [41] [42] [43]", "SIMPLE_CHEMICAL", 0, 24], ["Our overall RT-PCR yield", "TEST", 25, 49], ["viral agents", "TREATMENT", 62, 74], ["previous studies", "TEST", 211, 227]]], ["[44] [45] [46] [47] [48] [49] The results suggest that it is probably because adults have acquired substantial immunity during their life, leading to the rapid clearance of the infecting viruses from their respiratory tract, thereby shortening the duration of viral shedding.| Animal exposureOur study has some limitations.", [["respiratory tract", "ANATOMY", 206, 223], ["[44] [45] [46] [47] [48] [49]", "SIMPLE_CHEMICAL", 0, 29], ["respiratory tract", "ORGANISM_SUBDIVISION", 206, 223], ["the infecting viruses", "PROBLEM", 173, 194], ["their respiratory tract", "PROBLEM", 200, 223], ["viral shedding", "PROBLEM", 260, 274], ["Animal exposureOur study", "TEST", 277, 301], ["respiratory tract", "ANATOMY", 206, 223]]], ["First, no human subjects without animal exposure were recruited as controls.", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["no", "UNCERTAINTY", 7, 9]]], ["Therefore, we were unable to assess the effect (if any) of animal exposure on the| Animal exposureThe seasonal distribution of symptomatic EVs-, HRV-, influenza A virus-, ADV-, and CoV (subtype OC43 and NL63)-infected cases detected by RT-PCR assay.", [["HRV-, influenza A virus", "ORGANISM", 145, 168], ["ADV", "ORGANISM", 171, 174], ["CoV (subtype OC43", "ORGANISM", 181, 198], ["NL63", "GENE_OR_GENE_PRODUCT", 203, 207], ["influenza A virus", "SPECIES", 151, 168], ["influenza A virus", "SPECIES", 151, 168], ["ADV", "SPECIES", 171, 174], ["CoV", "SPECIES", 181, 184], ["animal exposure", "PROBLEM", 59, 74], ["symptomatic EVs-", "PROBLEM", 127, 143], ["HRV", "TEST", 145, 148], ["influenza A virus", "TEST", 151, 168], ["ADV", "TEST", 171, 174], ["CoV", "TEST", 181, 184], ["subtype OC43", "TEST", 186, 198], ["NL63", "TEST", 203, 207], ["infected cases", "PROBLEM", 209, 223], ["RT-PCR assay", "TEST", 236, 248], ["symptomatic", "OBSERVATION_MODIFIER", 127, 138]]], ["The bars show the proportion of the viruses detected among total samples tested (the line chart) each month.", [["samples", "ANATOMY", 65, 72], ["the viruses", "PROBLEM", 32, 43], ["total samples", "TEST", 59, 72], ["viruses", "OBSERVATION", 36, 43]]], ["EVs and influenza A virus were more likely detected in the rainy season than in the dry season (P = .002 and P = .023, respectively), while the ADV detections were more frequent in the dry season as compared with the rainy one (P = .044).", [["EVs", "ANATOMY", 0, 3], ["EVs", "CELL", 0, 3], ["influenza A virus", "ORGANISM", 8, 25], ["influenza A virus", "SPECIES", 8, 25], ["influenza A virus", "SPECIES", 8, 25], ["ADV", "SPECIES", 144, 147], ["EVs", "TEST", 0, 3], ["influenza A virus", "PROBLEM", 8, 25], ["P", "TEST", 96, 97], ["P", "TEST", 109, 110], ["the ADV detections", "TEST", 140, 158]]], ["There was no significant difference in the detections of HRV and CoV (subtype OC43 and NL63) between dry and rainy seasons (P = .333 and .227, respectively).", [["CoV", "GENE_OR_GENE_PRODUCT", 65, 68], ["HRV", "PROBLEM", 57, 60], ["CoV", "TEST", 65, 68], ["subtype OC43", "TEST", 70, 82], ["NL63", "TEST", 87, 91], ["P", "TEST", 124, 125], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["ADV, adenovirus; CoV, coronavirus; EV, enterovirus; HRV, human rhinovirus; RT-PCR, real-time polymerase chain reaction frequency of the respiratory disease incidence, as well as the observed viral patterns.", [["respiratory", "ANATOMY", 136, 147], ["ADV", "CHEMICAL", 0, 3], ["respiratory disease", "DISEASE", 136, 155], ["ADV", "ORGANISM", 0, 3], ["adenovirus; CoV", "ORGANISM", 5, 20], ["coronavirus; EV", "ORGANISM", 22, 37], ["enterovirus", "ORGANISM", 39, 50], ["human", "ORGANISM", 57, 62], ["rhinovirus", "ORGANISM", 63, 73], ["coronavirus", "SPECIES", 22, 33], ["human", "SPECIES", 57, 62], ["rhinovirus", "SPECIES", 63, 73], ["ADV", "SPECIES", 0, 3], ["human rhinovirus", "SPECIES", 57, 73], ["adenovirus", "PROBLEM", 5, 15], ["CoV", "PROBLEM", 17, 20], ["coronavirus", "PROBLEM", 22, 33], ["EV", "PROBLEM", 35, 37], ["enterovirus", "PROBLEM", 39, 50], ["HRV", "PROBLEM", 52, 55], ["human rhinovirus", "PROBLEM", 57, 73], ["RT-PCR", "TEST", 75, 81], ["the respiratory disease incidence", "PROBLEM", 132, 165], ["respiratory disease", "OBSERVATION", 136, 155], ["viral patterns", "OBSERVATION", 191, 205]]], ["Second, despite a holistic effort, nonviral agents as bacterial pathogens were not tested.", [["nonviral agents", "TREATMENT", 35, 50], ["bacterial pathogens", "PROBLEM", 54, 73]]], ["Third, a slight decrease in sensitivity of the multiplex RT-PCR platforms used in the present study as compared with that of the corresponding monoplex RT-PCRs have previously been reported, 23", [["monoplex RT-PCRs", "DNA", 143, 159], ["a slight decrease", "PROBLEM", 7, 24], ["the multiplex RT-PCR platforms", "TEST", 43, 73], ["the present study", "TEST", 82, 99], ["the corresponding monoplex RT-PCRs", "TEST", 125, 159], ["slight", "OBSERVATION_MODIFIER", 9, 15], ["decrease", "OBSERVATION_MODIFIER", 16, 24]]]], "f7fcc3c7bae84f633089543aee8610baf6e8cc19": [["ABSTRACTThe COVID-19 pandemic exposed numerous deficiencies of the U.S. primary care infrastructure.ABSTRACTThe system is overstretched with little to no surge capacity to deal with crisis situations, its reach restrained due to overreliance on brick and mortar clinics, and its behavior overwhelmingly more reactive than preventive.", [["surge capacity", "PROBLEM", 154, 168], ["crisis situations", "PROBLEM", 182, 199], ["reactive", "OBSERVATION_MODIFIER", 308, 316]]], ["As delivery systems reorganize on the fly to fight COVID-19, many are turning to tools like telemedicine, pre-visit planning, and centralized population health programs.ABSTRACTWe propose how these rapid transformations happening across the country, born out of necessity, present a silver lining opportunity to fix primary care.", [["silver", "CHEMICAL", 283, 289], ["COVID", "TEST", 51, 56], ["rapid", "OBSERVATION_MODIFIER", 198, 203], ["transformations", "OBSERVATION", 204, 219]]], ["We describe how integrating telemedicine, patient-generated data, and preventive care into a retooled intake and care optimization process is achievable through an approach powered by humans and augmentable with artificial intelligence.ABSTRACTPrimary care must retool to meet the challenge of COVID-19 and emerge in the post-crisis world better equipped to care for a wounded nation.", [["patient", "ORGANISM", 42, 49], ["humans", "ORGANISM", 184, 190], ["patient", "SPECIES", 42, 49], ["humans", "SPECIES", 184, 190], ["humans", "SPECIES", 184, 190], ["preventive care", "TREATMENT", 70, 85], ["a retooled intake", "TREATMENT", 91, 108], ["care optimization process", "TREATMENT", 113, 138], ["ABSTRACTPrimary care", "TREATMENT", 236, 256], ["COVID", "TEST", 294, 299], ["a wounded nation", "TREATMENT", 367, 383]]], ["Our collective willingness to invest in primary care teams, relaxation of rules around telemedicine reimbursement and patient-generated data sharing, workforce training, and movement to value-based payments are necessary to achieve this vision.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["telemedicine reimbursement", "TREATMENT", 87, 113], ["workforce training", "TREATMENT", 150, 168]]], ["3MAIN TEXTThe COVID-19 pandemic exposed numerous deficiencies of the U.S. primary care infrastructure.MAIN TEXTThe system is overstretched with little to no surge capacity to deal with crisis situations, its reach restrained due to overreliance on brick and mortar clinics, and its behavior overwhelmingly more reactive than preventive.", [["surge capacity", "PROBLEM", 157, 171], ["crisis situations", "PROBLEM", 185, 202], ["reactive", "OBSERVATION_MODIFIER", 311, 319]]], ["Even before the outbreak, U.S. primary care physicians faced excessive patient panel sizes in an environment of a workforce shortage.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["sizes", "OBSERVATION_MODIFIER", 85, 90]]], ["[1] [2] Without enough time to provide all the necessary acute, chronic and preventive care for their patients, primary care physicians are forced to prioritize acute care; not surprisingly, patients receive only half of all the recommended chronic and preventive care services.", [["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 191, 199], ["acute care", "TREATMENT", 161, 171], ["chronic and preventive care services", "TREATMENT", 241, 277], ["chronic", "OBSERVATION_MODIFIER", 64, 71]]], ["4 These system failures -however damaging during normal times -have been magnified exponentially by the unprecedented challenge of COVID-19.MAIN TEXTAs primary care systems reorganize on the fly to fight COVID-19, many are turning to tools such as telemedicine, pre-visit planning, and centralized population health management.", [["These system failures", "PROBLEM", 2, 23], ["COVID", "TEST", 131, 136], ["centralized population health management", "TREATMENT", 286, 326], ["failures", "OBSERVATION", 15, 23]]], ["Telemedicine has been indispensable in delivering care to patients sheltered at home, while minimizing risks to providers.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["Prior to COVID-19, only 28% of U.S. physicians were using telemedicine; 5 today it is the preferred, if not dominant, method of delivering care.", [["COVID", "TEST", 9, 14]]], ["6 Pre-visit planning strategies like clinic schedule sweeping, pre-visit screening of patients, and triaging visit priorities -once regarded as \"nice-to-have\" protocols -have been adopted as \"must-haves,\" quickly and widely.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["Systems that have been flirting with centralizing their population health services to improve care quality have accelerated their transitions to free up primary care physicians to handle the surge of COVID-19 4 patients.", [["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219]]], ["These rapid transformations happening in health systems across the country, born out of necessity, present an opportunity -a silver lining -to fix primary care.A paradigm shift for telemedicineWhen all is done, the COVID-19 pandemic will likely be seen as a tipping point for telemedicine in the U.S. -the point when it was no longer considered a niche service, but an essential piece of care delivery.", [["silver", "CHEMICAL", 125, 131], ["These rapid transformations", "PROBLEM", 0, 27], ["a silver lining", "TREATMENT", 123, 138], ["the COVID", "TEST", 211, 220], ["care delivery", "TREATMENT", 388, 401], ["rapid", "OBSERVATION_MODIFIER", 6, 11], ["transformations", "OBSERVATION", 12, 27]]], ["At one institution -Stanford University -the volume of telehealth and video visits leaped from 400 per day to 3,000 in a period of just two weeks when the pandemic hit California.A paradigm shift for telemedicineNationally, widespread telemedicine adoption was powered by the loosening of payer restrictions by Medicare and some private insurances.", [["hit California", "OBSERVATION", 164, 178]]], ["7 The longer COVID-19 lasts, the more it will push the envelope on the breadth, depth, and comprehensiveness of care that can be accomplished through virtual visits.", [["COVID-19", "DNA", 13, 21], ["The longer COVID", "TREATMENT", 2, 18]]], ["What we need now is a national telemedicine curriculum to be taught in residencies and medical schools, 8 and for Congress to make coverage for telemedicine visits permanent.Let patients help their providers with patient-generated dataSince COVID-19, nurses have held the primary care front lines.", [["patients", "ORGANISM", 178, 186], ["patient", "ORGANISM", 213, 220], ["patients", "SPECIES", 178, 186], ["patient", "SPECIES", 213, 220]]], ["Nurses assess, advise, and direct patients to the most appropriate level of care, conserving access to physicians for those who need them most.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["They follow-up and monitor COVID-19 patients for clinical deterioration.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 27, 32], ["clinical deterioration", "PROBLEM", 49, 71]]], ["Tools such as Apple's COVID-19 screening app, created with the CDC, gather patient-generated data and help patients contextualize their symptoms and determine if they need to see a clinician.", [["patient", "ORGANISM", 75, 82], ["patients", "ORGANISM", 107, 115], ["patient", "SPECIES", 75, 82], ["patients", "SPECIES", 107, 115], ["Apple's COVID", "TREATMENT", 14, 27], ["screening app", "TEST", 31, 44], ["the CDC", "TEST", 59, 66], ["their symptoms", "PROBLEM", 130, 144]]], ["9 This general approach of using patient-generated data to connect patients with the right level of care when, where, and how they need it should be broadened to all primary care intake processes.", [["patient", "ORGANISM", 33, 40], ["patients", "ORGANISM", 67, 75], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 67, 75]]], ["Integration of technology-assisted tools including symptom checker apps, web-based screeners, and wearable devices into health systems' electronic health records (EHR) holds promise to make the most of every precious encounter between patients and physicians.Prevention will be ignored if not done between visitsThe COVID-19 pandemic led to a dramatic shift in operational priorities from improving general population health and chronic disease management to identifying patients with and at risk for the virus.", [["patients", "ORGANISM", 235, 243], ["patients", "ORGANISM", 471, 479], ["patients", "SPECIES", 235, 243], ["patients", "SPECIES", 471, 479], ["chronic disease management", "TREATMENT", 429, 455], ["the virus", "PROBLEM", 501, 510], ["chronic", "OBSERVATION_MODIFIER", 429, 436], ["disease", "OBSERVATION", 437, 444], ["virus", "OBSERVATION", 505, 510]]], ["Nearly all preventive care have been postponed and chronic disease management programs scaled back or put on hold.", [["chronic disease management programs", "TREATMENT", 51, 86], ["chronic", "OBSERVATION_MODIFIER", 51, 58], ["disease", "OBSERVATION", 59, 66]]], ["Before COVID-19, systems were slow to adopt centralized strategies that leverage team-based care and technology, despite demonstrated benefits on quality of care.", [["COVID", "TEST", 7, 12]]], ["10 The post-COVID-19 era presents a crucial opportunity to overcome the hurdles of culture change in a time when systems are pressured to reimagine nearly all aspects of daily work.", [["culture change", "PROBLEM", 83, 97]]], ["The alternative to prioritizing and centralizing preventive care is to exhaust our already overextended teams, asking them to catch up for lost time once systems emerge from this pandemic.Future directions and challengesIntegrating telemedicine, patient-generated data, and preventive care into a retooled primary care intake and care optimization process is achievable (Figure) .", [["patient", "ORGANISM", 246, 253], ["patient", "SPECIES", 246, 253], ["preventive care", "TREATMENT", 274, 289], ["a retooled primary care intake", "TREATMENT", 295, 325], ["care optimization process", "TREATMENT", 330, 355]]], ["Such an approach would be powered by humans and augmentable by artificial intelligence.", [["humans", "ORGANISM", 37, 43], ["humans", "SPECIES", 37, 43], ["humans", "SPECIES", 37, 43], ["an approach", "TREATMENT", 5, 16]]], ["11 Up until the recent loosing of restrictions on virtual care, the primary barriers to telemedicine adoption were payer coverage and regulatory limitations.", [["virtual care", "TREATMENT", 50, 62], ["telemedicine adoption", "TREATMENT", 88, 109], ["payer coverage", "TREATMENT", 115, 129]]], ["Looking to the future, the lack of reimbursement for pre-visit planning and inter-visit care management activities will be a key driver of change.", [["pre-visit planning", "TREATMENT", 53, 71], ["inter-visit care management", "TREATMENT", 76, 103]]], ["Human and technical challenges exist:Future directions and challengesfor patients, convenience, privacy, and data security are chief concerns; for providers, fears about 6 data overload, technology/EHR interoperability, and workflow integration are paramount.", [["Human", "ORGANISM", 0, 5], ["patients", "ORGANISM", 73, 81], ["Human", "SPECIES", 0, 5], ["patients", "SPECIES", 73, 81], ["6 data overload", "PROBLEM", 170, 185]]], ["Health systems' willingness to invest in primary care teams, relaxation of rules around patient-generated data use, workforce training, and advancement to value-based payments are necessary to achieve this vision.Future directions and challengesPrimary care must retool to meet the challenge of COVID-19 and emerge in the post-crisis world better equipped to care for a wounded nation, and possibly millions of patients who have delayed usual care for months on end.", [["patient", "ORGANISM", 88, 95], ["patients", "ORGANISM", 411, 419], ["patient", "SPECIES", 88, 95], ["patients", "SPECIES", 411, 419], ["workforce training", "TREATMENT", 116, 134], ["value-based payments", "TREATMENT", 155, 175]]], ["Although issues of over-empaneled providers, workforce shortage, and disparities in access, quality and affordability of care will not disappear after COVID-19, we can use tools like telemedicine, pre-visit planning, and population health management -powered by humans and AI -to expand primary care's reach in all communities, increase system capacity and visit efficiency, and prioritize prevention to keep patients healthy.", [["humans", "ORGANISM", 262, 268], ["patients", "ORGANISM", 409, 417], ["humans", "SPECIES", 262, 268], ["patients", "SPECIES", 409, 417], ["humans", "SPECIES", 262, 268], ["population health management", "TREATMENT", 221, 249]]], ["The COVID-19 pandemic taught us valuable lessons.", [["The COVID", "TEST", 0, 9]]]]}